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Summary.
G-proteins have been demonstrated to be necessary to allow transduction of 
information from hormone-activated cell surface receptors to a variety of effector 
systems. This study has focused on their expression and regulation in response to 
agonists at receptors which produce stimulation of adenylyl cyclase or stimulation of 
phospholipase C activity.
To understand receptor regulation of cyclic AMP generation, it is important 
to know the relative or absolute levels of expression of each component (receptor, G- 
protein (Gs) and adenylyl cyclase) in individual cells, their cellular disposition and 
how alteration in levels of each component might alter the effectiveness of cellular 
signaling.
In chapter 3, neuroblastoma x glioma hybrid, NG108-15, cells are shown to 
express GsOt in a substantial molar excess over its effector adenylyl cyclase. 
Sustained exposure of a cell to an agonist for a G-protein coupled receptor can lead 
to the down-regulation of levels of the receptor and the G-protein and this process 
can play a substantial part in the regulation of cellular sensitivity to the presence of 
agonist. Regulation of agonist access to the receptor population by pretreatment of 
NG108-15 cells transfected to express the human ^ 2-adrenoceptor with varying 
concentrations of an irreversible ^-adrenoceptor antagonist (BAAM) demonstrated 
that the extent of agonist-mediated GgOC down-regulation was dependent upon the 
availability of receptor to agonist and that the levels of receptor expression defines 
the intrinsic activity and potency of agonists.
As noted above, however, the availability of sufficient Gga to interact with 
the total cellular population of adenylyl cyclase suggests that the adenylyl cyclase is 
likely to be the limiting component for information transfer. As a means to examine 
quantitative aspects of the expression of adenylyl cyclase, human p2-adrenoceptor 
expressing NG108-15 cells were further transfected to overexpress adenylyl cyclase 
type 2. The results demonstrated that receptor-mediated maximal output of the
XIX
stimulatory arm of the adenylyl cyclase cascade can be increased by increasing total 
levels of adenylyl cyclase but this did not result in any significant alteration in the 
concentration-effect curves for stimulation of adenylyl cyclase activity produced by 
either the transfected human p^-adrenoceptor or any of the endogenously expressed 
(IP prostanoid, A2  adenosine or secretin) Gga-linked receptors.
In chapter 4, human embryonic kidney (HEK-293) cells which express the
long splice variant form of the rat thyrotropin-releasing hormone (TRH) receptor
(clone E2) were examined to address whether both G qa and/or G n a  and G§a are 
.involved in TRH-stimulation of phospholipase C p i  and/or adenylyl cyclase or 
whether different splice variants of the receptor selectively interact with different G- 
proteins to regulate different signal transduction cascades. Activation of this receptor 
with TRH caused only a large stimulation of production of inositol phosphates in a 
manner which was mediated by the pertussis-toxin-insensitive phospholipase C- 
linked Gq and G l i proteins despite the fact that TRH has been reported to stimulate 
adenylyl cyclase activity via activation of Gga.
In addition, with development of a 6  M urea containing SDS-PAGE (10% 
(w/v) acrylamide, 0.0625% (w/v) bisacrylamide) system which allowed resolution of 
G qa and G n a  I assessed whether a single receptor type could utilise species 
variants of the same G-protein equivalently? Treatment of clone E2M 11 (which 
expresses the long isoform of the rat TRH receptor and both the endogenous human 
and exogenous introduced murine G n a )  with TRH resulted in a qualitatively 
similar pattern of cellular redistribution and down-regulation of G n a  isoforms. 
Quantitative analysis indicated, however, that the murine isoform of G n a  was less 
effectively regulated by the long isoform of the rat TRH receptor than the 
endogenous human form of G n a .
XX
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Chapter 1. 
Introduction.
11.1. G-protein coupled receptors.
1.1.1. The identification of a G-protein coupled receptor.
Cell surface receptors may be functionally classified into several categories. 
Growth factor receptors have an intrinsic tyrosine kinase activity, such as receptors for 
insulin and epidermal growth factor (EGF) (Hunter et a l,  1985). Receptors like the 
nicotinic acetylcholine receptor are multi-subunit ion channels (Changeux et aL,
1987), whereas the transferrin receptor functions as a carrier protein (Goldstein et aL, 
1985). However, the largest class of receptors are those which interact with and 
activate G-proteins to mediate a variety of transmembrane signals.
The effect of guanine nucleotides on ligand binding to receptor initially 
demonstrated the possibility of a G-protein link to a rat liver glucagon receptor: the 
affinity of glucagon binding was decreased in the presence of guanine nucleotides 
(Rodbell et aL, 1971). Analysis of competition curves at P-adrenoceptors suggested 
the existence of two receptor affinity states for an agonist as opposed to one affinity 
state for an antagonist. It was proposed that in the presence of guanine nucleotides 
receptors adopted a low affinity state, whereas a high affinity state for agonist 
persisted in the absence of guanine nucleotide (De Lean et aL, 1980). In an attempt to 
account for the data emerging on guanine nucleotide effects on ligand binding the 
ternary complex model was proposed. In the unstimulated state the inactive G-protein 
a  subunit (Ga), coupled to Py, interacts with the receptor (R), leading to agonist (H) 
promoted formation of a high affinity ternaiy complex (HRGa). In the presence of 
guanine nucleotides which activate G a, the ternary complex is destabilized and both 
agonist and G-protein can dissociate from the receptor. Although the ternary complex 
was originally based on the observations of agonist-induced stimulation of adenylyl 
cyclase, receptors linked to the inhibitory arm of this transduction pathway were also 
found to fit this interpretation (Koski et aL, 1981a, b). These observations led to the 
general conclusion that guanine nucleotide-induced agonist affinity alterations 
implicate a G-protein coupled receptor.
I
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mapping have provided supporting evidence for the existence of seven transmembrane
Another property characteristic of a G-protein linked receptor is agonist 
stimulated GTPase activity. Although GTPase activity was firstly identified as Gga 
mediated, it was only possible to measure receptor stimulated high affinity GTPase 
activity by Gga in a very limited number of model systems, namely the turkey 
erythrocyte (Cassel et al., 1976) and the human platelet (Houslay et a i,  1986). In f
contrast, stimulation of GTPase activity by receptors which interact with pertussis 
toxin-sensitive G-proteins has been reported for a variety of membrane systems, in 
particular those mediating inhibition of adenylyl cyclase (McClue et a l, 1992).
Agonist-stimulated GTPase activity has also recently been demonstrated for 
pertussis toxin-insensitive G-proteins. Thromboxane A2 stimulated a small, yet 
significant, increase in GTPase activity in human platelet membranes mediated via the 
G q-like G-proteins (Shenker et at., 1991). The low level of stimulated GTPase
:activity may explain the lack of success of previous attempts to measure this activity ’
upon stimulation of receptors that couple to pertussis toxin-insensitive Gq-like G-
sproteins. It is becoming evident that the intrinsic GTP hydrolytic properties of the 
different G a  subtypes may differ. Indeed, the intrinsic GTPase activity of purified 
G ga is lower than that of purified G ia  (Gilman et at., 1987) and purification data 
suggests that the G q a /G n a  proteins do bind GTPyS with slow rates. Thus, with
these caveats, receptor-stimulated high affinity GTPase activity is a useful indication ï |
Iof a G-protein coupled receptor. I
1.1.2. The structural features of G-protein coupled receptors.
Although G-protein linked receptors have numerous structural adaptations to 
their extracellular domains to allow them to respond to diverse signals, characterisation 
by amino acid sequence has shown that all these receptors aie likely to share the same 
basic structure in which seven hydrophobic segments of 20-25 amino acids in length
Iform transmembrane helices. Protease digestion studies and detailed immunological |
i
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spanning domains linking an extracellular N-terminus and an intracellular C-terminus 
(Dohlman et aL, 1987).
Figure 1.1 shows a scheme in which the receptor has been flattened to simplify 
description of its primary features. I and II; The tertiary structure and relative 
positioning of the transmembrane segments depends not only on connecting extra- and 
intracellular loops, but also on interactions among transmembrane segments. Co­
expression of an N-terminal half (N-terminus plus TM's I-V plus part of the 3rd 
intracellular loop) and a C-terminal half lead to an active receptor (Kobilka et al., 
1988); proteolytic digestion of purified receptor protein leads to a limit digest formed 
of all seven TM's (Rubenstein et al., 1987); mutations that interfere with TM-I: TM- 
V n interaction prevent receptor folding (Suryanaryana et al., 1992).
A) The NH^-terminus.
The higher apparent moleculai" mass of receptors than that predicted from their 
amino acid sequences suggests that many are glycosylated. This is supported by the 
observations that nearly all G-protein coupled receptors have one or more asparagine 
residues (usually in the N-terminal region), which are present in glycosylation 
consensus sequences. Direct evidence for glycosylation has been shown for a number 
of receptors, including the purified p2 -adrenoceptor, in which endoglycosidase 
treatment decreases its molecular mass from some 65 kDa to 49 kDa (Rands et al., 
1990). For most receptors it is believed that glycosylation has little role in agonist ■I
binding but that it may be of importance in determining the correct distribution of the 
receptor in the cell. For example, treatment of the p 2 -adrenoceptor w ith
endoglycosidases or mutational alteration of the two asparagine residues predicted to 
undergo glycosylation has little effect on agonist or antagonist binding or coupling of 
the receptor to adenylyl cyclase (O'Dowd et al., 1989).
BI Cysteine disulphide bridges.
The presence of a cysteine residue towards the carboxy end of the first 
extracellular loop and a second one towards the middle of the second extracellular loop 
is a constant finding in many G-protein coupled receptors. Direct chemical evidence
if
Figure 1.1,
Common structural features of G-protein coupled receptors.
A schematic diagram of the seven transmembrane helices of a G-protein 
coupled receptor is adapted from Birnbaumer et a l, 1995. The structural elements and 
their functions ai'e discussed in section 1.1.2.
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1has been obtained for a disulphide linkage between these two cysteine residues in 
rhodopsin and it has been shown that this is essential for achieving the correct tertiary 
structure (Karnik et al., 1988). Two further cysteine residues located next to each 
other in the third extracellular loop of the p2-adrenoceptor are also linked by a 
disulphide bond (Ostrowski et a l,  1992).
Cl Ligand binding domains.  ^ _ /
The seven hydrophobic domains represented in (pox À participate in the /  
formation of the ligand binding pocket. Small hormone and neurotransmitter 
molecules, such as catecholamines, acetylcholine, histamine and serotonin are 
assumed to interact with the transmembrane domains to trigger a response (Strader et 
at., 1989). Photoaffinity labeling studies have been used to identify the ligand binding
.
site of the turkey P-adrenoceptor, the hamster p2-adrenoceptor (Dohlman et a l ,
1988), and the human platelet a 2-adrenoceptor (Matsui et a l, 1989).
In the P2-adrenoceptor, the carboxyl group on the conserved aspartate residue 
in TM-III is postulated to act as a counter-ion for the catecholamine nitrogen in the 
presence of an agonist or antagonist containing a protonated amine group, like 
isoprenaline and propranolol. Two conserved serines (204 and 207) in TM-V of the 
receptor were found to form a hydrogen bond with the para- and meta- hydroxyl of 
isoprenaline respectively (Strader et a l,  1989). This gives a model of isoprenaline 
binding to the P2-adrenoceptor through a carboxy-amine salt bridge at aspartate 113 
and hydrogen bonds at serines 204 and 207.
Additional studies of the ligand binding domain have suggested that 
antagonists and agonists bind to distinct sites, and although these sites are not identical 
there is likely to be some overlap. Site B (Figure 1.1) on transmembrane region VI 
and VH define specificities for antagonists in biogenic amine receptors. A chimera that 
comprises the p2-adrenoceptor for TM's I-V and the a 2-AR for TM's VI-VII (plus C- 
terminal tail) activates adenylyl cyclase (p2-effect) but is blocked by yohimbine (ct2- 
adrenoceptor antagonist) (Kobilka et a l, 1988). In area b, antagonist binding may be 
more important than B domain (Figure 1.1). For example, a non-peptide N K l
ii
tachykinin receptor antagonist, interacts with epitopes that are on top of both TM-VI 
and TM-VII, even though neither epitope is required for NKl (substance P) binding
(Gether a/., 1993). s
Although the general features of ligand binding are beginning to be mapped, 
the residues involved in determining ligand specificity and receptor subtype ligand 
selectivity remain to be fully defined.
PI G-protein coupling domains.
The first and second cytoplasmic loops are reasonably well conserved between 
different receptors, but the third cytoplasmic loop and the carboxy terminal tail are 
quite divergent, possibly reflecting a molecular basis for variable ligand and G-protein 
specificity (Cotecchia a/., 1990; Kobilka etaL, 1988).
The N-terminal segment of the 3rd intracellular loop (domain C) may be 
involved in defining specificity of G-protein interactions (Figure 1.1). Replacement of 
17 amino acids of the N-terminal end of intracellular loop 3 of the PLC activating M3 
muscarinic acetylcholine receptor with the cognate 16 amino acid stretch of the 
adenylyl cyclase inhibiting M2 muscarinic acetylcholine receptor resulted in loss of 
PLC stimulation and acquisition of adenylyl cyclase inhibitory activity to a level that 
was 25% of control (Wess etaL, 1990).
Domain E within the carboxy terminus of the third intracellular loop may also 
be a potential protein: protein interaction site for receptor: G a  interactions (Figure 
1.1). Point mutations in the C-terminal end of the 3rd intracellular loop may lead to 
constitutive (agonist independent) activation of receptors as shown by artificial 
mutations of the aiB-(Cotecchia et a l, 1990; Kjelsberg et al., 1992), a2A~ (Ron et a l. I
's;:;;.,
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1993) and P2~adrenoceptors (Samama et al., 1993). Two natural mutations of the 
TSH receptor in this region result in a similar effect (Parma et al., 1993). Peptides 
derived from this region of receptors can activate purified G-proteins in vitro (Dalman 
et al., 1991; Cheung et al., 1991). Although the third intracellular loop appears to be 
essential for G-protein coupling, the first and second loops may also play a minor role
.
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(O'Dowd et al., 1988; Cotecchia et al., 1992), possibly through allosteric interactions 
with the third intracellular loop and other components of the receptor.
The C-terminal tail (designated F in figure 1.1) may also contribute to 
interaction with G-proteins for some receptors such as the EP3-prostaglandin receptor 
(Sugimoto 1993).
A "DRY" motif (consensus D/e-R-Y/f/h/c of which the R is invariant) 
designated as G (Figure 1.1) is found in some/zOÇ/G-protein coupled receptors. 
Exceptions exist however, including receptors for the glucagon-related peptides 
(glucagon, secretin, vasoactive intestinal peptide (VIP) type 1 and 2, pituitary adenylyl 
cyclase activating peptide (PACAP)). The DRY motif is thought to be important for 
coupling to and activation of G-proteins but this cannot be an invariant feature because 
of the exceptions noted above. Mutation of this "R" in the vasopressin receptor type 2 
(VP2) results in loss of coupling to Gga without changes in agonist binding or loss of 
sequestration in response to hormone binding (Rosenthal et al., 1993).
El The carboxy (COOH-) terminus.
The p2 -ndrenoceptor and rhodopsin have one and two cysteine residues, 
respectively, in their C-terminal sequence which have been shown to bind palmitate 
via a thioester linkage (O'Dowd et al., 1989). It is believed that the covalently bound 
palmitate becomes intercalated into the membrane bilayer, thereby creating a 'fourth 
cytoplasmic loop'. Removal of the cysteine residue in the p2-adrenoceptor uncouples 
the receptor from its associated G-protein, G$a (O'Dowd et al., 1989; Moffett et a i ,  
1993), but equivalent mutations caused no functional effect in rhodopsin (Kainik et 
al., 1988) or the (X2A-ndrenoceptor (Kennedy et al., 1993). The presence of one or 
two cysteines in a similai position in most other G-protein coupled receptors suggests 
that this may be a common structural feature.
FI Regulation of receptor function.
Responses to G-protein coupled receptors undergo rapid desensitisation 
following prolonged exposure to agonists and there is a great deal of evidence to 
support a role of protein phosphorylation in this process (Hausdorff et al., 1990).
8
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Serine-threonine rich regions in either or both the 3rd intracellular loop and the C- 1
terminal tail as shown in figure 1.1 (designated as D) are substrates for G-protein X
coupled receptor kinases (GRKs) and second messenger activated protein kinases 
such as protein kinase A (PKA) and C (PKC). These sites are thought to be exposed
Xupon activation of receptor by agonist. Except for rhodopsin kinase (also named 
GRKl) which is anchored to the membrane through C-terminal polyisoprenylation 
and phosphorylates light-activated rhodopsin without requiring other proteins, the 
other GRKs appear to phosphorylate G-protein coupled receptors only in the context 
of an HR-py complex (Inglese et a l,  1993; Lohse et al., 1992; Haga et al., 1992;
Benovic er 1989).
Exposure of the p2-adrenoceptor to agonist is followed by a rapid uncoupling 
of the receptor from GsOC and desensitization mediated by protein kinase A (PKA)
(Benovic et al., 1985) and p-adrenoceptor kinase (pARK) (also named GRK2)
(Benovic et ah, 1987). Phosphorylation of the receptor by PKA interferes with the 
interaction of the receptor and Gga. Phosphorylation of the receptor by PARK is not 
sufficient to interfere with the activation of GgOC by the receptor. P-arrestin recognizes 
pARK phosphorylated receptor and blocks activation of Gga (Lohse et al., 1990;
■4!1993). With sustained exposure to agonist the receptor may then be removed from the
plasma membrane by sequestration and/or down-regulation. Sequestration is the rapid 
(within five minutes), reversible removal of functional receptors from the plasma 
membrane to distinct membrane vesicles. On removal of agonist the receptor quickly 
returns to the plasma membrane and is fully functional (Hertel et al., 1983). Down- 
regulation, on the contrary, occurs more slowly than sequestration and leads to the 
irreversible loss of receptors from the plasma membrane. The rate of receptor loss is 
greatest during the first four hours of down-regulation (Bouvier et al., 1989). Within
24 hours, the process usually approaches a new steady state. Howeyer, it is not 
entirely clear whether receptor sequestration and down-regulation are distinct
processes mediated via different pathways, or if the two processes are sequential. ^  |
)>
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Apparently several different mechanisms contribute to the process of down- 
regulation. Down-regulation of the p2“^ drenoceptor can be mediated via reduction of f
the receptor mRNA (Hadcock et a l, 1988; Bouvier et a l, 1989). This reduction is due I
to a destabilization of the mRNA since it can also be observed after inhibition of 
mRNA synthesis by actinomycin D (Hadcock e ta l,  1989). Agonist-induced reduction 
of receptor mRNA has been described for a number of G-protein coupled receptors 
including the TSH receptor (Akamizu et al., 1990), a  i g - adrenoceptor (Izzo et al.,
1990), M l, M2, M3-muscarinic acetylcholine receptors (Wang et al., 1990) and the 
thyrotropin releasing hormone (TRH) receptor (Fujimoto et al., 1992). It is not yet ■i'
clear whether this agonist-induced mRNA destabilization is agonist specific, or 
whether it is protein kinase mediated.
The marked increase in intracellular cAMP observed following agonist binding
to the P2-adrenoceptor leads to the activation of many cellular substrates, including 
members of CRE-binding protein (CREB) family of transcription factors (Karpinski et 
al., 1992). Activation of CREB, through a cascade of events, results in its binding to 
the cAMP response element (CRE) in the 5’ promotor region of the p2-adrenoceptor
■f.gene (Collins et al., 1990), which in turn increases the rate of transcription, leading to 
a transient increase in receptor expression. This could appear to be counter to the 
concept of agonist-mediated down-regulation of the receptor but the increase in
receptor transcriptional rate is transient.
1.2. Guanine nucleotide binding proteins (G-proteins).
1.2.1. Signal transduction mediated by G-protein subunits.
A large number of neurotransmitters, peptide hormones, neuromodulators, 
growth factors an^ ordorantslnduce changes in cellular metabolism by interaction with
cell membrane associated receptors that are coupled to intracellular effector enzymes 
by guanine nucleotide binding regulatory proteins (G-proteins). G-proteins, which are 
heterotrimeric proteins composed of a , P and y subunits encoded by distinct genes, !
Figure 1.2.
Signal transduction mediated by G-protein subunits.
A: Model of G-protein dependent transmembrane signaling. 
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An activated receptor produced by a specific ligand (L) binding to its 
appropriate receptor (R) can catalyze the exchange of GTP for GDP bound to the a  
subunit of a specific G-protein, and the subsequent separation of a-GTP from the Py 
complex. Activated a  subunits (a-GTP) and py complex can interact with different 
effectors. Wavy lines emerging both from a  and y subunits denote myristoylation or 
palmitoylation and prénylation respectively. The receptor is desensitized by specific 
phosphorylation (-P). Pertussis toxin (PTX) blocks the catalysis of GTP exchange by 
the receptor while cholera toxin (CTX) blocks the GTPase activity of some a  subunits 
fixing them in an activated form. The figures are adapted from Simon et al., 1991.
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are localized to the inner surface of the plasma membrane where they serve as 
receptor-mediated signal transducers.
A model for G-protein signal transduction is described in Figure 1.2. When 
GDP is bound the a  subunit associates with the Py subunit to form an inactive 
heterotrimer that binds to the receptor. Monomeric GDP-liganded a  subunits can 
interact with receptors but their association is greatly enhanced by Py. Activation 
follows interaction with ligand bound receptor and the GDP-liganded a  subunit 
responds with a conformational change that decreases GDP affinity, so that GDP 
comes off the active site. The guanine nucleotide release proteins (GNRPs) catalyse 
release of bound GDP, promoting its replacement with GTP in a Mg^+ dependent 
manner (Brandt et al., 1986). The GNRP for the signal transducing G-proteins can be 
considered as a contribution from both the ligand-activated receptor and the py 
subunit. The binding of GTP reduces the affinity of the receptor for the agonist, 
resulting in a Mg^+ dependent dissociation of the Ga-GTP both from the receptor and 
the py. Agonists act to reduce the concentration of Mg^+ required for activation 
(Iyengar et al., 1982). The free Ga-GTP (active conformation) and Py subunits can 
specifically interact with effector proteins such as adenylyl cyclase, phospholipases, 
ion channels etc. The activated state lasts until the GTP is hydrolyzed to GDP by the 
intrinsic GTPase activity of the a  subunit (Rodbell et a l,  1980). The intrinsic rate of 
GTP hydrolysis varies greatly from one type of a  subunit to another. K^at values of 
2-5 min~l have been reported for Gga and G ia (Brandt et al., 1986; Linder et al., 
1990; Carty et al., 1990) while considerably lower values have been detected for G qa 
(Kcat 0 .8  min"l) (Berstein et al., 1992) and G%a (Kcat 0.05 min"^) (Casey et al., 
1990). Once GTP is hydrolysed to GDP, the a  and Py subunits reassociate, become 
inactive, and return to the receptor. Although the py subunit does not bind GTP its 
active lifetime depends on the rate of GTP hydrolysis by an a  subunit.
Fluoride (present as AIF4") is a GTP-independent G-protein activator because 
it binds the nucleotide site adjacent to the P-phosphate of GDP. This mimics the y- 
phosphate of bound GTP and triggers G-protein activation (Bigay et al., 1985). In
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addition, poorly-hydrolyzed analogues of GTP such as guanosine-5'-o-(3- 
thioti’iphosphate) (GTPyS) and guanylyl-imidodiphosphate (Gpp(NH)p) also produce 
G-protein activation due to their resistance to GTPase activity although the reaction 
still requires Mg^+ (Godina et ah, 1983).
Cholera toxin (CTX) and pertussis toxin (PTX) interfere with the GTPase 
cycle as indicated in Figure 1. 2B. Cholera toxin (from Vibrio cholerae ) transfers the 
ADP-ribose moiety from NAD+ to a conserved Arg residue within Gga and Gta. This 
modification requires the presence of an additional protein, ADP-ribosylating factor 
(ARF) (Donaldson et al., 1994) and supresses GTPase activity, thereby locking the 
G-protein in the active GTP bound conformation (Kahn etaL, 1984). Pertussis toxin 
(from Bordetella pertussis ) ADP-ribosylates G-protein a  subunits at a Cys located 
four residues from the C-terminal of G il-3 a ,  G oa and G ta. This modification
Models of G-protein a  subunits have been proposed based on the crystal
13
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appears dependent upon an a p y  heterotrimeric state and results in G-protein 
uncoupling from receptor (Navon et al., 1987).
1.2.2. Structure of G-proteins,
Al g  subunits.
structure of GTP- and GDP-liganded transducin and G il a  and allowed identification 
of potentially important residues in guanine nucleotide binding and the GTP 
hydrolysis reaction (Noel et al., 1993; Lambright et a l, 1994; Coleman et a l, 1994).
The structure of the GTP binding domain comprises of a hydrophobic core of 
alternating p-sheets and hydrophilic a-helices. This structure has been implicated in 
regulating both guanine nucleotide release (GDP) and the binding and hydrolysis of
GTP. A key residue (Arg-178 in G ta) is needed for GTP hydrolysis and so help to set
the GTPase activity (Conklin et a l, 1993b). The helical domain is postulated to restrict 
movement out of and into the guanine nucleotide binding pocket of the core domain. 
To promote the replacement of GDP by GTP the activated receptor potentially moves 
the helical domain, via a conformational change, allowing the exchange of guanine s
nucleotides. The helical domain may also contribute to the effector binding site 
(Coleman et aL, 1994), along with other regions of the GTPase domain but its 
function is still not clear.
The N-terminal region of G-protein a  subunits is important for membrane 
anchorage, lipid modification and interaction with Py subunits. Tryptic digestion 
releases soluble a  subunits missing an N-terminal fragment of 1-2 kDa, suggesting an 
important role for this region in membrane anchorage (Eide et al., 1987). Proteolytic 
cleavage of the 20-29 N-terminal residues of G ta and G oa or deletion of 2-29 from 
Gga inhibits a  subunit interaction with py subunits and receptor dependent activation 
(Navon etaL, 1987; Neer et al., 1988; Journot et al., 1991). Mutational studies of the 
N-terminal 20 residues of G oa have suggested that residues 7-10 have an important 
role in Py interaction independent of myristoylation (Denker etaL, 1992a).
The effector binding region has been mapped only for the pairs Gga/adenylyl 
cyclase and Gta/cGM P phosphodiesterase (Conklin et aL, 1993b). The effector 
binding region of Gga includes and partially overlaps the putative Py binding surface. 
Therefore, it is unlikely that the a  subunit can simultaneously bind effector and py. 
Further, when an effector, such as type 2 adenylyl cyclase, is activated both by a  and 
by py subunits, it is likely that a  and py bind to distinct sites on the enzyme.
The C-terminus is an important site of interaction with receptors and in 
defining the specificity of G-protein-receptor interactions (Conklin et a l, 1993a; Neer 
et al., 1994a). An activated receptor triggers an intracellular response by dramatically 
decreasing the affinity of the a  subunit for GDP, perhaps by moving or twisting the 
C-terminal a  helix to loosen the grip of the a  subunit on GDP. This effect is 
mimicked by deletion of 14 amino acids from the C-terminus of G ga (Denker et al., 
1992b). The Gga point mutation R389P (responsible for the une S49 phenotype) 
located six residues from C-terminus results in a G-protein uncoupled from receptor 
(Sullivan et al., 1987). In addition, mutational replacement of a  subunit C-terminal 
residues alters specificity for receptor interaction (Cerione et al., 1986). For example, 
the G i6 a  subunit interacts with the complement C5a receptor, while the G n a
14
subunit does not. Chimeras of G n a /G i6 0 t with a large portion of the G j^ a  C- 
teiminus did not function as G n a  unless an additional region of G ig a  (residues 2 2 0 - 
240) was present (Lee et al., 1995).
B1 p and y subunits.
The P subunit is predicted to contain two types of structures: an N-terminal 
region thought to form an amphipathic a  helix (Lupas et al., 1992) followed by seven 
repeating units of approximately 40 amino acids (WD-40 repeat) (Simon et al., 1991). 
The WD-40 repeat, {X6-94— [GH—X23-41—WD]|N4-8 ( x  = variable length loop; 
WD = constant length core), consists of a conserved core of 23-41 residues usually 
bounded by Gly-His and Tip-Asp (Neer et al., 1994b).
The p and y subunits bind very tightly to each other and can only be separated 
by dénaturants. The putative a  helix at the N-terminus of P makes up pait, but not all, 
of the py interaction site (Lupas et al., 1992; Garritsen et at., 1994). The N-terminal 
portion of p must lie close to y because it contains a Cys that can be cross-linked to a 
Cys in y (Bubis et al., 1990). However, selectivity (the ability of pi to dimerize with 
y l but not y2) is determined by multiple sites in the WD repeat region, especially 
residues 215-255 in repeat 5 (Pronin et al., 1992; Katz et al., 1995).
The y subunit is predicted to be largely a  helical (Lupas et al., 1992). The y 
subunit is extended along the repeating units of p subunit and held in place by the N- 
terminal a  helix of the P subunit. The prenyl group at the C-terminal of y is likely to 
be on the outer surface of py because it is essential for membrane attachment (Casey et 
al., 1994). Selectivity of the y subunits for different P subunits is determined by a 
stretch of 14 amino acids in the middle of the y subunit (Spring et al., 1994). This 14 
amino acid region contains the Cys that can be cross-linked to P (Bubis et a l,  1990). 
Because the specificity region of y is in the middle of the y molecule, Py could be 
oriented C-terminus to N-terminus or N-terminus to N-terminus.
The a  subunit seems to be able to interact with y as well as P (Rahmatullah et 
al., 1994), so perhaps the surface of py that binds a  subunit to Py blocks the ability 
of py to stimulate effectors, either because G a-G D P induces a conformational change
15
in Py, or because it covers the site of Py-effector interaction. The relationship of the 
G a-G D P binding site on py to the effector-binding site remains to be defined.
1,2,3, Membrane association of G-proteins,
A) Mvristoviation and palmitovlation of a  subunits.
G-protein a  subunits are localized predominantly to membrane fractions 
despite their hydrophilic nature. It has been suggested that py complexes may serve as 
a hydrophobic anchor holding hydrophilic a  subunits (Sternweis et a l ,  1986). 
Interestingly, some a  subunits (Goa, G ii-ga, Gta, Ggusta and G%a) have recently 
been shown to undergo co-translational modification by addition of the 14-carbon fatty 
acid myristate on glycine 2 after cleavage of the N-terminal methionine. Transducin 
undergoes a similar N-terminal modification altliough by heterogenous fatty acids. The 
consensus sequence for fatty acylation is unclear but includes a prerequisite for glycine 
2 and a preference for a hydroxy amino acid such as serine at position 6 (MGXXXS) 
(Jones et al., 1990). Mutagenenesis of glycine 2 to alanine in both G n a  and G oa 
results in non-myristoylated a-subunits whose localization is shifted from the plasma 
membrane to the cytosol, suggesting myristoylation to be necessary for membrane 
attachment and to facilitate binding of Py (Mumby et a l, 1990; Casey et al., 1994).
However, myristoylation is an irreversible modification and thus does not 
serve a regulatory role. The Gq, G i2  and Gg families of G-protein a  subunits are 
membrane bound although they lack the consensus sequence (MGXXXS) for 
myristoylation (Wu et at., 1992a). For these (and other) a  subunits, palmitoylation of 
cysteine residues within the N-terminal region has been recorded (Parenti et al., 1993; 
Degtyarev et al., 1993a, b; Milligan et al., 1995a). In contrast to myristoylation, 
palmitoylation is reversible. Activation of the P2 -adrenoceptor leads to rapid 
depalmitoylation of Gga, and depalmitoylated G§a does not activate adenylyl cyclase. 
Depalmitoylation might thus be a mechanism to turn off Gga and so to desensitize the 
cell to P2-adrenergic stimulation (Mouilliac etaL, 1992).
Prenvlation and carboxvmethvlation of y subunits.
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G-protein P and y  subunits remains tightly associated under non-denaturing 
conditions and y  subunits have been shown to be isoprenylated in the Cys-A-A-X, 
(A= aliphatic residue, X=unspecified) of the C-teiminus which increases protein 
hydrophobicity. Firstly, a long chain isoprenyl group is attached to the Cys after 
which a protease cleaves the AAX residues and the Cys is then carboxymethylated 
(Fung et al., 1990). Different y  subunits are modified with different isoprenyl groups 
as the rod photoreceptor y  subunit (yl) is modified with the C15 farnesyl moiety 
whereas brain y subunit (y2) has a C20 geranylgeranyl modification (Fukada et al., 
1990; Mumby et al., 1990). Blocking isoprenoid synthesis or mutagenesis of the 
crucial Cys in the y subunit prevents C-terminal processing and results in production 
of a py dimer which is both localized to the soluble fraction and functionally 
inactivated (Katz et al., 1992). Prénylation of y subunits is not necessary for py 
formation, but is necessary for membrane attachment of the Py dimer and, perhaps, 
for association with the a  subunit.
1.2.4. Diversity of G-proteins and interaction with effectors.
A) Ga subunits.
Molecular cloning and sequencing techniques have been most productive in 
identifying and classifying new a  subunits. Mammalian a  subunits can be grouped 
into four classes based on amino acid identity (Figure 1.3). 
al Gs family.
The Gs family includes both the Gga and G o lfa  isotypes, which are 
adenosine diphosphate (ADP)-ribosylated by cholera toxin (CTX). So far, four 
molecularly distinct forms of Gga resulting from differential splicing of a single gene 
have been identified (Bray et al., 1986). The Gga gene contains 13 exons and while 
all become incoporated into the long forms (Gga-L), exon 3, encoding 15 amino 
acids, is excluded from the short form (Gga-S). These splice variants probably 
account for the diverse molecular weight forms of Gga but spliced forms appear 
similarly active. Although Gga was identified as the G-protein required for receptor-
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Figure 1.3.
Relationship between mammalian Ga subunits.
The a  subunits are grouped according to amino acid sequence identity with 
branch junctions corresponding to approximate compai ative values for the a  subunits 
indicated. The splice variants of Gga and Ggusta are not included. This diagram is 
adapted from Simon et al., 1991.
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mediated stimulation of adenylyl cyclase, the protein has also been shown to couple to 
activation of dihydropyridine-sensitive Ca^+ channels in cardiac (Mattera et a l,  1989) 
and skeletal muscle (Yatani et a l ,  1987a), inhibition of the Ca^+ pump in liver 
membranes (Jouneaux et a l ,  1993) and inhibition of Na"^ channels in cardiac 
myocytes (Schubert et a l, 1989).
G olfa  shows 8 8 % amino acid homology to Gga. Expression of G olfa  is 
restricted to specific neural tissues and it is enriched in neurons in the olfactory 
neuroepithelium where it is responsible for olfactory regulation of adenylyl cyclase 
(type 3) (Jones et a l, 1987). Golfa is also co-localized with D1 dopamine receptors in 
striatonigral neurons and with adenylyl cyclase type 5 in coipus striatum (Wong et a l, 
1992).
h) Gi family.
Members of Gi family of a  subunits contain sites susceptible to modification 
by pertussis toxin (PTX) (except for G%a) and are therefore expected to mediate 
activation of PTX-sensitive processes. The Gi family is composed of at least three 
closely related Gi-like a  subunits (G ila , Gi2 a  and Giga), Goa, G ta and G%a .
Gi-like G-proteins are widely distributed and are highly expressed in the 
central nervous system and neuronal cell lines (Kim et a l, 1988). Sensitivity to PTX 
as well as reconstitution and heterologous expression have suggested several roles 
including adenylyl cyclase inhibition (Wong et a l ,  1992), PLC-dependent 
phosphoinositide hydrolysis (Ohta et a l, 1985), K+ channel activation (Yatani et a l, 
1988; Godina et a l ,  1987), and inhibition of Ca^+ channel opening (Linder et a l ,  
1990). In addition, Gi3 a  stimulated activity of Na+ channels via an activation of 
phospholipase A] in retinal epithelial cells (Ausiello et a l,  1992) and of large 
conductance renal apical Cl~ channels has been noted (Schwiebert et a l,  1990). Gi2 a  
has been reported to be phosphorylated by PKC (Yatomi et a l, 1992) and to interact 
with mitogen-activated protein (MAP) kinase with mediation via Py (Crespo et a l,
1994).
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biochemical properties distinct from other G-protein a  subunits, including unusual 
M g2+ ion dependence and very slow guanine nucleotide exchange and GTPase
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G o a  is the major G-protein in brain, where it constitutes about 1% of 
membrane protein (Neer et aL, 1984). Closely related to the Gi-like group, 
nevertheless, its kinetics of guanine nucleotide binding is about an order of magnitude 
faster than that determined for the Gi-like proteins. Two variants forms (GoAOt and 
G oga) both with 354 residues, result from differential RNA splicing of a single G oa
'gene with the C-terminal 113 amino acids encoded by alternative use of duplicated 
exons 7 and 8 (Kaziro et al., 1991). The function of G oa remains unsolved, the 
majority of the evidence suggests that this G-protein is involved in the regulation of 
receptor-mediated inhibition of voltage operated Ca^+ channels (Heschler et al., 1987;
Kleuss et a l,  1991). Recent studies have demonstrated selective interactions of G oa 
splice variants with different receptors, P- and y-subunits (Kleuss et a l,  1992; 1993).
A role for G oa coupling to the aiB-adrenoceptor to cause stimulation of PLC- 
dependent phosphoinositide hydrolysis (Blitzer et a l ,  1993) and in K^ channel 
activation have also been reported (Kobayashi et a l, 1990).
Two forms of transducin, transducin 1 (G tia ) and 2 (Gt20 t), were found in
:retinal rod and cone cells respectively (Lerea et a l, 1986). These mediate activation of 
rod- and cone-specific cyclic GMP phosphodiesterases following rhodopsin and opsin 
photoactivation (Stryer et a l,  1986a, b; 1991). A novel transducin-like G-protein, 
gustducin (Ggustot) has been identified from tongue where it is enriched in 
circumvallate, foliate and fungiform papillae (McLaughlin et a l ,  1992) and it is 
considered that a cyclic GMP phosphodiesterase may be involved in its means of 
signal transduction, due to sequence homology in those regions of G-protein a  
subunits known to interact with receptor and effectors (Boon et a l,  1995). G ta  and 
GgustOt each have the amino acid sites for ADP-ribosylation by both PTX and CTX.
The G ^a subunit is found predominantly in brain and platelets (Fong et a l.
1988), however, it mediates inhibition of adenylyl cyclase (types 1 and 5) in a PTX- 
insensitive manner (Wong et a l,  1992; Taussig and Gilman 1995)). G ^a exhibits
f
activity (Casey et al., 1990). In a series of experiments, it has been shown that Gga 
becomes phosphorylated when platelets are activated by phorbol ester or thrombin 
(Carlson et a l,  1989; Loundsbury e ta l ,  1991), suggesting that G za is a substrate for 
PKC. Subsequent reconstitution studies and site-directed mutagenesis of G%a 
demonstrated that PKC stoichiometrically phosphorylates GzOt, predominantly on a 
serine residue near the N-terminus, and that this effect is selective for GzOt, since PKC 
did not lead to phosphorylation of G ia or G qa (Loundsbury et a l,  1993).
c) Gq family.
The Gq family contains the widely distributed G qa and G n a  (Sti'athmann et 
at., 1990) as well as G i4 a ,  G i s a  and Giboc which are more restricted in 
distribution. They lack the site for PTX modification and thus mediate agonist 
stimulated hydrolysis of membrane phosphoinositides by PLC-pl, PLC-p2, PLC-P3 
(Wu et a l ,  1992b; Lee et a l,  1992; Sternweis et a l ,  1992) in a PTX-insensitive 
manner. G i4 a  is found primarily in stromal and epithelial cells (Wilkie et a l,  1991; 
Nakamura et a l,  1991), while G i5 a  and G i6 a  are found in cells of haematopoietic 
lineage. G 15a  is found in murine B lymphocytes (Wilkie et a l,  1991) and G 16 a  in 
human T lymphocytes (Araatruda et a l, 1991). These are likely to represent species 
homologues of the same G-protein.
d) G12 family.
The G i2  family includes G 12a  and G 13a . They are not substrates for PTX 
and like both Gg and Gq family members are not myristoylated. Both G i2 a  and 
G 1 3 a  are widely distributed (Strathmann et a l ,  1991). G\2(X has exhibited an 
increase in arachidonic acid mobilization via phospholipase Aa (PLAa) activity (Xu et 
a l,  1993) and coupling to thromboxane A2 (TXA2) and thrombin receptors in platelet 
membranes provides evidence that both proteins indeed play a functional role in 
receptor-mediated transmembrane signal transduction (Offermanns e ta l ,  1994a, b). 
The involvement of G l3 a  in activating Na+-H*^ exchange has been suggested 
(Voyno-Yasenetskaya et a l, 1994). Other effector functions regulated by members of 
the G i2  family however, remains to be elucidated.
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B) p and y subunits.
In mammals, four distinct P subunit isotypes have been found; p 1 (Fong et 
al., 1987); P2 (Fong et al., 1987); p3 (Levine et a l, 1990); p4 (von Weizsacker et al.,
;
1992). They share more than 80% amino acid sequence identity and molecular mass in f
the range of 35-36 kDa. All of the P subunits share eight amino acid segments. Each 
segment shares a repetitive 40 amino acid sequence motif (WD-40 repeat), p i, p2 and 
p3 are ubiquitously expressed while p4 is abundant in brain and lung tissues. To date, 
seven y subunits have been identified from a variety of tissues with molecular masses 
in the range of 6-10 kDa. yl is highly localized to rod cells of the retina (Gautam et 
al., 1990), while other y subunits are expressed at different levels in all tissues (Cali et 
a l,  1992).
p i interacts with retinal G tia  (Lerea et a l, 1986) and yl or y3 (Peng et a l,
1992) to mediate stimulation of rod cell cyclic GMP phosphodiesterase by
Ik
photoactivated rhodopsin (Stryer et a l,  1991). In GH3 cells p i interacts specifically
■;with GoBOC and y3 to form a G-protein mediating somatostatin receptor-dependent 
inhibition of Ca^"  ^channel activity (Kleuss e ta l ,  1991; 1992; 1993). p i forms dimers 
with each of y l ,  y2, y3 or y5. P l y l ,  p i y 2  and p l y 5  dim ers stim ulate 
phosphoinositide hydrolysis by PLC-p2 (Katz et a l,  1992). p2 forms dimers with
either y2 or y3 subunits and the p2y5 dimer can activate PLC-P2 (Wu et a l ,  1993).
,.3Specific co-expression of p3 has demonstrated interaction with retinal Gt20C (Lerea et §
:ia l,  1989) and y2 or y3 to mediate stimulation of cone cyclic GMP phosphodiesterase 
by phosphoactivated opsin (Peng et a l,  1992). In GH3 cells, ps interacts with GqAOC 
and y4 to induce muscarinic M4 receptor dependent inhibition of Ca^+ channel 
activity. It has also been reported that py activates a cardiac K"^  channel ( I k a c h )  
which is activated by the M2 muscarinic acetylcholine receptor (Wickman et a l,
'1995). In addition, py dimers regulate certain types of adenylyl cyclase; while Py 
inhibits AC-1 activity, they stimulate AC-2 and AC-4 and have no effect on the others 
(AC-3, 5, and 6 ). Inhibition by py is independent of Gga, whereas stimulation by py
$has an underlying prerequisite for the stimulation of adenylyl cyclase by Gga (Tang et
A variety of different approaches have been used to define the specificity of
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al., 1991; 1992). The Py subunit may also act through p2F^-^ or interact with raf-1 
directly to activate mitogen-activated protein (MAP) kinase regulated pathways
(Blumer et al., 1994; Crew et al., 1993; Crespo et al., 1994; Pumiglia et al., 1995).
On the other hand, the py dimer forms a complex with G-protein coupled receptor 
kinases (GRKs) by binding to a py binding domain, which shares sequence homolgy ■'f:r:''with the pleckstrin homology (PH) domain. This results in translocation to a variety of 
G-protein coupled receptors (GPCRs) and their phosphorylation and inactivation 
(Inglese et al., 1995). Phosphoinositide 3 kinase (PI3K) is another enzyme involved 
in signaling processes that can be modulated by py subunits. PI3K phosphorylates 
different substrates on the 3 position of the inositol ring and is regulated by several 
protein tyrosine kinases. Stimulation of PI3K activity by py subunits has been 
reported in platelets and neutrophils (Stephens et al., 1994).
2
1,3. Specificity of receptor-G-protein-effector interactions.
m
coupling between receptors and effectors provided by G-proteins. The methods to 
address this issue include reconstitution of purified proteins (Yatani et al., 1987a;
Cerione et al., 1991), transfection of cDNA (Conklin et al., 1992; Cotecchia et al.,
t1990), PTX sensitivity (Moriarty et al., 1990; Nakamura et al, 1991), the use of C- 
terminal a  subunit antibodies (McFadzean et a l,  1989; Milligan et al., 1990),
.solubilization of native receptor-G-protein complexes followed by immunoblotting
,
(Senogles et al., 1987; Murray-Whelan et al., 1992), agonist-dependent labeling of G- 
proteins with [32p]GTP azidoanilide or [32p]ADP-ribose plus bacterial toxins (CTX,
PTX) (Milligan et al., 1991a; Offermans et al., 1990; Wange et al., 1991) and ■:w2;selective antisense oligonucleotide technology (Kleuss e ta l ,  1991).
Reconstitution and transfection experiments may measure interactions between 
signajing components that are occurring unnaturally compared to native membranes 
but can be controled. The use of reconstitution and transfection methods can be 
exploited to explore the structural basis of receptor-G-protein-effector coupling by
,4:
level of receptor expression and the choice of cell used for transformation, including
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using site-directed mutagenesis of the components. The use of selective antisense 
oligonucleotides was designed to perturb functional coupling of the specific 
components and this is suitable for determining the function of any protein provided 
that assay of its activity is possible in a single cell.
One cell is distinguished from another by the particular complement of 
receptors, G-proteins and effectors that it expresses, although the complement may 
change substantially with developmental or metabolic state. The precise stoichiometry 
among the signaling components can determine the predominant response pathway.
For example, when the porcine M2 muscarinic receptor was transfected into CHO
■cells, the stimulation of phosphoinositol turnover was very dependent on receptor 
number, while inhibition of adenylyl cyclase was similar regardless of receptor 
number (Ashkenazi et al., 1987). The results suggested that in these cells, adenylyl 
cyclase inhibition is limited by enzyme or G-protein, while PLC activation is limited J#
by receptor number.
Conclusions about coupling specificity have been shown to depend on the
Ithe type of G-proteins and effectors the cell contains.
1.4, Aims of research.
The experiments of this study were focused on two questions; one, the 
stoichiometry of interaction among the receptor, G-protein and effector species in
individual cells and how does this relate to the absolute levels of expression of these 
polypeptides? Further, can the effectiveness of cellular signaling be altered by jx 
regulating the levels of expression of these components in a cell?
The other, how is the specificity and selectivity of interaction between 
receptors and effectors via G-proteins defined, especially in terms of the interaction of 
the long splice variant of the thyrotropin releasing hormone (TRH) receptor with 
species variants of the G n o t protein?
.
Chapter 2. 
Materials and Methods.
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2.1. Materials.
All reagents used in this study were of analytical or similar grade and were 
purchased from the following suppliers;
2.1.1. General reagents and Chemicals.
Appligene, Birtley, Durham.
Aquaphenol.
Boehringer Mannheim Ltd., Lewes, East Sussex, England.
Aprotinin, Bovine serum albumin (BSA), Creatine phosphate, Creatine- 
phosphokinase, Dithiothreitol, DNase free RNase, DOTAP (transfection reagent), 
Gpp(NH)p, GTPyS, Thymidine, Triethanolamine hydrochloride, Tris,
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Ï':Calbiochem-Novabiochem Ltd., Beeston, Nottingham, England.
Pansorbin cells.
Cinna Biotecx, Texas, U.S.A.
RNAzol TM B.
Costal Scientific Corporation, Cambridge, MA, U.S.A. )
Nitrocellulose (0.45 pM pore size).
Difco, Detroit, Michigan, U.S.A.
Bacto agar, Bacto tryptone. Yeast extract.
Formachem (Research International) pic., Strathaven, Scotland, U.K.
D-Glucose.
F.S.A. Lab. Supplies, Loughborough, England.
Acetic acid (glacial), Acrylamide, Folin-Ciocalteu's phenol reagent, N, N’- 
methylene bisacrylamide. Hydrogen peroxide.
1';.Genetic Research Instrumentation Ltd., Essex, England.
Fuji RX X-ray film. |
Gibco Life Technologies, Paisley, Scotland, U.K.
Agarose, 1 kb DNA ladder, 123 bp DNA marker, Lipofectin reagent, pSV2- |Ineo, Ultrapure urea.
Invitrogen, San Diego, CA, U.S.A.
MC1061/P3, pcDNAl, pcDNA3.
Koch-Light Lab. Ltd., Haverhill, Suffolk, England.
Dimethylsulphoxide (DMSO), Magnesium sulphate, Sodium potassium
tartrate.
May and Baker, Dagenham, England.
Ammonium persulphate.
National Diagnostics, Aylesbury, Buckinghamshire, England.
"Ecoscint" scintilation fluid.
Pharmacia Biotech Inc., U.S.A.
First strand cDNA synthesis kit.
Porton Products, Porton Down, Wiltshire, England.
Pertussis toxin.
Promega Ltd., Southampton, England.
Bacterial strain JM109, Calf intestinal alkaline phosphatase (CIAP), DNA 
Clean-Up system, DNA maxipreps, DNA minipreps, PCR preps, T4 Ligase, all 
resti'iction endonucleases.
Research Biochemicals International, Natick, MA, U.S.A.
Bromoacetyi alprenolol methane (BAAM).
Schering Health Care Ltd., Sussex, England.
Iloprost.
Scottish Antibody Production Unit, Lanarkshire, Scotland, U.K.
Horseradish peroxidase conjugated donkey anti-rabbit IgG.
Sigma Chemical Company, Poole, Dorset, England.
Alumina (neutral). Antipain, Ampicillin, Aprotinin, Arginine hydrochloride, 
ATP (disodium salt), Benzamidine, Bromophenol blue. Cholera toxin, Coomassie 
blue R-250, cAMP (sodium salt), Dowex AG50 W-X4 (200-400 mesh), [D-Ala^, D- 
Leu^j-Enkephalin (acetate salt) (DADLE), Forskolin, Geneticin, Gelatin (Type A), 
Imidazole, Isoprenaline, Low melting point agarose. Nicotinamide adenine
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dinucleotide (NAD), N-ethylmaleimide, Nonidet P-40 (NP-40), 7-deoxycholic acid, 
Ortho-dianisidine dihydrochloride, Phenyl-methyl-sulfonyl fluoride (PMSF), Protein 
A Sepharose, Propranolol, Sodium azide, Soybean tiypsin inhibitor, N, N, N', N',- 
Tetramethylethylene-diamine (TEMED), Thimerosal, Thymidine, Triton X-100, 
Trypsin, Prestained SDS Molecular Weight Markers consisting of (%2-Macroglobulin 
(180 kOa), (3-GaIactosidase (116 kDa), Fructose-6 -phosphate kinase (84 kOa), 
Pyruvate kinase (58 kDa), Fumaiase (48.5 kDa) Lactic dehydrogenase (36.5 kDa), 
Triosephosphate isomerase (26.6 kDa).
Whatman International Ltd., Maidstone, England.
Chromatography paper (3 mm). Filter paper (No 1), GF/C Glassfibre filters.
Tissue culture flasks (25, 75 cm^).
All other reagents and chemicals used were analytical grade and obtained from 
BDH (Dorset, Poole, England) and Fisons Scientific Equipment 
(Loughborough, Leicestershire, England).
2.1.2. Radiochemicals.
Amersham pic., Amersham, Buckinghamshire, England.
[8~3H]Adenosine 3', 5'-cyclic phosphate, ammonium salt. Adenosine 5'-[a- 
32p] triphosphate, triethylammonium salt, [propyl-2, 3-^HJDihydroalprenolol, [12- 
3H]Forskolin, [2-^H]D-myo-Inositol, [5, 6 (N)-^H]Prostaglandin E l.
Du Pont NEN Ltd., Stevenage, Hertfordshire, England.
[Adenylate-32p]Nicotinamide adenine dinucleotide, tri-ethanol-ammonium salt, 
[l25i]Goat anti-rabbit IgG, [L-proline 3, 4-^H(N), histidyl-3R(N)]Thyrotropin 
releasing hormone (TRH).
ICN Biomedicals, Inc., Irvine, CA, U.S.A.
Tran [35S]-Label™.
2.1.3. Tissue Culture Plasticware.
Bibby Science Products Ltd., Stone, Staffordshire, England.
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Tissue culture flasks (25, 75 cm2).
2.1.4. Cell culture media.
2.1.5. Standard buffers.
Hank's bufferred saline (Hank's) (pH 7.4).
1.26 mM Calcium chloride (hexahydrate), 0.5 mM Magnesium chloride
aCostar, Cambridge, MA, U.S.A.
Bio-freeze vials.
Elkay Products, Shrewsbury, MA, U.S.A.
Centrifuge tubes (50 ml).
Nunc, Roskilde, Denmark.
Bio-freeze vials. Centrifuge tubes (50 ml).
Gibco Life Technologies, Paisley, Scotland, U.K.
Dulbecco's modification of Eagle's medium (10 x) (DMEM), Inositol free
■DMEM, Newborn calf semm. Glutamine (200 mM), Ham's F-10 medium, HAT (50
;
x): Hypoxanthine (0.1 mM), Aminopterin (1 mM), Thymidine (16 mM), Penicillin
;(100 I.U./ml) and Streptomycin (100 mg/ml) solution (100 x). Sodium bicarbonate 
(7.5 %).
ICN Biomedicals, Inc., CA, U.S.A.
DMEM: (-) methionine and cysteine.
Imperial Labs., West Portway, Andover, Hants, England.
Foetal calf semm (FCS), Newborn calf semm.
Sigma Chemical Company, Poole, Dorset, England.
Controlled process semm replacement-3 (CPSR-3).
(hexahydrate), 0.4 mM Magnesium sulphate (heptahydrate), 5.37 mM Potassium 
chloride, 137 mM Sodium chloride, 4.2 mM Sodium hydrogen carbonate, 0.35 mM
iSodium di-hydrogen phosphate.
Hank's buffered saline with glucose and BSA (HBG).
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Hank's buffer (pH7.4) containing 10 mM D-Glucose and 1% (w/v) BSA 
(fraction V).
Phosphate buffered saline (PBS) (pH 7.5).
2.7 mM Potassium chloride, 137 mM Sodium chloride, 1.5 mM Potassium 
dihydrogen orthophosphate, 8 mM Disodium hydrogen orthophosphate 
(heptahydrate).
Sterile trypsin solution for tissue culture.
Trypsin was prepared as a solution of 0.1 % (w/v) trypsin, 0.025 % (w/v)
EDTA and 10 mM Glucose in PBS (pH 7.5). The solution was filtered through a 
sterile 0.22 mM membrane (flow pore D), prior to aliquoting into sterile tubes and 
storing at -20 °C.
2.2. Experimental Methods.
2.2.1. Cell Culture.
A) Cell growth.
The cells were grown in continuous monolayer culture in 75 cm^ sterile tissue 
culture flasks in sodium pyruvate free Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 2 mM L-glutamine, 100 I.U./ml penicillin, 100 p g / m l  
streptomycin, 5 or 10% (v/v) serum (as indicated in Table 2.2.1) which had been heat 
inactivated at 56 °C for 90 min. Buffering of the medium was achieved by the addition 
of 0.375% (v/v) sodium bicarbonate and growing the cells in an atmosphere of air:
CO 2 in the ratio of 95%: 5%. Cells were incubated at 37 °C in a VSL incubator 
(Scotlab, Coatbridge, Scotland) with change of medium regularly until confluent.
NG108-15 mouse neuroblastoma x rat glioma hybrid cells, a kind gift from
,Dr. W. Klee (N.I.H., Bethesda, M.D., U.S.A.) were grown to confluency according 
to the method of Hamprecht et a l,  1985. NG108-15 cells, pN clones, and AC clones 
were grown in DMEM which containing 5% (v/v) (for NG108-15) or 10% (v/v) (for 
pN and AC clones) controlled process semm replacement-3 (CPSR-3). The medium 
was further supplemented with HAT; Hypoxanthine (0.1 mM), Aminopterin (1 mM)
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and Thymidine (16 mM) as a selection mai’ker. Mouse NCB20 neuroblastoma (Leigh 
et al., 1985), human SH SY5Y and human IMR-32 neuroblastoma cells were grown 
in tissue culture as described previously (Ross et a l, 1985).
Table 2.2.1. Characteristics of the cell lines used.
Cell types Selection markers Remarks
NG108-15 5% CPSR-3, HAT. Mouse/Rat hybrid cell.
PN Clones 
(PN17, pN22)
10% CPSR-3, HAT, 
800 jig/ml geneticin.
N G l08-15 expressing 
p2-adienoceptor.
AC clones 
(AC 2.4, 
AC2.7)
10% CPSR-3, HAT, 
800 pg/ml geneticin,
200 pg/ml hygromycin B.
NG108-15 expressing 
p2-adrenoceptor and 
adenylyl cyclase type 2 .
HEK-293 5% Foetal calf serum. Human embryonic 
kidney cell.
Clone E2 5% Foetal calf serum, 
800 pg/ml geneticin.
HEK-293 expressing 
the long isoform of the 
rat TRH receptor.
Clone E2M11 5% Foetal calf semm, 
800 pg/ml geneticin,
200 pg/ml hygromycin B.
HEK-293 expressing 
the long isoform of the 
rat TRH receptor and 
mouse G not.
GH3 5% Foetal calf semm. Rat pituitary cell.
COS-1 10% Foetal calf semm. Monkey cell 
for transient 
transfection.
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Passaging of confluent cell cultures.
Confluent cells (approximately 1 xlO^ cells per 75 cm2 flask) were trypsinized 
using 0.1% (w/v) trypsin, 0.67 mM EDTA and 10 mM glucose in PBS (pH 7.5).
#
Human embryonic kidney HEK-293 and rat pituitary GH3 cells were obtained 
from the American Tissue Type Collection. HEK-293 cells, E2 clone (HEK-293 cells: 
co-transfected with the long splice variant of the rat TRH receptor and geneticin 
sulphate resistance genes) and E2M11 clone (E2 clone: co-transfected with the mouse 
G l i a  and hygromycin B resistance genes) were grown in DMEM containing 5% 
foetal calf serum. GH3 cells were grown in Ham's F-10 medium (Ham et a l,  1963) 
supplemented with 5% foetal calf serum (FCS) as described by Tashjian et a l,  1979. 
Monkey COS-1 cells were grown to confluency in DMEM medium supplemented with 
10% (v/v) foetal calf serum.
To minimise cell reversion, several transfected clones were routinely passaged 
in DMEM containing geneticin sulphate (800 pg/ml) or hygromycin B (200 pg/ml). I
When the cells were detached from the surface of the flask, trypsinisation was 
terminated by the addition of two volumes of growth medium. This cell suspension 
was centrifuged at 800 x gav in an MSE centaur centrifuge for two minutes to pellet 
the cells. The cell pellet was resuspended in growth medium and plated out as 
required. Each flask of cells was split 1: 7 usually into new flasks.
Cl Preservation of cell lines.
Confluent cells were removed from the surface of the flask by trypsinisation
sulphoxide (DMSO) in CPSR-3 (for NG108-15 cells, pN clones and AC clones) or
and the cells resuspended in freezing medium, which consisted of 8% (v/v) dimethyl
8 % (v/v) DMSO in FCS (for COS-1 cells, HEK293 cells, E2 and E2M11 clones). 
This suspension was aliquoted in 1 ml volumes into Bio-freeze vials. The cells were 
frozen overnight at -80 °C, packed in cotton wool to prevent formation of ice crystals 
in the cells and then transferred to liquid for storage.
Cells to be brought up from liquid N2 storage were thawed immediately at 37
°C, resuspended in 10 ml of appropriate growth medium, and centrifuged at 800 x gav
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in an MSE centaur centrifuge for two minutes to pellet the cells. The cell pellet was 
resuspended in growth medium and plated out in a final volume of 10 ml in a 7 5  cm^ 
flask.
D) Cell harvesting.
When adherent cells were confluent or the particular treatment time had 
elapsed, growth medium was removed from the flask and 10 ml of ice-cold PBS 
added. Cells were harvested by gentle washing of the surface of the flask or by 
scraping the monolayer into the PBS, collected in a 50 ml conical tube and centifuged 
at 800 X gav 4 °C in a Beckman TJ6  centrifuge for 10 min. The resulting cell pellet 
was resuspended in 40 ml of ice-cold PBS and re-centrifuged. The final pellet was 
stored at -80 °C until required. Pellets which had been stored for up to one year were 
found to retain full activity.
2.2.2. Preparation of membrane fractions.
A) Preparation of crude plasma membranes.
Membranes were prepaied according to the method of Koski et al., 1981b. 
Frozen cell pastes were thawed and suspended in 4 ml of ice-cold TE buffer (10 mM 
Tris-HCl, 0.1 mM EDTA, pH 7.4) and transferred to a pre-chilled glass homogeniser 
tube. The cells were then homogenised in a Potter-Elvejhem homogenisor with 25 
up/down strokes of a teflon pestle, on ice. The homogenates were centrifuged at 500 x 
gav for 10 min at 4 °C in a Beckman L5-50B ultracentrifuge with a type Ti 50 rotor to 
remove unbroken cells and nuclei. Crude plasma membranes were obtained by 
centrifugation of the supernatant at 48, 000 x gav for 10 min at 4 °C, resuspension of 
the resulting pellet in 5 ml of the ice-cold TE buffer and a repeat centrifugation at 48, 
000 X gav for 10 min at 4 °C. The pellet was resuspended in TE buffer to give an 
approximate protein concentration of 1-3 mg/ml, aliquoted and stored at -80 °C until 
required.
In some experiments membranes were prepared in the presence of an anti- 
proteolytic cocktail consisting of benzamidine (0.5 mg/ml), leupeptin (11.5 pM ),
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soybean trypsin inhibitor (2  pg/ml), PMSF (0.5 mM), pepstatin A (1.5 pM) and 
antipain (1.5 pM).
Preparation of plasma membrane and cytoplasmic fractions.
Ceil pastes were homogenised in 1 ml ice-cold TE buffer to prevent excessive 
dilution of the resulting cytoplasmic protein. Homogenates were centrifuged at 500 x 
gav for 10 min as described above. The resulting supernatant was transferred to 11 
mm X 34 mm centrifuge tubes and placed in a TLIOO rotor and centrifuged at 200,000 
X gav  for 30 min at 4 °C in a Beckman TLIOO tabletop-ultracentrifuge. The 
supernatant (designated "cytoplasmic fraction") was retained and aliquoted. The pellet 
(designated " plasma membrane fraction") was resuspended in TE buffer to give an 
approximate protein concentraton of 1-3 mg/ml and aliquoted. Both fractions were 
stored at -80 °C until required.
2.2.3. Subcelluar fractionation by sucrose density gradient.
Subcellular fractionation was performed as described by Svoboda et al., 1994. 
Cells were harvested by centrifugation at 900 x gav 4 °C for 10 min in a Beckman TJ- 
6  benchtop centifuge, washed twice in 140 mM NaCI, 20 mM Tris-HCl, 3 mM 
MgCla, 1 mM EDTA, pH 7.4 and then frozen at -80 °C for at least 2 h. Frozen cell 
pastes were thawed, resuspended in 2.5 ml of ice-cold TME buffer (20 mM Tris-HCl, 
3 mM MgCl2 , 1 mM EDTA, pH 7.4) and then homogenized using a Potter-Elvejhem 
homogenize!" (Teflon pestle-Glass homogenizer) on ice. 2 ml homogenate was layered 
on the top of a discontinuous sucrose density gradient consisting of (from top to 
bottom) 19% (by mass; 5 mi), 23% (5 ml), 27% (5 ml), 31% (5 ml), 35% (5 ml) and 
43% (10 ml) sucrose, 20 mM Tris-HCl, 3 mM MgCl2 , 1 mM EDTA, pH 8.0. The 
gradients were centrifuged for 30 min at 27, 000 rpm in a Beckman L5-50B 
ultracentrifuge with a type SW 28 rotor (acceleration and deceleration speed set to 4). 
The density gradient was fractionated manually from the meniscus (fraction 1-7, 5 ml 
each). The first 5 ml (fraction 1) represented an interphase between the overlayed 
homogenate and 19% (w/v) sucrose. The gradient pellet (fraction 8 ) was suspended
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by rehomogenation in 1 ml TME buffer. The gradient fraction were frozen at -80 °C 
until use.
2.2.4. Solubilization of membrane protein.
This assay was performed using a modification of the reconstitution assay 
described by Milligan et a l ,  1985. 200-400 \il of the solubilization buffer consisting 
of 1% (w/v) sodium cholate, 10 mM Tris-HCl (pH 7.4), 0.1 mM EDTA was added 
directly to the particulate cell fraction (crude membrane) described in chapter 2 .2 .2 . 
and resusupended by passing the sample a few times through a 2 0 0  pi pipette tip. 
Samples were incubated for 1 h at 4 °C and centifuged at 200, 000 x gav 4 °C for 30 
min in a Beckman TLIOO tabletop ultracentrifuge to generate a solubilized fraction 
(supernatant fraction) and a particulate fraction containing any insoluble material such 
as proteins which had formed aggregated masses. The solubilized supernatant fraction 
and insoluble pellet were retained and resuspended in a known volume of Laemmli 
sample buffer (5 M urea, 0.17 M SDS, 0.4 M DTT, 50 mM Tris-HCl (pH 8.0), 
0 .0 1 % bromophenol blue) so that exactly equivalent amounts of solubilized and 
insolubilized fractions could be analysed by western blotting.
2.2.5. Determination of protein concentration.
Protein concentrations were determined by the method described by Lowry et 
aL, 1951.
Stock solutions :
A) 2% (w/v) Sodium carbonate in 0.1 M sodium hydroxide.
B) 1% (w/v) Copper sulphate
C) 2% (w/v) Sodium potassium tartrate
Just prior to use, the stock solutions were mixed in the following ratio. A): B):
C), 100: 1; 1 to produce solution D. Protein standards were prepaied using various 
amounts of 1 mg/ml bovine serum albumin (fraction V), and a standard curve 
constructed up to 30 pg BSA, in duplicate. Unknown amount of proteins were
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assayed in 5 and 10 pi volumes in duplicate. 1 ml of solution D was added to each 
sample, mixed and left at room temperature for 10 min. 100 pi of Folin's Ciocalteau
I.reagent diluted 1: 1 with dH2 0  was added to each sample, mixed and allowed to stand ifor a further 20 min. The absorbance of each sample was assessed spectro- 
photometricaily at 750 nm in an LKB Biochiom Ultraspec II spectrophotometer.
. ,3
2.2.6. Production of antipeptide antisera.
All antisera were generated against synthetic peptides, essentially as described 
by Goldsmith et a l ,  1987. This section is included for information purposes, as I did 
not perform this tecnique. aSynthetic peptides were obtained from Dr. C. G. Unson, the Rockerfeller
S.:U niversity, New York, NY, U.S.A. with the exception of the peptide #
NLKLEDGISAAKDVK (IM), which was synthesised by Dr. A. I. Magee,
3N.I.M.R., Mill Hill, London; the peptide KNNLKECGLY (I3B) was obtained from §
Biomac Ltd., Glasgow, and the peptide YLTDVDRIATVGY (E976) which was a gift
,:w
from Dr. John Exton, Vanderbilt University, Nashville, TN, U.S.A. An anti-peptide 
antiserum raised against the sequence IGARKPQYDIWGNT which is highly 
conserved in all currently and molecularly identified hormone regulated adenylyl
■cyclase isoforms was obtained from Prof. Ravi Iyengar, Mount Sinai School of 
Medicine, New York, NY, U.S.A.
3 mg of the appropriate peptide and 10 mg of keyhole limpet haemocyanin 
were dissolved slowly in 1 ml of 0.1 M phosphate buffer pH 7.0. 0.5 ml of 21 mM
, ' 3
glutaraidehyde (also in 0.1 M phosphate buffer, pH 7.0). This was then added 
dropwise with stirring and the combined 1.5 ml incubated overnight at room 
temperature.
The 1.5 ml solution was mixed with an equal volume of complete Freund's 
adjuvant and briefly sonicated with a Branson 'soniprobe' (Type 7532B). 1 ml
::ï
3
aliquots of the resulting emulsion were injected in multiple subcutaneous sites in New 
Zealand White rabbits. Four weeks later each animal received a booster immunization
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with material identically prepared, except one half as much keyhole limpet 
haemocyanin and peptide were injected in incomplete Freund's adjuvant.
Bleeds were performed monthly with approximately 15 ml taken from the ear 
artery and collected in a glass universal. Blood was left to clot overnight at 4 °C and 
the plasma removed and centrifuged at 1000 x gav in a Beckman TJ6  centrifuge for 10 
min to pellet any remnants of the clot. The supernatants thus produced were aliquoted 
into 250 jil volumes and stored at -80 °C until use.
A range of antisera used in this study were produced in a similar manner. 
These are summarised in table 2.2.2.
Table 2.2.2. Anti G-protein antipeptide antisera.
G protein Antiserum
Antiserum Peptide Sequence Sequence identifies
IM NLKEDGISAAKDVK G oa 22-35 G oa
SO KENLKDCGLF Tda 341-350 Tda, G il a , Gi2 a
I3B KNNLKECGLY G isa  345-354 G isa
CS RMHLRQYELL G sa 385-394 G sa
CQ QLNLKEYNLV Gqa 349-359 G qa, G l i a
IQB EKVTTFEHQYVNAIKT Gqa 119-134 G qa
E976 YLTDVDRIATVGY G l i a  160-172 G l i a
pN MSELDQLRQE Gp 1-10 P1,P2
AC IGARKPQYDIWGNT Adenylyl
cyclase.
2.2,7. Labelling of cells with Tran [^^S]-label^^.
When cells were approximately 60% confluent on 6  well tissue culture plates, 
the growth medium was replaced with 1.0-1.5 ml of 1: 3 (v/v) DMEM: (-) methionine 
and (-) cysteine DMEM (ICN Biomedicals, Inc.) supplemented with 50 pCi/ml Tran
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[35s]-label™ and semm and then incubated for 20-48 h. For treatment of agonist, the 
cells were washed twice with 1 ml of growth medium and then a fresh 1.5 ml of 
DMEM containing agonist was added to each well for an appropriate time. To lyse the 
cells, 200 pl/well of 1% SDS was added to the cells, the cells were scraped and 
transferred to 2 ml screw-cap eppendorf tubes. These were boiled in a heating block 
for 2 0  min to denature the proteins and tubes left at room temperature for 2  min to 
allow to cool. After a pulse spin on a micro-centrifuge, the lysates were kept at -80 °C 
until further use. i
2.2.8. Immunoprécipitation of G-protein a  subunits.
Immunoprécipitations were perfomed using a modification of the method
described by Rothenburg et a i ,  1988. Membranes were extracted by the addition of 
100 pi Pansorbin and 800 ml Kahn’s solubilization buffer (1% Triton X-100, 10 mM 
EDTA, 100 mM NaH2P 0 4 , 10 mM NaF, 100 pM NagVOa, 50 mM HEPES (pH 
7.2)) containing 2 mM phenylmethane sulphonyl fluoride (PMSF), 10 pg/m l 
leupeptin, 10 pg/ml aprotinin. After incubation for 1 h at 4 °C, non-solublilized
material was removed by centrifugation at 13, 000 rpm, 4 °C for 10 min. 
Immunoprécipitation was achieved by the addition of 10 pi of the relevant G-protein 
antiserum and incubation for 12 h at 4 °C. Subsequently, 100 pi of the protein A 
conjugated to agarose (50% slurry in PBS, Sigma) was added and the incubation 
continued for a further 2-5 h with occasional mixing. Immuno-complexes were 
collected as a protein A-agaiose pellet by centrifugation at 13, (X)0 rpm for 2 min. The 
pellet was washed 2 times with 1 ml of Kahn's immunoprécipitation washing buffer 
(1% Triton X-100, 0.5% SDS, 100 mM NaCl, 100 mM NaF, 50 mM NaH2PÛ4 , 50 
mM HEPES (pH 7.2)) and resuspended in Laemmli sample buffer (5 M urea, 0.17 M 
SDS, 0.4 M DTT, 50 mM Tris-HCl (pH 8.0), 0.01% bromophenol blue). After 
boiling for 5 min, samples were resolved by SDS-PAGE. The gels were stained with
■Coomassie blue R-250, destained, dried and then autoradiographed as described in
2.2.9. Preparation of samples for electrophoresis by TCA/deoxy- 
cholate precipitation.
The required amount of crude plasma membranes or cytoplasmic fractions, as 
indicated for each experiment, were taken and prepared for SDS-PAGE by sodium
I
deoxycholate/trichloroacetic acid precipitation; 6.25 p i of 2% (w/v) sodium 
deoxycholate was added to each sample, followed by 750 pi of dH2 0 , then 250 pi of 
24% (w/v) trichloroacetic acid. The samples were vortexed briefly and incubated on 
ice for 15 min before being centrifuged on an MSE microcentrifuge at 13,000 rpm for 
5 min. The supernatants were removed and the pellets dissolved in 20 pi of 1 M Tris 
base followed by 20 pi of Laemmli buffer (mentioned in 2.2.8). The sample was then
ready for loading onto the SDS-polyacrylamide gel.
2.2.10. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE).
Protein separation was achieved using the discontinuous SDS- polyacrylamide 
gel electrophoresis (SDS-PAGE) system described by Laemmli et al., 1970 and 
modified by Milligan et aL, 1985.
A) Lower resolving gel : 10% (w/v) SDS-PAGE.
Î 'Stock solutions /stored at 4
Solution A: 1.5 M Tris, 0.4% (w/v) SDS, pH 8.8  with HCl. 
Solution B: 0.5 M Tris, 0.4% (w/v) SDS, pH 6.8  with HCl. 
Solution C: 30% (w/v) Acrylamide, 0.8% (w/v) N, N'-methylene 
bisacrylamide.
Solution D: 50% glycerol
Solution E: 10% (w/v) Ammonium persulphate (freshly prepared). 
Solution F: N, N, N', N'-Tetramethylenediamine (TEMED).
Reservoir Buffer (pH 1.5): 0.025 M Tris, 0.192 M Glycine, 0.1% (w/v) SDS.
10% (w/v) acrylamide/0.25 % (w/v) N, N'-methylene-bis-acrylamide gels 
were prepared from the stock solutions as follows:
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Solution Volume (mil
A 6
C 8
D 1.6
E 0.09
F 0.008
To a final volume of 24 ml with dH20.
The solution was immediately mixed and poured into a Bio-Rad Protean ™  j 
electrophoresis system (Bio-Rad Laboratories Ltd., Watford, Herts), which consisted 
of 180 mm x 160 mm glass plates with 1.5 mm spacers. The gel was layered with 
0.1% (w/v) SDS to exclude air and left to set at room temperature for approximately 
2 h.
B) Lower resolving gel : 4-8 M Urea gradient SDS-PAGE.
In order to maximise separation of each G-protein a  subunit, urea gradient 
SDS-PAGE was carried out as a modification of the method described by Scherer et 
aL, 1987 and Codina et aL, 1991 using 160 mm x 200 mm gels and a Bio-Rad 
Protean ™  II system. Resolving gels containing a linear 4-8 M urea gradient were 
fashioned by preparing stock solutions of acrylamide (30% (w/v) acrylamide, 0.15% 
(w/v) N, N'- methylene bisaciylamide) and solution A (as above) in both 4 M and 8 M 
urea. This gave final concentrations of 12.5% (w/v) acrylamide, 0.0625% (w/v) N, 
N'-methylene-bisacrylamide, 0.375 M Tris HCl (pH 8 .8 ), 0.1% (w/v) SDS. The two 
mixtures were polymerized by the addition of 3 pi of TEMED and 15 pi of fresh 10% 
(w/v) ammonium persulphate, then the 4 M and 8 M urea mixtures were quickly added 
to the two 20 ml chambers of a gradient maker separately. The gradient was pumped 
into the gel plates and the gel allowed to polymerize overnight. Upper stacking gels 
were as described in 2.2.10.D and electrophoresis was carried out as described in
2.2.10.E.
C) Lower resolving gel ; 6 M urea SDS-PAGE.
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In order to separate species variants of G qa and G n a ,  membranes were
resolved by SDS-PAGE in 160 mm x 200 mm slab gels using 10 % (w/v) aciylamide,
0.0625% (w/v) N, N'-methylene-bisacrylamide gels containing a final concentration 
of 6 M urea. The gel was layered with 0.1% (w/v) SDS to exclude air and left to set at 
room temperature for 5-6 h. After polymerisation, upper stacking gel was layered as 
described in 2.2.10.D and electrophoresis was carried out as described in 2.2.10.E.
D) Upper stacking gel.
Solution Volume (mil
B 3.75
C 1.5
E 0.15
F 0.008
To a final volume of 15 ml with dH2 0 .
The solution was mixed, layered on top of the resolving gel and allowed to 
polymerize around a 15 well teflon comb. After polymerization, samples were loaded 
onto each well using a Hamilton microsyringe (Hamilton Co., Reno, Nevada, 
U .S.A .).
El Electrophoresis.
Molecular mass determinations were based on prestained SDS molecular 
weight markers (Sigma Chemical Company). The electrophoresis of 10% (w/v) 
acrylamide gels was performed at 60 volts until the bromophenol blue dye front was 
0.5 cm from the bottom, while, 12.5% aciylamide 0.0625% bis-acrylamide gels 
containing a linear gradient of 4-8 M urea or 6 M urea were exposed to 100 volts until 
the prestained lactic dehydrogenase molecular weight marker was 5 cm from the 
bottom.
FI Staining of SDS-PAGE gels.
After electrophoresis, the gel was soaked in staining solution which consisted 
of 0.1% (w/v) Coomassie blue R-250 in 50% (v/v) H2O, 40% (v/v) methanol, 10% 
(v/v) glacial acetic acid and gently shaken on a rotary shaker for 1 h. The stain solution
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was discarded and then frequently changed with destaining solution (identical to 
staining solution except lacking Coomassie blue R-250) until the proteins were 
apparent on the gel as discrete bands.
2.2.11. Autoradiography.
After staining gels as described above, the gels containing [^2p].labelled 
proteins or Tran [35S]-labelled proteins were dried onto Whatman No. 3 chromato­
graphy paper under a vacuum line attached to a Bio-Rad 583 gel drier at 80 °C for 1 h. 
The dried gel was placed next to Fuji X-ray film in a cassette with intensification 
screens for various periods at -80 °C, or Kodak X-O-mat X-ray film in a cassette for 
up to three days at room temperature. Films were developed using either a Kodak X- 
o-mat developing machine with Kodak LX 24 developer and FX 40 fixer for Fuji X- 
ray film, or a Fuji BAS 1000 phosphorimager linked to an Apple Macintosh Quadra 
650 microcomputer for Kodak X-O-mat X-ray film.
Analysis of incoiporation of radioactivity into the polypeptides of interest was 
performed by scanning the autoradiographs with a Bio-Rad scanner driven by an 
Olivetti M 24 personal computer or with a Bio-Rad Model GS-670 Imaging 
Densitometer which linked to a Canberra Packard Instant Imager model 2024 and an 
Apple Macintosh Quadra 800 microcomputer. Absorption was measured in arbitrary 
units.
4
I2.2.12. Western Blotting.
Proteins were separated under appropriate resolving conditions on SDS- 
polyacrylamide gels overnight at 60 V or 100 V and then transferred to nitrocellulose 
membranes for 2 h at 1.5 mA in an LKB transblot apparatus with blotting buffer 
which consisted of 0.192 M glycine, 25 mM Tris, 20% methanol using a modification 
of the method of Towbin et aL, 1979. The nitrocellulose membrane was then 
"blocked" in 5% (w/v) porcine gelatin in PBS (pH 7.5), containing 0.004% (w/v) 
thimerosal as an anti-bacterial agent at 37 °C for a minimum 2 h. The gelatin/PBS was 
removed and the membrane was washed three times with 100 ml dH2 0 . The
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nitrocellulose was then incubated with the appropriate dilution of antipeptide 
antiserum, diluted in 1% (w/v) porcine gelatin in PBS (pH 7.5), containing 0.2% 
(v/v) non-ionic detergent Nonidet P-40 (NP-40) for at least 2 h at 37 °C. The primary 
antiserum was then removed and the nitrocellulose membrane given two washes with 
PBS (pH 7.5)/0.2% (v/v) NP-40 for 10 min, after which the blot was incubated with 
a second antibody (horseradish peroxidase conjugated donkey anti-rabbit IgG) at a 
dilution of 1: 200 in 1% (w/v) gelatin/PBS (pH 7.5)/0.2% (v/v) NP-40 and the 
nitrocellulose membranes were incubated for 2 h at 37 °C. The secondary antiseaim 
was removed and the blots washed three times with PBS (pH 7.5) containing 0.2% 
(v/v) NP-40 for 10 min and then three times with PBS for 10 min. The blot was then 
developed in 40 ml of PBS (pH 7.5) with 0.02% (w/v) O -dianisidine dihydrochloride 
as substrate for detection of the antibody complex. Development of the immunoblot 
was initiated by the addition of 20 pi of H2O2 (30% (v/v)), and then stopped by 
immediately immersing the blot in 1 % (w/v) sodium azide. The developed immunoblot 
was rinsed in dH2 0  and allowed to diy.
2.2.13. Quantification of the primary immunoreactive signal with an 
[l^^IJ-labelled secondary antibody.
After incubation of the immunoblot with a non-radioactive primary antisemm, 
an -labelled goat anti-rabbit IgG (0.05-0.1 pCi/ml) was prepared in a small tube 
as described in 2 .2 .1 2  for the primary antipeptide antisemm and the immunoblot then 
replaced in this secondary antibody. The immunoblot was then incubated at 37 for a
minimum of 2  h, the antibody was discarded and the nitrocellulose washed as 
described in 2.2.12. During the washing procedure the immunoblot was monitored to
assess the background levels of incoporation of and the wash conditions altered 
accordingly to achieved a low background signal. The immunoblot was dried and 
autoradiography was then performed as described in 2 .2 .11 .
2.2.14. Quantitation of immunoblots.
4 3
Following western blotting, the developed immunoblots were scanned with 
either a Shimadzu CS-9000 dual wavelength flying-spot laser densitometer on 
reflectance mode at 450 nm and analysed on a Shimadzu FDU-3 central processing 
unit or with a Bio-Rad GS-670 imaging densitometer to enable quantitation of the 
immunoblots. Background was subtracted by scanning equivalent sized areas of 
nitrocellulose which did not contain immunoreactive protein. Absorption was 
measured in arbitraiy units and the results were expressed as a percentage of control 
values.
Quantification of the levels of the G§a or G qa in membranes were achieved in 
the same manner on immunoblots which contained varying concentrations of E. coli 
expressed Gga (Freissmuth et aL, 1989) (this material was a kind gift of Dr. M. 
Freissmuth, Dept, of Pharmacol., Univ. of Vienna, Austria) or G qa (a kind gift of 
Dr. S. Arkinstall, Galaxo Institute for Molecular Biology, Geneva, Switzerland). On 
such immunoblots, added quantities of E. coli generated recombinant Gga or G qa 
ranged over 0-30 ng. Densitometric analysis of the developed immunoblots allowed 
construction of a standard curves for recombinant Gga or Gqa, which were used to 
assess the level of these G-proteins in membranes of the cells.
2.2.15. In vitro mono ADP-ribosylation.
In vitro mono ADP-ribosylation of G-proteins in membranes was performed 
using a modification of the method described by Hudson et aL, 1980. Prior to use, 
both cholera toxin (1 mg/ml in H2O) and pertussis toxin (200 pg/ml in 50 mM 
phosphate buffer (pH 7.2), 500 mM NaCl, 50% (v/v) glycerol) were activated by 
preincubating with an equal volume of freshly prepared 100 mM DTT at room 
temperature for 90 min. The appropriate toxin was added at a final concentration of 
either 10 pg/ml for pertussis toxin or 50 pg/ml for cholera toxin.
Membranes to be ADP-ribosylated were diluted in TE buffer (10 mM Tris- 
HCl, 0.1 mM EDTA, pH 7.4) to a protein concentration of between 1 to 3 mg/ml. 20 
pi of aliquots were assayed in a final volume of 50 pi containing the following:
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250 mM Sodium phosphate buffer (pH 7.5),
[32p]NAD+ (2 pCi/assay tube)
20 mM Thymidine 
1 mM ATP (pH 7.5),
100 mM GTP (pH 7.5),
20 mM Arginine/HCl.
Assay :
Protein (membranes) 20 pi
Activated toxin (or DTT as negative control) 5 pi
Agonist (or dH20 as negative) 5 pi
Mix (as above) 20 pi
total volume 50 pi
After the assay was initiated by addition of the membranes, the tubes were 
incubated at 37 °C for 2 h. The reaction was terminated by the transferral of the tubes 
to an ice slurry followed by sodium deoxycholate/TCA precipitation as described in 
2.2.9. The samples were then subjected to appropriate SDS-PAGE conditions, as 
described in 2.2.10 and the [32p]ADP-ribosylated proteins visualized by autoradio­
graphy of the dried gel as mentioned in 2 .2 .11 .
2.2.16. Radioligand Binding Assay.
Radioligand binding assays were performed by a rapid filtration method as 
described by Pert et aL, 1973. The conditions of different assays are indicated in the 
relevant figure legends.
Membrane binding assays were performed routinely with [^H]-labelled ligand 
and 5-300 pg of membrane protein at either 20 °C (for [^Hjforskolin) or 30 (for 
[3H]DHA) for 60 min in TSM binding buffer consisted of 20 mM Tris-HCl (pH 7.4), 
50 mM sucrose, 20 mM MgCl2 . In pH]ligand binding experiments, the absence and 
presence of unlabelled ligand was used to define maximal and non-specific binding
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respectively. Blank values were determined by replacement of membrane protein with 
TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.4).
The specific high affinity binding of [^Hjforskolin to the GSAC complex in 
whole cells was performed as described by Alousi et aL, 1991. NG108-15 cells and 
the p2"adrenoceptor expressing clones derived from these cells were harvested and 
resuspended in DMEM buffered to pH 7.4 at 4 °C with 20 mM HEPES (DMEM-H). 
Cells were then counted using a haemocy tome ter and maintained on ice for 20 min 
prior to use in whole cell binding assays. Resuspended cells were added to tubes 
containing [^HJforskolin (approximately 10 nM) in either the absence or presence of 
10 pM cold forskolin to define non-specific binding. The tubes also contained varying 
concentrations of either the P-adrenoceptor agonist isoprenaline or the IP prostanoid 
receptor agonist iloprost. In cases in which cells were pretreated with BAAM, 
following harvest of the cells and removal of the growth medium as above they were 
subjected to three wash and centrifugation cycles with 20 ml volumes of DMEM-H 
prior to final resuspension. They were then incubated at 4 °C for 60 min.
All binding experiments were terminated by rapid filtration through Whatman 
GF/C filters, which had been pre-soaked in ice cold TSM binding buffer, followed by 
three times 5 ml washes with ice-cold TSM binding buffer using a Brandell cell 
harvester. The filters were soaked overnight in 10 ml of ecoscint scintillation fluid 
prior to counting in a Rackbeta scintillation counter. Binding data was analysed by 
either a non-linear least squares analysis or the Kaleidograph curve fitting programme 
driven by an Apple McIntosh computer. The Kp and Bmax of a receptor population, 
was estimated either by the equation of DeBlasi et aL, 1989 (K j = IC50 - L and Bmax 
Bo (K(j+L) / L ; Bq, specific binding; L, the concentration of radiolabelled ligand used; 
IC50, the concentration of unlabelled ligand that displaced half the specific binding of 
radioligand) or by the method of Scatchard etaL, 1949.
2.2.17. Assay of adenylyl cyclase catalytic activity.
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Adenylyl cyclase assays were performed as described by Milligan et aL, 
1987a. Sepaiation of radiolabeled cyclic AMP and ATP was achieved by the method 
of Salomon et aL, 1979; Johnson et aL, 1991, except that the amount of [a-32p]ATP 
was reduced to 1 pCi per sample. The catalytic activity of adenylyl cyclase is 
determined by methods which rely on the measurement on cAMP formed from 
unlabeled substrates, with cAMP-binding proteins and radio-immunoassay 
procedures, or by methods that rely on the use of radioactively labeled substrate 
followed by isolation and determination of the radioactively labelled product. These 
two different approaches have different purposes, different sensitivities, and different 
ease of use. The procedures described here focus on measuring the production of 
[32p]cAMP from the substrate [a-^^P]ATP. The cAMP thus produced is separated 
from the unreacted [a-^^P] ATP by a two-step column method.
A) Preparation of Sample.
Reaction mixtures of 50 pi containing 2.0 pM GTP (pH 7.5), 2.0 mM cAMP, 
0.4 mM ATP (pH 7.5), 200 mM Tris HCl (pH 7.5), 4 mM creatine phosphate, 100 
U/ml creatine phosphokinase, 10 mM MgCl2 , [a-^^P]ATP (1x10^ cpm), 100 mM 
NaCl were added to tubes containing between 5-20 pg membrane protein and 
appropriate ligands to a final volume of 100 pi. Reaction tubes were kept on ice slurry 
at all times and the reaction stai ted by incubation at 30 °C in a water bath. After 15 min 
incubation, the reaction was terminated by placing the tubes back into the ice-slurry 
and addition of 100 pi of stopper solution (2% (w/v) SDS, 45 mM ATP, 1.3 mM 3' 
5'-cAMP). 50 pi of [8-^H]3' 5' cAMP (approximately 10, 000 cpm) was added to 
each tube prior to boiling for 10 min. 750 pi of water was then added to each sample, 
and the [32p]cAMP content of each tube determined.
BJ Preparation of dowex and alumina Columns.
The method used to quantitate the amount of cAMP produced by each sample 
was identical to that of Salomon et aL, 1979 and involves the separation of cyclic 
AMP from other nucleotides by dowex and then alumina chromatography. The dowex 
H+ 50 X 4 (200-400) was mixed with water to a slurry (1; 1 (v/v)) and then 2 ml
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removed and added to glass wool stoppered columns. The dH^O was allowed to drain 
out and the columns washed with 2 ml of 1 M hydrochloric acid, then stored at room 
temperature. Prior to use, the columns were washed with 4 ml of 1 M NaOTI then 4 
ml of 1 M hydrochloric acid and approximately 20 ml of dH2 0 . After each use, dowex 
H+ 50 columns were regenerated by washing with 4 ml of 1 M HCl, then stored until 
re-use.
The alumina columns were prepared by the addition of dry neutral alumina : 
0.1 M imidazole (pH 7.3) slurry (1: 1 v/v ) to glass wool stoppered columns. The 
columns were washed with 10 ml of 1 M imidazole (pH 7.3) followed by 15 ml of 0.1 
M imidazole (pH 7.3) and stored at room temperature until used. After each use, the 
columns were washed with 10ml of 0.1 M imidazole (pH 7.3).
C) Nucleotide elution profile for both dowex and alumina columns.
Before intial use, the nucleotide elution profiles for each column must be 
determined. This was performed by applying a mixture of [^HJcAMP and [^^P]ATP 
to the column and determining the elution volume.
To quantitate sample recovery, stock [^HjcAMP was diluted in dH2 0  to give 
approximately 10, 000 cpm in 50 pi and [32p]ATP was diluted from a stock of 1 
pCi/ml to give approximately 2, 000 cpm in 50 pi. 50 pi of each of the cAMP and 
ATP solutions were added to 950 pi of water and then the mixture applied to a dowex 
column. The ATP and cAMP were eluted from the column by successive washes of 
the column with 0.5 ml of dH2 0 . Fractions were collected in a vial with 5 ml of 
Ecoscint and radioactivity determined by liquid scintillation counting using a dual label 
programme. The elution volumes required to elute the cAMP from the dowex columns 
were then detennined graphically. The elution volume required to elute the cAMP from 
the alumina columns was determined as for the dowex columns except that only 
[3H]cAMP was used, and the eluting buffer was 0.1 M imidazole (pH 7.3). 
Recoveries were similar to that obtained for the dowex columns.
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During the experiments, typical recovery from the dowex columns was always 
greater than 70%. When recovery fell below 60% the columns were discarded and 
fresh columns prepared. The life of columns is approximately 6  months.
D) Determination of cAMP production from membrane proteins.
Samples (total volume 950 ml) were loaded to prepared dowex columns and 
the ATP eluted with 1.5 ml of dH2 0 . 6  ml of dH2 0  was then added to the dowex 
columns and this eluate allowed to run directly onto the alumina columns. The cAMP 
fraction was eluted into vials containing 14 ml of Ecoscint, with 6  ml of 0.1 M 
imidazole (pH 7.3).
The cAMP fractions obtained were counted on a dual label liquid scintillation 
counting programme which automatically corrected for spillover from each channel. 
The amount of cAMP produced by each sample was calculated by taking into account 
the recovery from each column, based on the recovery of the [^HJcAMP internal 
standard that represented 100% recovery of the added [^HjcAMP. Data was then 
calculated as pmoles of cAMP formed per minute per milligram of membrane protein, 
and the assay was sensitive to approximately 5 pmoles/min/mg.
2.2.18. Measurement of stimulated inositol phosphate generation.
Occupation of a cell surface receptor by a hormone stimulates the generation of 
a second messenger. Many hormones, neurotransmitters and growth factors stimulate 
the breakdown of phosphatidylinositol 4, 5-bisphosphate (PIP2) by activating a 
specific phospholipase C, this generates the two second messenger molecules inositol 
1, 4, 5-trisphosphate (IP3) and sn-1, 2-diacylglycerol (DAG). IP3 can be measured at 
the mass level by a specific binding assay but it is easier to make use of the "Li+ 
assay". The normal pathway of IP3 degradation is by specific phosphatases to 
generate inositol which can be re-incorporated into PIP2. Inositol monophosphatase is 
an enzyme inhibited by Li+, therefore in the presence of this ion the inositol 
phosphates will accumulate. If the cells are prelabelled with [^HJinositol the inositol 
phosphates formed will be [^H]-labelled and thus can be measured. In order to do this
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the inositol phosphates are separated from inositol by ion-exchange chromatography 
on dowex-1-formate columns.
A) Preparation of dowex formate.
Dowex 1 x 8  resin has a quaternary group attached (compound formed from an 
amine by addition of a proton to produce a +ve ion) but in the presence of Cl“ there is 
an overall neutral charge. Dowex Cl" cannot be used because there is too strong an 
electrovalent bond between dowex and Cl" such that there would be no displacement 
by the phosphate group of the inositol phosphates of Cl". To convert dowex chloride 
to dowex formate, 100 g of dowex chloride (Dowex 1 x 8-200) were washed twice 
with 1 L dH2 0  and the beads gently allowed to settle. These were transfered to a 
scintered glass funnel and washed with 2 L 2 M NaOH. This was followed by 5-6 L 
dH2 0  to remove NaCl and excess NaOH and then with 0.5 L 1 M formic acid. The 
formate form of dowex was finally washed with about 20 L dH2 0  until the pH was 
constant at 5-5.5 as measured with narrow range pH paper (pH 4-6) and stored in a 
covered beaker at room temperature in an sluny of approximately 1: 1 dowex : dH2 0 .
B) Preparation of cells.
Cells were seeded in 24 well plates for 2-3 days in DMEM containing 5-10% 
serum. When cells were approximately 70% confluent, medium was replaced with 
inositol-free DMEM containing 1 % dialyzed foetal calf serum and [2-^H] myo-inositol 
(1 pCi/ml) and the cells incubated for a further 48 h.
C) Agonist regulation of inositol phosphate production.
Prior to agonist addition, the labelling medium was removed and the cells 
washed twice with 0.5 ml Hank's buffered saline (pH 7.4) containing 1% (w/v) BSA 
and 10 mM glucose (HBG) as described in 2.1.5. The cells were incubated for 10 min 
with HBG containing 10 mM Lithium chloride (HBG/LiCl) and stimulation canied out 
with agonist in HBG/LiCl for 20 min. All incubations were performed at 37 °C. 
Reactions were terminated by the addition of 0.5 ml ice cold methanol. The cells in 
each well were then scraped and transferred to vials. Chloroform was added in a ratio 
of 1: 2 (CHCI3 : MeOH) and the samples extracted overnight. The phases were split
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by the addition of chloroform and dH2 0  to a final ratio of 1: 1: 0.9 (CHCI3 : MeOH: 
dH2 0 ) and the upper phase was taken for analysis of total inositol phosphates. Total 
inositol phosphates were analysed by batch chromatography on dowex-1-formate as 
described by Plevin et aL, 1990.
2.2.19. Data analysis.
Where appropriate, data was analysed for statistical significance using either 
the paired or unpaired Student's t-distribution test with "n" numbers representing the 
degree of freedom, as indicated. In the paired test this "n" value was calculated from 
the number of experiments (n') performed-1, whereas in the unpaired test it was 
calculated from n l, +n2'-l. Dose response and displacement curves were analyzed 
using the Kaleidograph Curve Fit programme, courtesy of Syntex Research Centre, 
Edinburgh, Scotland, U.K.
2.2.20. Escherichia coli strains and plasmids.
All strains of E. coli were grown in L broth (10 g/L Bacto-tryptone, 5 g/L 
yeast extract, 0.17 M NaCl; pH 7.5 with NaOH), containing appropriate antibiotics at 
37 "^ C with continuous shaking (120-150 rpm).
The plasmid pCMV containing the cDNA for mouse G n a ,  cloned into the Cla 
I/Xho I sites, was a kind gift from Dr. Melvin I. Simon, Califonia Institute of 
Technology, Pasadena, CA, U.S.A. The full length cDNA for type 2 adenylyl cyclase 
was a gift from Dr. Paul Herzmark and Prof. Henry Bourne, Department of 
Pharmacology, University of Califonia, San Francisco, CA, U.S.A and PBS II 
containing the full length cDNA for type 6 adenylyl cyclase cloned into the BamH I 
(N-terminal)ZEcoR I (C-terminal) sites was a kind gift from Dr. Joseph P. Pieroni, and 
Prof. Ravi Iyengar, Mount Sinai, School of Medicine, New York, NY, U.S.A.
E. coli strains and plasmids used in the experiments are listed in Table 2.2.3.
51
Table 2.2.3. E, coli strains and plasmids.
Strains and 
Plasmids Genotype or Phenotype Sources
JM109 endAl, recAl, gyrA96, thi, hsdR17, 
(rk',mk+), relAl, supE44, 
D(lac-proAB),
[F', traD36, proAB, lacKzDMlS].
Promega
Corporation.
M C1061/P3 deoR+, rpsL, thi, mcrB, 
galK, D lacX74, strA, 
araD139, D(araABC-leu)7679.
{p3:amber Amp^, amber Trt^, Km^}.
Invitrogen.
pSV2-neo G418R, AmpR,
5.6 kb, SV40 (COS), pMBl (E. coli).
Gibco/BRL.
pBABE Hygro Amp^, Hygromycin 
5.2 kb, SV 40.
LK444
(pJM16)
G418R, AmpR, 
p-actin promoter, 10.0  kb.
Gunning et al., 
1987.
pcD N A l CMV promoter, SV 40,
M 13 origin. Sup F, Col E l origin, 
T7 and Sp6 RNA promoter,
4.1 kb.
Invitrogen.
pcDNA3 CMV promoter, SV40, 
G418R, Amp*^,
Col E l origin, fl origin,
T7 and Sp6  RNA promoter, 
BGHpA, 5.4 kb.
Invitrogen.
pCMV4 CMV promoter, SV 40 ori, Andersson et al., 
Amp^, f l  origin, hGH fragment, 1989. 
4.9 kb.
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2.2.21. Transformation of competent E. coli with plasmid DNA.
E. coli strains (JM109 or MC1061/P3) were grown in 500 ml L-broth until 
ODôoo was approx 0.25 (equivalent to approx 1x10% cells/ml). The cell suspension 
was allowed to cool on ice for approximately 30 min and spun at 10, 000 rpm for 10 
min at 4 °C on a Beckman J2~21 centrifuge using a JA14 rotor. The supernatant was 
discarded and the pellets resuspended in 20 ml each of ice-cold sterile buffer I (100 
mM RbCl2 , 50 mM MnCl2 .4 H2 0 , 30 mM potassium acetate, 10 mM CaCl2 . 2 H2O, 
15 % (w/v) glycerol, pH 5.8). The suspension was left on ice for 15 min and 
recentrifuged as before. The supernatants were discarded again and the pellets 
resuspended in a total volume of 3.5 ml of ice-cold buffer II (10 mM RbCl2 , 10 mM 
MOPS, 75 mM CaCl2 .2 H2 0 , 15% (w/v) glycerol, pH 6 .8 ) and pooled into one tube. 
The suspension was left on ice for 15 min before 200 pi aliquots were frozen in dry 
ice and stored at -80 °C.
2 0 0  pi of competent cells were thawed and added to an appropriate amount of 
plasmid DNA, 10-100 ng of supercoiled plasmid DNA or 5 pi of a ligation reaction. 
After gently mixing, the mixture was incubated on ice for 60 min before being heat 
shocked at 42 °C for 90 sec and returned to ice for 2 min. 800 pi of L-broth was 
added and the tubes incubated, with shaking at 150 rpm, 37 °C for 45-60 min. 
Different densities of the mixtures were spread onto L-broth agar plates containing 
appropriate antibiotics to select the colonies which had taken up the plasmid. The 
plates were incubated overnight at 37 °C and antibiotic resistant colonies picked and 
grown overnight in 5 ml L-broth containing the required antibiotics as above. 3 ml of 
this was used to prepare plasmid DNA and the remainder used to make glycerol stocks 
(Sterile 85% (v/v) cultured E. coli and 15% (v/v) glycerol were mixed). The glycerol 
stocks were snap frozen in dry ice and then stored at -80 °C until required.
2.2.22. Transfection of eukaryotic genes into mammalian cells.
A) Preparation of plasmid DNA.
53
Plasmid DNA was prepared using either the alkaline lysis procedure of 
Sambrook e ta l ,  1989, or Promega Mini-preps, Promega Maxi-preps Kits according 
to the manufacturer's instructions.
Most of subcloning experiments including digestion of plasmid DNA with 
restriction endonucleases, calf intestinal alkaline phosphatase (CIAP) treatment of 
DNA fragments, separation of digested plasmid DNA by electrophoresis and ligation 
of the desired DNA fragments of plasmid vector and insert DNA were also performed 
according to Sambrook et al., 1989 but purification of the desired DNA fragments 
from low melting agarose gel electophoresis followed the protocol of a Promega PCR 
purification kit.
The amount of DNA in a given sample was quantitated by measuring the 
absorbance at 260 nm (A260) i» a UV-1201 UV-VIS spectrophotometer with a 1: 200 
dilution of the sample in sterile Milli Q dH20. An A26O of 1 was assumed to be equal 
to 50 p,g/ml of double stranded DNA or 20 |Ltg/ml of single stranded oligo-nucleotide. 
The purity of the DNA was assessed by measuring the A28O in parallel and calculating 
the A260/A28O ratio. A ratio of approximately 1.8 was considered to be sufficiently 
pure for use otherwise a phenol:chloroform extraction and then EtOH precipitation 
was carried out as described in Sambrook et al., 1989.
B) Lipid-mediated DNA-transfection.
Transfections using mouse neuroblastoma x rat glioma hybrid NG108-15 
cells, human embryonic kidney (HEK-293) cells and monkey COS-1 cells were 
performed using either Lipofectin reagent (Gibco/BRL) or DOTAP (Boehringer 
Mannheim Biochemica) according to the manufacturer's instructions. Firstly, the 
minimum concentration of selection markers (geneticin or hygromycin B) to kill the 
wild type cells within 7 days was determined prior to transfection.
Cells were grown to approximately 40% confluency on 100 mm tissue culture 
dishes in an appropriate culture medium containing serum. 10 |ig (for stable) or 100 
p,g (for transient) of DNA was diluted with dH20 up to 250 |il in a sterile 
polypropylene tube. 70 p.1 of DOTAP or Lipofectin was separately diluted up to 250
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|il with dH2 0  in a 13 ml sterile polypropylene tube. Both DNA and transfection 
reagent complexes were incubated for 15 min during which time the cells were washed 
twice with serum containing DMEM (DOTAP) or serum free DMEM (Lipofectin). 10 
ml serum containing DMEM (DOTAP) or semm free DMEM (Lipofectin) was added 
to the complexes and then added to the cells. Cells were then incubated for 10-24 h to 
allow the DNA/transfection reagent complexes to adhere to the cell surface, fuse with 
the cell membrane and release the DNA into the cytoplasm before the medium was 
replaced with serum containing DMEM. Cells were then incubated for approximately 
72 h. For transient transfection the cells were then harvested whereas, the cells for 
stable transfection were plated out in the appropriate selection medium either 
containing 800 p,g/ml geneticin sulphate or 200 pg/ml hygromycin B alone, or both 
800 jxg/mi geneticin sulphate and 200 p,g/ml hygromycin B. Stable colonies were 
selected on the basis of resistance to antibiotics and expanded for detailed analysis.
2.2.23. Reverse transcriptase-polymerase chain reaction (RT-PCR).
A) Isolation of RNA.
Total RNA was isolated according to the acid phenol/guanidium thiocyanate 
method of Chomczynski et aL, 1987. Cells grown in monolayer were lysed by the 
addition of 1 ml of RNA zol B per flask (75 cm^). RNA was solubilized by 
passing the lysate a few times through the pipette. 2 0 0  pi of chloroform was added to 
the homogenate. The homogenate was vortexed briefly and put on ice for 5 min. The 
suspension was centrifuged on an MSB microcentrifuge at 13, 000 rpm for 15 min (4 
°C). After addition of chlorform and centrifugation, the homogenate foims two phases: 
the lower chloroform and the colourless upper aqueous phase whereas DNA and 
proteins are in the inteiphase and organic phase. The aqueous phase was transferred to 
a fresh tube, an equal volume of isopropanol added and the samples stored for 15 min 
at 4 °C. After centrifuging the samples for 15 min at 13, 000 rpm (4 °C), the 
supernatant was discarded and the RNA pellet was washed once with 1ml of 75% 
EtOH by vortexing and subsequent centrifugation at 13, 000 rpm for 5 min (4 °C).
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The pellet was dried briefly under vacuum and then dissolved in 1 mM EDTA (pH 
7.0) by vortexing or by passing a few times through a pipette tip. All solutions and 
materials were treated with 0.1% Diethylpyrocarbonate (DEPC). Purity and 
quantitation were assessed by OD260/OH280 ratios.
B) Reverse transcription.
0.2-2 pg samples of DNAsed RNA were heat-denatured by incubation at 65 
for 10 min followed by chilling on ice and reverse transcribed in either 15 pi or 33 
pi of reaction mixture consisting of 50 mM Tris/HCl (pH 8.3), 40 mM KCl, 10 mM 
M gCl2 , 1 mM DTT, RNAguard (17 units), 2 pg Oligo d(T)12-18 and 13 units of 
reverse transcriptase with a first strand cDNA synthesis kit (Pharmacia Biotech Inc.) 
as detailed by the manufacturer. Incubation was carried out at 37 °C for 1 h and 
stopped by incubation at 95 °C for 5 min to denature the RNA-cDNA duplex and 
inactivate the reverse transcriptase. Reaction mixtures were not extracted and were 
stored at -20 °C prior to amplification.
C) Polvmerase chain reaction (PCR) amplication.
PCR was carried out using the following 24 mers (synthesized on an Applied 
Biosystems Synthesizer) according to a modification of the method described by Steel 
etaL, 1993.
TRH-963 sense 5 -CAACCTCATGTCTCAGAAGTTTCG;
TRH-1333 anti-sense 5 -AATGAAGACCTTCGATCAGTTGG;
Type 2 Adenylyl cyclase-2122 sense
5-CACGGATCTCCCTCACAATCGTCA; 
Type 2 Adenylyl cyclase-2356 anti-sense
5-GCCCATGGTTGATACCCACTCGCA;
Type 6 Adenylyl cyclase-2059 sense
5'-CGGAAAGTAGACCCTCGTTTCGGA; 
Type 6  Adenylyl cyclase-2652 anti-sense
5-GCCAAGCCATGGACGCTAAGCA;
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PCR for the TRH receptor isoforms was performed in the presence of 20 
pmols of sense and antisense primer, dNTPs (0.2 mM each of dATP, dCTP, dGTP, 
dTTP), 6  mM MgCl2 and Taq polymerase (2,5 units) in a final volume of 100 pi. 
Cycling conditions were 95 °C/ 2 min, 48 °C/1 min, 72 °C/1 min (1 cycle); 95 °C/30 
sec, 48 °C/1 min, 72°C/1 min (33 cycles); 95 °C /30 sec, 48 °C/30 sec, 72 °C/1 min (1 
cycle), followed by a final extension at 72 °C for 2 min.
In addition, amplifications for the type 2 and type 6  adenylyl cyclases were 
performed over 35 cycles in the presence of 20 pmols of sense and antisense primer, 
dNTPs (0.2 mM each of dATP, dCTP, dGTP, dTTP), 6  mM M gC^ and Taq  
polymerase (2.5 units) in a final volume of 100 pi. Cycling conditions were as 
follows; 95 °C/ 5 min, 56 °C/1 min, 72 °C/1 min (1 cycle); 95 °C/30 sec, 56 °C/1 min, 
72°C/1 min (30-35 cycles); 95 '^ C /30 sec, 56 °C/1 min, 72 T /5  min (1 cycle).
Reaction mixtures were covered with 50 pi mineral oil and amplication was 
performed in a Hybaid Omnigene Thermocycler. Reaction products were then 
resolved by 1-1.5 % (w/v) agarose gel electrophoresis. No signal was observed in 
samples that were amplified without prior reverse transcription. To confirm the 
specificity of the primers to amplify only mRNA corresponding to the anticipated 
signals, PCR was done under identical conditions using cDNA species corresponding 
to receptor, G-proteins, or adenylyl cyclase as positive controls.
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Chapter 3.
The stoichiometry and the regulation of the levels of protein 
components of the stimulatory adenylyl cyclase cascade in
NG108-15 cell lines.
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3,1. Introduction.
Many hormones, neurotransmitters and growth factors exert their effects on 
target cells and tissues by modulating the intracellular levels of various second 
messengers, via members of a family of G-proteins. It has been known that receptor 
mediated generation of cyclic AMP requires the participation of at least three classes of 
proteins, which are receptors, G-proteins and adenylyl cyclases. As I mentioned in 
chapter 1 molecular analysis has indicated that all receptors of this class are 
represented by a single polypeptide which topographically is predicted to have seven 
transplasma membrane helices to provide an extracellular N-terminus, a cytoplasmic 
C-terminus and a series of intracellular and extracellular loops (Savarese et aL, 1992). 
In contrast, Gg is a heterotrimeric protein in which the a  subunit can exist as four 
distinct splice variants derived from a single gene (Bray et al., 1986; Robishaw et aL, 
1986). This complex is located at the intracellular face of the plasma membrane. The 
mammalian adenylyl cyclase family of proteins is expanding as new molecular forms 
continue to be identified as novel cDNA species but a common feature of those 
identified to data is the presence of two highly hydrophobic areas which are each 
predicted to contain six transplasma membrane helices linked by a large cytoplasmic 
loop (Tang etaL, 1992).
While receptor regulation of cyclic AMP generation has been widely examined, 
very little information is available on the relative or absolute levels of expression of Gg 
and adenylyl cyclase in individual cell types, on what proportions of these proteins 
become activated following agonist occupation of a receptor and whether different Gg- 
linked receptors have access to the total cellular population of G-protein and effector 
enzyme or if each receptor may be restricted to utilizing different pools of either Gg 
and/or adenylyl cyclase. In this study, the neuroblastoma x glioma hybrid cell line, 
NG108-15 (Hamprecht et aL, 1985) has been studied as a model system to analyse 
signal transduction by the adenylyl cyclase cascade as these cells express a 
considerable range of receptors which act in both a stimulatory and inhibitory manner 
on the generation of cyclic AMP (Milligan et aL, 1990).
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The neuroblastoma x glioma hybrid NG108-15 cell, (also called 108CC15) 
was generated by the fusion of the 6 -thioguanine-resistant clonal mouse 
neuroblastoma cell line N18TG2 and the bromodeoxyuridine-resistant rat glioma cell 
line C6-BU1, followed by selection with hypoxanthine, aminopterin, thymidine 
(HAT) medium and cloning (Hamprecht et aL, 1985). The transmembrane signaling 
systems which have been examined in detail in NG108-15 cells are stimulation and 
inhibition of adenylyl cyclase (Klee et aL, 1985), activation of phosphoinositidase C 
and regulation of voltage-sensitive Ca^+ channels (Tsunoo et aL, 1986) and activation 
of a Ca^"  ^dependent K+ channel (Fukuda et aL, 1988). Each of these effector system 
is coupled to relevant receptors by G-proteins (Milligan et aL, 1990). Activation of the 
Œ2B-adrenoceptor (Bylund etaL, 1988), M4 muscarinic (Fukuda etaL, 1988) and 6 - 
opioid receptors expressed by NG108-15 cells inhibits adenylyl cyclase activity and 
voltage-dependent Ca^+ flux thiough coupling to Gi2  and Go respectively (McClue et 
aL, 1990; McKenzie etaL, 1990; McFadzean etaL, 1989; Hescheler etaL, 1987). In 
contrast, NG108-15 cells express receptors for adenosine A2  (Kenimer et aL, 1981) 
and IP prostanoid receptors (Carroll et aL, 1989) which couple to the activation of 
adenylyl cyclase via activation of Gga as well as receptors for glucagon and secretin 
(Traber etaL, 1975).
Sustained exposure of cells or tissues to agonists which activate a G-protein- 
linked receptor frequently results in a time- and concentration-dependent decrease in 
plasma membrane, and subsequently cellulai’, levels of that receptor. This process is 
called down-regulation, and can contribute to desensitization, which limits cellular 
responsiveness to the maintained presence of extracellular signaling molecules 
(Benovic et aL, 1985; 1987; Sibley et aL, 1985). In NG108-15 cells, agonist- 
mediated selective down-regulation of G g O t ,  activated upon receptor occupancy, has 
been produced by treatment of the cells with either prostanoid receptor agonists 
(McKenzie et aL, 1990b) or with chi'onic exposure to ethanol (Mochly-Rosen et aL, 
1988) and results in a heterologous desensitization of receptor mediated generation of 
cyclic AMP.
60
In chapter 3.2, therefore, I have examined the quantitative stoichiometry of the 
cascade which leads from activation of a prostanoid receptor which has phaimacology 
consistent with it being of the IP prostanoid subtype (Carroll et aL, 1989) via Ggoc to 
adenylyl cyclase and the generation of cyclic AMP. I have used the stimulation of 
specific high-affinity binding of [^HJforskolin produced by either NaF or Gpp(NH)p 
to total membranes and intact cells of NG108-15 to attempt to define the maximal 
number of GSAC complexes that can be formed in these cells.
The diterpene forskolin binds with high affinity to the complex of Gga and 
adenylyl cyclase (GSAC) but with substantially lower affinity to isolated adenylyl 
cyclase (Laurenza et aL, 1989; 1991). This property has been utilized as a means to 
purify the complex of these two polypeptides, following treatment with either 
fluoroaluminate or a poorly hydrolysed analogue of GTP to persistently activate Gga, 
by passage of cellular detergent extracts over a forskolin affinity resin (Pfeuffer et aL, 
1985; Marbach et aL, 1990) although adenylyl cyclase in the absence of Gg has also 
been purified by use of a forskolin affinity column to which membrane extracts have 
been applied without incubation with persistent G-protein activators (Smigel et aL, 
1986).
In addition, NG108-15 cells transfected to express the human P2 adrenoceptor 
(Adie et aL, 1994 a, b) have been used in chapter 3.3 to define the regulation of 
agonist access to the receptor population by pretreatment of the cells with varying 
concentrations of an irreversible p-adrenoceptor antagonist bromoacetyl alprenolol 
methane (BAAM) which covalently attaches to receptor protein through 
bromoalkylation of sulfhydryl group and thu/irreversible occupancy of the receptor ^ 
binding site (Mahan et aL, 1985). Prior to the availability of cDNA species encoding 
G-protein-linked receptors (Bouvier et aL, 1988b; Johnson et aL, 1979; Whaley et aL, 
1994), measurements of differences in agonist efficacy and intrinsic activity could be 
gained only either from comparing responses to an agonist in different tissues or by 
use of irreversible antagonists (e.g. BAAM) to block varying proportions of the 
receptor population. The terms efficacy (Stephenson et aL, 1956) and intrinsic activity
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relate to the maximal ability of a drug-receptor complex in evoking a response in a cell 
or tissue. Partial agonists display lower intrinsic activity compared to full agonists as 
assessed by their inability to produce the maximal response of a system even at 
maximal receptor occupancy. However, receptor theory anticipates that the observed 
intrinsic activity of ligands will also depend on the level of receptor expression and 
receptor reserve, and potentially on the level at which the transmitted signal is 
measured (Kenakin et aL, 1989; Hoyer etaL, 1993),
Data on the levels of an adenylyl cyclase stimulatory receptor, the G-protein, 
Gg and adenylyl cyclase have previously been presented by Alousi et aL, 1991. It was 
demonstrated that, in S49 lymphoma cells, the absolute numbers of p2-adrenoceptor: 
GgOt: adenylyl cyclase are 1,500: 100,000: 3,500. In the cells studied herein case the 
measured levels of the adenylyl cyclase catalytic subunit are substantially lower than 
those of the corresponding G-protein, suggesting that the adenylyl cyclase is likely to 
be the limiting component for information transfer. Furthermore, expression of higher 
levels of the receptor do not result in greater adenylyl cyclase activity but only in a 
progressive shift in the agonist concentration-response curve to lower concentrations 
(Adie et aL, 1994b), indicative of the presence of spare receptors. Increased 
expression of G ga in this genetic background, as anticipated from the basal 
stoichiometries noted above, does not result in any significant alteration in the maximal 
effectiveness of the adenylyl cyclase cascade, although receptors can access and 
activate the introduced Gga as effectively as the endogenous G-protein pool (Mullaney 
et aL, 1994). These findings aie in accord with studies in which transgenic mice were 
produced over-expressing Gga in a cardiac specific manner (Gaudin et aL, 1995). In 
chapter 3,3, the levels of expression of adenylyl cyclase have been altered by 
transfection of adenylyl cyclase type 2  in this genetic background to evaluate whether 
this would result in a greater maximal output following agonist activation of the 
adenylyl cyclase cascade and to examine how potencies of agonists might be 
regulated.
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3.2. Analysis of agonist-induced formation of the complex of Gga with 
adenylyl cyclase in NG108-15 cell lines.
3.2.1. Results.
Levels of the IP prostanoid receptor in a total membrane fraction (PI) of 
NG108-15 cells were measured using [^HJprostaglandin E l (PGEl) as ligand in the 
presence of a high concentration of Mg2+ (20 mM) (Figure 3.2.1). 0.22 ± 0.03 mg 
(mean ± S.E.M., n = 6 ) of the total membrane protein (PI) was generated from 1 x 
10^ NG108-15 cells. Non-specific binding was assessed by parallel assays containing 
10 pM PGEl because it was previously established that this concentration is sufficient 
to fully displace specific binding of pH jPG El under these assay condition (Adie et 
aL, 1992). As saturation analyses generated from such self-displacement studies are 
prone to error at concentrations of competitor considerably greater than that of the 
[3H]ligand used, I applied the formalisms of DeBlasi et aL, 1989 [Kd = IC50-L; Bmax 
Bo (Kd+L) / L ; IC50 , median inhibitory dose; L, the concentration of radiolabelled 
ligand used; Bq, the specific binding (total binding - non specific binding)] to assess 
Kd and Bmax at this site. Non-linear least-squares analysis indicated that this site 
bound [^HjPGEl with a Kd of 34 ± 2 nM (mean ± S.E.M., n = 10) and was present 
at some 850 ±  70 fmol/mg membrane protein (mean ± S.E.M., n = 10). This is 
equivalent to the presence of some 113,000 ± 9,000 receptors/cell. Transformation of 
the specific binding by the method of Rosenthal et aL, 1967 indicated the presence of a 
single high-affinity site with similar binding characteristics (Figure 3.2. IB).
Analysis of levels of Gga was achieved by immunoblotting the PI membrane 
fraction of NG108-15 cells with an antiserum (CS) which was raised against a 
synthetic peptide predicted to represent the C-terminal decapeptide of all of the splice 
variants of this G-protein (Milligan et aL, 1989). Quantitation of the levels of Gga, 
which in NG108-15 cells is represented predominantly by a 45 kDa polypeptide 
(McKenzie et aL, 1990b; Adie et aL, 1992), was accomplished by concurrent 
immunoblotting of known amounts of recombinant Gga purified following expression
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in E. coli (Figure 3.2.2A). Such analysis demonstrated the GgOt 45 kDa protein to be 
expressed at some 9.6 ± 0.7 pmol/mg membrane protein (mean ± S.E.M., n = 5). 
This is equivalent to some 1,275,000 ± 93,000 copies/cell. Quantification of the levels 
of Gga based on the radioactivity incoiporated into this polypeptide by cholera toxin- 
catalysed [32p]ADP ribosylation produced considerably lower values (maximum = 
550 ± 30 fmol/mg membrane protein). Measured levels of cholera toxin-catalysed 
[32p]ADP ribosylation of this polypeptide varied with the presence or absence of 
guanine nucleotides in the assay. Maximal incoiporation was achieved in the presence 
of the poorly hydrolysed analogue of GTP, GTP[S] (Table 3.2.1).
[JH]forskolin binds with high affinity to the complex of adenylyl cyclase and 
Gga. As flouride ions [due to the formation of the fluoroaluminate ion (AlFa") which 
is able to interact with GDP-ligated, inactive G-proteins and hence mimic the presence 
of the y phosphate of GTP] causes persistent activation of G-proteins, I performed 
[3H]forskolin binding experiments designed to detect the maximal number of 
Gga/adenyiyl cyclase complexes in the presence of NaF. Preliminary experiments 
demonstrated that 10 mM NaF was sufficient to produce the greatest level of 
[3H]forskolin binding (Figure 3.2.3) and that, in the absence of NaF, only some 10% 
of the maximal specific binding of the radioligand could be detected (Figure 3.2.3). A 
linear increase in specific high affinity NaF-dependent [^H]forskolin binding was 
observed with membrane amounts up to 500 |0.g and no difference in non-specific 
[3H]forskolin binding (measured by the presence of 10 pM forskolin) was noted in 
the presence or absence of NaF (data not shown). Dose response curves for NaF 
activation of adenylyl cyclase and for stimulation of high affinity [3H]forskoiin 
binding were similar (Figure 3.2.3). Addition of the poorly hydrolysed analogue of 
GTP, Gpp(NH)p stimulated specific high affinity [^HJforskolin binding (Figure 
3.2.4) and dose response curves for both this parameter and for Gpp(NH)p-mediated 
stimulation of adenylyl cyclase were essentially identical with median effective (EC50) 
values close to 100 nM (Figure 3.2.4). Non-radioactive forskolin displaced the NaF- 
dependent binding of [3H]forskolin (approximately 20 nM) were detected under these
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conditions with IC50 of some 30 nM (Figure 3.2 .5A). Further displacement of 
[^H]forskolin by non-radiolabeiled forskolin was not obtained at concentrations 
beyond 10 pM  and, as such, this concentration was used routinely to define non­
specific binding. In such self-competition studies (Figure 3.2.5), using the formalism 
of DeBlasi et al., 1989, the estimated Kd for the high affinity binding of forskolin 
to membranes of NG108-15 cells was 14 nM. Analysis of the specific binding of
V:[3 H] forskolin in self-competition experiments was also performed by the method of 
Rosenthal et aL, 1967 following correction of the specific binding for dilution of the 
specific activity of the radiolabel. Curve fitting of such data clearly fitted a biphasic- 
curve consistent with both a high affinity (Kd =18 nM) lower capacity site (Bmax “
144 fmol/mg membrane protein) and a low-affinity (Kd = 550 nM) but higher capacity 
site (approximately 750 fmol/mg membrane protein) although the characteristics of the 
low-affinity site were difficult to measure accurately due to the low affinity of the 
ligand for this site. The biphasic nature of [^H]forskolin binding was not unexpected 
as computer analysis of the self-displacement curves had indicated a pseudo-Hill 
coefficient of 0.80 ± 0.07, suggestive of the likely existence of two sites. The nature 
of the low-affinity [^Hlforskolin binding site is unknown, but the interaction of 
forskolin with a variety of cellular proteins including glucose transporters has been 
reported and it is not believed to represent binding to adenylyl cyclase (Laurenza et aL,
1989).
In a range of experiments, the high-affinity binding component of 
[3H]forskolin binding to membranes of NG108-15 cells in the presence of 10 mM 
NaF demonstrated the presence of some 130 + 7 fmol/mg membrane protein (mean ±
S.E.M., n = 12) of this complex, equivalent to some 17,300 + 900 copies/cell.
Similar levels of specific high-affinity [^Hjforskolin binding was detected when 
experiments were performed and defined by the presence of the poorly hydrolysed 
analogue of GTP, Gpp(NH)p (100 jiM; data not shown).
Such results indicated that the GsOt/adenylyl cyclase complex is quantitatively 
the limiting component for stimulatory regulation of cyclic AMP production in 1 
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NG108-15 cells. Such results, however, present a paradox as it has been noted that IP 
prostanoid receptor agonist treatment of NG108-15 cells results in down-regulation of 
not only receptor but also of G§a (McKenzie et aL, 1990b; Adie et aL, 1992; Kelly et 
aL, 1990) and that down-regulation results in a heterologous form of desensitization 
of receptors which cause activation of adenylyl cyclase (Kelly et aL, 1990).
When NG108-15 cells were treated with the IP prostanoid receptor agonist, 
iloprost (1 |xM, 16h) and membranes subsequently prepared from these cells, 
membrane levels of the IP prostanoid receptor were substantially reduced in 
comparison to membranes prepared in parallel from untreated cells (untreated 900 ± 
100 fmol/mg membrane protein; iloprost treated 290 ± 50 fmol/mg membrane protein, 
each mean ± S.E.M., n = 4). Immunologically detectable membrane-associated levels 
of G§a were also reduced significantly (p -  0.011) by some 35% from 9.6 ± 0.7 
pmol/mg membrane protein (mean ± S.E.M., n = 5). The remaining Gga appears as if 
it should be sufficient to generate unchanged amounts of the Ggoc/adenylyl cyclase 
complex, particularly as the remaining G-protein appears to be fully active as a 
regulator of adenylyl cyclase (Adie et aL, 1992). However, maximal NaF-dependent 
high-affinity [^H]forskolin binding in membranes derived from iloprost-treated cells 
(110 ± 6  fmol/mg membrane protein) was significantly lower (25%; P = 0.02) than in 
membranes from the untreated cells (130 ± 7 fmol/mg membrane protein; each mean ± 
S.E.M., n = 4).
Furthermore, the specific binding of [^H] forskolin (approximately 10 nM), 
defined by the presence and absence of 10 p,M non-radioactive forskolin, to a total 
membrane preparation of both clones pN22 and pN17 were assessed in the presence 
of Gpp(NH)p (100 |iM) as previously performed with membranes of parental 
NG108-15 cells. The derivation of clones pN22 (which expresses 3990 ± 700 fmol of 
human p2-adrenoceptor/mg of membrane protein ) and pN17 (which expresses 292 ± 
62 fmol of the human p2-adrenoceptor/mg of membrane protein) by transfection of 
NG108-15 cells has been described in detail previously (Adie et aL, 1994a, b). 
Displacement of Gpp(NH)p-stimulated specific [^HJforskolin binding was achieved
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by forskolin in PN22  membranes (Figure 3.2 .6 A) and in PN17 membranes (data not 
shown) with high affinity. Use of the formalism of DeBlasi et aL, 1989 (IQ  ™ IC50- 
[(3fj) L] when the radioligand and displacing drug are one and the same) provided 
estimates of the affinity of binding of [^Hlforskolin (Kd) in these membranes in the 
presence of Gpp(NH)p of between 20 and 30 nM in a range of experiments.
The specific high affinity binding of forskolin and its regulation by Gg- 
linked receptor agonists were assessed in intact wild type NG108-15 cells and those of 
clones pN22 and pN17 using the method of Alousi et aL, 1991. Preliminary time 
courses for agonist stimulation of [^H]forskolin binding demonstrated that maximal 
levels of iloprost (10 jiM)-stimulated [^Hjforskolin binding in NG108-15 cells were 
achieved by 60 min (Figure 3.2.7A), as was maximal stimulation of specific 
[3H]forskolin binding by either iloprost (10 pM) or the p-adrenoceptor agonist 
isoprenaline (10 jiM) in cells of clone pN22 (Figure 3.2.7B). This length of 
incubation was subsequently used for all the other studies. Time courses of 
[^H] forskolin binding achieved in the absence of agonist also suggested that maximal 
levels were obtained within 60 min (Figures 3.2.7A and 7B), but these were not 
generally amenable to computer analysis because of the low level of specific binding 
obtained. Little specific binding of 10 nM pHJforskolin (1,600 ± 800 sites per cell; 
mean ± S.E.M., n = 3) was observed at 60 min in wild type NG108-15 cells in the 
absence of a receptor ligand but treatment of NG108-15 cells with the IP prostanoid 
receptor agonist iloprost (10 |iM) resulted in a large increase in specific forskolin 
binding to 15,000 ± 180  sites per cell (mean ± S.E.M., n = 3; p = 0.04). Addition of 
the p-adrenoceptor agonist isoprenaline (10 jxM) failed, however, to increase specific 
[2H]forskoiin binding (1,900 ± 1,100 sites per cell; mean ± S.E.M., n = 3; p = 0.86). 
When similar experiments were performed on cells of clone pN17, the specific 
binding of [3H]forskolin in the absence of a receptor ligand was similar to that 
observed in wild type NG108-15 cells (2,700 ± 530 sites per cell, mean ± S.E.M., n 
= 3; p = 0.34) but iloprost (10 |xM) produced a larger stimulation of specific 
[3H]forskolin binding than observed in wild type NG108-15 (31,000 ± 3,900 sites
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per cell; mean ± S.E.M., n = 3; p = 0.047) and now addition of isoprenaline (10 p,M) 
resulted in a substantial increase in specific [^H]forskolin binding (26,000 ± 2,500 
sites per cell; mean ± S.E.M., n = 3; p = 0.001). A similai* pattern was observed in 
PN22 cells except that the specific binding of [^Hjforskolin in the absence of receptor 
agonist (11,000 ± 1,200 sites per cell; mean ± S.E.M., n = 3) was substantially 
elevated in comparison to both wild type NG108-15 cells (p = 0.009) and pN17 cells 
(p = 0.02). However, the maximal level of specific binding of [3H]forskolin produced 
by isoprenaline (10 |U.M) (p = 0.21) or by iloprost (p = 0.68) was not significantly 
greater than in pN17 cells (Table 3.2.3). The ability of forskolin to displace 
isoprenaline-stimulated [3H]forskolin binding in intact pN22 cells showed that the Kd 
for specific binding of [^Hjforskolin was the same in whole cells as in cell membranes 
(Figure 3.2.8). Applying the formalism of DeBlasi et aL, 1989, as noted above, to 
such data a Kd for pH]forskolin of 29 ± 6 nM was determined.
To assess whether the elevated levels of basal spécifié binding observed in 
clone PN22 reflect spontaneous empty-receptor activation of GSAC formation by the 
expressed p2-adrenoceptor, I performed [3H]forkolin-binding experiments with both 
NG108-15 cells and clone PN22 cells in the absence of agonist or in the presence of 
either isoprenaline (10 jxM) or propranolol (10 jxM) (Table 3.2.4). Propranolol has 
previously been shown to be an inverse agonist, able to cause a reduction in basal 
adenylyl cyclase activity in membranes of PN22 cells (Adie et aL, 1994b). 
Furthermore, although isoprenaline had no ability to stimulate specific [3H]forskolin 
binding in NG108-15 cells, isoprenaline stimulation of specific [3H]forskolin binding 
in pN22 cells was competed for by propranolol (Table 3.2.4).
Iloprost treatment of wild type NG108-15 cells resulted in a dose-dependent 
increase in specific binding of [3H]forskolin. A maximum was observed with 1(X) nM 
iloprost and this was not increased further by incubation with concentrations of 
iloprost up to 10 jxM. Half-maximal stimulation of specific [^H]forskolin binding was 
achieved with some 5 nM iloprost (Figure 3.2.9A). Identical dose-effect curves for 
iloprost stimulation of high affinity [^HJforskolin binding were recorded for cells of
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both clones pN2 2  (EC50 = 5.1 ± 1.5 nM) and PN17 (EC50 = 2.5 ± 0 .3  nM) and the 
parental NG108-15 cells (Figure 3.2.9B). The p-adrenoceptor agonist isoprenaline 
also stimulated specific high affinity [3H]forskolin binding in both clones PN2 2  and 
pN17 in a dose-dependent manner (Figure 3.2.10) which reached a similar maximal 
level. Unlike the situation with iloprost, however, the dose-effect curves for 
isoprenaline were substantially different in the two clonal cell lines. In clone pN22 
cells the measured EC50 for isoprenaline (1.5 ± 0.4 nM; mean ± S.E.M., n = 3) was 
some 15 fold lower than in clone pN17 (20.0 ± 1.5 nM; mean ± S.E.M., n = 3).
It has previously been demonstrated that the basal cellulai- levels of Gga are 
not different in clones pN22 and PN17 from these in parental NG108-15 cells (Adie et 
aL, 1994a). To examine if a possible reason for the elevated levels of basal high 
affinity [^HJforskolin binding in PN22 cells compared to pN17 and parental NG108- 
15 cells might relate to an elevated level of expression of the adenylyl cyclase catalytic 
moiety specifically associated with this clone, I immunoblotted membranes of each of 
these cell types with a antipeptide antibody raised against a section of primary amino 
acid sequence which is highly conserved in all currently identified hormonally- 
regulated adenylyl cyclase isoforms. These immunoblots demonstrated a single 
polypeptide of some 120 kDa, the levels of which were not substantially different in 
the three cell lines (Figure 3.2.11).
To assess whether IP prostanoid receptor-mediated stimulation of high affinity 
[3H]forskolin binding in NG108-15 cells would be compromised by the activation of 
a receptor that mediates inhibition of adenylyl cyclase in these cells, I measured 
stimulation of high affinity [^H] forskolin binding by iloprost (10 |liM) in the presence 
and absence of a receptor saturating concentration (10 pM) of the peptide DADLE, 
which in NG108-15 cells mediates inhibition of adenylyl cyclase via the ô opioid 
receptor and activation of Gi20C (McKenzie et aL, 1990a). However, even with 
submaximal stimulation of [^H]forskolin binding by iloprost, the opioid peptide was 
unable to reduce iloprost-stimulated [^HJforskolin binding and DADLE had no effect 
in isolation on basal [3H]forskolin binding (Table 3.2.5). Similar results were
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obtained for both iloprost- and isoprenaline-stimulated high affinity [^Hjforskolin 
binding in PN17 and PN22  cells (data not shown).
Figure 3.2.1.
Analysis of levels of the IP prostanoid receptor in membranes of 
NG108-15 cells.
The specific binding of [^HjPGEl (defined by the presence and absence of 10 
nM PGEl) to total (PI) membranes (100 pg) of NG108-15 cells was performed at 30 
°C for 1 h and assessed in self-competition studies as described in chapter 2.2.16. 
Data was analysed either by the method of DeBlasi et aL, 1989 (panel A) or by the 
method of Rosenthal et aL, 1967 (panel B). In the example displayed, [^HJPGEl was
10.1 nM. Calculated data varied between Bmax = 849 fmol/mg membrane protein, Kd 
= 30 nM (panel A) and Bmax = 985 fmol/mg membrane protein, Kd = 39 nM (panel 
B).
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Figure 3.2.2.
Quantitation of Gga levels in membranes of NG108-15 cells.
Differing amount of E. coli generated recombinant Gga long form (lane 1, 2.5 
ng; lane 2, 5 ng; lane 3, 10 ng; lane 4, 15 ng; lane 5, 20 ng; lane 6 , 25 ng) were 
resolved in SDS-PAGE (10% (w/v) acrylamide, 0.25% (w/v) bisacrylamide) along 
with membranes (25 jig) from untreated (lane 7) and iloprost-treated (1 pM, 16h) 
(lane 8 ) NG108-15 cells. The gel was then transferred to nitrocellulose and 
immunoblotted using antiserum CS (which identifies all splice variants of Ggtt) as 
primary reagent. The developed immunoblot (panel A) was scanned to construct a 
standard curve of amounts versus immunological signal (panel B). A similar standard 
curve was used in each experiment in which quantitation of Gga was performed. The 
standard curve was routinely sigmoidal but only values encompassed by the linear 
section of the curve were used for quantitation. The negatively stained polypeptide 
observed at 67 kDa in the standard curve samples in panel A is bovine serum albumin, 
which was added to the purified recombinant G-protein at a final concentration of 1 
pg/ng Gga to limit losses of the G-protein during dilution and acid precipitation. In 
the example displayed, Gga in the untreated membranes was 11.2 ng/25 pg 
membrane protein and in membranes from iloprost treated cells was 7.2 ng/25 pg 
membrane protein.
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Figure 3.2.3.
Sodium fluoride stimulates high affinity binding of [^H]forskolin and 
activates adenylyl cyclase activity with similar dose response curves.
Adenylyl cyclase activity (filled squares) and the high affinity binding of 
[^H]forskolin (open squares) were measured on total (PI) membranes of NG108-15 
cells in the presence of NaF (10'^ - 10'F7 M) as described in chapter 2,2.17 and 
2.2.16 respectively. Results are plotted as % of the maximal stimulation over basal 
levels. In the examples displayed for adenylyl cyclase, the basal activity was 15.9 ± 
5.8 pmol/min/mg membrane protein, while the maximum activity was 166.9 ± 9.6 
pmol/min/mg membrane protein. In this experiment, [3H]forskolin was 12.5 nM. 
Basal specific forskolin binding measured was 148 d.p.m. and maximal binding 
was 1147 d.p.m.
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Figure 3.2.4.
Gpp(NH)p stimulates high affinity binding of [^H lforskolin and
activates adenylyl cyclase with similar dose response curves.
The high affinity binding of [^H] forskolin (filled squares) and adenylyl cyclase 
activity (open squares) was measured on total (PI) membranes of NG 108-15 cells in 
the presence of Gpp(NH)p ( I Q - 10 - 10-4 M). Results are plotted as % of the maximal 
stimulation over basal levels. In the examples displayed, for adenylyl cyclase, the 
basal activity was 19.1 ± 2.0 pmol/min/mg membrane protein, while the maximum 
activity was 156.3 ± 0.8 pmol/min/mg membrane protein. In this experiment, the 
membranes of NG108-15 cells were incubated with 12.5 nM [^HJforskolin. Basal 
specific [^HJforskolin binding was 169 d.p.m. and maximal binding was 1003 d.p.m.
Î
100 1
80  “
I
I
20 -
1 0 6 4 21 2 8
Log [ Gpp(NH)p ] (M)
73
-
=
IT"T;
'.f
Is
Figure 3.2.5.
[^H]forskolin binding studies and self competition with forskolin to 
total (PI) membranes of NG108-15 cells.
The binding of [^HJforskolin to total (PI) membranes (250 pg) of NG108-15 
ceils was performed in the presence of 10 mM NaF and varying concentrations of 
unlabeled forskolin. Non-specific binding was defined by the presence of 0.1 mM 
forskolin. Analysis of such data was performed by the methods of either DeBlasi et 
al.y 1989 (panel A) or Rosenthal et al.y 1967 (panel B) to define Bmax and Kd for 
forskolin binding. In the experiment displayed, [^Hjforskolin was 18 nM and the 
observed specific binding was 18.0 fmol. Manipulation of this data according to 
DeBlasi et al.y 1989 provides an estimate of Bmax = 129 fmol/mg membrane protein 
and Kd = 14 nM. Analysis of the high affinity [^Hjforskolin binding site as in 
Rosenthal et al. 1967 estimated that Bmax = 145 fmol/mg membrane protein and Kd = 
18 nM.
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Figure 3.2.6.
Analysis of the affinity of the GSAC complex for [^H]forskolin in 
membranes of clone (3N22 cells.
Displacement of guanine nucleotide-stimulated [^HJforskolin binding to 
membranes of PN22 cells by unlabeled forskoiin was performed. Aliquots of a total 
(PI) membrane fraction (250 p,g) of clone pN22 cells were incubated with 100 jilM 
Gpp(NH)p and [^HJforskolin (15.8 nM) along with varying concentrations of 
forskoiin at 2 0  °C for 60 min as described in chapter 2.2.16 and then bound 
[^H]forskolin was measured. In the example displayed, the estimated IC50 for 
forskoiin was 42.8 nM. Application of the formalism of DeBlasi et al. 1989 (Kd = 
IC50 -[(^H)L]) resulted in an estimation of Kd for pHjforskolin of 27.0 nM.
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Figure 3.2,7.
Time course of agonist stimulated specific [^H]forskoIin binding in 
intact NG108-15 derived cell lines.
NG108-15 cells (panel A): The ability of iloprost (10 pM) (filled circles) to 
promote specific forskoiin (13.2 nM) binding in intact NG108-15 cells (4.0 x 
10^/assay) with time was assessed as described in chapter 2.2.16 as was the rate of 
specific binding of pH]forskoiin in the absence of agonist (open squares). Results are 
mean ± S.E.M. for three determinations. Maximal levels of binding were achieved by 
60 min.
Clone PN22 cells (panel B): The ability of iloprost (10 pM) (open diamonds) 
or isoprenaline (10 pM) (filled squares) to promote specific [^H]forskoiin (11.0 nM) 
binding in intact clone PN22 cells (4.5 x lO^/assay) with time was assessed as 
described in chapter 2.2.16 as was the rate of specific binding of [^Hjforskolin in the 
absence of agonist (filled circles). Results are mean ± S.E.M. for three 
determinations. Maximal levels of binding were achieved by 60 min.
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Figure 3.2.8.
Displacement of isoprenaline stimulated [^H]forskolin binding in intact 
clone PN22 cells by forskoiin.
Clone PN22 ceils (3.1 x lO^/assay ) were incubated with isoprenaline (10 
pM), l^HJforskolin (11.1 nM) and various concentrations of forskoiin at 4 °C for 60 
min as described in chapter 2.2.16 and bound [^H]forskoiin subsequently measured. 
The estimated IC50 was 33.4 nM. Application of the formalism of DeBlasi etaL, 1989 
as in Figure 3.2.6 resulted in an estimation of Kd for forskoiin of 22.3 nM.
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Figure 3.2.9.
Iloprost stim ulation of specific [^H]forskolin binding to intact wild
type NG108-15, pN22 and pN17 cells: Dose-effect data.
Panel A represents iloprost stimulation of specific [^H] forskoiin binding data 
to intact NG108-15 cells. The specific binding of pH]forskolin (10.6 nM) and its 
regulation by various concentrations of iloprost was measured in NG108-15 cells (2.1 
X 10^ cells/assay). In the example shown the EC50 for iloprost was 3.6 nM.
Panel B represents iloprost stimulation of specific [^H]forskoiin binding data 
to intact PN22 and pN17 cells. The specific binding of [^HJforskolin (10.0 nM) and 
its regulation by various concentrations of iloprost were measured in both PN22 (2.3 
X 10  ^ cells/assay) (filled symbols) and PN17 (2.4 x 10  ^ cells/assay) cells (open 
symbols). In the example shown the estimated EC50 for iloprost in PN22 cells was
5.1 nM and in pN17 cells 2.5 nM.
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Figure 3.2.10.
Differences in dose-effect curves for isoprenaline stimulation of 
specific pH]forskolin binding to pN22 and PN17 cells.
The specific binding of [^Hjforskolin (9.7 nM) and its regulation by various 
concentrations of isoprenaline was measured in both PN22 (2.3 x 10^ cells/assay) 
(filled symbols) and pN17 (2.0 x 10  ^ cells/assay) cells (open symbols). In the 
example shown the EC50 for isoprenaline in pN22 cells was 0 .8  nM and in pN17 
cells 18.4 nM.
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Figure 3.2.11.
Immunological detection of adenylyl cyclase in membranes of wild type 
NG108-15 and clones pN22 and pN17 cells.
Membranes (100 pg) of NG108-15 (lanes 1 and 4) and clone PN17 (lanes 2 
and 5) or PN22 (lanes 3 and 6 ) cells derived from untreated (lanes 1-3) or isoprenaline 
(10 pM, 16h) treated (lanes 4-6) cells were resolved by SDS-PAGE (7.5% (w/v) 
acrylamide 0.25% (w/v) bisacrylamide), transferred to nitrocellulose and 
immu noblotted with the anti-adenylyl cyclase common peptide serum mentioned in 
chapter 2,2.6 (1:500 dilution). The nitrocellulose filter was subsequently treated as 
described in chapter 2.2.13 and detection was achieved by treatment with 
protein A (0.04 mCi/ml) followed by exposure to a phosphor storage plate.
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116 Adenylylcyclase
Table 3.2.1.
Quantitation of GsCX in membranes of NG108-15 cells using cholera 
toxin-catalysed P^P]ADP ribosylatlon.
Cholera toxin-catalysed [32p] aDP ribosylatlon was performed on membranes 
of NG108-15 cells as described in chapter 2.2.15. Data represent mean ± S.E.M. (n = 
4).
Condition Apparent G$a levels
fmol/mg membrane protein
Control 254+  11
GDP[S] (100 pM) 300 ± 12
GTP[S] (100 pM) 547 ± 29
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Table 3.2.2,
Quantitation of components of the stimulatory arm of the adenylyl 
cyclase cascade in NG108-15 cells.
The levels of each polypeptide component expressed as copies/cell (mean + 
S.E.M.; n = 10 for IP prostanoid receptor, n = 5 for Gga, n = 12 for Gga/adenylyl 
cyclase complexes).
Components Copies/cell
IP prostanoid receptor 113,000 ± 9,000
G sa 1275,000 ± 93,000
GgOt/adenylyl cyclase complex 17,300 ± 900
I
i
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[^H]forskolin bound (sites/cell)
PN17 PN22
Basal 2,700 ± 530 1 1 ,0 0 0  ± 1 ,200
Isoprenaline (10 pM) 26,000 ± 2,500 35,000 ± 4,900
Iloprost (10 pM) 31,000 ±3,900 34,000 ± 4,100
Table 3.2.3.
Agonist stim ulated maximal specific [^Hjforskolin binding in intact
PN17 and pN22 cells.
Specific binding of [^H]forskoiin (10.0 nM) to intact PN17 and PN22 cells 
was assessed as described in the chapter 2.2.16 in the absence (basal) or presence of 
either iloprost (10 pM) or isoprenaline (10 pM). Data are presented as mean ± 
S.E.M., n = 3 for the calculated number of high affinity [^H]forskoiin binding site per 
cell detected by this concentration of [^H]labelled ligand.
s':K
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Table 3.2.4.
Effect of propranolol on basal specific pHJforskolin binding in intact
NG108-15 and clone pN22 cells.
The specific binding of [^HJforskolin (13.0 nM) was determined in either 
intact parental NG108-15 cells or clone pN22 cells (2.2 x lO^/assay). Data are 
presented as mean ± S.E. of triplicate determinations from a single experiment. 
Similar data were observed in a further experiment. N.D., Not determined.
[^Hlforskolin binding (d.p.m.)
NG108-15 PN22
Basal o 110± 19 260± 11
Isoprenaline (10 pM) 97 ± 3 840± 160
Propranolol (10 pM) 100 ± 3 160 ± 26
Isoprenaline (10 pM)
+ Propranolol (10 pM) N. D. 430+  16
#
:
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Table 3.2.5.
Effect of the opioid agonist DADLE on agonist-stimulated specific 
[^HJforskolin binding to NG108-15 cells.
[^Hlforskolin binding 
to NG108-15 cells (d.p.m.)
Basal 7 9 + 4
Iloprost (10 pM) 320 ± 8
DADLE (10 pM) 85+ 11
Iloprost (10 pM)
+ DADLE (10 pM) 310± 14
Î■t
1The specific binding of [^Hjforskolin (12.0 nM) was assessed in intact 
NG108-15 cells (2.0 x 10^ cells/assay) as described in the chapter 2.2.16 either in the 
absence of agonist or in the presence of the IP prostanoid receptor agonist iloprost (10 
pM), the opioid receptor agonist DADLE (10 pM) or both. Data are presented as 
mean ± S.D. of quadruplicate determinations from a single experiment. Similar results 
were obtained in two further experiments.
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3.2 .2 , D iscussion .
The absolute or even relative levels of the individual polypeptides which 
comprise cellular signaling cascades across the plasma membrane of individual cells 
have hardly been investigated despite enormous interest in the mechanisms of agonist- 
mediated second-messenger generation. Considerable information is available for the 
receptors because of the availability of radiolabelled drugs of high selectivity, but the 
same is not true for the G-proteins and/or effectors. However, to appreciate the 
potential role of regulation of levels of these polypeptides in the control of cellular 
sensitivity, it is necessary to know their amounts. In this study, I have measured 
levels of each of IP prostanoid receptor, Gga and the complex of Gga and adenylyl 
cyclase in membranes of neuroblastoma x glioma NG108-15 cells (Table 3.2.2). 
Furthermore, I have examined the ability of receptors to activate adenylyl cyclase in 
NG108-15 cells and in clones generated from these cells that have been transfected to 
express different levels of the human p2"^drenoceptor.
Levels of the IP prostanoid receptor were assessed by analysis of self­
competition experiments using pH jPG El. The traditional approach used to measure 
receptor levels is to perform saturation experiments using increasing concentrations of 
radioligand but in situations in which the ligand has relatively low affinity or the 
specific binding represents a low proportion of the measured total binding, such an 
approach is not feasible. In this case, I have analysed the specific binding of 
[^H]PGE1 both taking into account the dilution of the specific activity of the 
radioligand by the presence of unlabelled PGEl and using the formalisms described 
by DeBlasi et a l ,  1989 to calculate both receptor number and the affinity of the 
receptor for PG El. Both of these approaches have limitations. In the case of
recalculation for the reduction in specific activity, this is primarily due to the potential 
for high errors in calculations in which the bulk of the radioligand has been displaced 
and which, therefore, require a large dilution-factor correction to be applied to a 
relatively small number of specific counts. In the case of the analysis of DeBlasi et aL, 
1989, if the measured IC50 for the unlabelled ligand is high in comparison to the
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ligand concentration employed, errors can be lai'ge as Kd™ IC50-L. Despite these 
concerns, the two approaches provided veiy similai’ results, indicating that the receptor 
is expressed at approximately 100,000 copies/cell and with a Kd of some 30 nM for 
[^HJPGEl. The receptor number data are very much higher than those originally
:
reported for this receptor on NG108-15 cells by Keen et al., 1991 but are in good 
agreement with more recent data from both Adie et at., 1992 and Donnelly et al.,
1992.
Potentially, two distinct approaches are available to measure levels of the
.stimulatory G-protein, Gsa. The first of these is cholera toxin-catalysed [^^P]ADP
sribosylatlon of this polypeptide and the second is by immunological means.
Quantitation of cholera toxin-catalysed [32p]ADP ribosylatlon of G sa is subject to a 
number of constraints including the nature of the guanine nucleotide bound to the 
polypeptide and hence the interaction of the a  subunit with the py complex and the 
availability of polypeptides of the ADP ribosylatlon factor (ARE) family (Donaldson et 
al., 1992). I made no attempt to add purified py subunits to the membranes to assess 
the effect of these on the extent of cholera toxin-catalysed ADP ribosylatlon. Using an 
equivalent quantitative immunoblotting approach to that used herein to measure levels 
of G sa levels of the steady-state level of the p subunit in membranes of NG108-15
cells is some 80 pmol/mg membrane protein (Adie and Milligan unpublished results) 
and, as lower levels of incoiporation of p2p]ADP-ribose into G sa 45 kDa protein
were obtained in the presence of GDP[S] (which should promote the interaction of G- 
protein a  subunits with py) than with GTP[S] (which will dissociate the complex), 
then I would anticipate that addition of py would even reduce incorporation of 
radiolabel and hence the apparent levels of Gga measured by this approach even 
further. As such, cholera toxin-catalysed [^2p]Aj)p ribosylatlon can only provide a 
minimum estimate of the cellulai' levels of Gga. Immunological quantification offers a 
more quantitatively rigorous approach. In these studies, I have used varying amounts 
of the long form of G sa expressed in and subsequently purified from E. coli to 
construct standard curves against which amount of G sa  present in membranes of
%
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NG108-15 cells could be measured. Prokaiyotically expressed G-proteins lack post- 
translational modifications which are essential for the effective functioning of these 
proteins in mammalian cells, but there is no known modification of G$a in the region
'of the polypeptide which serves as the epitope for recognition by the antiserum used in 
these studies. As such, it must be anticipated that immunoreactivity of the recombinant 
G-protein and that expressed in NG108-15 membranes will be equivalent. As with 
other uses of quantitative immunoblotting, the measured signal versus amount of the 
G-protein produced a sigmoidal curve (Figure 3.2.2B) a linear region of 
approximately 2.5-20 ng recombinant protein was routinely recorded which allowed 
quantitation of G§a and demonstrated the presence of some 1,250,000 copies of this 
polypeptide/cell, a value some 12 fold in excess of the IP prostanoid receptor. As it 
has previously been calculated that agonist activation of this receptor is able to result in 
the concurrent down-regulation of some 8 mol GgOt/mol receptor in a cyclic AMP 
independent manner GsOt and it has been argued that this ratio may represent 
stoichiometry of interaction of the IP prostanoid receptor with Ggoc in the presence of 
agonist (Adie et aL, 1992), then full receptor activation might thus be anticipated to be 
able to activate some 6 6 % of the total G-protein pool. The level of Gga assessed using 
cholera toxin-catalysed ribosylatlon was only 6 % of that measured
immunologically and thus further confirms the problems associated with using this 
approach for quantitative purposes. The number of copies of Ggcx/cell calculated here 
is some 5 fold higher than that reported for Gga in S49 lymphoma cells (Levis et aL,
1992) but it must be considered that NG108-15 cells are larger that S49 cells. 
Similarly, higher numbers, but a similar 5 fold higher ratio of Gga/adenylyl cyclase 
complexes/cell was detected in these studies in comparison to S49 cells (Alousi etaL,
ÿ.
1991).
The activation of multiple G-proteins by a receptor allows for amplification of 
the signal but how effective this amplification is must also depend upon the level of 
expression of the effector moiety. The effective adenylyl cyclase catalytic moiety is a 
functional complex of Gga and the adenylyl cyclase polypeptide. This complex is the
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high affinity target for forskoiin binding (Laurenza et a l, 1989; Levis et a l,  1992).
Thus, to measure levels of this complex in NG108-15 cell membranes, I have 
assessed specific high-affinity binding of [^Hjforskolin. As both the fluoroaluminate 
ion (AIF4"; provided as NaF) and the GTP analogue, Gpp(NH)p, are able to activate 
adenylyl cyclase in a pseudo-constitutive fashion, I initially assessed whether the dose 
response curves for activation of adenylyl cyclase and for promotion of high affinity 
binding of [^Hjforskolin in NG108-15 cells membranes by both of these agents were 
identical. As they were (Figures 3.2.3 and 4), this provided strong support for the 
notion that maximal high affinity [^HJforskolin binding under such conditions
provides a quantitative measure of the GgOt/adenylyl cyclase complex. A low affinity 
(approximately 550 nM) but higher capacity site was also evident upon computer
%
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analysis of the forskoiin self-competition binding experiments. The nature of this site 
is undefined (Laurenza et a l ,  1989) but it is possible that the low affinity 
[^HJforskolin site does represent interaction with a population of adenylyl cyclase and 
that the actual level of adenylyl cyclase in the cells is some 5 fold greater than I have 
estimated. However, if so, this adenylyl cyclase does not appear to be relevant to 
either guanine nucleotide or NaF-stimulated adenylyl cyclase activity, as the dose 
response curves of these two agents to activate adenylyl cyclase and to promote the 
high affinity binding of [^Hjforskolin were identical (Figures 3.2.3 and 4). Others 
have also argued that this site, which is observed in a wide range of cells and tissues 
(Laurenza et a l,  1989) is not relevant to adenylyl cyclase regulation by agonists 
(Alousi et a l, 1991).
Recently, isolation of cDNA clones encoding distinct molecular forms of 
adenylyl cyclase have indicated the expression of multiple forms of this enzyme. 
These individual forms are regulated to varying degree (and in both a stimulatory and 
inhibitory fashion) by a number of factors which include py subunits and 
Ca/calmodulin (Tang et a l,  1992; Pieroni et a l, 1993). Within these studies, I have 
not been able to address the nature of the adenylyl cyclase isoforms expressed by 
NG108-15 cells. However, as the membranes of the cells were generated by
I
homogenization in a buffer to which no calcium was specifically added and which 
contains EDTA, then levels of this ion must be low. As such, I may have, to some 
extent, depleted the membranes of calmodulin. This may have reduced the level of 
adenylyl cyclase Î have measured if a calmodulin-sensitive form of the enzyme 
represents a significant fraction of the cellular adenylyl cyclase pool in these cells.
The measured ratio of G^a to the complex of this polypeptide and adenylyl 
cyclase might appear to provide evidence for the effector providing the limiting 
component for the effectiveness of stimulatory regulation of adenylyl cyclase in 
NG108-15 cells. However, it has previously been noted that reduction in cellular 
levels of GgOC following treatment with either the prostanoid agonist iloprost (Kelly et 
al., 1990) or with ethanol (Monchly-Rosen et al., 1988) can be associated with the 
development of sustained heterologous desensitization of the stimulatory arm of 
adenylyl cyclase in NG108-15 cells. Such studies have been used to imply that Gga 
might represent the limiting component for this cascade, at least in these cells. 
Morover, similar studies in rat white adipocytes, where treatment with either 
prostaglandin E l or phenyl-isopropyladenosine leads to a down-regulation of the Gi- 
like G-proteins (Green et a l, 1990) and heterologous desensitization to all antilipolytic 
hormones (Green et a l ,  1992) also indicate the potential for the regulation of G- 
protein level to act as a locus to control cell signaling sensitivity.
One of the aims of these experiments was therefore to assess whether the 
reduction of G§a following prostanoid treatment of NG108-15 cells would be 
sufficient to reduce the ability to form the complex of Gga and adenylyl cyclase. In 
these studies, I found that sustained treatment of NG108-15 cells with iloprost 
resulted in a 35% reduction in cellular amounts of Gga but that despite leaving some 
45 fold excess of Gga in comparison to the measured levels of high affinity 
[% ]forskoiin binding sites, this treatment resulted in a decline by 25% of these sites. 
These obseiwations suggest that it is possible that only a limited fraction of the Gga in 
the cell has access to adenylyl cyclase or that the stoichiometry of G-protein/effector 
must be high to generate a maximal signal. There aie a number of potential reasons for
90
91
both of these possibilities. It has previously been shown in brain that GgOC can interact 
both strongly and selectively with tubulin (Wang et a i, 1990a). Recent studies on S49 
lymphoma cells clearly indicates that agents (e.g. colchicine and vinblastine) wliich are 
able to act to disrupt microtubules increase receptor-mediated cyclic AMP formation 
(Leiber et al., 1993). Furthermore, these agents can increase the amount of 
Gga/adenylyl cyclase complex in cells as assessed by the high affinity binding of
[^HJforskolin (Leiber et ah, 1993). Such observations provide clear evidence for a 
role of the cytoskeletal network in delineating and limiting the physical interactions of 
Gga with adenylyl cyclase. Both in the visual system, where the G-protein transducin 
has been reported to be present in some 10 fold molar excess of the effector, cyclic 
GMP phosphodiesterase (Stryer et al., 1986b) and in S49 lymphoma cells where 
values of 30-80 fold molar excess of Gga over the adenylyl cyclase/Gga complex has 
been calculated (Alousi et al., 1991) the G-protein appears to be more prevalent that 
the effector system it regulates. This may be a reflection of the life time of the GTP- 
bound and hence activated G-protein. Studies with the G-protein G qa and its effector 
phospholipase C (51 indicate that the effector can act as a GTPase activating protein for 
the G-protein (Berstein et al., 1992b), thus limiting the period for which a single G- 
protein can regulate the effector. The same appears to be true for the interactions of 
transducin with the cyclic GMP phosphodiesterase of the visual system (Arshavsky et 
a l, 1992). Although it is yet to be demonstrated directly, these reports suggest that all 
effector systems, including adenylyl cyclase, may act as GTPase-activating protein for 
their relevant G-proteins. If this is true, it may provide a rationale for why a high 
stoichiometry of G-protein/effector is required to provide maximally effective 
regulation of a signaling cascade.
On the other hand, data on the levels of an adenylyl cyclase stimulatory 
receptor, the G-protein, Gg and adenylyl cyclase have been presented concurrently 
only for two cell lines. Alousi has demonstrated that, in S49 lymphoma cells, the 
absolute numbers of 152-adrenoceptor: Gga: adenylyl cyclase are 1,500: 100,000: 
3,500 (Alousi et al., 1991), while in neuroblastoma x glioma hybrid, NG108-15 cells,
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I have shown levels of IP prostanoid receptor: GgCt: adenylyl cyclase are 113,000: 
1,275,000: 17,000. In both these cases the measured levels of the adenylyl cyclase 
catalytic subunit are very much lower than those of the corresponding G-protein, 
suggesting that the adenylyl cyclase is likely to be the limiting component for 
information transfer. If this is so, receptor activation of the cascade might be expected 
to be able to result in virtually complete activation of the theoretically available 
adenylyl cyclase. Therefore, I have examined the ability of receptors to activate 
adenylyl cyclase in NG108-15 cells and in clones generated from these cells which 
have been transfected to express differing levels of the human p2-adrenoceptor. To do 
so I have adopted the strategy of Alousi et al., 1991 in which the ability of agonist to 
promote the formation and maintenance of a high affinity binding site for the diterpene 
forskoiin provides a measure of the formation of the physical complex between 
GgCX and adenylyl cyclase (GSAC). However, one potential concern with these 
studies is that agonist regulation of [^H] forskoiin binding had to be performed at 4 °C. 
I have attempted to measure agonist-stimulation of [^H]forskoiin binding in both 
membranes and whole cells at higher temperatures, but with a lack of success. Such a 
limitation was also noted by Alousi et al., 1991. This is likely to be a reflection that, as 
noted by a variety of workers G-protein GTPase activity is negligible at 4 “C and 
therefore, following stimulation, the GSAC complex will be maintained because the 
G-protein will remain in the active GTP-liganded form, whereas at higher 
temperatures the G-protein would be deactivated and the high affinity complex for 
forskoiin will thus not be stably maintained.
In this study I have demonstrated in membranes of NG108-15 cells that both 
NaF and Gpp(NH)p stimulation of high affinity [^HJforskolin binding (Kd 
approximately 20 nM) have similar dose-effect curves as stimulation of adenylyl 
cyclase activity by these two agents (Figures 3.2.3 and 4). I also demonstrate that the
measured Kd for the binding of [^H]forskoiin to the GSAC complex is similar 
whether it is assessed by examining forskoiin competiton curves for the [^Hjforskolin
binding site following activation of the complex in membranes with the GTP analogue 
Gpp(NH)p or in whole cells by addition of receptor agonist (Figures 3.2.6 and 8 ).
Incubation of parental NG108-15 cells with [^HJforskolin in the absence of 
receptor agonists resulted in veiy little specific binding of this ligand (Figure 3.2,7A). 
However, addition of the IP prostanoid receptor agonist iloprost produced a 
substantial elevation of specific [^Hjforskolin binding. Time courses of these effects 
indicated that maximum levels of binding were obtained by 60 min, both in these cells 
and in the clonal cell lines transfected to express the p2-adrenoceptor (Figure 3.2.7B). 
Dose-effect curves for iloprost demonstrated an EC50 for this effect of some 5 nM 
(Figure 3.2.9). The lack of significant levels of high affinity [^HJforskolin binding in 
the absence of agonist may be taken to indicate that there is little preformed, 
precoupled GSAC complex in NG108-15 cells. The question of whether receptors and 
G-proteins and G-proteins and effectors exist in some fomi of precoupled arrangement 
is one which has been argued over the years from a number of points of view 
(Levitski et a l ,  1990; 1993). In the case of GgOt and adenylyl cyclase, the ability to 
co-purify (Pfeuffer et aL, 1985; Marbach etaL , 1990) or co-immunoprecipitate 
(Morris et al., 1990) a complex containing both adenylyl cyclase and Gga in an 
apparently 1:1 stoichiometric ratio would appear to provide evidence for the 
precoupling of these polypeptides. These experiments, however, have usually been 
performed on samples following preactivation of the G-protein with either a poorly 
hydrolysed guanine nucleotide (e.g. Gpp(NH)p or GTPy(S)) or with a mixture of 
Al^+, Mg2+ and F ' ions. These agents are all predicted to promote an essentially 
irreversible formation of a GSAC complex as they persistently activate adenylyl 
cyclase by producing a quasi-constitutive activation of GgOC. Furthermore it is 
following such pretreatments that forskoiin affinity columns have been noted to be 
most useful for the retention and hence purification of adenylyl cyclase (Pfeuffer et al., 
1985; Marbach et al., 1990). Other studies which have detected the presence of 
preformed GSAC complex have been performed at low ionic strength, an 
inappropriate approach when compared to the intact cell studies reported herein. It has
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forskoiin (Premont et al., 1993; Tang et al., 1992). This antiserum identified an 
appai'ently single polypeptide of some 120 kDa which was present at the same level in 
the three cell lines (Figure 3.2.11). This indicates that there is either a greater 
preponderance of preformed GSAC complex in the absence of hormonal stimulation in 
these cells or that more of this complex, if it exists preformed, is in the GTP-occupied
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also been argued from kinetic considerations that a GSAC complex must exist in the 
absence of hormonal stimulation (Levitski et al., 1990; 1993). However, if the high 
affinity state for [^Hjforskolin binding indeed represents this complex, then it cannot 
exist to any significant degree either in unstimulated whole NG108-15 cells or
membranes from these cells as I observed little or no high affinity binding in the 
absence of hormonal or direct stimulation in the parental cells. An alternative 
possibility is that the high affinity state for [^H]forskoiin is only produced by a 
complex of GTP-GSAC and not by GDP-GSAC. It is difficult, however, to devise 
experiments in whole cells which would allow these possible models to be 
differentiated.
Whereas few specific high affinity [^Hjforskolin binding sites could be 
measured either in the absence of hormonal stimulation in intact wild type NG108-15 
cells or cells of clone pN17 which express relatively low levels of the P2 - 
adrenoceptor, this was not the case in cells of clone PN22  in which levels of this 
receptor are considerably higher (Adie et al., 1993; 1994a). The basal level of high 
affinity forskoiin binding was substantially (some 3 fold) higher than in the other 
two cell lines (Tables 3.2.3 and 4). However, it has previously been demonstrated that 
the basal cellular levels of Gga are the same in these cells (Adie et al., 1994a). 
Furthermore, to exclude that pN22 cells endogenously express higher levels of the 
adenylyl cyclase catalytic moiety, membranes from pN22, pN17 and parental NGlOB­
IS cells were immunoblotted with an antiserum raised against a sequence predicted to 
be highly conserved amongst the known mammalian adenylyl cyclase isoforms 
(Premont et al., 1993). Although there are at least ten known molecular forms of
I
mammalian hormonally regulated adenylyl cyclase, all are targets for regulation by
State. These findings aie entirely in accord with previous observations that membranes 
of pN22 cells have a substantially elevated basal adenylyl cyclase activity compared to 
membranes from either wild type NG108-15 or clone pN17 cells, an effect which was 
interpreted as reflecting the spontaneous intrinsic activation of a fraction of the cellulai' 
GgOt population in clone PN2 2  due to the high levels expression of the pg- 
adrenoceptor (Adie et al., 1994b). This is a general concept which has found support 
in a number of other recent studies which have examined 'negative agonism' at the p2- 
adrenoceptor following expression of this receptor in either mammalian cell lines or in 
insect Sf9 cells (Samama et al., 1994a; Chidiac et al., 1994). Furthermore, after 
expression of the human p2~adrenoceptor in E. coli and reconstitution of membranes 
of these cells with Gg, the p-adrenoceptor antagonist propranolol has been shown to 
be able to reduce the rate of binding of GTPyS below basal levels (Schütz et a i,
1993). Studies of transgenic mice expressing the p2-adrenoceptor in high levels in a 
cardiac tissue specific manner have also provided data consistent with such a model as 
in these animals a spontaneous increase in p2-adrenoceptor function was observed 
(Milano et al., 1994). This observation is consistent with propranolol either displaying 
'negative intrinsic activity' (Milano et a t ,  1994) or simply suppressing the 
spontaneous activity resulting from the high levels of expression of the receptor. An 
alternative explanation for these observations might be that the cells generate sufficient 
endogenous catecholamine during the incubations to activate the receptor population. 
If this were so, it would be expected to result in elevated levels of basal specific
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[2H]forskoiin binding in clone pN22 cells by competing with the endogenously
produced ligand. Although such a hypothesis is consistent with the observations 
made, there are a number of reason why such reasoning is incorrect in this case. (1) If 
propranolol were competing with endogenously generated catecholamine for the ligand 
binding site, then it would be expected to totally reverse the elevated 'basal' level if 
present in sufficiently high concentration. This was not observed; high concentrations 
of propranolol were used in these assays specifically to address this point. Basal 
specific [^HJforskolin binding in clone (3N22 cells was reduced by propranolol but not
detectable levels of catecholamines during the period of the [^Hjforskolin binding 
assay. I have failed to detect measurable levels of catecholamine in the assay medium 
after such incubations.
of the p-adrenoceptor agonist isoprenaline resulted in a substantial increase in high
I
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to the levels observed in the parental NG108-15 cells. (2) Exactly the same partial 
reversal of elevated activity by propranolol has been observed in membranes derived 
from these cells (Adie et al., 1994b). (3) Previous attempts to measure levels of 
endogenously generated catecholamines in the tissue culture medium of pN22 cells at
the moment of cell harvest to assess whether carryover from this could account for the 
increased adenylyl cyclase activity via agonist mediated stimulation of the receptor 
have indicated that both adrenaline and noradrenaline were below detectable levels.
whereas standards at concentrations as low as 125 pM were easily detected (Adie et
%al., 1994b). (4) I have extended these studies to determine whether the cells produce -I
I
In both pN22 and pN17 cells, but not in parental NG108-15 cells, the addition
affinity [^Hjforskolin binding. Maximally effective concentrations of isoprenaline %
caused not significantly greater maximal stimulation of high affinity [^H]forskoiin Ibinding in pN22 cells than that produced in PN17 cells (Table 3.2.3) but the dose- 
effect curve for isoprenaline indicated an EC50 of only 1.5 nM in PN2 2  cells in 
contrast to an EC50 of some 20 nM in pN17 cells (Figure 3.2.10). It has been noted 
previously that the EC50 for isoprenaline-stimulation of adenylyl cyclase in 
membranes of pN22 cells is also substantially to the left of that observed in pN17 If
..3f
cells (Adie et at., 1994b). The absolute EC50 values noted in the [^H]forskoiin 
binding assay were somewhat lower than those recorded for stimulation of adenylyl 
cyclase but this may be a reflection of the differing assay conditions used (whole cells 
vs. membranes, different temperatures). The differences in isoprenaline dose-response 
curves for stimulation of high-affinity pH]forskoiin between these cells indicates that 
a lower fractional occupancy of the receptor population is required to cause stimulation 
of GSAC complex formation in clone PN22 than in clone PN17. It does provide
I
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evidence for a large P2-'adrenoceptor reserve for activation of the adenyiyl cyclase 
cascade in clone BN22 cells.
The addition of iloprost (acting at the endogenously expressed IP prostanoid 
receptor) also led to a dose-dependent increase in formation of the GSAC complex in 
both clone PN17 and clone pN22 cells (Figure 3.2.9B). Iloprost produced a similar 
maximal activation of [^HJforskolin binding in these two cells lines but in contrast 
with the situation for isoprenaline, similar dose-effect curves for iloprost were 
observed. It has been noted previously that clones PN17 and pN22 express similar 
levels of the IP prostanoid receptor (Adie et al., 1994a). A similar dose-effect curve 
for iloprost-stimulation of pHjforskolin binding was also observed in wild type 
NG108-15 cells (Figure 3.2.9A).
Analysis of the mechanism(s) of receptor-mediated inhibition of adenyiyl 
cyclase have led to a variety of proposals (Hildebrandt et al., 1993), but recent studies 
have indicated that at least both a direct inhibition by G |a  and an inhibition via 
receptor-generated free G-protein py subunits may occur in specific situations. One 
model for direct inhibition would envisage competition between G§a and G ia  for a 
common site on the adenyiyl cyclase enzyme. To assess this I added the opioid agonist 
DADLE, which causes inhibition of adenyiyl cyclase in NG108-15 cells via binding to 
the Ô opioid receptor and subsequent activation of Gi20t (McKenzie et al., 1990a) and 
determined whether this altered the increase in specific [^HJforskolin binding induced 
by varying concentrations of iloprost (Table 3.2.5). The failure of DADLE to alter 
either iloprost stimulation of [^H]forskolin binding or to itself promote [^Hlforskolin 
binding can be interpreted to indicate that G^a and G ja do not share a common or 
overlapping site on the adenyiyl cyclase polypeptide.
The results presented in this chapter demonstrate the absolute levels of each 
polypeptide component of G-protein linked transmembrane cellular signaling cascades 
in membranes of wild type NG108-15 cells. In addition, it also demonstrates that 
agonist-stimulation of high affinity binding of [^HJforskolin in intact wild type and 
p2-adrenoceptor expressing NG108-15 cells can provide a good measure of formation
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of the GSAC complex and can be used to quantitatively evaluate the stoichiometry of 
receptor activation of adenyiyl cyclase. The data provided herein argue that previously 
observed elevated levels of basal adenyiyl cyclase activity in cells expressing high 
levels of the p2-adrenoceptor reflect empty receptor stimulation of the cascade, as 
these cells basally contain more preformed, activated copies of the GSAC complex. 
Further information on the cellular location and levels of expression of receptors, G- 
proteins and effectors in a wide range of systems will be required to increase our 
understanding of why cells appear to express considerably greater levels of G-proteins
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than of the relevant effector enzymes and whether there is physical or functional
-
pooling or compartmentalization of these polypeptides as has been suggested in a 
number of recent studies (Ott et a l,  1989; Monchly-Rosen et a l,  1990).
;;S
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3.3.1. Results.
Membranes derived from cells of clones pN22 and PN17 which were 
generated following transfection of neuroblastoma x glioma hybrid, NG108-15, cells 
with a plasmid containing a cDNA encoding the human P2-adrenoceptor (Adie et a i.
‘ù
1994a, b), were examined for expression of this receptor by measuring the specific 
binding of the P-adrenoceptor antagonist pH]dihydroalprenolol (DHA) (2 nM). PN22 
and pN17 cells were treated with varying concentrations of the irreversible P~ 
adrenoceptor antagonist bromoacetyl alprenolol methane (BAAM) for 4 h prior to cell 
harvest. Membranes prepared from these cells were then assessed for the number of 
remaining specific [^HJDHA binding sites (Figure 3.3.1 A). Half-maximal reduction in 
the number of available p2-adrenoceptors was achieved by treatment with some 25 nM 
BAAM and treatment with 10 jiM BAAM reduced the number of p2-adrenoceptors 
binding sites detected by pH]DHA by some 90%. Saturation binding studies using 
pH]DHA demonstrated that the effect of BAAM (100 nM) treatment was to reduce the 
available P2-adrenoceptor population (Bmax) in membranes prepared from the treated- 
cells without altering the measured affinity of the remaining receptors for [3H]DHA 
(Kd in control membranes was 0.84 ±0.1 nM and in membranes of BAAM-pretreated 
cells was 0.90 ± 0.23 nM) (Figure 3.3.IB). Such data indicated that BAAM had been 
effectively removed during the production and washing of the membrane preparations 
and thus was not present to compete and potentially interfere in subsequent functional 
assays.
Sustained (8  h) exposure of clone pN22 cells to maximally effective 
concentrations of either the IP prostanoid receptor agonist, iloprost (10 pM) or the p- 
adrenoceptor agonist isoprenaline (10 pM) resulted in some 50% down-regulation of 
cellular levels of the a  subunit of the stimulatory G-protein of the adenyiyl cyclase
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cascade, Gga (Figure 3.3.2). Such treatments did not alter cellular levels of other G-
proteins expressed by these cells (Adie et al., 1994a). Following pretreatment of the 
cells with BAAM (10 pM, 4h) no alteration in the ability of this concentration of 
iloprost to down-regulate GgOt was noted. By contrast, a substantial reduction in the 
effect of 10 pM isoprenaline was observed (Figure 3.3.2). This pattern of reduced 
effectiveness of isoprenaline to cause down-regulation of GgOt was observed over a 
range of isoprenaline concentrations (Figure 3.3.3) following treatment with 10 pM 
BAAM. At all concentrations of isoprenaline tested the degree of down-regulation of 
Ggoc was reduced and there was a substantial shift (some 50 fold) to higher 
concentrations in the requirement for isoprenaline to cause half-maximal reduction in
GgOC levels (Figure 3.3.3). However, no significant alteration in the dose-effect curve 
for iloprost-mediated GgOt down-regulation was observed following such treatment 
with BAAM (data not shown).
Preincubation of cells of clone pN22 with varying concentrations of BAAM (1 
nM - 10 pM) followed by subsequent exposure to a maximally effective dose of 
isoprenaline (10 pM) demonstrated that the ability of the agonist to cause GgOC down- 
regulation was compromised as increasing numbers of the p2-adrenoceptor were 
eliminated (Figure 3.3.4). Half-maximal reduction in the ability of 10 pM isoprenaline 
to cause elimination of Gga was obtained following treatment with 100 nM BAAM 
(Figure 3.3.4). Even following treatment with 10 pM BAAM the maximal ability of
-
isoprenaline to stimulate adenyiyl cyclase activity in membranes of PN22 cells was 
only slightly lower than in membranes of untreated cells although the dose-effect curve 
for isoprenaline was shifted to significantly higher concentrations (Figure 3.3.5).
In addition, adenyiyl cyclase assays were performed on membranes of both 
pN22 and PN17 cells using a range of p-adrenoceptor ligands. Basal adenyiyl cyclase 
activity varied some two fold in membrane preparations from individual cell passages 
(an observation not unusual for cultured cell lines) but in the absence of receptor 
ligands was routinely higher in membranes of PN22 cells than in those from pN17 
cells as reported previously (Adie et al., 1994b). Concentration-response curves for
:£
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adenyiyl cyclase stimulation in pN22 and pN17 membranes by each of isoprenaline, 
salbutamol and ephedrine demonstrated that each dmg had greater potency (as well as 
higher measured intrinsic activity in the cases of ephedrine and salbutamol) in 
membranes of PN2 2  than in PN17 and that the maximal effectiveness of stimulation of 
adenyiyl cyclase which could be achieved by each of these agents was produced with 
concentrations at or below 10 pM (Table 3.3.1). It was observed that isoprenaline (10 
pM) stimulated adenyiyl cyclase activity to similar maximal levels in membranes from 
cells of clones PN2 2  and PN17 (PN17 isoprenaline-stimulated adenyiyl cyclase
Iactivity was 82.0 ± 8.2% (mean ± S.D., n = 6 ) of that seen in pN22 cells); see also (Adie e ta l,  1994a). Using the values obtained for isoprenaline (10 pM) as a reference 
( 1 0 0%), the other p-adrenoceptor ligands were observed to display a range of intrinsic 
activities in these membranes (Table 3.3,1). A similar profile to that obtained in the 
adenyiyl cyclase assay was also generated by use of agonist-driven high affinity 
[^Hjforskolin binding in whole cells (MacEwan etaL, 1995). Concentration-response 
curves for epinephrine indicated similar potency in PN22 cells in both the adenyiyl 
cyclase and [3H]forskolin binding assays (EC50 = 30.3 ±3.1  nM and 7.5 ± 0.9 nM
receptively, mean ± S.D. of triplicate determinations) I have previously noted that the 
[^HJforskolin binding assay also resulted in a somewhat lower EC50 value for
isoprenaline in cells of clone pN22 and pN17 compared to the adenyiyl cyclase assay 
(chapter 3.2 and Adie et al., 1994b).
If the alteration in measured intrinsic activity of the P-adrenoceptor partial 
agonists between clones PN22 and pN17 was truly a reflection of differences in 
receptor levels between these two clones rather than a trivial difference based on 
specific features of these particular clonal isolates, I predicted that functional ablation 
of varying proportions of the P2-adrenoceptor population in cells of clone PN2 2  
would decrease the potency and also the measured intrinsic activity of p-adrenoceptor 
partial agonists. Adenyiyl cyclase assays performed on membranes derived from
■ Icontrol and BAAM (10 pM, 4h)-treated pN22 cells demonstrated that while there was 
a significant decrease in potency for isoprenaline in the BAAM-treated cells, the
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intrinsic activity of isoprenaline was reduced to only some 80% of that observed in 
membranes from the untreated cells (Table 3.3.1). BAAM (1 pM) treatment of pN22 
cells resulted in a 14 fold shift in the epinephrine concentration-effect curve, with 
minimal diminution in the maximal epinephrine-stimulated adenyiyl cyclase activity, 
demonstrating a receptor reserve. However, for each of salbutamol and ephedrine both 
a reduction in potency and in measured intrinsic activity was observed following 
BAAM (1 pM) treatment (Table 3.3.1 and Figure 3.3.6). To examine this point in 
more detail the intrinsic activity of isoprenaline, salbutamol and ephedrine was 
measured in either adenyiyl cyclase assays (Figure 3.3.6A) or using agonist-driven 
high affinity [^HJforskolin binding (Figure 3.3.6B) in pN22 cells and membranes 
following treatment with a range of concentrations of BAAM for 4h. At the highest 
concentration of BAAM examined (10 pM) the measured intrinsic activity of 
isoprenaline was reduced, as noted above, by only some 15-20% in either assay, but 
the measured intrinsic activity of the partial agonists ephedrine ( 10% of maximal 
isoprenaline response) and salbutamol (approximately 25% of maximal isoprenaline 
response) were reduced substantially compared with those observed in untreated cells 
(Figure 3.3.6). The intrinsic activity of ephedrine, which was demonstrated to be 
lower than that of salbutamol in untreated pN22 cells (Table 3.3.1) was clearly 
compromised following treatment with lower concentrations of BAAM than was that 
of salbutamol (Figure 3.3.6). Furthermore, the data indicated that isoprenaline would 
require elimination of a greater amount of the receptor population than could be 
achieved in these experiments to significantly compromise its intrinsic activity (Figure 
3.3.6).
To examine to what extent the p2~adrenoceptor population would have to be 
reduced to restrict the intrinsic activity of isoprenaline to 50% of that observed in 
untreated cells, cells of clone pN17 were treated with varying concentrations of 
BAAM. Subsequently the ability of a concentration of isoprenaline sufficient to fully 
occupy the available receptors to stimulate adenyiyl cyclase or to promote the specific 
high affinity binding of [^HJforskolin was then assessed (Figure 3.3.7). A reduction
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in the intrinsic activity of isoprenaline to 50% of that in untreated pN17 cells was 
achieved following treatment with approximately 2 pM BAAM. As this concentration 
of BAAM was demonstrated to eliminate binding of [^HjDHA to 90% of the 
expressed p2-adrenoceptors on these cells (Figure 3.3.1), this indicates that maximal 
occupancy of a p2-adrenoceptor population of approximately 50 fmol/mg membrane 
protein (corresponding to around 3000 receptors/pN17 cell) with this agonist would 
be sufficient to generate a half-maximal adenyiyl cyclase response in these cells. To 
extend such analysis I assessed the levels of receptor required to be occupied by each 
of isoprenaline, salbutamol and ephedrine to obtain different degrees of intrinsic 
activity for these ligands (Figure 3.3.8). Ephedrine, as mentioned above, failed to act 
as a full agonist even in membranes and cells of clone PN22 but 50% of the maximal 
possible receptor-mediated activation of the adenyiyl cyclase was achieved by 
occupancy by maximally effective concentrations of ephedrine of some 1800 fmol/mg 
membrane protein of the P2 -adrenoceptor while salbutamol required occupancy of 
some 500 fmol/mg membrane protein of the receptor (Figure 3.3.8). Such data
demonstrate why isoprenaline and salbutamol act as full agonists in cells and 
membranes of clone PN2 2  while isoprenaline but not salbutamol is a full agonist in 
clone pN17. It further explains why ephedrine is not a full agonist in either system.
I have already demonstrated, in NG108-15 cells transfected to express vaiying 
levels of the human P2-adrenoceptor, that maximal adenyiyl cyclase activity can be 
achieved by occupation by isoprenaline of only some 2 0 0  fmol/mg membrane protein 
of this receptor. Expression of higher levels of the receptor do not result in greater 
adenyiyl cyclase activity but only in a progressive shift in the agonist concentration- 
response curve to lower concentrations (Adie etal., 1994b), indicative of the presence 
of spare receptors. Increased expression of Gga in this genetic background, as 
anticipated from the basal stoichiometries noted above, does not result in any 
significant alteration in the maximal effectiveness of the adenyiyl cyclase cascade (I. 
Mullaney and G. Milligan, unpublished observations), even though receptors can 
access and activate the introduced Ggoc as effectively as the endogenous G-protein
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pool (Mullaney et a l ,  1994). To further extend such analyses, I have isolated stable 
clonal cell lines following transfection of adenyiyl cyclase type 2 (Feinstein et a l.
1991; Lustig et a l,  1993) into this genetic background and examined how this alters 1
the effectiveness of signal transduction from both endogenously expressed and stably 
ti’ansfected GsOC-coupled receptors in clones in which the total adenyiyl cyclase content 
of the cell is increased by up to ten fold.
To do so, clone PN22 was further transfected in a 10:1 ratio with a 
combination of a cDNA encoding adenyiyl cyclase type 2 in plasmid pcDNAl and 
plasmid pBABEhygro which allows expression of resistance to the antibiotic 
hygromycin B. Colonies were selected following exposure to hygromycin B (200 
pg/ml) and expanded. The presence of mRNA encoding adenyiyl cyclase type 2 in 
both parental pN22 cells and a number of the isolated colonies was assessed by 
reverse transcriptase-polymerase chain reaction performed on RNA isolated from these
cell lines with a primer pair (chapter 2.2.23) designed to amplify a 980 bp fragment 
specifically from the type 2 isoform of adenyiyl cyclase. At this level of sensitivity no
adenyiyl cyclase type 2 mRNA could be detected in clone pN22 cells but a clear 
signal, of varying magnitude, was detected in a number of the clones isolated 
following transfection with the adenyiyl cyclase type 2 cDNA (Figure 3.3.9). As a 
positive control for the effectiveness of the primers in these experiments, the adenyiyl 
cyclase type 2 cDNA in plasmid pcDNAl was used. Such reactions also generated an 
980 bp fragment (Figure 3.3.9). Equivalent polymerase chain reaction experiments 
performed with primer pairs designed to detect the presence and expression of either 
type 1 or type 6  adenyiyl cyclase have demonstrated the expression of mRNA
encoding the type 6  but not the type 1 adenyiyl cyclase in these cells (E. Kellett and G.
Milligan unpublished observations).
I have previously made use of the stimulation of specific high affinity binding 
of [^HJforskolin to cell membrane preparations by the poorly hydrolysed analogue of 
GTP, Gpp(NH)p, to detect the presence and formation of a complex of GgOC and 
adenyiyl cyclase in NG108-15 and PN22 cells (chapter 3.2). Equivalent studies on
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membranes of clone pN22 and of clones designated AC2.4, AC2.5, AC2.7 and 
AC2.9 demonstrated that the guanine nucleotide-stimulated binding of [^HJforskolin 
to membranes of each of these cells was substantially higher than in clone pN22, with 
the highest levels of binding observed in clone AC2.7 (Table 3.3.2). Confirmation 
that this elevated specific binding of [^Hlforskolin represented an increase in the total 
number of GgOC-adenylyl cyclase complexes which could be formed in clone AC2.7 
by exposure to Gpp(NH)p was produced by performing such binding assays on 
membranes of clones PN22 and AC2.7 in the presence of Gpp(NH)p (100 pM) with a 
fixed concentration of [^HJforskolin and increasing concentrations of non-radioactive 
forskolin. Specific [^Hjforskolin binding to 100 pg of membranes from clone AC2.7 
was displaced by self-competition with unlabelled forskolin in a concentration- 
dependent manner (Figure 3.3. lOA). Greater amounts of membranes (300 pg) from 
clone PN22 were needed to generate enough specific [^HJforskolin binding for 
analysis. Subsequent correction of the specific binding data for dilution of the specific 
activity of [^H]forskolin and display of the derived data as a linear transformation
I
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(Figure 3.3. lOB) allowed demonstration of at least 6  fold higher levels of Gga-
adenyiyl cyclase complexes in clone AC2.7 compared to clone pN22. Slightly 
different best estimates of the binding affinity of [^H]forskolin to the membranes of 
these two clones was observed (Figure 3.3.lOB) but I cannot be certain if this 
indicates somewhat different binding affinities of pH]forskolin to the complex of Gga
'with different adenyiyl cyclase isoforms or simply reflects the quantitative difficulties 
inherently associated with estimations of such parameters when they can only be 
obtained via such self competition studies (DeBlasi et a i, 1989).
Both clones AC2.4 and AC2.7 were demonstrated to have retained similarly 
high levels of the p2~adrenoceptor as clone PN22, as measured by the specific binding
of the P-adrenoceptor antagonist [^HJDHA (Table 3.3.3). Furtherm ore, 
immunodetectable level of the adenyiyl cyclase stimulatoiy G-protein, Gga or the 
phosphoinositidase C-linked G-proteins, GqO/Gl l a  were not different in membranes 
of clones AC2.4 and AC2.7 compared to clone PN22 (MacEwan et al., 1996),
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Basal adenyiyl cyclase activity in membranes of clones AC2.7 and AC2.4 was
■substantially elevated in comparison to clone PN22 (Figure 3,3.11, (also Figures 
3.3.12A and 13A)) and addition of forskolin (100 pM), Gpp(NH)p (100 pM) or NaF
:(10 mM) produced markedly higher adenyiyl cyclase activities in each of these two 
clones compared to clone pN22 (Figure 3.3.11). Isoprenaline (acting at the P2- 
adrenoceptor) or iloprost (acting at the endogenously expressed IP prostanoid 
receptor) (both at 10 pM) resulted in an activation of adenyiyl cyclase activity in 
membranes of both clones AC2.4 and AC2.7 far above that obtained in membranes 
from clone pN22 (Figure 3.3.12A). However, agonist occupancy of the endogenous 
bradykinin B2  receptor (a receptor which stimulates the activity of phosphoinositidase
C) resulted in no stimulation of the adenyiyl cyclase activity in membranes derived
from any of the clones studied (Figure 3.3.12). A similar pattern was observed by 
measuring the ability of isoprenaline or iloprost to stimulate the specific high affinity 
binding of [^HJforskolin in whole cells of these clones (Figure 3 .3 .12B). 
Concentration-response curves to isoprenaline indicated, however, little difference in 
EC 50 values for adenyiyl cyclase stimulation in clones pN22, AC2.4 and AC2.7 
(EC50S of 12.8, 12.1 and 13.8 nM respectively) (Figure 3.3.13). The p-adrenoceptor 
partial agonist ephedrine caused greater adenyiyl cyclase activity in clones AC2.4 and 
AC2.7 than in membranes of clone pN22 (data not shown). Despite this, when 
compared to the effect of isoprenaline the measured efficacy of ephedrine was 
unaltered between the clones (Figure 3.3.14) and concentration-effect curves for 
adenyiyl cyclase stimulation by ephedrine were very similar in membranes of clone 
pN22 and clone AC2.7 (Figure 3.3.14). A variety of p-adrenoceptor ligands of 
differing efficacy again showed little alteration in their intrinsic activities when 
stimulating adenyiyl cyclase activity in membranes from clone pN22 and AC2.7 
(Figure 3.3.15).
Both secretin and A2  adenosine receptors are expressed endogenously by 
NG108-15 cells. Agonists at each of these receptors (secretin and 5'-N- 
ethylcarboxamidoadenosine (NECA) respectively) also produced substantially greater
'I
total adenyiyl cyclase activity in clone AC2.7 compared to clone PN22 (Table 3.3.4). 
However, when compared to the effect of isoprenaline the activities of these two 
agonists was again very similar and concentration-effect curves displayed no 
significant alterations in the EC50S for these agents in stimulation of adenyiyl cyclase 
activity (Figure 3.3.16).
Figure 3.3.1. 
The effect of BAAM treatment on specific binding of [^H]DHA to 
membranes of pN22 and pN17 cells.
Panel A shows that BAAM pretreatment reduces the detected number of 
specific [^H]DHA binding sites. Cells of clone PN22 and pN17 were treated in 
culture with varying concentrations of BAAM (up to 10 pM) for 4 h. Following cell 
harvest and membrane preparation the specific binding of a single concentration of 
[^HJDHA to available p2-adrenoceptors was measured as described in chapter 2.2.16.
The results are the mean ± S.D. of triplicate determinations, from 2 experiments.
Panel B shows that BAAM pretreatment reduces maximal binding of [^HJDHA 
without altering the affinity of the remaining receptors for [^H]DHA. Cells of clone 
PN22 were untreated (circles) or treated with BAAM (100 nM) for 4 h (squares). 
Membranes were subsequently prepared and saturation binding studies performed 
with [^HjDHA to determine both the maximal capacity and affinity of this ligand for 
the available receptors. Data is presented as a Scatchard analysis. In the example 
displayed Bmax was 3796 fmol/mg membrane protein in the control membranes and 
1142 fmol/mg membrane protein in the BAAM-pretreated cells while the Kd for 
[3H]DHA was 0.74 nM in the controls and 0.67 nM following treatment with BAAM.
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Figure 3.3.2,
Treatment of clone |3N22 cells with BAAM restricts Pi-adrenoceptor but 
not IP prostanoid receptor agonist-mediated down-regulation of GgOt.
«
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Clone pN22 cells were untreated (control) or treated with BAAM (10 pM, 4h), 
washed extensively and then either left in the absence of ligand (CON) or treated with 
iloprost (10 pM) (ILO) or isoprenaline (10 pM) (ISO) for 8 h. The cells were 
harvested, membranes generated and immunoblotted for the presence of Gsoc. Data aie 
presented as mean ± S.D.M. from 3 separate experiments.
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Figure 3.3.3.
BAAM treatm ent of clone |3N22 cells reduces the potency of 
isoprenaline-mediated Gga down-regulation.
Clone pN22 cells were untreated or treated with BAAM (10 jxM, 4h) and 
subsequently challenged with varying concentrations of isoprenaline for 8 h. 
Membranes were prepared and the relative levels of GgOt determined immunologically 
using antiserum CS, at dilution of 1: 250, as described in chapter 2.2.12.
Immunoblots A and B represents cells of clone pN22 which were treated and 
untreated with BAAM respectively. Subsequent treatment with isoprenaline: lane 1, 
control; lane 2, 1(X) pM; lane 3, 1 nM; lane 4, 10 nM; lane 5, 100 nM; lane 6 , 1 pM; 
lane 7, 10 pM.
The data of immunoblots A and B was analysed and is displayed as the % of 
maximal effect of isoprenaline (produced by 10 pM) on membrane levels of Gga. In 
the example displayed the estimated EC50 for isoprenaline-induced down-regulation of 
Gga was 1.3 nM in the cells which had not been exposed to BAAM (filled symbols) 
and 78 nM in the cells which had been pretreated with BAAM (open symbols). Similar 
results were obtained in two other independent experiments.
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Figure 3,3.4.
The effect of BAAM on isoprenaline-induced down-regulation of Gga;
Dose-effect analysis.
Clone pN22 cells were untreated or treated for 4 h with varying concentrations 
of BAAM and subsequently with isoprenaline (10 pM, 8 h). Relative levels of Gga in 
membranes from these cells were then assessed immunologically. Data is presented as 
the % of the membrane Gga which was down-regulated by isoprenaline at each 
concentration of BAAM.
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Figure 3 .3 .S.
The effect of BAAM on isoprenaline stimulation of adenyiyl cyclase 
activity.
Membranes were prepared from control (open symbols) and BAAM (10 pM, 
4h)-treated (filled symbols) pN22 cells and the ability of varying concentrations of 
isoprenaline to stimulate adenyiyl cyclase activity measured as described in chapter 
2.2.17. Results are presented as % of the maximal effect of isoprenaline in membranes 
of untreated cells. This was a representative experiment (mean ± S.D.) of which two 
others were performed which gave similai' results.
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Figure 3.3.6.
Receptor availability regulates the measured intrinsic activity of P- 
adrenoceptor active ligands in pN22 cells.
Panel A represents adenyiyl cyclase assays. Membranes were prepared from 
clone PN22 cells which had been pretreated with varying concentrations of BAAM for 
4 h. Adenyiyl cyclase activity and its regulation by maximally effective concentrations 
(10 pM) of isoprenaline (filled circles), epinephrine (open circles), salbutamol (filled 
squares) and ephedrine (open squares) was subsequently assessed. Results are 
presented as % of the effect obtained in membranes of untreated cells by 10 pM 
isoprenaline. In the experiments displayed, basal adenyiyl cyclase activity in PN22 
and pN17 preparations was 61.4 ± 4.2 and 40.5 ± 5.2 pmol/min/mg membrane 
protein respectively. 10 pM isoprenaline-stimulated adenyiyl cyclase activity in PN22 
and pN17 preparations was 186.4 ± 6.4 and 136.3 ± 23.9 pmol/min/mg membrane 
protein respectively (mean ± S.D.M., n=3).
Panel B represents pH]forskolin binding assays. The ability of maximally 
effective concentrations (10 pM) of isoprenaline (filled circles), salbutamol (open 
circles) and ephedrine (filled squares) to stimulate high affinity [^H]forskolin binding 
in clone pN22 cells which had been pretreated with varying concentrations of BAAM 
for 4 h was assessed as described in chapter 2.2.16. Results are presented as % of the 
effect produced in untreated cells by 10 pM isoprenaline. Control specific 
pH]forskolin binding represented 643 ± 103 dpm/10^ cells (mean ± S.D.M., n = 3).
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Figure 3.3.7.
Regulation by receptor availability of the measured intrinsic activity of 
isoprenaline in PN17 cells.
Clone pN17 cells were pretreated with varying concentrations of BAAM for 
4h. Either these were used directly in [^HJforskolin binding assays (squares) or 
membranes were prepared from these cells and adenyiyl cyclase activity (circles) 
measured as described in chapter 2.2.16 and 2.2.17 respectively. The effect of a 
maximally effective concentration of isoprenaline (10 jiM) was assessed in both these 
assays. Results are presented as % of the effect obtained in membranes of untreated 
cells by 10 pM  isoprenaline. The results are the mean ± S.E. of triplicate 
determinations.
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Figure 3.3.8.
Analysis of receptor levels in defining the observed intrinsic activity of 
p-adrenergic ligands.
Adenyiyl cyclase activity (filled symbols) and agonist regulation of 
[^Hjforskolin binding (open symbols) was measured in the presence of 10 jiM 
isoprenaline (circles), salbutamol (squares) or ephedrine (triangles) in membranes 
(adenyiyl cyclase activity ) or whole cells ([^H] forskolin binding) of clone pN22 and 
pN17 which were either untreated or exposed to varying concentrations of BAAM. 
Data is presented for each ligand as the % of the maximal response which could be 
achieved in this genetic background (10 pM isoprenaline, untreated pN22 cells and 
membranes) vs. the number of P2-adrenoceptors available to be occupied.
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Figure 3.3.9.
Generation and isolation of clones derived from PN22 cells which 
express adenyiyl cyclase type 2.
A cDNA encoding adenyiyl cyclase type 2 (4.0 kb) (a kind gift from Dr. H.R. 
Bourne, UCSF, CA) was subcloned into the EcoRl site of the eukaryotic expression 
vector pcDNAl (4.1 kb). Cells of clone PN22 were co-transfected with a 10: 1 ratio 
of the cDNA encoding adenyiyl cyclase type 2 in plasmid pcDNAl and plasmid 
pBABEhygro, which is able to direct expression of the hygromycin B resistance 
marker, by using DOTAP transfection reagent (Boehringer Mannheim) according to 
the manufacturer's instructions. After transfection the cells were maintained in medium 
containing hygromycin B (200 pg/ml). Individual colonies were selected, expanded 
and subsequently examined for the maintained expression of the p2-adrenoceptor and 
novel expression of adenyiyl cyclase type 2 .
Expression of adenyiyl cyclase type 2 in clone pN22 cells was detected by RT- 
PCR. RNA was isolated from clone pN22 cells (lane 2) and from clones AC2.5 (lane 
3), AC2.7 (lane 4), AC2.9 (lane 5) and AC2.4 (lane 6 ). These RNA preparations 
were reverse transcribed and polymerase chain reaction then performed using the 
primers for adenyiyl cyclase type 2 noted in chapter 2.2.23 (C). These were designed 
to generate a 980 bp fragment from adenyiyl cyclase type 2. As a positive control a 
cDNA encoding adenyiyl cyclase type 2 in plasmid pcDNAl was also subjected to 
polymerase chain reaction under identical conditions (lanes 7 and 8 ). Size markers (1 
kb DNA ladder) in bp are displayed in lane 1.
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Figure 3.3.10.
Adenyiyl cyclase type 2 positive clone AC2.7 expresses higher levels 
of guanine nucleotide-stimulated [^H]forskolin binding than parental 
PN22 cells.
Panel A: Membranes (100 jxg) from clone AC2.7 were incubated with 10 nM 
[3H]forskolin and Gpp(NH)p (100 jiM) as described in the chapter 2.2.16 in the 
presence of vaiying concentrations of non-radioactive forskolin as indicated. The data 
represent the mean ± S.D. of triplicate determinations. Similar self-competition 
displacement assays for PN2 2  clone were performed as here, except using 300 jig of 
membranes per assay and 10 nM [^Hjforskolin (data not shown but see chapter 3.2).
Panel B: Membranes from clones PN22 (300 pg) and clone AC2.7 (100 pg) 
were incubated with forskolin and Gpp(NH)p (100 pM) as described in chapter 
2.2.16 in the presence of varying concentrations of forskolin. The specific binding 
data from such experiments were corrected for dilution of the specific activity of the 
[^H]forskolin and analysed by the method of Rosenthal et al., 1967. The number of 
high affinity binding sites for [^HJforskolin were markedly higher in membranes of 
clone AC2 .7  compared to clone pN2 2  (Bmax estimated at 609 and 125 fmol/mg 
respectively in the example displayed). Estimates of the Kd for binding of forskolin to 
membranes of clones PN22 and AC2.7 were 36 and 63 nM respectively. The data 
represent the mean of determinations performed in triplicate.
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Figure 3.3.11.
Increased basal and G s«-stim ulated adenylyl cyclase activity in 
membranes of adenylyl cyclase type 2 expressing cells.
Adenylyl cyclase activity was measured in membranes (10 |ig) of clones 
pN22, AC2.4 and AC2.7 in the absence (basal) or presence of forskolin (100 pM), 
isoprenaline (10 pM), Gpp(NH)p (100 pM) or AIF4- (provided as NaF (10 mM)). In 
the experiment shown, the basal adenylyl cyclase activities in clones pN22, AC2.4 
and AC2.7 were 60 ± 2, 605 ± 24 and 896 ±21 pmol/min/mg respectively. The data 
represent the mean ± S.D. of triplicate detemiinations.
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Figure 3.3.12.
Increased adenylyl cyclase activity and numbers of G s« -a d en y ly l 
cyclase complexes formed in réponse to isoprenaline or iloprost in 
adenylyl cyclase type 2 expressing cells.
Adenylyl cyclase activity (panel A) was measured in membranes (10 pg) of 
clones pN22, AC2.4 and AC2.7 in the absence or presence of isoprenaline (10 pM), 
iloprost (10 pM) or bradykinin (10 pM). The data represent the mean ± S.D. of 
triplicate determinations.
Whole cell specific forskolin (14 nM) binding (panel B) was measured in 
clones PN22, AC2.4 and AC2.7 in the absence (basal) or the presence of isoprenaline 
(10 pM), iloprost (10 pM) or bradykinin (10 pM). The presence of 10 pM forskolin 
determined non-specific binding which was subtracted from the remaining conditions. 
The data represent the mean ± S.D. of quadruplicate determinations.
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Figure 3.3.13.
Isoprenaline-stimulated adenylyl cyclase activity: concentration-effect 
analysis in membranes from clones pN22, AC2.4 and AC2.7.
Adenylyl cyclase activity (panel A) was measured in membranes (10 pg) of 
clones PN22, AC2.4 and AC2.7 in the absence or presence of varying concentrations 
of isoprenaline. The data represent the mean ± S.D. of triplicate determinations from a 
typical experiment.
In panel B, the data from panel A was normalised relative to adenylyl cyclase 
activity produced by a maximally effective concentration of isoprenaline (10 pM in 
each case).
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Figure 3.3.14.
The efficacy and potency of ephedrine to stimulate adenylyl cyclase is 
not altered by overexpression of adenylyl cyclase type 2.
Ephedrine concentration-response curves for adenylyl cyclase activity in 
membranes (10 pg) of clones (3N22 and AC2.7 were compared. Data is normalised to 
the response concurrently observe to a maximal concentration (10 pM) of 
isoprenaline. In the experiment shown, basal adenylyl cyclase activity was 54 ± 8 and 
693 ± 20 pmole/min/mg and 10 pM isoprenaline-stimulated activity was 169 ± 7 and 
3006 ± 45 pmole/min/mg in clones |3N22 and AC2.7 respectively. The data represent 
the mean ± S.D. of triplicate determinations.
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Figure 3.3.15.
The efficacies of p-adrenoceptor agonists are not altered by 
overexpression of adenylyl cyclase type 2.
The effect on adenylyl cyclase activity of a maximally effective concentration 
(10 pM) of agonists acting at the p^-adrenoceptor displaying a range of efficacies was 
compared in membranes (10 pg) of clones PN22 and AC2.7. Data is normalised to 
that seen with isoprenaline. In the experiment shown, basal adenylyl cyclase activity 
was 33 ± 3 and 491 + 14 pmole/min/mg and 10 pM isoprenaline-stimulated activity 
was 160 ± 6  and 1748 ± 43 pmole/min/mg in clones PN22 and AC2.7 respectively. 
The data represent the mean ± S.D. of triplicate determinations.
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Figure 3.3.16.
The efficacy and potency of secretin and the adenosine receptor agonist 
NECA are not altered by overexpression of adenylyl cyclase type 2.
Secretin and S'-N-Ethylcarboxamidoadenosine (NECA) concentration- 
response curves for adenylyl cyclase activity in membranes (10 pg) of clones PN22 
and AC2.7 were compared. Data is normalised to the response concurrently observe to 
a maximally effective concentration (10 pM) of isoprenaline. The data represent the 
mean ± S.D. of triplicate determinations. The data is representative of a single 
experiment. Three further experiments produced similar results.
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Table 3.3.2.
Adenylyl cyclase type 2 positive clones express elevated levels of 
guanine nucleotide-stimulated [^HJforskolin binding.
Membranes (100 pg) prepared from each of clone PN22 and the adenylyl 
cyclase type 2 mRNA positive clones used in Figure 3.3.9 were examined for 100 pM 
Gpp(NH)p-dependent specific high affinity [^HJforskolin (10 nM) binding as 
described in chapter 2.2.16. The data represent the mean ±  S.D. of triplicate 
determinations, from a single experiment. Thiee further experiments produced similar 
results.
Clones
Gpp(NH)p-stimulated adenylyl
cyclase activity (pmole/min/mg)
pN22 48.4 ± 0.6
AC2.4 294.2+ 5.4
AC2.5 292.1 ± 4.2
AC2.7 432.6+ 11.9
AC2.9 160.5 ± 8.9
3
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Table 3.3.3.
Clones pN22, AC2.4 and AC2.7 express similar levels of the p2 - 
adrenoceptor.
:
ip2-adrenoceptor expression was measured in membranes (1 0  pg) of clones 
PN22, AC2.4 and AC2.7 as judged by the specific binding of a single concentration 
of [^HjDHA (see chapter 2.2.16). The data represent the mean ± S.D. of triplicate 
determinations. The data is representative of two experiments performed on separate 
membrane preparations.
Specific [^H]DHA binding
Clones (fmole/mg protein)
PN22 2790± 150
AC2.4 2740± 150
AC2.7 3040 ± 160
01
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Table 3.3.4.
Stimulation of adenylyl cyclase activity in clones pN22 and AC2.7 by 
secretin and NECA.
Adenylyl cyclase activity was measured in membranes (10 pg) of clones pN22 
and AC2.7 in the absence (basal) or presence of a maximally effective concentration of 
secretin, 5'-N-Ethylcarboxamidoadenosine (NECA) or isoprenaline. The data 
represent the mean ± S.D. of triplicate determnations, from a single experiment. Three 
other experiments produced similar results.
Condition
Basal
Secretin (30 pM) 
NECA (lOpM) 
Isoprenaline (10 pM)
Adenylyl cyclase activity 
(pmole/min/mg)_____
PN22 A C 2.7
85 + 20 
245 + 10 
155 ± 10 
350 ± 15
1320 ± 60 
3530± 190 
2430+ 65 
4970 ± 380
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3 .3 .2 . D iscussion.
Although agonist-induced down-regulation of receptors has been studied for 
many years and is appreciated to provide a means to regulate cellular sensitivity to 
agonist ligands (Lohse et al., 1993) the concept that agonist treatment can also regulate 
the cellular content of G-proteins has taken longer to be accepted and has been more 
recalcitrant to analysis. In a variety of circumstances sustained exposure of a cell to an
expressing much lower levels (some 300 fmol/mg membrane protein) of the receptor 
(Adie et al., 1994a). While such results provide evidence for the concept that agonist-
agonist ligand does result in a substantial reduction in cellular levels of the G- 
protein(s) which is activated by the receptor (Milligan et al., 1993c). However, such 
effects are not observed for all systems and for all agonists. For example, in the 
neuroblastoma x glioma hybrid NG108-15 cell, treatment with agonists at the IF 
prostanoid receptor but not with agonists at either the A2  adenosine or secretin 
receptors results in a substantial down-regulation of GgOt even though all of these
receptors couple to Gga and thus cause activation of adenylyl cyclase (Kelly et al., 
1990; McKenzie et al., 1990b). As addition of analogues of cAMP or agents able to 
elevate intracellular cAMP in a non-receptor-dependent fashion is unable to mimic the 
effect of prostanoid agonists (McKenzie et al., 1990b) it has been argued that the 
differences between the receptor ligands is unlikely to represent the ability of each 
receptor to activate adenylyl cyclase and may reflect the levels of cellular expression of 
each receptor (Milligan et al., 1991b). This, however, has been difficult to establish 
clearly in these cells as only agonist [^HJligands aie available for use in binding 
studies for the IP prostanoid and secretin receptors and there have been concerns as to 
whether ligands for the A2 adenosine receptor may label other sites (Keen et al., 1989) 
such as the adenosine transporter.
Following transfection of NG108-15 cells with a cDNA encoding the human 
P2-adrenoceptor (Adie et al., 1994 a, b) a clone expressing high levels of the receptor 
(some 3000 fmol/mg membrane protein) responded to challenge with isoprenaline by
1
down-regulating levels of GgOt whereas little effect was observed in a clone
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mediated G-protein down-regulation is likely to reflect levels of expression of a 
receptor they suffer from the fact that they had to be performed on different individual 
clonal isolates. To counteract this concern in this study I have used a clone pN22 
which expresses relatively high levels of the p2-adrenoceptor and then limited access 
of isoprenaline to the receptor by pretreating the cells with varying concentrations of 
the irreversible P-adrenoceptor antagonist BAAM. BA AM undergoes covalent 
attachment to receptor protein through bromoalkylation of sulfhydryl groups and thus 
irreversible occupancy of the recptor binding site. BAAM (10 |lM, 4h) treatment of 
clone pN22 cells results in a substantial reduction in the maximal down-regulation of 
GgOt which can be achieved by isoprenaline without altering the amount of down- 
regulation of Gga produced by occupancy of the IP prostanoid receptor by iloprost 
(Figure 3.3.2). Half-maximal down-regulation of Gga which can be produced by 
isoprenaline required substantially higher levels of the agonist following treatment 
with BAAM (10 p.M) compared to the control cells (Figure 3.3.3). By contrast, dose- 
effect curves for iloprost-mediated down-regulation of Gga were unaffected by 
treatment with BAAM. Treatment of clone pN22 cells with a concentration of BAAM 
sufficient to reduce the amount of [^HjDHA to some 300 fmol/mg membrane protein 
substantially reduced, but did not eliminate entirely, isoprenaline-induced down- 
regulation of Gga (Figure 3.3.4). Such treatment, however, resulted in only a small 
reduction in the maximal ability of isoprenaline to stimulate adenylyl cyclase activity 
(Figure 3.3.5). A 50% reduction in the maximal ability of isoprenaline to regulate Gga 
levels was produced by treatment of the cells with 100 nM BAAM, a concentration 
able to block agonist access to some 70% of the receptor population (Figure 3.3.1).
These data demonstrate that the degree of G-protein down-regulation observed 
is related to the number of receptors available for the agonist ligand to occupy and not 
to the ability of this receptor occupancy to result in the activation of adenylyl cyclase. 
This should be anticipated as previous studies have shown that such effects are 
restricted to the G-protein activated by the receptor, that the effect is a reflection of 
enhanced degradation of the G-protein without significant transcriptional or
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translational control (Milligan et al., 1993c; Mitchell et al., 1993), that it is not 
mimiced by treatment with analogues of cAMP (McKenzie et al., 1990b) and because
mutationally activated G-protein a  subunits are known to have reduced half-lives
compared with the wild type proteins (Milligan et al., 1993c; Levis et ah, 1992). 
Thus, if greater levels of available receptors are able to activate more copies of the G- 
protein then greater down-regulation of this polypeptide should be anticipated. 
However, the observations that reduction of p2“adrenoceptor availability levels in 
clone pN22 cells to some 300 fmol/mg membrane protein still resulted in a detectable 
down-regulation of Gga whereas this was not observed in clone pN17 which 
expresses this level of receptor endogenously (Adie et al., 1994a) demonstrates that it 
is unwise to extrapolate results from data obtained in different clonal isolates.
G ga is expressed at some 1.25 x 10^ copies per cell and the IP prostanoid 
receptor at some 10^ copies per cell in NG108-15 cells and in the transfected clonal 
cell lines derived from it (chapter 3.2). In clone pN2 2  the P2 -adrenoceptor is 
expressed at some 3-4 fold higher levels than the IP prostanoid receptor (Adie et al., 
1994a, b). It has previously been calculated that the IP prostanoid receptor can activate
some 65% of the cellular Ggoc in NG108-15 cells (Adie et al., 1992) and therefore if
the P2-adrenoceptor is able to activate the G-protein with similar stoichiometry then 
less than maximal occupancy of this receptor would be expected to result in maximal 
down-regulation of Gga as I observe herein. The inability to observe detectable G- 
protein down-regulation in a range of systems may thus be a reflection of a 
combination of the levels of receptor expression and that of the G-protein. Clearly in 
cells which express high levels of a G-protein, agonist may be able to cause down- 
regulation of only a small fraction of the polypeptide and this would be virtually 
undetectable when measured immunologically. Equally it is unlikely to be observed 
with agonists at receptors which are expressed at only low levels. This may then 
provide the explanation for the inability of either secretin or an A% adenosine receptor 
agonist to alter Gga levels detectably in NG108-15 cells (Kelly et al., 1990; McKenzie 
et al., 1991).
I
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In this study, furthermore, I have examined that the importance of receptor 
levels in defining the intrinsic activity and potency of agonist dmgs without alteration 
in amounts of the other components of the signal transduction cascade in both clones 
pN22 and PN17 by treatment with BAAM to vary receptor availability to ligands. The 
concept that different degrees of intrinsic activity of agonist dmgs should be observed 
in cells and tissues expressing different levels of a G-protein-linked receptor is a 
classical element of receptor theory (Stephenson et al., 1956; Kenakin et al., 1989; 
Hoyer et al., 1993). Experimental examination of this has traditionally focused on the 
observations that many dmgs act as full agonists in some tissues but not in others or 
by the use of irreversible antagonists to limit access of agonists to receptors. The first 
of these approaches is limited by the fact that levels of both the G-protein(s) and the 
effector systems which aie coupled to a particular receptor are likely to vary widely 
between the cell type and are generally unknown, and the second by the possibility 
that irreversible antagonism of a fraction of the receptors might be anticipated to limit 
access of the remaining receptors to a proportion of the G-protein population. In cells 
in which G-protein levels are comparable to those of the receptor this might alter 
receptor output.
The standard approach to alter available receptor levels in a tissue is to treat it 
with varying concentrations of an irreversible antagonist at that receptor. When pN22 
cells were treated with the ineversible P-adrenoceptor antagonist BAAM (1 [iM, 4h), a 
treatment sufficient to prevent binding of [^HJDHA to some 75% of the initial receptor 
population (Figure 3.3.1), the intrinsic activities and EC50 values of ephedrine and 
salbutamol were changed to levels close to those observed in untreated pN17 cells 
(Table 3.3.1). Maximally effective concentrations of isoprenaline (up to 10 p,M) 
resulted in a similar adenylyl cyclase activity in membranes of clone pN2 2  and pN17 
(Adie et al., 1994b). However, when a series of traditional P-adrenoceptor partial 
agonists were examined, the measured intrinsic activity of these compared to 
isoprenaline was observed to be routinely higher in membranes of clone PN2 2  than 
pN17 (Table 3.3.1). For example, salbutamol which in membranes of clone pN17
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was a partial agonist displaying an intrinsic activity of around 70% compared to 
isoprenaline, acted as a full agonist in membranes of clone pN22; while ephedrine, 
with an intrinsic activity of some 2 0 % in membranes of clone pN17 was also 
considerably more efficacious in clone pN22 membranes (intrinsic activity of 6 6 %).
As noted above, there are some relationship between the measured EC50 for a 
drug response and the nature and level of receptor expression (Whaley et al., 1994; 
Samama et al., 1994). Whaley et al., 1994 observed increased potency (decreased 
EC50) of the natural ligand epinephrine with increasing receptor number. I also have a 
similar observation for full agonists and extend this relationship to partial agonists. 
Differences in EC50 values in whole tissues or in systems in which the receptor 
population for a ligand is poorly chaiacterised are often inteipreted to reflect receptor 
subtypes (Ashkenazi et al., 1987; Milligan et al., 1993b), although this would not be 
the likely conclusion if, for example, activation occurred via distinct G-proteins, or if 
the agonist structure activity profile was to remain unaltered across a variety of 
chemical structures. Mathematical predictions have recently been developed to analyse 
alterations in P-adrenoceptor full agonist EC50 values with receptor number (Whaley 
et a i,  1994) and, in systems in which the effector species is quantitatively the limiting 
component of a signal transduction cascade, it is often observed that elevation in 
receptor number will result in a leftward shift in the dose-effect curve (i.e. a reduction 
in EC50 value), consistent with the notion of a receptor population reserve. It have 
previously recorded exactly this phenomenon when measuring isoprenaline- 
stimulation of adenylyl cyclase activity in membranes of pN22 and pN17 cells (Adie 
et al., 1994b) and a number of other reports have recorded similar data with cells 
expressing various levels of this receptor (Whaley et al., 1994; Bouvier et al., 1988b) 
although one report in S49 lymphoma cells did not observe this effect (Johnson et al., 
1979). This is rather surprising as S49 lymphoma cells are the one other cell system 
apart from NG108-15 cells in which the absolute number of copies of receptor, Ggoc 
and adenylyl cyclase have been calculated (Alousi et al., 1991), and like NG108-15 
cells (chapter 3.2), a large molar excess of GgOC over adenylyl cyclase has been
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observed. It may be that in this system the differences in levels of receptor expression 
in the individual clones were insufficient to allow detection of the effect.
The relationship of intrinsic activity of paitial agonists to receptor number was 
examined in detail using membranes and cells treated with varying levels of BAAM 
and noticeably and interestingly the measured regulation of agonist intrinsic activity 
was reduced by BAAM with greater potency the lower the measured intrinsic efficacy 
of the ligand in the untreated cells (Figure 3.3.6). As such, the measured intrinsic 
activity of ephedrine in membranes and cells of clone pN22 was reduced to half- 
maximal levels by treatment with approximately 25 nM BAAM, a concentration 
sufficient to eliminate 50% of the receptor population while this was not achieved for 
salbutamol until some 75% of the receptors were irreversibly blocked (i.e. by 
treatment with 1.5 |iM BAAM) (Figure 3.3.6A). It was unable to use sufficiently high 
concentrations of BAAM to substantially reduce the measured intrinsic activity of 
isoprenaline in pN22 cells and membranes (Figure 3.3.6). To extend the generation of 
primary data I have made use of a subsequent assay, in which agonist activation of the 
p2 -adrenoceptor on intact clone PN22 and pN17 cells causes an increase in high 
affinity [^H] forskolin binding because the complex formed between Gga and adenylyl 
cyclase is the high affinity binding site for this ligand (Alousi et aL, 1991; Barber et 
al., 1989). This assay allowed whole cell analysis of measured intrinsic activities and 
thus a comparison with data generated on cell membranes. As with the adenylyl 
cyclase assay, similar levels of forskolin binding in PN22 and pN17 were 
observed (Figure 3.3.6B). However, as a means to address the question of how many 
receptors would need to be occupied by a full agonist to half-maximally activate the 
cellular adenylyl cyclase population, clone PN17 was treated with a range of 
concentrations of BAAM and then assessed the intrinsic activity of isoprenaline 
(Figure 3.3.7). I observed that 50% of the intrinsic activity for isoprenaline compared 
to that in untreated cells was produced by pretreatment of pN17 cells with 2  [iM 
BAAM, a concentration consistent with access of isoprenaline to only some 50
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fmol/mg membrane protein of the p2 -adrenoceptor in both the whole cells and 
membranes derived from them.
Presentation of data derived from such experiments in a form which allowed 
levels of receptor required to be occupied by each of isoprenaline, salbutamol and 
ephedrine to obtain different degrees of intrinsic activity for these ligands (Figure 
3.3.8) allows direct comparison of the absolute intrinsic activities of these ligands. 
Some 35 fold higher levels of P2-^drenoceptors had to be occupied with ephedrine 
than with isoprenaline to obtain 50% of the maximal activation of the adenylyl cyclase 
cascade whether this was measured as adenylyl cyclase activity in membranes or as 
stimulation of [^Hjforskolin binding in whole cells (Figure 3.3.8) while salbutamol 
required occupancy of only a third as many receptors as ephedrine. Such data 
demonstrate why isoprenaline and salbutamol act as full agonists in cells and 
membranes of clone pN22 while isoprenaline but not salbutamol is a full agonist in 
clone pN17. It fuither explains why ephedrine is not a full agonist in either system.
Such results are also help to explain why certain drugs may act as full agonists in one 
tissue but as partial agonists in other tissues.
So far, I have mentioned that the alteration of levels of both a GsOC-linked 
receptor and G ga in NG108-15 cells transfected to express the human p 2 - 
adrenoceptor. I have noted that in clones expressing above 200 fmol/mg membrane 
protein of this receptor full agonists were able to activate adenylyl cyclase to the same 
maximal level (Figure 3.3.8). At lower levels than this submaximal stimulation was 
achieved while at higher levels of the receptor the concentration-effect curve for
stimulation of adenylyl cyclase was simply moved to lower concentrations of agonist 
(Adie et a i ,  1994b). These observations are consistent with the notion of spare 
receptors at higher levels of expression. As such, the significant benefit of increasing 
receptor level beyond 200-300 fmol/mg membrane protein would be to induce a 
response at lower concentrations of agonist. It further observed that expression of 
higher levels of the p2~adrenoceptor in these cells resulted in partial agonists 
displaying greater efficacy than produced in cells expressing lower levels of the
receptor. In addition, stable tranfection of NG108-15 cells with an epitope-tagged 
variant of Gga and isolation of a clone in which levels of this G-protein was now 
increased to 2.5 x 10^ copies per cell (more than doubling the Gga levels in the cells) 
(Mullaney et aL, 1994) had little effect on the ability of iloprost to stimulate adenylyl 
cyclase activity either in terms of potency or maximal effect (I. Mullaney and G. 
Milligan, unpublished observations). It was able to demonstrate that the IP prostanoid 
receptor had both equal access to, and was able to interact with, both the 
endogenously expressed Gga and the transfected epitope-tagged Gga (Mullaney et 
al., 1994). These results are in accord with recent studies in which trangenic mice 
were produced over-expressing Gga in a caidiac specific manner (Gaudin et al., 
1995). Only minor differences were observed in regulation of the effectiveness of the 
adenylyl cyclase cascade (Gaudin et a l, 1995).
Therefore, in this study, I have also altered the levels of expression of adenylyl 
cyclase in this genetic background to evaluate whether this would result in a greater 
maximal output following agonist activation of the adenylyl cyclase cascade and to 
examine how potencies of agonists might be regulated. As mentioned in chapter 3.2, 
at least 10 individual adenylyl cyclase isoforms have now been identified and isolated 
as distinct cDNA species (Pieroni et al., 1993; Taussig et al., 1995). One of the most 
studied isoforms to date is adenylyl cyclase type 2 (Feinstein et al., 1991; Lustig et a i, 
1993; Jacobowitz et a i, 1994; Tsu et a i, 1995; Chen et a i, 1995) and thus for these 
studies I selected this isoform for transfection into clone pN22. As clone pN22 was 
selected based on its resistance to genetecin sulphate, this further transfection and 
selection of new clones derived from these cells was based on co-transfection of the 
adenylyl cyclase type 2 cDNA along with a plasmid which allows expression of 
resistance to the antibiotic hygromycin B. pN22 cells do not express detectable 
adenylyl cyclase type 2 mRNA (Figure 3.3.9). Following transfection of clone PN22 
cells with a cDNA for adenylyl cyclase type 2 it was able to identify a series of clones 
exhibiting stable expression of adenylyl cyclase type 2 mRNA (Figure 3.3.9).
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High affinity [^H]forskolin binding assay in the presence of Gpp(NH)p on 
membranes of these clones also demonstrated excess total stable expression of 
adenylyl cyclase in these same clones compared to clone PN22 (Table 3.3.2). Our 
estimates of the quantitative increases in total cellular levels of adenylyl cyclase in the 
type 2  expressing clones were based on the maximal levels of high affinity 
[^H] forskolin binding which could be achieved. Although forskolin is able to interact
‘with all of the currently examined adenylyl cyclase isoforms (Taussig et aL, 1995) it is 
possible that the individual isoforms may display rather different affinities for this 
ligand. It is also possible, though yet to be explored in any significant detail, that 
individual adenylyl cyclase isofoims will display different activities in the absence of 
receptor-mediated activation of Gga, As such, I cannot discriminate whether the 
potentially curvilinear Scatchard analyses for guanine nucleotide stimulated 
[^H]forskolin binding to membranes of clone AC2.7 (Figure 3.3. lOB) is an indication 
of the mixed complement of adenylyl cyclase isoforms now expressed by these cells 
and displaying somewhat different affinities to forskolin, or is simply a reflection of 
the technical limitations of the need to perform [^H]forskolin versus forskolin self 
competition curves followed by corrections for isotopic dilution to assess Bmax- H is 
impractical given the affinity of [3H]forskolin for the Gga-adenylyl cyclase complex 
to perform conventional saturation curves. As discussed in chapter 3.2, it is also 
known that forskolin can interact with other cellular polypeptides (Laurenza et aL,
1989), particularly those such as the GLUT family of facilitative glucose transporters 
which share certain topographic features with the adenylyl cyclase polypeptides.
However, the guanine nucleotide-stimulated high affinity binding of [^H]forskolin 
appears to represent binding only to the active form of adenylyl cyclase. Analogues of
I
forskolin which show higher selectivity between adenylyl cyclase and the GLUT 
proteins have been described (Appel et aL, 1992) but these are not widely available 
and certainly not in a radiolabelled form.
Activation of the P2-adrenoceptor resulted in a markedly elevated adenylyl 
cyclase activity in the adenylyl cyclase type 2 -expressing clones compared to clone
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pN22, as did activation of the endogenously expressed IP prostanoid receptor (Figure
3.3.12). These results demonstrate that the transfected adenylyl cyclase type 2 can be 
activated in these clones by both of these receptors and that in this genetic background 
adenylyl cyclase expression is the limiting function for maximal output from this 
cascade. I have not, at this stage, examined the cellular distribution of the introduced 
adenylyl cyclase type 2  compared to the endogenously expressed type 6  isoform but it 
clearly has access to the activated GgOC produced upon relevant receptor occupation. 
This was an important observation given known constraints on free mobilities of 
polypeptides involved in inhibitory regulation of adenylyl cyclase in NG108-15 cells 
(Graeser et aL, 1993) and the emerging view that organisational structure exists in G- 
protein coupled signalling systems (Neubig et aL, 1994).
Although greater receptor-mediated maximal output from the adenylyl cyclase 
cascade could be produced in the adenylyl cyclase type 2  expressing cells it have been 
observed that this did not result in any significant alterations in the concentration-effect 
curves for stimulation of adenylyl cyclase activity produced by either the transfected 
p2-adrenoceptor or any of the endogenously expressed (IP prostanoid, A2  adenosine 
or secretin) GgŒ-linked receptors. On the other hand, the levels of expression and 
activity of downstream regulators of G-protein-linked signaling cascades such as the 
G-protein-linked receptor kinases are also likely to be able to modify the effectiveness 
of G-protein-linked receptor signaling. In a recent report transgenic overexpression of 
P-adrenoceptor kinase (pARK-1 also called GRK 2) (Fremont et aL, 1995) in the 
heart of mice has been shown to be able to diminish the signaling capacity of P- 
adrenoceptors (Koch et aL, 1995). The modification of the level of expression of these 
kinases in the cell lines utilised herein will be a interesting subsequent studies.
The implication of these studies is that targeted efforts to improve the maximal 
signaling capacity of the stimulatory arm of the adenylyl cyclase cascade, as for 
example has been suggested as a strategy to combat the failing heart (Milano et aL, 
1994) is likely to be achieved most effectively by increasing levels of the adenylyl 
cyclase polypeptide(s) rather than other components of the cascade. Future studies will
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determine whether different adenylyl cyclase isoforms will be more or less efficient in 
this regard. Informed choices of alterations in levels of receptors, G-protein or 
effectors will be dependent upon far greater knowledge of levels of expression of the 
components of signal transduction cascades in individual cells and tissues which might 
be targeted for modification.
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Chapter 4.
The coupling of the long splice variant of the rat TRH 
receptor to Gq family proteins.
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4.1, Introduction.
Thyrotropin-releasing hormone (TRH) is a tripeptide (pyroglutamic acid- 
histidine-proline amide, <Glu-His-Pro-NH2) that regulates functions of the anterior 
pituitary gland, central and peripheral nervous systems and may serve paracrine roles 
in retina, testis and endocrine pancreas. TRH has also been recognized as a potent 
stimulator of prolactin synthesis and secretion in lactotrophs, although its roles as a 
major regulator of normal prolactin physiology remains controversial (Metcalf et aL, 
1989). Much of what is known regarding the mechanisms of TRH action derives from 
the use of clonal rat pituitary cell lines, of which the mammotropic /somatotropic 
tumour-derived GH cell lines are the most widely used (Tashjian et aL, 1968; 
Gershengorn et al., 1986; Hinkle et aL, 1989).
It has been indicated that TRH appears to interact with a single class of binding 
sites in each of normal and tumour pituitary cells or in brain (Hinkle et aL, 1989; 
Johnson et aL, 1989). However, a classification of brain and anterior pituitary TRH 
receptors as a heterogeneous group has been performed according to their equilibrium 
dissociation constants (Funatsu et aL, 1985) and binding of the hormone to GHg cells 
with two classes of Kd values has been reported (Gautvik et aL, 1981). Some 
differences in isoelectric point and regulation by guanyl nucleotides have also been 
observed for TRH receptors from pituitary tumour cells and brain (Johnson et aL, 
1989). The possibility that these differences result from substantial divergences in the 
primary stmcture of the receptor molecules remains to be established.
So far several types of TRH receptor cDNA clones have been isolated from 
mouse pituitary (Straub et aL, 1990; Perlman et aL, 1992), human pituitary (Duthie et 
aL, 1993) and rat anterior pituitaiy GHg cells (de la Pena et aL, 1992a, b; Sellar et aL,
1993) which encode two different isoforms of the receptor produced by alternative 
splicing. The cloning and expression of TRH receptor cDNAs has confirmed them to 
be members of the seven putative transmembrane spanning element GPCR family 
which acts through binding to and activation of G-proteins. Each of the isolated
I
cDNAs predicts a similar amino acid sequence with a small degree of variance at the 
C-terminal region for each species.
Although specific sequences have not been identified, domains within the 
carboxy terminus (or cytoplasmic tail) of several GPCRs have been shown to be 
involved in internalisation (Bouvier et al., 1988a; Strader et a l, 1987). The TRH 
receptor, like other GPCRs, also undergoes rapid internalisation after binding TRH 
(Hinkle et at., 1989). The carboxyl terminus of the mouse TRH-R is comprised of 72 
amino acid residues. By generating site-directed mutants with truncations of the 
carboxy terminus of different lengths (C335 Stop, K338 Stop) and substitution 
mutants in which Cys-335 and Cys-337 were substituted with Ser or Gly residues, 
Nussenzveig et al., 1993 have found two domains within the carboxyl terminus of the 
mouse pituitary TRH-R that are involved in internalisation. These two Cys residues, 
which are located near the seventh transmembrane domain, are conserved in many 
GPCRs and have been shown to be acylated by palmitate in rhodopsin (Ovchinnokov 
etal., 1988) and the P2~adrenoceptor (O'Dowd Qtal., 1989). Recently, ligand-induced 
internalisation and recycling of TRH receptor has been confirmed and visualized by 
conventional and confocal fluorescence microscopy (Ashworth etal., 1995).
Since Rodbell's hypothesis (Rodbell et al., 1971) for the existence of multiple 
guanine nucleotide-binding proteins, G-proteins have been identified as crucial 
intermediaries linking a specific cell surface receptor to an intracellular "second 
messenger" system. Purification studies and molecular cloning technology have 
shown the function and the variety of G-proteins. A great deal of evidence supports 
the idea of the TRH receptor coupling to G-proteins. Addition of GTP converts the 
membrane receptor to a lower affinity state (Hinkle et al., 1984); TRH stimulates PT- 
sensitive and PT-insensitive high affinity GTPase in membranes of GH3 cells 
(Offermanns et al., 1989) and the TRH receptor shares the characteristic topological 
stmcture with other GPCRs. (Straub et al., 1990).
Hinkle et a l, 1984 had suggested that the TRH receptor might be associated 
with a guanine nucleotide-binding regulatory protein which coupled the receptor to
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activation of phospholipase C and subsequently a variety of studies have indicated the 
involvement of a G-protein distinct from the inhibitory (Gi) or stimulatory (G§) GTP- 
binding protein (Aub et aL, 1986; Straub et al., 1986; Martin et al., 1986). A 
combination of biochemical purification and reconstitution approaches (Pang et al., 
1990; Taylor et al., 1991b; Berstein etal., 1992) and cDNA cloning strategies based 
on conserved elements which are known to play a key role in the function of all G- 
proteins has led to the realisation that G-proteins of the Gq family (Strathmann et al., 
1989; 1990) (which consists of three closely related members G qa, G n a  and G jq a  
(Simon et al., 1991) as well as a rather more distantly related G \^ a  (Amatruda et al., 
1991) can fulfill this function. Indeed, the TRH receptor stimulates PI-PLC p i by 
coupling to members of this family as has been established directly using an antiserum 
against a peptide derived from the C-terminal region of G qa and G n a  (Hsieh et a l, 
1992; Aragay et al., 1992). Furthermore, the involvement of both G qa and G i l a  in 
PI-PLC p i activation (Taylor et al., 1991b; Wu et al., 1992a) has been demonstrated 
by either transiently transfecting cells with G qa and G n a  cDNAs or injection of 
antisense oligonucleotides to G qa and G n a  (Lipinsky et al., 1992; Quick et al.,
1994). These results strongly support G qa and G n o t as the subunits that couple to 
the TRH receptor and mediate the activation of the phospholipase C-p which catalyzes 
the cleavage of the membrane lipid phosphatidy 1-inositol 4, 5-bisphosphate to generate 
inositol 1,4, 5-trisphosphate and 1, 2-diacyiglycerol.
On the other hand, an essential role of PT-sensitive G ja family G-proteins in 
Ca^+ channel stimulation by TRH has been hypothesized, based on findings in GHg 
cells where TRH stimulation of a Ca^+ channel in a PT-sensitive manner was 
observed (Gollasch et al„ 1991). This approach suggested that TRH modulated 
intracellular free Ca^+ through two mechanisms: if the Ca^"^ stores were filled, 
hormone induced a PT-insensitive inositol trisphosphate-mediated Ca2+ release; if 
they were empty, the hormone stimulated voltage-dependent Ca^+ channels in a PT- 
sensitive manner.
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Identification of the involvement of PT-sensitive G ja  subtypes became 
possible by intranuclear injection of antisense oligo-nucleotides specifically 
hybridizing with mRNAs of G ja  and G oa subunit sequences to suppress the 
expression of these proteins in pituitary GH3 cells (Kleuss et a l, 1991; 1992). Recent 
results have shown that stimulation of dihydropyridine sensitive (L-type) Ca^+ 
channels by TRH is mainly mediated by the widely distributed Gi2 a  with a minor 
contribution of Gi3 a  (Gollasch e ta l ,  1993). As revealed by the use of corresponding 
antisense oligonucleotides and PKC inhibitors, this pathway requires concurrent 
protein kinase C (PKC) activation mediated by PT-insensitive G-proteins. That is, 
TRH induced hydrolysis of phosphatidylinositol 4, 5,-bisphosphate to InsP3 and 
diacyl glycerol with subsequent PKC activation is required to allow Gi2 a  mediated 
Ca^+ channel stimulation. It is likely that PKC represents the active component of the 
priming inositol phospholipid response and that Gi2 a  may serve as a target for PKC 
action, allowing stimulatory Gia-Ca^+channel interaction (Gollasch e ta l,  1993).
TRH has been also shown to increase levels of intracellular cAMP, possibly 
through a direct action on adenylyl cyclase (Gautvik et a l, 1983). It has previously 
been postulated that cholera toxin may act directly on a G-protein that is associated 
with TRH receptors in GH3 cells (Yajima et a l, 1988). Recently, it has been shown 
that the expression of antisense Gga RNA reduced levels of Gga mRNA and resulted 
in reduction of membrane content of Gga in GH3 cells. The reduction of Gga levels 
was paralleled by an attenuation of the adenylyl cyclase response to TRH. 
Furthermore, experiments employing antisera blocking the receptor coupling ability of 
different G-proteins confirmed that TRH-activated adenylyl cyclase involves coupling 
to Gga and not to G oa or G ja (Paulssen et a l,  1992).
As mentioned above, the TRH receptor appears to be able to stimulate the 
phospholipase C p i isoform via G qO /G na and either adenylyl cyclase via Gga or a 
Ca2+ channel via G ia under some circumstances. Many of the down-stream effects of 
TRH aie believed to be dependent on mobilization of intracellular* Ca^+ and activation 
of protein kinase C (Drust et a l,  1984). The association of She with growth factor
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ireceptor bound protein 2 (Grb2), which contains src homology (SH) domains, has been implicated in activation of the p2 H -^  ^pathway by tyrosine kinases via association 
with son of sevenless (SOS), the ras nucleotide exchange factor (Oliver ef a l,  1993; 
Egan et al., 1993). TRH induces the association of the 52 kDa She protein with Grb2, 
as well as increases in activity of raf-1 kinase, presumably activated as a consequence 
of stimulation (Wood et al., 1992). It has been suggested that TRH can activate 
mitogen activated protein (MAP) kinase by two distinct pathways. One is protein 
kinase C dependent and the other involves tyrosine phosphorylation of She proteins 
(Ohmichi et at., 1994). Furthermore, recent data indicate that cytosolic phospholipase 
A2 may be phosphorylated and subsequently activated by MAP kinase (Lin et al., 
1993) indicating a potential role for arachidonic acid release (Nemennoff et al., 1993) 
which is known to be stimulated by TRH (Ohmichi et al., 1990).
The mechanisms of MAP kinase activation by TRH still remain unclear. MAP 
kinase activity possesses the potentiality for directly regulating gene expression by 
phosphorylating transcription factors (c-jun and c-fos) since c-jun and c-fos are 
members of a family of potent transcriptional regulators (Angel et al., 1991; Blenis et 
al., 1993; Karin et al., 1994), some of which aie direct DNA-binding proteins (Abate 
et al., 1991; Curran et al., 1988). As such, the activation of c-jun and/or c-fos has the 
potential to initiate a cascade of gene induction events (Blenis et al., 1993). There is 
some evidence that TRH can regulate gene transcription by Ca^+ mobilization and 
protein kinase-C activation which represent distinct components of the signaling
A
events initiated by TRH, resulting in increased c-jun and c-fos mRNA levels 
(Weisman et at., 1987). Furthermore, TRH-induces prolactin (PRL) mRNA 
accumulation, possibly by a mechanism that involves increased PRL gene 
transcription (Morin et a l ,  1984) but also alterations in PRL mRNA turnover 
(Laveriere et a l,  1983). Regulation of transcription of the PRL gene involves the 
pituitary specific transcription factor pit-1, for which responsive elements have been 
found (Day et a l,  1989; Yan et a l, 1991) and the responsive elements conferring 
TRH regulation may thus interact with pit-1 or other transcription factors. Based on
%
several studies, it is suggested that TRH stimulation of c-jun and/or c-fos may be a 
key element in mediating the intracellular processes regulating thyrotropin p-subunit 
(TSH p) and prolactin (PRL) gene expression (Carr et al., 1993), followed by 
synthesis and release of pituitary TSH as well as PRL.
As mentioned above, the TRH receptor has been assumed to be able to act as a 
bifunctional one which is able to regulate multiple signalling cascades by activating 
distinct G-proteins in pituitary GH3 cells. However, as GH3 cells express at least two 
splice variants of the TRH receptor it is thus clearly possible that the multiple 
signalling effects of TRH noted in pituitary GH3 cells are actually produced by
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pharmacologically similar but genetically distinct receptors. Differential signal 
transduction by splice variants of receptors has recently been described for both the 
EP3 prostanoid receptor (Namba et al., 1993) where, like the TRH receptor, the splice 
variants occur in the C-terminal tail and the pituitary adenylyl cyclase activating 
polypeptide (PACAP) receptor (Spengler et al., 1993).
Therefore, the main puipose of the study in chapter 4.2 was to assess whether 
both GqOC and/or G n a  and Gga are involved in TRH stimulation of phospholipase C 
p i  and/or adenylyl cyclase or whether different splice variants of the receptor 
selectively interact with different G-proteins to regulate different signal transduction 
cascades. However, as GH3 cells have been reported to express at least two distinct 
splice variants of the TRH receptor it is difficult to use these cells to assess potential 
differences in the function of each variant. In this study human embryonic kidney 
HEK-293 cells, which do not endogenously express TRH receptors, were transfected 
to stably express the long variant of the rat TRH receptor (clone E2) to examine these 
questions.
In chapter 4.3 the studies focused on developing a 6  M urea containing SDS- 
PAGE (10% (w/v) acrylamide, 0.0625% (w/v) bisacrylamide) system to resolve a 
number of polypeptides which are recognized by an antiserum directed against the C- 
terminal decapeptide which is common to G qa and G n a  to examine the expression 
of Gq-like G-proteins in cells. Because of the high degree of sequence identity (for
I
example, between G qa  and G n a ,  89%; G n a  species variants, 97%) and 
heterologous expression of G protein-linked receptors into cell lines derived from 
different species regularly results in the expression of functionally coupled receptors, 
there has been little consideration as to whether individual receptors might display a 
degree of selectivity of interaction if concurrently offered the choice between species 
variants of the same G-protein.
Based on the 6  M urea incorporated SDS-PAGE system, I assessed whether a 
single receptor type can utilise species valiants of the same G-protein equivalently? In 
this study, clone E2 HEK-293 cells were further transfected with a cDNA encoding 
murine G q i a  (clone E2M11) to stably co-express the endogenous human and 
exogenously introduced murine G n a .
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4.2. The long splice variant of the rat TRH receptor interacts with and 
down-regulates members of the Gq family of G-proteins only. 
4.2.1. Results.
Human embryonic kidney HEK-293 cells were co-transfected with the 
plasmids pcDNAl containing the long splice variant of the rat TRH receptor under 
control of the cytomegalovirus promoter and pSV2-neo which contains the neomycin 
resistance gene. Cells expressing this second gene product were selected by their 
resistance to geneticin sulphate (800 pg/ml) (Figure 4.2.1). A number of these clones 
were assayed for a TRH (1 jxM) stimulation of inositol phosphate production and 
specific binding of [^H]TRH to determine the cells stably expressing the TRH 
receptor.
Clone E2 which expressed the highest levels of the receptor was selected for 
examination in these studies. To confirm that the E2 HEK-293 cells contained only 
mRNA encoding the long isoform of the TRH receptor, RNA was isolated from these 
cells and subsequently reverse transcriptase-PCR performed using primer pairs which 
were designed to amplify mRNA encoding either the short or the long isoform as 
described in chapter 2.2.23. cDNAs of both the long and short isoforms of the rat 
TRH receptor were used as positive controls for the effectiveness of the primers in 
these experiments. As anticipated, the long isoform cDNA produced a band of 370 
bases and the short isoform cDNA a band of 318 bases confirming the validity of the 
selected primers to generate fragments which would demonstrate the presence or 
absence of the 52-bp segment in the C-terminal tail which differs between the 412 
amino acid (long) isoform and the 387 amino acid (short) isoform (de la Pena et al., 
1992b) (Figure 4.2.2, lanes 4 and 5). Only a product representing mRNA 
corresponding to the long isoform of the receptor was detected in E2 HEK-293 cells 
(Figure 4.2.2, lane 3). This band was absent when using RNA isolated from parental 
HEK-293 cells (Figure 4.2.2, lane 1). Reverse transcriptase-PCR of RNA isolated 
from our clone of GH3 cells indicated that the expression of TRH receptor isoforms in
■r, ■:
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these cells was entirely the long isoform (Figure 4.2,2, lane 2). This was surprising as 
the short isoform of the TRH receptor was cloned from a GH3 cell library and co­
expression of the two forms in GH3 cells has previously been noted (de la Pena et al., 
1992b). This may be a reflection of clonal variation between GH3 cell lines.
1 mg of P2 membrane protein was generated from 51.6 ± 10.8 x 1Q6 untreated 
clone E2 HEK-293 cells (mean ± S.E., n = 4). The yield of membrane was not altered 
(p ™ 0.51) by pretreatment of the cells with TRH (Img from 61.6 ± 9.2 x 10  ^ cells 
(mean ± S.E., n = 4)). The level of TRH receptor expression was measured in 
membranes of E2 HEK-293 cells by dilution of the pH]TRH (10 nM) with cold TRH 
and subsequent correction for alteration in the specific activity of the ligand (Figure 
4.2.3). The experiments were performed in the presence of Gpp(NH)p (100 |LiM) to 
convert the population of TRH receptors to a single affinity state as no radiolabeled
antagonists are available for this receptor and attempts to measure the total receptor 
population using pH]TRH in the absence of Gpp(NH)p produced data which were 
consistent with both high and low affinity sites for the [^H]-ligand and generation of 
curvilinear data when presented as a Scatchard plot (data not shown). Displacement of 
approximately 10 nM [^HJTRH under these conditions by cold TRH was achieved 
with as estimated ICgoof 98 nM when the Hill coefficient was restrained to 1.0 
(Figure 4.2.3A). No further displacement was produced by concentrations of TRH 
above 100  |xM, and this concentration was thus used subsequently to define non­
specific binding. Correction of the specific binding of [^H]TRH for dilution of 
specific activity in such self-displacement experiments (Figure 4.2.3A) allowed 
transformation of these data which indicated the Bmax to be some 17.6 ± 0 .8  pmol/mg 
membrane protein (Figure 4.2.3C) and the Kd for [^HJTRH at this receptor binding 
site, under these conditions, to be some 133.7 ± 2.7 nM (Figure 4.2.3B).
Previous studies in GH3 pituitary cells have reported that TRH can cause 
activation of both phosphoinositidase C and adenylyl cyclase activities (Paulssen et 
al., 1992). In clone E2 HEK-293 cells, application of TRH resulted in the generation 
of high levels of inositol phosphates when the experiments were performed in the
presence of LiCl (10 mM) to limit the activity of inositol monophosphatases. The 
EC50 for TRH stimulation of inositol phosphate generation was 2 0 + 1 0  nM (mean ± 
range, n = 2) (Figure 4.2.4A). This was markedly higher that the EC50 for TRH 
stimulation of inositol phosphate generation in GH3 cells (3.0 ± 1 . 2  nM mean ± 
range, n ~ 2) (Figure 4.2.4B). TRH at maximally effective concentrations (1 pM and 
above) produced some 2 0  fold stimulation of inositol phosphate generation in 
comparison to that noted in the absence of TRH (Figure 4.2.4B). This effect was 
completely eliminated by pretreatment of E2 HEK-293 cells with TRH (10 pM, 16h) 
(Figure 4.2.4B). The ability of TRH to subsequently stimulate the generation of 
inositol phosphates was not modified (Table 4.2.1), however, by pertussis toxin 
treatment (25 ng/ml for 16h) of the cells under conditions which caused essentially 
complete ADP-ribosylation of the 'Gi~like' proteins (G ila , Gi2 a , Gi3 a  and G oa) 
expressed in these cells (Figure 4.2.5). By contrast with its effect on inositol 
phosphate production TRH was unable to either significantly stimulate basal or to 
inhibit forskolin-amplified adenylyl cyclase activity in membranes derived from cells 
of clone E2. This was also the case, however, in our clone of GH3 cells (Table 
4.2.2).
As receptor regulation of pertussis toxin-insensitive phosphoinositidase C 
activity is transduced by members of the Gq family of G-proteins (Berstein et al., 
1992a; Pang et a l, 1990; Taylor et a l,  1991b) and the stimulation of adenylyl cyclase 
activity by the splice variants of Gga then the absolute levels of expression of these G- 
proteins were examined in membranes of E2 HEK-293 and GH3 cells (Figures 4.2.6 
and 4.2.7, Table 4.2.3). Gga immunoreactivity in membranes of E2 HEK-293 as 
detected by antiserum CS (an antipeptide antiserum directed against the C-terminal 
decapeptide which is common to all forms of Gga) (Milligan et a l ,  1989) was 
provided by both 45 kDa and 42 kDa polypeptides which were expressed at similar 
steady state levels (Figure 4.2.6A). Construction of immunological standard curves of 
recombinant E. coli expressing the long splice variant isoform of Gga (Figure 4.2.6B) 
allowed measurement of cellular levels of the two isoforms of Gga (Table 4.3). Gga
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45 kDa was expressed at some 10.3 ± 1.3 pmol/mg membrane protein (mean ± S.E., 
n = 6 ) and Gga 42 kDa at some 11.3 ± 1.1 pmol/mg membrane protein (mean ± S.E., 
n = 6 ). Similar standard curves were constructed with recombinant E. coli produced 
G qa (Figure 4.2.7B). Immunoblotting such curves with antisemm CQ (an antipeptide 
antiserum directed against the C-terminal decapeptide which is common to G qa and 
G l i a )  (Mitchell et aL, 1991) in parallel with membranes of E2 HEK-293 cells 
demonstrated the expression of some 12.2  ± 1.2 pmol/mg membrane protein (mean ± 
S.E., n = 6 ) of total Gq-like G-proteins in these cells (Table 4.2.3).
On the basis of several reports that sustained activation of both Gq and Gg- 
linked receptors can result in a down-regulation of cellular levels of these G-proteins 
due to enhanced turnover of the activated G-protein (McKenzie et a l, 1990b; Milligan 
et a l ,  1993c; Mitchell et aL, 1993; Shah et al., 1995) the effect of the maintained 
presence of TRH on cellular levels of the G-proteins expressed by the E2 HEK-293 
cells was examined. Incubation of these cells with TRH (10 |iM, 16h) resulted in 
marked decrease in membrane levels of the Gq-like G-proteins. Quantitative 
immunoblotting demonstrated that levels fell from 12.2  ± 1.2 pmol/mg membrane 
protein to 5.7 ± 0.8 (mean ± S.E., n = 6 ) pmol/mg membrane protein (Table 4.2.4). 
This effect was highly significant (p = 0.001). In contrast, sustained treatment of 
clone E2 cells with TRH had no effect (p = 0.37) on levels of Gg (total Gga) 21.6 ± 
1.7 pmol/mg membrane protein in untreated cells and 24.6 ± 2.6 pmol/mg membrane 
protein in untreated cells (mean ± S.E., n = 6 ) (Table 4.2.4). Parallel experiments also 
demonstrated that TRH treatment did not alter membrane associated levels of the a  
subunits of the pertussis toxin-sensitive G-proteins, G il a , Gi2 a , G iga or G oa all of 
which are expressed by these cells (Figure 4.2.8 and Table 4.2.4). Furthermore, 
assessment of the relative levels of the a  subunits of the pertussis toxin-sensitive G- 
proteins and of the isoforms of Gga in membranes derived from untreated and TRH 
(10 |LiM, 16h) treated E2 HEK-293 cells by performing either pertussis or cholera 
toxin-catalysed p2p]ADP-ribosylation demonstrated no obvious alterations produced 
by TRH treatment in the ability of these polypeptides to act as substrates for the ADP-
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tribosyltranferase activities of these toxins (Figure 4.2.9). To assess whether TRH- 
induced down-regulation of Gq-like G-proteins was restricted to E2 HEK-293 cells or 
would also be observed in GH3 cells, these cells were also treated with TRH (10 |xM,
16h). As with E2 HEK-293 cells a substantial down-regulation of a combination of 
G q/G iiot (20.4 ± 4.3 % (mean ± S.E., n = 3)) without any alteration in membrane 
associated levels of Ggtt was recorded (Figure 4.2.10).
Exposure of E2 HEK-293 cells to 10 jiiM TRH resulted in half-maximal 
reduction in levels of the Gq-like G-proteins within 4 h and a new steady-state plateau 
of membrane associated levels was achieved by 10-12 h (Figures 4,2.1 lA  and B).
Treatment of E2 HEK-293 cells with varying concentrations of TRH for 16h followed 
by immunological detection of a combination of the Gq-like G-proteins in SDS-PAGE 
(10% (w/v) acrylamide, 0.25% (w/v) bisaciylamide) demonstrated that half-maximal 
TRH-induced down-regulation of these polypeptides was produced by some 30 nM 
ligand (data not shown but see Figures 4.2.12A and B).
Resolution of membranes from untreated and TRH pretreated E2 HEK-293 
cells in SDS polyacrylamide gels which contained a linear 4-8 M gradient of urea 
demonstrated the presence of two CQ reactive polypeptides in these cells (Figure
4.2.12). Treatment of E2 HEK-293 cells with varying concentrations of TRH caused 
an equivalent down-regulation of both of these Gq-like G-proteins (Figure 4.2.12A). 
Dose-response curves for the effect of TRH on down-regulation of these two Gq-like 
proteins were extremely similar (EC50 = 15-25 nM) (Figure 4.2.12B). Membranes 
from many rodent derived cell lines when resolved under these conditions can, 
however, be shown to express at least three distinct CQ reactive polypeptides (Figure 
4.2.14A). It has previously been demonstrated that the most rapidly migrating of these
■polypeptides in a range of cells including GH3 pituitary, CHO fibroblasts and 
NG108-15 neuroblastoma x glioma hybrid cells is the a  subunit of rodent G n a  
(Milligan et al., 1993d). E2 HEK-293 cells did not express an immunodetectable 
polypeptide which migrated in this position (Figure 4.2.14A). This, however, is a 
reflection of a considerable difference in mobility of rodent and primate G n a  in such
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gels (described in chapter 4.3) in which rodent G n a  migrates more rapidly than the 
primate form of this G-protein. Immunoblotting membranes of E2 HEK-293 cells 
with antisera both selective for G n o t (E976) and common for G qa/G  n  a  (CQ) 
demonstrated the co-expression of these two G-proteins in E2 HEK-293 cells. 
Furthermore antiserum E976 was able to identify two distinct polypeptides in 
membranes of these cells (Figure 4.2.14B). The relationship between these two E976 
immunoreactive polypeptides however is unknown. Separation of GH3 cell 
membranes in these gel conditions produced excellent resolution of G qa and G n a  
(Figure 4.2.14A) as described previously for other rodent cell lines (Milligan et al., 
1993e). Analysis under such conditions demonstrated that TRH treatment of GH3 
cells caused equivalent down-regulation of both G qa (27.9 ± 7.4 %) and G n a  (31.2 
± 6 .6  %) (mean ± S.E., n -  3) (Figure 4.2.13).
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F igure 4.2.1.
Generation and isolation of clone E2 HEK-293 cells expressing the 
long splice variant of the rat TRH receptor.
The long splice variant of the rat TRH receptor (2.2 kb) was subcloned into the 
EcoR I site of the multiple cloning region in the eukaryotic expression vector pcDNAl 
(4.1 kb) which is driven by the cytomegalovirus promoter. Monolayer cultures of 
HEK-293 cells (50% confluent) were co-transfected overnight with linearised 
pcDNAl/ TRH-receptor (800 ng) and pSV2-neo (5.6 kb) (200 ng) using lipofectin 
reagent in serum free Dulbecco's modified Eagle's medium (DMEM) as suggested by 
the manufacturer. After 24 hours medium was replaced with DMEM containing 800 
j.ig/ml of geneticin sulphate. Resultant geneticin resistant clones were picked, 
expanded and assayed for the expression of the TRH receptor. Cells were trypsinized, 
transferred to 24 well plates and labelled with myo-[^H] inositol (2 pCi/ml) in inositol 
free DMEM containing 1% dialysed foetal calf serum for 48 h. Total inositol 
phosphate (IP) production was then measured in TRH treated cells (1 |iM for 30 min). 
TRH-receptor containing clones were identified as those in which TRH produced a 
rise in total IP production. Expression of the TRH receptor in membranes from these 
clones was assessed by the specific binding of [^HjTRH. Clone E2 HEK293 cells 
was selected and maintained as described in chapter 2 .2.1 for further analysis in these 
studies.
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Figure 4.2.2.
E2 HEK-293 cells express exclusively the long isoform of the rat TRH 
receptor.
Reverse transcriptase-PCR was performed using RNA isolated from either 
HEK-293 cells transfected with the plasmids pcDNAl/pSV2-neo only (lane 5), from 
GH3 cells (lane 4), or from E2 HEK-293 cells (lane 3) as described in chapter 2.2.23. 
Amplification was also performed with plasmids containing either the short (lane 2) or 
long (lane 1) isoform of the rat TRH receptor. As anticipated amplification of the 
cDNA species representing the short and long isoforms resulted in the generation of 
fragments of 318 and 370 bases, respectively. Reverse transcriptase-PCR of RNA 
from both E2 HEK-293 cells and our clone of GH3 cells resulted in the generation 
only of a product consistent with the expression of the long isoform of the TRH 
receptor by these cells.
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Figure 4.2.3.
Binding characteristics of [^HJTRH to membranes of E2 HEK-293 
cells .
Panel A represents the ability of various concentrations of TRH to compete 
with [^HJTRH (9.2 nM) for binding to the TRH receptors expressed in membranes 
(25 \ig) of E2 HEK-293 cells in the presence of 100 pM Gpp(NH)p at 30 °C for 1 h 
as described in chapter 2.2,16. Maximal displacement, which was greater that 90% of 
the total binding, was achieved with concentrations of TRH at above 10 pM. No 
further displacement was produced by concentrations of TRH above 100 pM, and this 
concentration was thus used subsequently to define non-specific binding. 
Displacement of [^HjTRH under these conditions by cold TRH was achieved with 
estimated IC50 of 98 nM when the Hill coefficient was restrained to 1.0. Linear 
transformation of the specific binding data was performed following correction for 
dilution of the specific activity of [^H]TRH by addition of cold TRH. The estimated 
Bmax was 17.6 ± 0.8 pmol/mg membrane protein (Panel C) and the Kd for [^H]TRH 
at this receptor binding site, under these conditions, was 133.7 ± 2.7 nM (Panel B).
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F igure 4.2.4.
The stimulation of inositol phosphate generation by TRH in clone E2 
HEK-293 cells.
Panel A demonstrates that TRH stimulated inositol phosphate generation more 
effectively in GH3 cells than in E2 HEK-293 cells. The stimulation of inositol 
phosphate production by varying concentrations of TRH was assessed as in chapter 
2.2.17. in both GH3 (open symbols) and E2 HEK-293 (filled symbols) cells. Results 
are presented as percent of maximal effect, i.e. that produced by 1 pM TRH.
Panel B demonstrates that TRH stimulation of inositol phosphate generation is 
attenuated by pretreatment of the cells with TRH. E2 HEK-293 cells were either 
untreated (open symbols) or treated with TRH (10 pM, 16h) (filled symbols). The 
cells were washed twice with 0.5 ml of Hanks buffered saline (pH 7.4), containing 
1% (w/v) BSA and 10 mM glucose (HBG) and incubated for 10 min with HBG 
containing 10 mM LiCl prior to analysis of TRH regulation of inositol phosphate 
generation as described in chapter 2.2.18.
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F igure 4.2.5.
Pertussis toxin treatment of E2 HEK-293 cells causes complete ADP- 
ribosylation of the population of a  subunits of pertussis toxin-sensitive 
G-proteins.
Membranes (75 pg) derived from E2 HEK-293 cells which were untreated 
(lanes 1-6) or pretreated with pertussis toxin (25 ng/ml, 16h) (lanes 7-12) were 
incubated in the absence (lanes 3, 6 , 9 and 12) or presence of thiol-activated pertussis 
toxin (lanes 1, 2, 7 and 8 ) or cholera toxin (lanes 4, 5, 10 and 11) with for
2 h as described in 2.2.15. Samples were recovered by precipitation, resolved by 
SDS-PAGE (10% (w/v) acrylam ide, 0.25% (w/v) bisacrylam ide) and 
autoradiographed overnight.
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F igure 4.2.6.
Quantitation of Gscx levels in membranes of E2 HEK-293 cells.
Varying amounts of purified E. coli produced recombinant Gga long form 
(lane 1, 2.5 ng; lane 2, 5 ng; lane 3, 10 ng; lane 4, 15 ng; lane 5, 20 ng; lane 6 , 25 ng; 
lane 7, 30 ng) were subjected to SDS-PAGE (10% (w/v) acrylamide, 0.25% (w/v) 
bisacrylamide) along with membranes (5 |ig) from untreated (lane 8) and TRH-treated 
(10 |XM, 16h) (lane 9) E2 HEK-293 cells. The samples were subsequently 
imrnunoblotted for GgOC using antiserum CS (1: 250 dilution). The developed 
immunoblot (panel A) was scanned to allow construction of a standard curve for Gga 
(panel B). Such standard curves were generated routinely for quantitation of Gga 
levels. In the example shown Gga long was calculated to be 11.1 pmol/mg of 
membranes protein in untreated membranes and 9.7 pmol/mg in TRH-treated cell 
membranes. G ga short was 11.9 and 10.1 pmol/mg of membrane protein in 
membranes of untreated and TRH-treated E2 HEK-293 cells, respectively.
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Figure 4.2.7.
Quantitation of levels of the a  subunit of the Gq-like G-proteins in 
membranes of E2 HEK-293 cells.
Various amounts of purified E. coli caressed recombinant G qa (lane 1, 2 ng; 
lane 2 ,4  ng; lane 3, 6  ng; lane 4, 8 ng; lane 5, 10 ng; lane 6 , 15 ng; lane 7, 20 ng; lane 
8 , 25 ng) were subjected to SDS-PAGE (10% (w/v) acrylamide, 0.25% (w/v) 
bisacrylamide) along with membranes (30 pg) from untreated (lane 9) and TRH- 
treated (10 |iM, 16h) (lane 10) E2 HEK-293 cells. The samples were subsequently 
immunoblotted for Gq-like G-proteins using antiserum CQ (1: 1000 dilution). 
Developed immunoblots (panel A) were scanned to allow construction of a standard 
curve for Gqa/G i l a  (panel B). Such standard curves were generated routinely for 
quantitation of G qa/G i l a  levels. In the example displayed control membranes 
expressed 15.5 pmol/mg membrane protein of Gq-like G-proteins and the membranes 
of TRH treated cells 7.7 pmol/mg of membrane protein.
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F igure 4.2.8.
Sustained exposure of E2 HEK-293 cells to TRH does not alter 
immunologically detectable levels of G ila , Gi2 a, Gi3 a  and Goa.
Membranes (Panels A; 60 jig, B; 60 jig and C; 25 jig) of untreated (lane 1) 
and TRH pretreated (10 jiM, 16h) (lane 2) E2 HEK-293 cells were resolved in SDS- 
PAGE conditions (12.5% (w/v) acrylamide, 0.0625% (w/v) bisacrylamide) able to 
resolve G il a  and Gl2 a . The samples were then immunoblotted with antisera SG (1: 
500 dilution) (anti-Gi i a  + Gi2 a )  (Green et aL, 1990) (panel A), I3B (1: 1000 
dilution) (anti-Gisa) (Green et aL, 1990) (panel B) or IM (1: 500 dilution) (anti-Goa) 
(Mullaney et aL, 1990) (panel C) as described in chapter 2.2.6. Examples from a 
representative experiment are shown. In a range of experiments no significant 
alteration in membranes levels of any these polypeptides was produced by TRH 
treatment of the cells (see Table 4.2.4 for quantitative details).
159
B
Mr (kDa)
G,2a
1 2  1 2 1 2
F igure 4.2.9.
Sustained exposure of E2 HEK-293 cells to TRH does not modify the 
ability of pertussis or cholera toxin to modify their G-protein 
substrates.
Membranes (75 pg) from untreated (lanes 1-6) or TRH (10 pM, 16h) treated 
(lanes 7-12) E2 HEK-293 cells were incubated in the absence (lanes 3, 6 ,9  and 12) or 
presence of thiol-activated pertussis toxin (lanes 1 ,2 ,7  and 8 ) or cholera toxin (lanes 
4, 5, 10 and 11) with [^^P]NAD for 2 h. Samples were recovered by TCA 
precipitation, resolved by SDS-PAGE (10% (w/v) acrylamide, 0.25% (w/v) 
bisacrylamide) and the dried gel was autoradiographed overnight.
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Figure 4.2.10.
Sustained TRH treatment causes down-regulation of G q a /G n a  but not 
of Gstt in GH3 cells.
Membranes (lanes 1 and 2, 10 pg; lanes 3 and 4, 25 pg) from untreated (lanes 
1 and 3) and TRH pretreated (1 pM, 16h) (lanes 3 and 4) GH3 cells were resolved by 
SDS-PAGE (10% (w/v) acrylamide, 0.25% (w/v) bisacrylamide). Proteins were 
transferred to nitrocellulose and immunoblotted with antiserum CQ (1: 1000 dilution) 
(left-hand panel) to detect the presence of GqOt/Gi l a  or CS (1: 250 dilution) (right- 
hand panel) to detect the isoforms of G&a. The central lane (M) contains molecular 
weight standard markers (in kDa) which are described in chapter 2.1.1.
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F igure 4.2.11.
TRH induced down-regulation of Gq-like immunoreactivity in E2 HEK- 
293 cells: Time course.
Membranes (30 pg) of E2 HEK-293 cells which were untreated (lane 1) or 
exposed to TRH (10 pM) for (lane 2, 2h; lane 3, 4h; lane 4, 6 h; lane 5, 8h; lane 6 , 
lOh; lane 7, 12h; lane 8 , 16h) were resolved by SDS-PAGE (10% (w/v) acrylamide, 
0.25% (w/v) bisacrylamide) and immunoblotted with antiserum CQ (1: 1(X)0 dilution) 
in panel A. This experiment is representative of two others performed with different 
membrane preparations which gave essentially identical results. Densitometric 
scanning was used to assess the degree of reduction following exposure to TRH and 
demonstrated half-maximal reduction at 4 h with a maximal 70% reduction (panel B). 
Data are displayed as mean ± S.E. (n = 3).
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F igure 4.2.12.
TRH down-regulates equally each of the Gq-like G-proteins expressed 
by E2 HEK-293 cells.
Membranes (60 pg) of E2 HEK-293 cells which were untreated (lanes 1 and 
8) or treated for 16h with increasing concentrations of TRH (2) 0.1 nM , (3) 1 nM, (4) 
10 nM, (5) 100 nM, (6 ) IpM, (7) 10 pM were resolved in the 4-8 M urea gradient gel 
system described in chapter 2.2.9 and immunoblotted with antiserum CQ (1: 1000 
dilution). Both CQ immunoreactive polypeptides were down-regulated equivalently by 
ti’eatment of the cells with TRH (panel A).
Panel B represents quantitative analysis of the down-regulation of Gq-like G- 
proteins by TRH treatment. Immunoblots similar to those of panel A were 
densitometrically scanned and represented graphically. Data for the more rapidly 
migrating (open symbols) and the less rapidly migrating CQ immunoreactive 
polypeptides (filled symbols) are plotted as a percent of signal observed without TRH 
treatment and represent mean ± S.E. (n = 3).
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F igure 4.2.13.
Equivalent down-regulation of both Gqa and G n a  by TRH treatment 
of GH3 cells.
Membranes (lanes 1 and 2, 50 (Xg; lanes 3 and 4, 75 |Xg) of GH3 cells which 
were either untreated (lanes 1 and 3) or pretreated with TRH (10 p,M, 16h) (lanes 2 
and 4) were resolved in the 4-8 M urea gradient gel system described in chapter 2.2.9. 
The left-hand lane demonstrates the migration of prestained lactic dehydrogenase 
(LDH) in tliis gel system in which rodent G n o t migrates more rapidly than Gqa. 
Identification of the CQ reactive polypeptides in the rodent cells as G qa and G i l a  
based on their relative mobility in this urea gel system has been described previously 
(Milligan et aL, 1993b) and is described in chapter 4.3. TRH caused equivalent down- 
regulation of both G qa (27.9 ± 7.4 %) and G i l a  (31.2 ± 6 .6  %) (mean ± S.E., n = 
3).
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F igure 4.2.14.
Profile of expression of the Gq-like G-proteins by E2 HEK-293 and 
G H 3 cells.
In panel A, membranes (60 pg) from (lane 1) untreated, (lane 2) TRH treated 
(1 0  pM, 16h) E2 HEK-293 cells, (lane 3) GH3 cells and (lane 4) neuroblastoma x 
glioma hybrid NG108-15 cells were resolved in the 6  M urea gel system described in 
chapter 2.2.10 and immunoblotted with antiserum CQ (1: 1000 dilution) which 
identifies forms of both G q tt and G not.
Untreated E 2 H E K -2 9 3  cells were resolved as described for panel A  and 
immunoblotted with either the G q O /G l l a  common antiserum CQ  (1: 100 0  dilution) 
(lane 1) or the G n a  specific antiserum E 976  (1: 1000 dilution) (lane 2) (panel B ).
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Table 4.2.1.
TRH stimulation of inositol phosphate generation is not modified by 
pertussis toxin pretreatment of E2 HEK-293 cells.
The ability of TRH to stimulate inositol phosphate generation is unaffected by 
pre-treatment of the cells with pertussis toxin (25 ng/ml for 16h), conditions able to 
cause ADP-ribosylation of essentially the entire population of pertussis toxin sensitive 
'Gi-iike' proteins (G ila , Gi2 (X, G isa  and Goa) in clone E2 HEK-293 cells. Data are 
presented as mean ± S.D. from triplicate samples derived from a single experiment. A
:!similar pattern of fold stimulation of inositol phosphate levels above basal was 
recorded in a second independent experiment using a separate passage of the cells.
Condition Inositol phosphate generation
Inositol phosphate (PPM) /1 0  k PPM  in lipid
Basal 48.8 ± 4.4
TRH (10 pM) 934.2 ±113.9
Pertussis toxin pre-treated 864.7 ± 129.6
+ TR H (10uM )____________________________________________________________
Table 4.2.2,
The long isoform of the rat TRH receptor is unable to regulate adenylyl 
cyclase activity when expressed in HEK-293 or in a clone of GH3 
ce lls .
Adenylyl cyclase activity was measured as described in chapter 2.2.17 in 
membranes (10 pg) from clone E2 HEK-293 cells and GH3 cells either basally or in 
the presence of TRH (10 pM), forskolin (100 pM) or a combination of these two 
agents. Results are presented as mean ± S.E.M. from triplicate samples derived from a 
single experiment on each cell line. A similar pattern was recorded in a second 
independent experiment using membranes derived from separate passages of the cells.
s
Condition Adenylyl cyclase activity
E2 HEK-293 GH3
(pmol/min/mg membrane protein)
Basal 82 ± 2 79.5 + 10.9
Forskolin (100 pM) 1052+ 11 1135.7 + 21.6
TRH (10 pM) 73+ 1 80.1 ± 6 .6
Forskolin (100 pM) 1166± 2 1053.6 + 14.2
+ TRH(10pM)
;;
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Table 4.2.3.
Levels of expression of G §a and the Gq-like G -proteins in G H 3  and  E2 
H EK -293 cells.
Data were derived by quantitative immunoblotting using cellular membranes 
and E. coli expressed recombinant G-protein a  subunits as described in chapter 
2.2.14. In the case of E2 HEK-293 cells data are presented as mean ± S.E.M., n = 6 . 
In the case of GH3 cells, n = 3.
G -pro teins GH3 E2 HEK-293
(pmol/mg m em brane protein)
Gga (total) 101.8 + 4.3 21.6 ±  1.7
G sa (long) 97.8 + 4.4 10.3 ± 1.3
Gstt (short) 4 .0+  0.1 11.3+1.1
G qa like (Gqa+Gi la ) 14.4 + 0.5 1 2 .2 + 1.2
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Table 4.2.4.
Regulation of G-protein a  subunits in E2 HEK-293 cells by sustained 
TRH treatment.
Quantitative immunoblotting using E. coli recombinantly expressed standard 
G-proteins was used to measure absolute levels of Gga and G qa/G i l a  as described 
in Figures 4.2.6 and 4.2.7. In the absence of such standards, only relative intensity 
immunoblotting could be performed for the Gi-like G-proteins. Data for GsOC and 
G q a /G i l a  are presented as mean ± S.E.M., n = 6  and for the other G-proteins as 
mean ± range, n = 2 ,
TRH treatment (10 pM, 16h)
G-proteins ( - )  ( + )
(pmol/mg membrane protein)
Gsa 21.6+ 1.7 24.6 ±2 .6
G qa/G iia 12.2 ± 1.2 5.7 ±0.8
G-protein levels following
TRH treatment
(% of untreated)
G iia 105 ± 3
Giaa 9 7 ± 8
G isa 110±3
Goa 88  ± 4
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4.2 .2 . D iscussion.
TRH has been reported to cause activation of both phosphoinositidase C (Imai 
et aL, 1987) and adenylyl cyclase activities (Paulssen et aL, 1992) and to regulate 
Ca^+ channel function (Gollasch et aL, 1993) in pituitary GHg cells. These effects 
have been shown directly to be produced by activation of, respectively, a Gq-like G- 
protein(s) (Hsieh et aL, 1992; Aragay et aL, 1992), by GgOt (Paulssen et aL, 1992) 
and by Gj20t (Gollasch et aL, 1993). Recent data on splice variants of both the EP3 
receptor (Namba et aL, 1993) and the pituitary adenylyl cyclase activating polypeptide 
receptor (Spengler et aL, 1993) have provided strong evidence for the regulation of 
different G-proteins and signalling cascades by individual receptor splice variants. 
Therefore, as GHg cells have been shown to express at least two distinct isoforms of 
the TRH receptor which arise by differential splicing mechanisms (de la Pena et aL, 
1992b) and there are currently no phaimacological agonists which are likely to be able 
to selectively activate the individual receptor isoforms it is difficult to assess in the 
cells which co-express these two distinct variants of the TRH receptor if each variant 
is able to activate all of these signalling cascades and hence act as a multifunctional 
receptor (Milligan et aL, 1993b) or whether the individual isoforms have the ability to 
differentially regulate signalling cascades by having differing abilities to activate 
different G-proteins.
In order to address some of these questions, HEK-293 cells which do not 
endogenously express a TRH receptor were stably transfected with the long isoform 
of the rat TRH receptor and the ability of this receptor to regulate both 
phosphoinositidase C and adenylyl cyclase activity and to interact with and regulate 
levels of the G-protein population of these cells was subsequently assessed.
Clone E2 HEK-293 which expresses high levels of the TRH receptor was 
selected on the assumption that the levels of expression of the splice variant form of 
the receptor and of the Gq-Iike G-proteins and GgOt are likely to determine the exact 
nature of the signal generated in response to TRH in receptor-mediated activation of 
cell signalling cascades. Furthermore, reverse transcriptase-PCR analysis confirmed
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Ithat transfection with cDNA encoding the long isofoiin of the TRH receptor resulted in 
the production of mRNA encoding the long isoform of the receptor only with no 
detectable contribution from the short isoform (Figure 4.2.2).
Addition of TRH to these cells produced a large activation of inositol 
phosphate generation but was unable to regulate adenylyl cyclase activity in 
membranes from these E2 HEK-293 cells (Table 4.2.2). It was also unable to produce 
regulation of adenylyl cyclase activity in the clone of GH3 cells used in these studies 
(Table 4.2.2). However I also failed to note any obvious expression of the short TRH 
receptor isoform in this clone (Figure 4.2.2) although this variant of the receptor was 
isolated from a GH3 cell library (de la Pena et aL, 1992b). It seems reasonable to 
assume that this reflects clonal vaiiation between GH3 cell lines.
Dose response curves for TRH stimulation of inositol phosphate generation 
indicated that TRH was substantially less potent in clone E2 HEK-293 cells than in 
GH 3 cells (EC50 = 20 ± 10 nM in clone E2 cells vs. 3.0 ±1 . 2  nM in GH3 cells) 
(Figure 4.2.4A). This was somewhat surprising as although receptor reserve is not 
normally a phenomenon associated with receptor regulation of phosphoinositidase C 
activation the high level expression of the long isoform of the TRH receptor in clone 
E2  (Bmax = 17.6 ± 0 .8  pmol/mg membrane protein) was not anticipated to result in an 
alteration in the concentration-effect curve to the right in comparison to GH3 (Bmax -  
4.4 ± 0.3 pmol/mg membrane protein) cells (Scatchard plot not shown). This may 
reflect a number of features including receptor availability and the differences in 
activity of rodent vs. human Gq-like G-proteins. However, the total population of CQ 
immunoreactive G-protein (and as such the Gq-like G-proteins) was not substantially 
different (per mg membrane protein) in the two cell lines (clone E2 = 12.2 ± 1.2 
pmol/mg membrane protein, GH3 cells = 14.4 ± 0.5 pmol/mg membrane protein). It 
may also reflect the expression of only the long isoform of the TRH receptor in clone 
E2 cells and in the clone of GH3 cells used in these studies as opposed to the co­
expression of the long and short isoforms of the receptor in GH3 cells reported by 
others (de la Pena et aL, 1992b).
Î.
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The inability of the long isofoim of the rat TRH receptor to stimulate adenylyl 
cyclase activity in membranes of cells of clone E2 indicates a lack of significant 
interaction with Gstt. Again, as noted above, this may reflect the expression of only 
the long isoform of the receptor in clone E2 cells but may also reflect the absolute and 
relative levels of expression of Gga and the Gq-like G-proteins in clone E2 vs. GH3 
cells. Clone E2 cells express somewhat lower total levels of Gq-like G-proteins (Gqa 
= 12.2 + 1.2 pmol/mg membrane protein) than of Gga (total (45 kDa + 42 kDa) Gga 
= 2 1 . 6+ 1 .7  pmol/mg membrane protein) (Table 4.2.3) whereas both the relative 
levels of expression of Gga vs. the Gq-like G-proteins (some 8 : 1) in GH3 cells and 
the absolute levels of expression of Gga in GH3 vs. clone E2 cells (101 ± 4,3 
pmol/mg membrane protein vs. 21.6 + 1,7 pmol/mg membrane protein) are 
considerably higher in GH3 cells than in E2 HEK-293 cells. If the long isoform of the 
rat TRH receptor indeed has some affinity for interaction with Gga then both the 
absolute and relative levels of Gg vs. Gq-like G-proteins in GH3 cells vs. E2 HEK 
cells would favour interaction with Gga and hence stimulation of adenylyl cyclase in 
GH3 rather than E2 HEK-293 cells. It should be noted in this context that even in 
GH3 cells the degree of adenylyl cyclase stimulation by TRH is relatively weak.
In 10% acrylamide SDS-PAGE, G qa and G n a ,  which appear to be co­
expressed in the majority of cells and tissues (Simon et aL, 1991; Amatruda et aL, 
1991), co-migrate and thus immunological detection with an antiserum directed to the 
C-terminal decapeptide, which is completely conserved between these two proteins, 
can only provide a composite signal for these two polypeptides (Figure 4.2.12A). 
Immunoblotting E2 HEK-293 membranes resolved in urea-containing SDS- 
polyacrylamide gels (also described in chapter 4.3) with the Gq-like G-protein 
antiserum CQ was able to demonstrate the presence of two polypeptides migrating 
close together which represent the human versions of G%ia and Gqa. In addition, an 
antiserum E976 (Taylor et aL, 1991a) specific for G n a  clearly demonstrated the 
expression of human G% l a  in these cells but that the human version of this 
polypeptide migrated in a different position to rodent G n a ,  close to the position
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obseiwed for rodent G qa (Figure 4.2.14B). It has previously been demonstrated that 
treatment of CHO cells transfected to express the human muscarinic M l acetylcholine 
receptor with varying amounts of the cholinergic agonist carbachol results in an 
equivalent degree of down-regulation of G qa and G n a  at each concentration of the 
agonist and this has been interpreted to indicated that the M l muscaiinic receptor does 
not functionally select between these two G-proteins (Mullaney et aL, 1993a). In these 
studies, TRH acting on the long isoform of the TRH receptor to down-regulate each of 
the Gq-like polypeptides expressed in E2 HEK-293 cells and caused the down- 
regulation of both of these Gq-like polypeptides with identical concentration-effect 
curves (Figure 4.2.12B). TRH-mediated down-regulation of Gq-like G-proteins was 
also observed in our clone of GHg cells (Figure 4.2.13) and this agonist-induced 
down-regulation was restricted to G qa  and G n a .  As agonist-induced down- 
regulation of G-proteins appears to be restricted to the G-protein(s) which are activated 
by a receptor (Milligan et aL, 1993b), these observations, in parallel with the lack of 
stimulation or inhibition of adenylyl cyclase by TRH in both E2 HEK-293 and our 
clone of GH3 cells indicate that the Gq family of G-proteins are the only ones which
y
are activated to a significant effect by the long isoform of the TRH receptor.
The results presented in these studies demonstrate a highly selective coupling 
of the long isoform of the rat TRH receptor with the G-proteins responsible for 
phosphoinositidase C regulation. Reported regulation of both adenylyl cyclase by 
activation of Gga (Paulssen et aL, 1992) and of Ca^ '*" channel function by activation 
by Gi2 a  (Gollasch et aL, 1993) in GH3 cells may thus be a reflection of the activity of 
other splice variants of the TRH receptor but if so this would suggest that different 
clones of GH3 cells would have to show different patterns of relative expression of 
TRH receptor isoforms.
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4.3. Stimulation of the long splice variant of the rat TRH receptor 
induces subcellular redistribution and differential dow n-regu la tion  of 
co-expressed G n a  species variants.
4.3.1. Results.
Resolution of membranes from frontal cortex of human, baboon, pig, guinea 
pig, rat and mouse in SDS-PAGE (10% (w/v) acrylamide 0.25% (w/v) bisacrylamide) 
followed by transfer to nitrocellulose and immunoblotting using anti serum CQ as 
primary reagent led to the detection of an apparently single polypeptide of 42 kDa in all 
species (Figure 4.3.lA). Immunoblotting equivalent gels using antisemm IQB which 
was generated against a synthetic peptide corresponding to amino acids 119-134 of 
murine G qa, as described in chapter 2 .2 .6 , as primary reagent produced similar 
results (Figure 4.3.IB).
When membranes from frontal cortex from the various species were resolved 
in SDS-PAGE (10% (w/v) acrylamide, 0.0625% (w/v) bisacrylamide) which 
additionally incorporated 6 M urea a much more complex pattern of CQ 
immunoreactivity was recorded (Figure 4.3.2). Rat frontal cortex demonstrated the 
immunological detection of three prominent CQ reactive polypeptides and the presence 
of a fourth polypeptide which was detected more weakly by the antibody. Previous 
studies have shown that the most rapidly migrating CQ reactive polypeptide in such 
urea containing gels is G n a  based on comigration in a range of gel systems with 
purified G n a  from bovine liver (Mullaney et aL, 1993a). This was confirmed by 
immunoblotting membranes separated in the urea containing gels with the G i i a  
specific antiserum E976 (Taylor et aL, 1991a) (Figure 4.3.3). The staining intensity of 
the polypeptides migrating in the position equivalent to G qa was considerable greater 
than that for Gi l a  in rat frontal cortex (Figure 4.3.2) in confirmation of previous 
results using SDS-PAGE system in which the relative mobilities (G qa < G n a )  are 
similar to those reported herein (Milligan et aL, 1993a). A weakly staining CQ reactive 
polypeptide migrated between G qa and G n a .  The pattern of immunostaining of CQ
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reactive polypeptides was similar in mouse frontal cortex except that the relative levels 
of expression of G qa to G n a  was close to 1: 1. Pig had a similar general pattern of 
expression of CQ reactive polypeptides to mouse and rat but very different patterns of 
expression of CQ reactive polypeptides were noted in the frontal cortex of the other 
species examined. Guinea pig exhibited very weak expression of a polypeptide 
migrating in the position of rat and mouse G n o t but similai- levels and patterns of the 
two polypeptides migrating with rat and mouse Gna. The most striking feature in 
guinea pig however, was high level immunostaining of the polypeptide migrating 
between G qa and G n a  (Figure 4.3.2). This polypeptide was shown to be the 
predominant guinea pig form of G n o t as this polypeptide was identified by antiserum 
E976 (Figure 4.3.3). Membranes from frontal cortex of baboon and human were 
again different with no detectable immunostaining in a position corresponding to rat 
and mouse G i i a  (Figure 4.3.2). Immunoblotting of human and baboon membranes 
with antiserum E976 demonstrated that the predominant form of G n a  in these 
species migrated more slowly than in rat and mouse in a position very close to G qa 
(Figure 4.3.3).
I'In order to examine further the differences in mobility of immunodetectable 
G n a  in primate frontal cortex compared to rodent species membranes from a range of 
both human and rodent neuroblastoma cell lines were resolved in the urea containing 
SDS-PAGE system (Figure 4.3.4). Both mouse neuroblastoma x rat glioma hybrid 
NG108-15 cells as demonstrated previously (Milligan et aL, 1993d) and mouse 
neuroblastoma x hamster embryonic brain cell NCB20 cells demonstrated the 
expression of a CQ immunoreactive polypeptide in the position anticipated for rodent 
G i i a  and which was confirmed to be G i l a b y  immunoblotting with antisemmE976 
(Figure 4.3.4B). However, in membranes from the human neuroblastoma cell line,
IMR-32 no polypeptide comigrating with rodent G n a  was detected by antisemm CQ 
(Figure 4.3.4A, lane 1) while antisemm E976 demonstrated the expression of a G n a  
in these cells which migrated in a position close to G qa (Figure 4.3.4B, lane 1).
:
To assess if both primate and rodent G n a  could be detected unambiguously 
and concurrently in membranes of a single cell by a difference in mobility of primate 
and rodent G n a ,  a murine G n a  cDNA subcloned into plasmid pCMV was 
transfected transiently into monkey kidney COS-1 cells. 72 h after transfection the 
cells were harvested and membranes prepared from mock-transfected and murine 
G n a  transfected cells. These membranes were separated in the resolving 6  M urea 
containing SDS-PAGE (10% (w/v) acrylamide, 0.0625% (w/v) bisacrylamide) and 
immunoblotted with either antiserum CQ or E976 (Figure 4.3.5). Using either 
antiserum an immunoreactive polypeptide was detected in the position anticipated for 
rodent G n a  in membranes of the cells transfected with the murine G n a  cDNA, but 
not in the mock transfected cells, which was well resolved from either the combination 
of endogenously expressed monkey G qa and G n a  (when immunoblotting was 
performed with antiserum CQ) (Figure 4.3.5A) or from monkey G i j a  (when the 
immunoblots were performed with antisemm E976) (Figure 4.3.5B).
The generation and analysis of clone E2 HEK-293 cells, which expresses high 
levels of the long splice variant of the rat TRH receptor, and the interaction of this 
receptor with the cell signalling machinery to cause stimulation of phosphoinositidase 
C activity has previously been described in detail (chapter 4.2). On the basis of 
concurrent immunological detection of both primate and rodent forms of G n a  
following their co-expression in a single cell (Figure 4.3.5) E2 HEK-293 cells were 
further co-transfected with the plasmids pCMV (10 fxg) encoding murine G n a  cDNA 
(Strathmann et aL, 1990) and the plasmid pBABE hygro (1 jxg), which allows 
expression of resistance to the antibiotic hygromycin B. Clones were selected on the 
basis of resistance to hygromycin B (200 fxg/ml) and the continued expression of the 
TRH receptor and novel expression of murine G n a  were examined (Figure 4.3.7). 
Membranes derived from a number of individual clones were examined for their ability 
to bind [^H]TRH specifically. A clone designated E2M11 was selected and expanded 
for detailed analysis. Clone E2M11 bound [^H]TRH with both high capacity and high 
affinity (Figure 4.3.8) and with values for both parameters similar to those reported
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previously for clone E2. Furthermore, following labelling of these cells with myo- 
[3H]inositol a large stimulation of accumulation of [^H]inosotol phosphates was 
produced by addition of TRH with similar EC50 as noted in clone E2 HEK-293 cells 
(data not shown).
Resolution of membranes from both clone E2 and clone E2M11 cells by SDS- 
PAGE in a gel containing 6  M urea as previously mentioned followed by transfer to 
nitrocellulose and immunoblotting with an antiserum (E976) (Taylor et a i ,  1991a) 
specific for G l i a  demonstrated endogenous expression of human G n a  in both 
clones and the expression of murine G n a  in clone E2M11 (Figure 4.3.9). As 
previously demonstrated rodent (murine) forms of G n a  migrate more rapidly 
through such gels than primate (human) versions of this polypeptide (Figure 4.3.5). A 
similar conclusion was reached following immunoblotting membrane samples from 
these cells with the Gi la /G q a  common antiserum CQ (Figure 4.3.9).
Sustained incubation of clone E2 cells with TRH (10 |liM, 16h) resulted in a 
large decrease in the level of human G l i a  in a crude membrane fraction (Figure
4.3. IDA) as previously described in chapter 4.2. Equivalent incubation of clone 
E2M 11 cells with TRH (10 pM, 16h) resulted in a reduction in membrane levels of 
both the human and murine isoforms of G n a  (Figure 4.3.10). Surprisingly, the 
degree of reduction of murine G n a  caused by TRH treatment was much less than of 
the human G n a  subunit. The human isoform was diminished to very low levels 
(15%) when compared with controls while the murine G i i a  was decreased to only 
65% when compared with untreated cells.
To get information about the total cellular content and distribution of G n o t 
proteins in E2M11 cells, homogenates prepared from untreated and TRH-treated (10 
jiM, 16h) cells were centrifuged for 2 h at 200, 000 x gav and crude membrane (MB) 
and cytosol (CYT) fractions prepared and examined (Figure 4.3 .lOB). Figure
4.3. lOA shows the decrease of both human and murine G n a  in the crude membrane 
fractions was clear. However, a substantial amount of immunodetectable murine 
G n o t and a cleaiiy detectable amount of human G n o t was also noted in the cytosol
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fractions of both control and TRH-treated cells and this was greater in cells which had 
been treated with TRH. The cytosolic content of G n a  of control samples was 
calculated to represent 7.5 ± 6.4 % (mean ± S.D., n = 4) of the total cellular pool of a 
combination of human and murine G not. By contrast, cytosol from the TRH-treated 
cells contained 28.8 ± 6.1 % (mean ± S.D., n == 4) of the remaining total cellular 
content of these proteins (Table 4.3.1). However, the net increase in cytosol located 
G l i a  proteins in E2M 11 cells i.e. from 24 to 145 arbitrary units in the example 
displayed in Table 4.3.1 (expressed per the same number of cells) was much less than 
the amount of G n a  removed from the total cellular membrane fraction by treatment 
with TRH, i.e. from 1153 to 476 arbitrai^ units as shown in Table 4.3.1. As such, 
the amount of G n a  no longer associated with the total membrane fraction following 
TRH treatment of E2M11 cells could not be quantitatively recovered in the cytosolic 
fraction. Calculation of the total cellular amount of G n a  proteins (membranes plus 
cytosol) indicated some 47% down-regulation in response to TRH when compared 
with controls (Table 4.3.1).
E2M11 cells were incubated with 10 p,M TRH for increasing lengths of time 
between 10 min and 16 h to examine the time course of TRH induced redistribution of 
G l i a  proteins. Murine and human variants of G n a  were resolved by 6 M urea 
containing SDS-PAGE as mentioned previously and the developed immunoblots were 
densitometrically scanned. As is demonstrated in Figure 4.3.10 the decrease of both 
G l i a  species variants in the crude membrane fraction was accompanied by an 
increase in these polypeptides in the cytosol. The redistribution of G n a  from 
membrane to cytosol as well as down-regulation (decrease of total cellular amount) 
(Figure 4.3.11 and Table 4.3.2), was considerably more pronounced for the human 
variant than for the murine G n a .  The cytosolic human G i l a  of untreated E2M 11 
cells, which represented 4% of the total cellular pool increased to 82% of the total 
immunodetectable pool after 8 h of TRH (10 pM ) treatm ent whereas the 
corresponding change of murine G n o t was from 14% in untreated to 28% in TRH- 
treated samples (Figure 4.3.12B and Table 4.3.2). The total cellular amount (sum of
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membrane plus cytosol pools) of G n a  proteins was reduced by TRH to 23% and 
6 8 % for human and murine G i i a  respectively compared to control (Table 4.3.2 and 
Figure 4.3.12B).
The TRH induced changes in subcellular localization of the co-expressed 
G l i a  species variants were further analysed using sucrose density gradient 
centrifugation as described in chapter 2.2.3 to allow separation of plasma membranes 
from other membrane structures. Application of 19, 23, 27, 31, 35, and 43% (w/v) 
sucrose density gradients, which have been used previously for subcellular 
fractionation of S49 lymphoma cells (Svoboda et a l,  1992), CHO cell lines (Svoboda 
e ta l ,  1994) and for brown adipose tissue (Svoboda et a l,  1993), to homogenates of 
clone E2M11 cells, indicated that the cellular distiibution profile of human and murine 
versions of G n a  were identical (Figure 4.3 .13A) and demonstrated a high 
enrichment of the G n a  proteins in untreated E2M11 cells in fractions (centred on 
fractions 4 and 5) previously characterised to contain plasma membranes (Svoboda et 
a l ,  1992) (Figure 4.3.13A). The specific content (density of the immunoblot signal 
divided by the total protein content) of G i l a  proteins in fraction 4 was nearly 100 
fold higher than in faction IS (cytosol) and some 2 0  fold higher than in fraction 8 
(nucleus plus cell debris), the fraction which continued the majority (some 85%) of the 
total cellular proteins (Figures 4.3.14 and 15).
TRH (10 \iM, 16h) treatment of clone E2M11 cells (Figures 4.3.13B and 15) 
resulted in a dramatic shift of the G i l a  polypeptides from high and medium-density 
(fraction 4-7) to lower-density regions of the gradient (fractions IS, IP, 2-3). This 
was achieved without an overall alteration in the protein profile of the gradient (Figure 
4.3.14). The greatest effect of TRH treatment was observed in cytosol fraction IS 
where the specific content of G n a  increased some 30 fold i.e. from 11.7 to 309.4 
arbitrary units (defined as density of immunoblot signal divided by the amount of 
protein applied per lane) (Figure 4.3.15(1)) or from 1.2% to 29.2% of total cellular 
G i l a  (Figure 4.3.15(H)). These values agree well with those obtained above using 
the simple crude membranes versus cytosol distribution studied by differential I
1;}
subunits in TRH-treated cells to 67% of control levels (Table 4.3.3). Although both a
pathway from plasma membrane to low-density membranes fraction (light-vesicles,
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centrifugation and represented an unparalleled finding (Figure 4.3.10 and Table 
4.3.1).
A direct comparison of the redistribution of human and murine G n a  in key 
fraction of the sucrose density gradients is shown in Figure 4.3.16. The plasma 
membrane containing fractions (fractions 3 ,4 ,5)  displayed a substantial reduction in 
immunodetectable levels of both human and murine G n a  in response to TRH with 
virtual complete removal of the human variants and somewhat lower reductions in 
levels of the murine form. By contrast, elevated levels of both species variants of 
G n a  were noted in the cytosol following treatment with TRH.
A potential explanation for the detailed quantitative differences in TRH receptor 
regulation of the human and murine variants of G l i a  in these cells might have 
reflected a difference in the physical state of endogenously expressed human G i i a '
compaied to the exogenously introduced murine G not, perhaps representing a non- 
physiological aggregation of the introduced proteins. However, treatment of 
membranes of E2M11 cells with the detergent sodium cholate (1% (w/v), 1 h, 4 °C) 
resulted in equivalent and essentially compete solubilization of both human and murine 
versions of G n o t (Figure 4.3.17).
To examine potential changes in the distribution and levels of G protein 13- 
subunits in response to TRH, parallel samples of gradient fractions analysed in Figure 
4.3.13, were tested immunologic ally for their content of p-subunit (Figure 4.3.18).
There was little if any detectable P-subunit in the cytosolic fraction IS prior to 
treatment with TRH and this was unchanged by TRH-treatment. However, similarly 
to the results presented for the G n a  subunits a major, dramatic, plasma membrane to 
low density membrane redistribution occurred with TRH treatment (Figure 4.3.18). 
Resolution of crude membrane and cytosol fractions from control and TRH treated 
E2M11 cells also indicated a down-regulation of the total cellular amount of p-
and p-subunits of G-proteins seem to follow similar intermembrane redistribution
endosomes, endoplasmic reticullum), movement to the cytosol is specific for a -  
subunits only.
F ig u re  4.3.1.
F ron tal cortex m em branes from  various m am m alian species all express 
a G q-like G -protein(s).
Membranes (panel A, 30 pg; panel B, 35 pg) from frontal cortex of human 
(H), baboon (B), pig (P), guinea pig (G-P), rat (R) and mouse (M) were resolved by 
SDS-PAGE (10% (w/v) acrylamide, 0.25% (w/v) bisacrylamide) and following 
transfer to nitrocellulose immunoblotted using antiserum CQ (panel A), antiserum IQB 
(panel B). Both of the primary antipeptide antisera were used at dilution of 1: 1000. 
All samples displayed an apparently single polypeptide of some 42 kDa.
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Figure 4,3.2.
Resolution of multiple Gq-like polypeptides in mammalian frontal 
cortex in SDS-PAGE containing 6 M urea.
Membranes (60 pg) from frontal cortex of human (H), baboon (B), pig (P), 
guinea pig (G-P), rat (R) and mouse (M) were resolved by SDS-PAGE (10% (w/v) 
acrylamide, 0.0625% (w/v) bisacrylamide containing 6  M urea) and following transfer 
to nitrocellulose immunoblotted using antiserum CQ (1: 1000 dilution).
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Figure 4.3.3.
Differences in mobility of immunodetectable G n a  between species.
Membranes (70 pg) from frontal cortex as used in Figure 4.3.2 were resolved 
in the 6  M urea containing gels detailed in chapter 2.2.10 and immunoblotted with the 
Gi la-specific antiserum E976 (1: 500 dilution).
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F igure 4.3.4.
Differences in electrophoretic mobility between immunodetectable 
human and rodent G n a  in neuroblastoma cell lines.
Membranes (60 pg) from the human neuroblastoma cell line IMR 32 (lane 1) 
or the rodent neuroblastoma hybrids NCB20 (lane 2) or NG108-15 (lane 3) were 
resolved in the 6 M urea gel system described in chapter 2.2.10, and subsequently 
immunoblotted with antisemm either CQ (1: 1000 dilution ) (panel A) or E976 (1: 500 
dilution) (panel B).
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Figure 4.3.5.
Co-expression and simultaneous detection of monkey and mouse G n a  
following transfection of COS-1 cells with a mouse G n a  cDNA.
Monkey COS-1 cells were either mock transfected (lane 1) or transfected with 
plasmid pCMV (100 pg) containing a full-length mouse cDNA (lane 2) using DOTAP 
reagent according to the manufacturer's instructions as described in chapter 2 .2 .2 2 . 
72h later cells were harvested and membranes prepared from these cells. Membranes 
(panel A, 55 pg; panel B, 100 pg) from transiently transfected monkey COS-1 cells 
were resolved in 6  M urea containing SDS-PAGE and immunoblotted with either 
antiserum CQ (1: 1000 dilution) (panel A) or antiserum E976 (1: 500 dilution) (panel 
B). Following transfection with murine G n a ,  a specific polypeptide which was 
substantially resolved from monkey G n a  and Gqa was detected by both antisera.
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Figure 4.3.6.
A. Comparison of species variations in sequences of the Gq-like G 
proteins in the regions used to generate antisera CQ, IQB and E976.
Antiserum CO.
I
Ï
mouse Gqa 
mouse G i l a  
human G n a  
bovine G i l a  
mouse G 14a 
bovine G i4a
350 QLNLKEYNLV 359 
QLNLKEYNLV 
QLNLKEYNLV 
QLNLKEYNLV 
QLNLREFNLV 
QLNLREFNLV
Antiserum IQB.
mouse Gqa 
mouse G i l a  
human G i l a  
bovine G n a  
mouse G 14a 
bovine G i4a
119 EKVSAFENPYVDAIKS 134 
EKVTTFEHQYVNAIKT 
EKVTTFEHQYVSAIKT 
EKVTTFEHRYVSAIKT 
DKVTALSRDQVAAIKQ 
DKVSTLSRDQVEAIKQ
Antiserum E976.
mouse G i l a  
human G i l a  
bovine G i l a
mouse Gqa 
mouse G 14a 
bovine G i4a
160 YLTDVDRIATVGY 172 
YLTDVDRIATLGY 
YLTDVDRIATSGY 
YLNDLDRVADPSY 
YLTDIERIAMPSF 
YLTDIDRIAMPAF
186
F ig u re  4.3.6.
B. C ross-com parison of am ino acid m ism atches in the  regions of the 
G q-like G -proteins used to generate an tisera  CQ, IQB and E976.
CQ IQB
Mq M il H ll B ll M14 B14 Mq M il ]H ll B ll M14 B14
Mq 0 0 0 2 2 6 6 6 9 9
M il 0 0 0 2 2 6 1 2 9 9
H ll  0 0 0 2 2 6 1 1 9 9
B ll  0 0 0 2 2 6 2 1 9 9
M14 2 2 2 2 0 9 9 9 9 3
B14 2 2 2 2 0 9 9 9 9 3
E976
M U Mq H ll B ll M14 B14
M il 6 1 1 6 5
Mq 6 6 6 6 6
H ll 1 6 1 6 5
B ll 1 6 1 6 5
M14 6 6 6 6 2
B14 5 6 5 5 2
amino acid peptide (160-172 of mouse G n a ) .
•;>î-
M = mouse, H = human, B = bovine, q = Gqa, 11 = G n a  and 14 = G n a .  
Antiserum CQ was raised against a C-terminal 10 amino acid peptide, IQB 
against a 16 amino acid peptide (119-134 of mouse G qa) and E976 against a 13
%
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F igure 4.3.7.
G enera tion  and  iso la tion  o f clones of E2M 11 H EK-293 cells w hich 
express the long splice v a rian t of the TRH receptor and both hum an and 
mouse form s of G n a .
Monolayer cultures of clone E2 HEK-293 cells described in chapter 4.2, were 
co-transfected with the eukaryotic expression vector pCMV into which a cDNA 
encoding mouse G n a ,  was inserted at the Cla I/Xho I sites, and the plasmid 
pBABEhygro, which allows expression of resistance to the antibiotic hygromycin B, 
in a 10: 1 ratio by using DOTAP reagent as suggested by the manufacturer. Clones 
were selected by resistance to hygromycin B (200 pg/ml) and the continued 
expression of the TRH receptor and novel expression of mouse G n a  were examined. 
Clone E2M11 was selected and expanded for detail analysis.
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6.2  kb Amp
Hygromycin
pBABE hygro
Amp
5.2 kb
Clone E2 expressing the long isoform 
of the rat TRH receptor was 
co-transfected.
t
Transfectants were selected with 
geneticin sulphate (800 pg/ml) and 
hygromycin B (200 pg/ml).
Clone E2M11 was selected, expanded and 
assayed for the expression of the TRH 
receptor and the mouse G H  a .
F ig u re  4.3.8.
[^H]TRH binds w ith high affinity and capacity to m em branes of E2M11 
c e ils .
Membranes (25 pg) from clone E2M11 cells were incubated with [^HJTRH 
(10.3 nM) in the absence and presence of varying concentrations of TRH as described 
in Figure 4.2.3. Displacement of [^HJTRH under these conditions by cold TRH was 
achieved with estimated IC50 of 98 nM when the Hill coefficient was restrained to 1.0. 
The data from this self-competition curve (Figure 4.3.8 A) were subjected to the 
formalisms of DeBlasi et aL, 1989. The estimated Bmax was 26 pmol/mg membrane 
protein and the Kd for [^HjTRH at this receptor binding site, under these conditions, 
was 120 nM. The data was also converted to a Scatchard plot (Figure 4.3.8B), 
analysis of which produced binding parameters of Bmax = 31 pmol/mg membrane 
protein and Kd for the binding of TRH to the low-affinity state of the long splice 
variant of the receptor was 140 nM. Two other identical experiments produced similar 
results in different membrane preparations.
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Figure 4.3.9.
Membranes from clone E2M11 but not clone E2 cells co-express human 
and murine G n a .
Membranes (60 pg) derived from either clone E2 (lane 1) clone E2M11 (lane 
2) were resolved in the urea-gradient SDS-PAGE system mentioned in chapter 2.2.10. 
Proteins were transferred to nitrocellulose and immunoblotted specifically for the 
presence of variants of G i l a  (panel A) by use of the G n a  specific antiserum E976 
(1: 500 dilution). E2 cells endogenously express human Gi l a  whereas E2M11 cells 
express a second form of G i la ,  the murine variant. Confirmation of the identity of 
the extra polypeptide expressed in E2M11 cells as murine G n a  was achieved by 
immunoblotting equivalent gels with antiserum CQ (1: 1000 dilution) (panel B).
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F ig u re  4.3.10.
T h e e ffe c t  o f  T R H  on the co n ten t o f  G i i a  G -p r o te in s  in cru d e  
m em hrane and cytoso l frac tion s o f  E2 and E 2M 11 cells.
75 cm^ tissue culture flasks of either E2 (panel A, left hand side) or E2M11 
cells (panel A, right hand side and panel B), grown to 70% confluency, were 
incubated for 16 h with (T) or without (C) 10 pM TRH. Crude membrane (MB) and 
cytosol (CYT) fractions were prepared as described in chapter 2.2.2. The G n a  
proteins in membranes and cytosol were resolved by 6  M urea SDS-PAGE as 
mentioned previously using 60 pg (panel A) or 150 pg (panel B) of protein per lane 
and identified by immunoblotting with antiserum CQ (1: 1000 dilution). Results are 
from a representative experiment.
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F igure 4.3.11.
Time course of membrane removal and cytosolic accumulation of 
variants of G n a .
E2M11 cells were untreated (C) or treated with TRH (10 pM) for varying 
times and crude membrane and cytosolic fractions subsequently prepared as in chapter 
2.2.2. Immunoblotting with antiserum CQ was performed following resolution of the 
fractions (cmde membranes, 60 pg/lane; cytosol, 150 pg/lane) in 6  M urea containing 
SDS-PAGE as in Figure 4.3.10
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F igure 4.3.12.
TRH induced cellular redistribution and down-regulation of human and 
murine variants of G n a  (Quantitative analysis).
Panel A represents the immunological signal of total (open circles), membrane 
bound (closed circles) and cytosolic (crosses) forms of human (I) and murine (II) 
variants of G] l a  as expressed in arbitrary units for each time interval.
In panel B, the relative amount of human (I) and murine (II) G n a  subunits in 
membrane and cytosol fractions was expressed as % of total signal (membranes + 
cytosol) for each time interval. The down-regulation (III) of human (open circles) and 
murine (closed circles) G n a  was expressed as the decrease of total immunological 
signal with time.
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F igure 4.3.13.
TRH treatment of E2M11 cells results in a transfer of G i l  a  variants 
from the plasma membrane to low-density membrane fractions 
(Immunoblot studies).
Homogenates prepared from the same amount (each derived from 6 x 75 cm^ 
tissue culture flasks) of untreated (control) (panel A and panel B) or TRH (10 pM, 
16h) treated cells (panel B) were fractionated on discontinuous sucrose density 
gradients as described in chapter 2.2.3. and the plasma membrane fraction (centred on 
fraction 4) was separated from cytosol (fraction IS), light vesicle (IP), low-density 
(microsomes, endoplasmic reticulum, fractions 2 and 3) and high-density 
(mitochondria, fractions 6  and 7) membranes as well as the gradient pellet (fraction 8 ).
Panel A displays the identical cellular distributions of both endogenous human 
G j i a  and exogenously introduced murine G% %(%. 0.75 ml of sucrose density 
fractions 1-8 of the homogenate from untreated E2M11 cells were TCA precipitated 
(6 % final concentration, 1 h, 0 °C) and resolved in 6  M urea-containing SDS-PAGE as 
in Figure 4.3.10 to detect the presence of the human and murine variants of G i la .
Panel B represents TRH induced redistribution of cellular G n a  from the 
plasma membrane to low-density membrane fractions. Homogenates from control and 
TRH treated E2M11 cells were subjected to centrifugation on discontinuous sucrose 
density gradients, proteins were resolved by 6M urea containing SDS-PAGE (the gels 
were shown in Figure 4.3.14.) and immunoblotted with antiserum CQ at a dilution of 
1: 1000. Data are taken from a representative experiment.
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F igure 4.3.14.
TRH treatment of E2M11 cells does not result in a gross redistribution 
of cellular polypeptides.
Homogenates of control and TRH-treated (10 pM, 16h) E2M11 cells were 
subjected to centrifugation on discontinuous sucrose gradients. 0.75 ml of sucrose 
density fractions 1-8 were precipitated with trichloracetic acid (6% final concentration, 
1 h, 0 °C) and the resulting proteins resolved by 6  M urea containing SDS-PAGE 
(10% (w/v) acrylamide, 0,0625% (w/v) bisacrylamide). The gels were stained with 
Coomassie brilliant blue R-250 as described in chapter 2.2.9..
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Figure 4.3.15.
Specific content and redistribution of G n a  proteins in control and 
TRH treated E2M11 cells along tbe sucrose density gradient.
In panel (I) the specific content of G n a  (both variants) present in gradient 
fractions IS, IP and 2-8 of control (open symbols) and TRH-treated (10 pM, 16h) 
(filled symbols) E2M11 cells was calculated by dividing the immunological signal by 
the amount of protein applied to the gel. The immunological signals (arbitrary units) 
corresponding to both human and murine variants of G n a  shown in Figure 4.3.13. 
were analysed by densitometric scanning and the amount of protein applied was 
determined in parallel samples TCA precipitated from 0.75 ml aliquots of the sucrose 
density gradient fractions.
The relative amount of G n o t present in a given fraction from homogenates of 
both control (open bars) and TRH treated (filled bars) E2M11 cells was expressed in 
panel (II) as a percentage over the entire gradient.
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F igure 4.3.16.
TRH-treatm ent of E2M11 cells results in a greater cellular 
redistribution and down-regulation of buman G n a  than of murine
G l i a .
Fractions IS (320 pg), IP (170 pg), 3 (40 pg), 4 (35 pg) and 5 (40 pg) (the 
protein content of 0 .3 5  ml of each fraction) from centrifugation on a discontinuous 
sucrose density gradient of control (C) and TRH-treated (T) (10 pM, 16h) E2M11 
cells were resolved in 6  M urea-containing SDS-PAGE and immunoblotted using 
antiserum CQ (1: 1000 dilution)
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F igure 4.3.17.
Both human and murine G i i a  are efficiently solubilized from  
membranes of E2M11 cells by sodium cbolate.
Crude membranes (60 pg) of E2M11 cells were either untreated (lane 1) or 
treated with 1% (w/v) sodium cholate (1 h, 4 °C) (lanes 2 and 3). The sodium cholate 
treated samples were then resolved into remaining particulate (lane 2 ) and solubilized 
(lane 3) fractions by centrifugation (200, 000 x gav for 30 min at 4 °C). Samples were 
resolved by 6  M urea-containing SDS-PAGE and immunoblotted using antiserum CQ. 
If the transfected polypeptide of murine G n a  had formed an aggregated mass, then 
after detergent solubilization as detailed in chapter 2.2.4, they would still be found in 
the particulate fraction whereas G-protein a  subunits which were membrane 
associated should be released into the solubilized supernatant fraction.
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F igure 4.3.18.
The cellular distribution of G-protein p-subunit is altered by treatment 
of E2M11 cells with TRH.
Homogenates of control (panel A) and TRH-treated (10 pM, 16h) (panel B) 
E2M11 cells were centrifuged on discontinuous sucrose density gradients as described 
in the legend to Figure 4.3.13. 0.75 ml of sucrose density gradient fractions 1-8 used 
in Figure 4.3.13 were precipitated with TCA (final conc.: 6 %, 1 h, 0 °C) and then 
resolved in SDS-PAGE (10% (w/v) acrylamide, 0.25% (w/v) bisacrylamide). p- 
subunit was subsequently detected by immunoblotting with antiserum pN (1: 200 
dilution).
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Table 4.3.1. 
Tbe distribution of G n a  G-proteins in clone E2M11 cells and tbe 
effect of TRH.
The immunological signals (arbitrary units) corresponding to both human and 
murine variants of G% l a  proteins shown in Figure 4.3.10 (panel B) were analysed by 
densitometric scanning and related to the amount of protein present in membrane and 
cytosol fractions prepared from the same number of cells (1 x 7 5  cm^ flask of cells). 
Down-regulation by TRH (1 pM, 16h) was expressed as a percentage of total signal 
(membranes plus cytosol) in untreated cells. Similar results were obtained in 3 other 
experiments.
A. Control.
G l ia  (%) Down-regulation (%)
Membrane
Cytosol
Total
1152.9 ( 98.0%) 
23.8 ( 2.0%) 
1176.7 (100.0%) 0
B. TRH-treated (10 pM , 16b).
G l ia  (% ) Down-regulation (%)
Membrane
Cytosol
Total
476.2 ( 76.6%)
145.2 ( 23.3%) 
621.4 (100.0%) 47.2
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Table 4.3.2.
Time course of TRH-induced alterations in membrane to cytosol 
distribution and down-regulation of human and murine G n a  G - 
proteins in E2M11 cells.
The immunological signal (arbitrary units) corresponding to both species 
variants of G n o t  shown in Figure 4.3.11 was analysed by densitometric scanning 
and related to the amount of protein present in membrane and cytosol fractions. Down- 
regulation by TRH (10 pM , 16h) was expressed as percentage of total signal 
(membranes plus cytosol) in untreated cells. Results are representative of 4 
experiments performed.
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Human G n a
Membrane Cytocol Total Down-regulation
Control 40.3 (96%) 1.7(4% ) 42.0 (100%) 0 %
10 nain 26.0 (96%) 1.0(4% ) 27.0 (100%) 36%
30 nain 18.4 (94%) 1 .2 ( 6 %) 19.6 (100%) 53%
Ih 19.5 (84%) 3.8 (16%) 23.3 (100%) 44%
4h 9.3 (61%) 6.0 (39%) 15.3 (100%) 63%
8 h 1.8 (18%) 8.4 (82%) 10.2  (10 0%) 76%
12h 1.6(17%) 7.8 (83%) 9.4 (100%) 78%
16h 1.6(17%) 8.0 (83%) 9.6 (100%) 77%
Mouse G n a .
Membrane Cytocol Total Down-regulation
Control 187.6 (8 6 %) 30.8(14%) 218.4(100%) 0 %
10 nain 169.1 (85%) 29.5 (15%) 198.6 (100%) 9%
30 nain 188.9 (8 6 %) 32.1 (15%) 2 2 1 .0 (1 0 0%) - 1%
lia 182.2 (81%) 43.8 (19%) 226.0 (1 0 0%) -3%
4h 149.0 (75%) 48.5 (25%) 197.5 (100%) 10%
8h 136.2 (72%) 52.4 (28%) 188.6 (100%) 14%
12h 95.3 (65%) 52.0 (35%) 147.3 (100%) 33%
16h 95.6 (65%) 51.8 (35%) 147.4 (100%) 32%
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Table 4.3.3. 
The regulation of G-protein P-subunits in E2M11 cells by treatment 
with TRH.
E2M11 cells (1x75  cm^ flask), which were either control or treated with TRH 
(10 pM, 16h), were homogenized in 0.5 ml of TME buffer and centrifuged for 2 h at 
50,000 rpm. The sediment was suspended with re-homogenization in 0.5 ml of TME 
buffer (crude membranes) and the supernatant represents the cytosol fraction. The 
immunodetectable signal corresponding to G-protein p-subunits (ai'bitrary units) was 
normalized to the amount of protein in these fractions. Down-regulation by TRH was 
expressed to compared to untreated cells. Results represent mean ± S.D. of 3 
experiments.
A. Control.
P subunit (%) Down-regulation (%)
Membrane
Cytosol
Total
437.0 +46.9 ( 99.0%) 
6 .6 + 3.3 ( 1.0%) 
443.6 (100.0%) 0
B. TRH-treated (10 pM, 16h).
P subunit (%) Down-regulation (%)
Membrane
Cytosol
Total
294.2 ± 39.5 ( 99.0%) 
2.4 ± 0.9 ( 1.0%) 
296.6 (100.0%) 32^
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%4.3 ,2 , D iscussion,
Many receptor expression studies are performed in heterologous systems, not 
only in terms of the cell type used for expression but also in teims of the species origin 
of the cell. Little attention is given to the possibility that there may be differences either 
at a qualitative or quantitative level in the interactions of a receptor with G-proteins 
derived from another mammalian species although, at the receptor level, there are 
many examples of how pharmacological profiles of receptor-ligand interactions may 
differ between species homologous based on as little as a single amino acid 
substitution (Hall e ta l ,  1993; lAnketaL, 1993).
The extreme C-terminal region of G-protein a  subunits plays a key role in 
receptor recognition. Mutation within this region, i.e., in the une phenotype of S49 
lymphoma cells in which a single base substitution leads to the alteration of Arg to Pro 
six amino acids from the C-terminus of Gga, prevents interaction of receptors with the 
mutant G-protein (Sullivan et al., 1987). Furthermore, pertussis toxin functions to 
prevent receptor interaction with G proteins of the G ia family by catalyzing ADP- 
ribosylation of the conserved Cys residue which is located four amino acids from the 
C-terminus of all of these G-proteins (Milligan et aL, 1988). It is also known that 
designed mutagenesis in this region of a G-protein can regulate the nature of receptors 
which interact with the G-protein (Conklin et al., 1993a). G-protein a  subunits are in 
general highly conserved between mammalian species (Kaziro et at., 1990) and the C- 
terminal region is predicted to be virtually identical in G n a  in all of the mammalian 
species. In the case of G n a ,  clones corresponding to which have been isolated from 
mouse (Strathmann et a l ,  1990), bovine (Nakamura e ta l ,  1991) and human (Jiang et 
a l,  1991) cDNA libraries, there is complete identity within this region (Figure 4.3.6) 
and the clones corresponding to G n a  predict some 97-98% overall amino acid 
identity between these three species. This high degree of conservation allows 
immunological probes generated against an amino acid sequence within the G-protein 
from one species to be useful in the detection of the same G-protein in cells and tissues 
from a range of species but poses a substantial limitation in attempts to define the
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species from which a form of a G-protein might be derived. However, the system 
which I have developed in this study offers a suitable means by which to measure the 
functional importance of any designed mutation as the functionality of modified form 
of murine G n a  expressed in a primate cell line can be measured using the function of 
the endogenously expressed primate G% l a  as control (McCallum et al., 1995).
The results reported herein demonstrate that a considerable number of Gq-like 
polypeptides are expressed in mammalian frontal cortex and that the profile of 
expression and mobility of these polypeptides varies markedly between species. I have 
also shown an ability to express species variants of the same G-protein in a single cell 
and to detect concurrently and unambiguously both of these polypeptides. The 
approach used in this study has relied on immunodetection using primarily an 
antiserum generated against a synthetic peptide corresponding to the sequence 
predicted to the C-terminal decapeptide of both mouse G qa and Gl l a  as mentioned 
above.
Resolution of frontal coitex from a number of mammalian species in 10% 
(w/v) acrylamide, 0.25% (w/v) bisacrylamide SDS-PAGE demonstrated not only no 
ability to resolve G n a  forms from different species but also that G n o t  was not 
resolved from the closely related G-protein G qa (Figure 4.3.1). Such results provide 
no information, however, on whether G qa and G n o t are co-expressed in these 
tissues and if they are about the relative levels of expression of these two peptides. To 
address this question it has been reported that an imidazole buffer system in a 13% 
acrylamide gel can provide separation of G qa and G i i a  (Blank et al., 1991). 
However, in my hands this method achieves a lesser degree of separation and is not as 
reproducible as the 4-8 M urea gradient method described in Milligan et al., 1993d. 
The disadvantage of the 4-8 M urea gradient method that it also was not routinely 
reproducible in separating G qa  and G n a .  Therefore, a new gel system was 
developed in this study to demonstrate that G n a  from different species can be 
separated from each other and from G qa. This gel system applied a 10% (w/v) 
acrylamide, 0.0625% (w/v) bisacrylamide matrix into which 6 M urea has been
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incorporated. It is technically easier than the urea gradient method previously reported 
and allowed me to examine a member of the Gq family from different species. 
Resolution of frontal cortex from a number of mammalian species under 10% (w/v) 
acrylamide, 0.0625% (w/v) bisacrylamide SDS-PAGE conditions which incorporated 
6  M urea into the gel demonstrated the presence of a number of Gq-like polypeptides 
in mammalian frontal cortex and that the profile of expression and electrophoretic 
mobility of these polypeptides varied markedly between species (Figure 4.3.2).
Detection of these polypetides was based principally on the use of two 
antisera. The first of these (CQ) (Mitchell et a l ,  1991) was generated against a 
synthetic peptide corresponding to the sequence predicted to the C-terminal 
decapeptide of both mouse GqOC and G u o t (Figure 4.3.6). The second antiserum 
used (E976) (Taylor et aL, 1991a) was generated against a peptide predicted to 
correspond to amino acids 160-172 in mouse G n o t (Figure 4.3.6). This sequence 
differs in but a single amino acid between the mouse (170 Valine), human (170 
Leucine) and bovine (170 Serine) forms but varies markedly from the equivalent 
sequences of G qa and G 14a  and thus provides a specific probe for G n a  which will 
identify rodent and primate forms of G n a  similai’ly.
In this study I was able to detect a polypeptide migrating in the position 
anticipated for G% %a, based upon the previously established mobility of rat G n a  
(Milligan et aL, 1993d), in membranes of frontal cortex from human, baboon or 
guinea pig. Confmnation of the presence of immunodetectable G n a  was produced in 
immunoblots using the G n o t specific antiserum E976. The position of migration of 
primate G l lot in these resolving gels was substantially different from rodent G not, 
migrating more slowly and in a position very close to G qa. Immunoreactivity 
corresponding to G l l a  in guinea pig was shown to migrate in a different position to 
either rat and mouse or the primates (Figure 4,3.3) and to correspond to the heavily 
CQ immunostained polypeptide migrating between rat and mouse G qa and G n o t 
(Figure 4.3.2). Antisenim CQ would also be anticipated to cross react with G 14a . 
Indeed in ELISA assays this antiserum reacts strongly with a peptide which
scorresponds to the C-terminal decapeptide of G 14a  (Milligan et a i ,  1992). This is 
because although this region of G 14a  has two amino acid differences to that of G qa 
and G l i a  (Figure 4.3.6 .B) they are both conservative substitutions (Figure 4.3.6 A). 
As such it is possible that one of the polypeptides identified by antiserum CQ is 
G 14a . However, conservation between Gqa, G n a  and G n a  is weak in the regions 
used to generate antisera IQB and E976 (Figure 4.3.6) and it is thus unlikely that these 
antisera would identify G n a .  It has also been indicated that the tissue distribution of 
G 140c is very restricted (Wilkie et aL, 1991). It was also a potential concern that some 
of the complexity of the CQ immunoreactive pattern uncovered by the urea containing 
gels might represent a series of proteolytic fragmentations. However, inclusion in the 
membrane preparation protocol of a cocktail of inhibitors of proteolysis had no ability 
to alter the immunoreactive pattern (data not shown).
It has been shown that a human muscarinic M l acetylcholine receptor is able to 
activate and regulate cellular levels of both rat G qa and G n a  equally (Mullaney et 
aL, 1993a). By contrast, there has been some limited evidence to support the concept 
that G qa and G n a  function differently and that receptors can select between them 
(Lipinsky et aL, 1992). Therefore, the ability to coexpress and subsequently 
independently detect species isoforms of Gnoc now offered the possibility to measure 
whether a receptor interacts equally or selectively with G-proteins derived from 
different species. The stable co-expression of a receptor and murine G n o t in a human 
cell line allowed measurement of the relative interaction of the receptor with each of 
mouse and human G n o t for example. As a means to begin to address questions of 
this nature mouse G n o t was expressed transiently in monkey COS-1 cells (which 
express endogenously the monkey form of the protein) and membranes derived from 
these cells was resolved by including 6  M urea in 10% (w/v) acrylamide, 0.0625% 
(w/v) bisacrylamide SDS-PAGE which is able to separate excellently between the 
mouse and monkey forms (Figure 4.3.5).
On the basis of transient expression of mouse G n o t in COS-1 cells, the stable 
co-expression of a receptor and murine G no t in a human cell line was developed. The
f;
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system used in this study is a clonal cell line derived from the human embryonic 
kidney cell line HEK-293 by two consecutive stable transfections. In the first stage the 
cells were transfected to express high levels of the long isoform of the rat TRH 
receptor and subsequently a clone from this transfection (E2) was transfected to
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express the murine form of G n a  (clone E2M11) (Figure 4.3.7). The requirement for
high levels of a receptor was based on our previous observations that to record agonist 
mediated down-regulation of a G-protein, high levels of receptors are required (Adie et 
al,  1994a, b; Milligan et a l,  1995b) as a significant fraction of the cellular population 
of the relevant G-protein must be activated by the receptor. Clone E2M11 allowed me 
to address a further question which has not been previously examined in any 
systematic manner i.e. can a single receptor type utilize species variants of the same G- 
protein equivalently?
As previously noted, rodent and primate variants of G n a  migrate in markedly 
different positions in urea-containing SDS-PAGE. In this study I demonstrated 
conclusively that clone E2M11 but not clone E2 expressed murine G no t while both of 
these clones express human G no t endogenously due to the genetic background of the 
HEK-293 cells. In Figures 4.3.9 and 10, murine G no t is expressed at some 2-3 fold 
higher levels than the human variant in E2M11 cells (this ratio varied somewhat in 
individual passages of the cells, a feature previously well appreciated for a variety of 
polypeptides in many transfected cell lines). Importantly, before these studies could 
progress usefully, It was necessary to demonstrate that the cellular distribution of the 
endogenous human G n o t and the introduced murine G n o t were identical (Figure 4. 
3.13A) as judged by their co-distribution in various membrane fractions prepared by 
centrifugation of cellular homogenates on discontinuous sucrose density gradients. 
Furthermore, both human and murine G n o t were effectively solubilized from a crude 
membrane fraction by exposure to sodium cholate (Figure 4.3.17). I have used this as 
an indication that the immunodetectable mouse G n o t did not reflect either incorrect 
folding or aggregation of the expressed protein,.
As previously shown in chapter 4.2 for clone E2, sustained exposure of 
E2M11 cells to a maximally effective concentration of TRH resulted in a marked 
reduction in G n a  levels in a crude membrane fraction of these cells, confiiming that 
TRH treatment of these cells can result in down-regulation of a substantial fraction of 
the expressed G n a .  However, a key observation over a lai'ge number of experiments 
was that down-regulation of human G noc was quantitatively more effective than 
down-regulation of murine G n a .  These data provide the first indication that a 
receptor may not interact identically with the same G-protein from two separate species 
when presented with a concurrent choice between them and when it is clear that the 
two G-proteins are identically presented and distributed in a cell. This was surprising 
as the two species variants are some 97% identical in primary sequence (Strathmann et 
a i,  1990) and are very highly conserved in regions believed to play important roles in 
interactions with receptors. Furthermore, in a range of studies little has been observed 
to suggest that receptors can functionally select between the a  subunits of 
endogenously expressed G n a  and G qa (Mullaney et a l ,  1993a) the prevalent and 
widely expressed phosphoinositidase C-linked G-proteins which, although derived 
from distinct genes, are highly homologous (Strathmann et a i ,  1990). It should be 
noted, however, that difference in the interaction of the mammalian neuromedin B 
receptor with Xenopus  forms of G qa  and G n a  have been recorded using an 
antisense based approach (Shapira et a l ,  1994) and between murine G qa and G n a  
with the murine TRH receptor following their expression by injection of cRNA into 
Xenopus oocytes (Lipinsky eM/., 1992).
By simple fractionation of E2M11 cell homogenates into cmde membrane and 
cytosolic fractions it was noted that in the unchallenged cells only some 4% of the total 
cellular content of the G n a  species variants could be found in the soluble fraction of 
the ceil. However, upon challenge of the cells with TRH an increase in the soluble 
content of G i i a  was observed (Figure 4.3.lOB and Figure 4.3.11). This could be 
observed for both the human and murine variants of Gnoc and was also observed to 
increase over an 8 h period. When presented as a fraction of the total cellular content
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of G l i a  at any time period, the cytosolic fraction increased to some 20-25% of the 
total, but it must be remembered that this value is made apparently more impressive as 
the total cellulai* content of Gncx falls (it is down-regulated). The increase in cytosolic 
content of G n a  was insufficient to account for the bulk loss of G n a  from the 
particulate fraction, confirming a tme cellular reduction in G n a  levels. A number of 
other studies have reported an accumulation of cytosolic G§a following agonist 
challenge of cells (Ransnas et a l ,  1989; Levis et a l ,  1992; Negishi et a l ,  1992). 
Recently there has been considerable emphasis of examining the interaction of G-
■i
protein a  subunits with membranes as all of the widely expressed a  subunits have 
been shown to be palmitoylated close to their N-terminus (Parent! et a l,  1993; Linder 
et a l,  1993; Degtyaiev et a l,  1993a; Wedegaertner^rcz/., 1993; Grassie et a l ,  1994). 
Studies indicate that the palmitoylation status (of at least GgOC) is dynamic and to be 
regulated by the activation status of the G-protein (Degtyarev et a l ,  1993a; 
Wedgaertner et a l ,  1994; Mumby et a l ,  1994). Furthermore, cytosolic G-protein a  
subunits have been reported to be devoid of palmitate. It will thus be of interest to 
examine, in time, the relative palmitoylation status of G n a  in the various cellular 
compartments during and following TRH-treatment of E2M11 cells.
Cellular redistribution of the a  subunit of the stimulatory G-protein Gga from 
membrane to cytosol has been recorded in a number of studies following agonist- 
occupation of a receptor which links to this G-protein (Ransnas et a l ,  1988, 1989; 
Levis et a l ,  1992; Negishi et a l ,  1992). However, the quantitative details relating to 
the fraction of the G-protein moved and the time course of this effect have either been 
somewhat variable or have not been examined in detail. Furthermore, there has been 
little previous attempt to analyse if the activated G-protein might redistribute within 
membrane fractions upon agonist activation of a receptor. It has recently been reported 
that sustained agonist occupation of a human muscarinic M l acetylcholine receptor 
stably transfected into CHO cells results in a cellular redistribution of the a  subunits of 
the phosphoinositidase C linked G-protein G qa and G n a  (Svoboda et a l ,  1994). 
Strong evidence also indicates that maintained exposure of a cell to an agonist can
s
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results in a reduction in cellular levels of the G-protein(s) activated by the receptor for 
that agonist (Mullaney et a i ,  1993a, b; McKenzie e ta l ,  1990b; Green et a l ,  1992), 
an effect which appears to reflect accelerated degradation of the activated G-proteins 
(Shah et a l ,  1995; Mitchell et a l ,  1993). There are thus clearly a variety of dynamic 
processes in which cellular G-proteins are paiticipants following receptor activation of 
a cell. The establishment of a suitable cellular system in this study has allowed me to 
examine concurrently both the qualitative and quantitative details of many of these 
processes.
Separation of the total pai ticulate fraction of untreated and TRH-treated E2M11 
cells into a series of membrane fractions by centrifugation of cellular homogenates on 
discontinuous sucrose density gradients (Svoboda e ta l ,  1994) demonstrated a further 
clear and novel cellular redistribution of G n a  in response to TRH. While the 
distribution of G n a  in the untreated cells indicated that a large preponderance of the 
G-protein was in the plasma membrane, as might be expected given its role, TRH- 
treatment produced a profound membrane redistribution such that the bulk of the 
remaining immunodetectable G n a  was now located in lower-density membrane 
fractions (Figure 4.3.13B where the main peak of G q i a  immunoreactivity is in 
fractions 2 and 3 following TRH treatment compared to fractions 4 and 5 in the 
untreated samples). This redistribution of G q i a  was achieved without a bulk 
redistribution of protein as the gross pattern of protein expression in the various 
sucrose density gradient fractions was not altered by TRH-treatment of the cells 
(Figure 4.3.14). This is reminiscent of the redistribution towards lower-density 
membranes observed for both Gq/Gi l a  and the muscarinic M l acetylcholine receptor 
following challenge with carbachol of CHO cells transfected to express this receptor 
(Svoboda et a l ,  1994).
Somewhat to my surprise, the membrane redistribution of G-protein subunits 
upon TRH-treatment was not restricted to Gi la . Equivalent analysis of the paiticulate 
distribution of G-protein p-subunit indicated that there was also a substantial 
movement of immuno-detectable p-subunit from the plasma membrane containing
fractions to light membrane fractions (Figure 4.3.18). In contrast to G n a ,  however, 
there was no increase in detection of cytosolic p-subunit upon TRH treatment and this 
remained as insignificant fraction. Thus, the hormone-induced movement of G n a  
subunits to the cytosol induced by TRH stimulation of E2M11 cells must be associated 
with physical dissociation from p-subunits which remain in the particulate fraction.
The physical processes involved in alteration in the membrane fraction 
distribution profile of G n o t and P-subunits upon sustained TRH stimulation remain 
undefined but these may contribute to the process of desensitization. Furthermore, 
these may represent pait of the process of membrane to cytosol transfer of G n a .  The 
low-density membranes represent a heterogeneous mixture of membrane stiuctures 
(endosome, endoplasmic reticulum, golgi) which has previously been suggested to 
contribute to internalization of hormone receptors following agonist challenge (Hai'den 
et a i ,  1980; Waldo et a l ,  1983; Strader et a l ,  1984; Rassis et a l ,  1986), again as 
part of mechanisms designed to regulate cellular sensitivity to agonists (Hausdorff et 
a l,  1990; Kobilka e ta l ,  1992; Zastrow e ta l ,  1992).
The results presented in this study demonstrate a complex pattern of cellular G- 
protein redistribution following agonist-induced activation of receptors which may be 
a complex as that of the G-protein-linked receptors themselves. They also provide the 
prospect that species variants of G-proteins may display subtle differences in their 
regulation by receptors, a concept which may indicate that greater care should be 
afforded the choice of genetic background for detailed analysis of cell signalling 
properties of transfected receptor. The detailed mechanisms responsible for agonist- 
induced cellular G-protein redistribution will be considered as the basis of future 
studies.
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Conclusions.
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This chapter summarise the major obseiwations of this thesis.
G-protein-linked transmembrane cellular signalling cascades include a 
receptor, G-protein and an effector. The studies presented in this thesis focus on 
agonist-induced signal transduction via G-proteins which result in the stimulation of 
adenylyl cyclase and stimulation of phospholipase C activity.
Although the basic characteristics of agonist-mediated second messenger
generation^has been widely studied little was known about the levels of expression of ^  
each polypeptide component in individual cells, their cellular disposition or the 
stoichiometry of their interactions. In chapter 3, neuroblastoma x glioma hybrid,
NG108-15, cells (Hamprecht et al., 1985) have been studied as a model system to 
analyse signal transduction by the adenylyl cyclase cascade as these cells express a 
considerable range of receptors which act in both a stimulatoiy and inhibitory manner 
on the generation of cyclic AMP (Milligan et al., 1990). In these cells, reduction in the 
levels of GgOt produced by treatment of the cells with the IP prostanoid receptor 
agonist, iloprost (McKenzie et al., 1990) results in a heterologous desensitization of 
receptor-mediated generation of cyclic AMP. Amounts of the IP prostanoid receptor,
Gga and the functional complex of Gga with adenylyl cyclase, which acts as the 
cyclic AMP generator, were measured in membranes of NG108-15 cells. As measured 
by the specific binding of [^Hjprostaglandin E l, the IP prostanoid receptor was 
present at some 100,000 copies/cell. Gga, assessed by quantitative immunoblotting 
with recombinantly expressed protein, was shown to be present in considerably higher 
levels (1,250,000 copies/cell). The stimulation of specific high-affinity binding of 
[^Hjforskolin as produced by either NaF or Gpp(NH)p to total membranes of and 
intact NG108-15 cells was used to attempt to define the maximal number of GSAC 
complexes that can be formed in these cells. However, the maximal formation of a 
complex of Gga and adenylyl cyclase represented only some 17,500 copies/cell. The 
previous established 8:1 stoichiometry of concurrent down-regulation of Gga and IP 
prostanoid receptor in these cells (Adie et al., 1992) indicates that full-agonist 
occupation of the receptor should be able to activate some 65% of the expressed Gga.
■ -r
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Despite the potential 70 fold excess of Gga over the Gga/adenylyl cyclase complex, 
IP prostanoid receptor agonist-mediated reduction of Gga levels by 35% resulted in a 
25% reduction in the maximal formation of GgO/adenylyl cyclase complex. Alousi et 
al., 1991 have also presented a similar ratio of each component in S49 lymphoma 
cells, the absolute numbers of P2~adrenoceptor: Gg(%: adenylyl cyclase being 1,500: 
100,000: 3,500. In both NG108-15 and S49 lymphoma cells the measured levels of 
the adenylyl cyclase catalytic subunit are substantially lower than those of the 
corresponding G-protein, suggests that much of the cellulai' Gga may not have access 
to adenylyl cyclase, which is likely to be the limiting component for information 
transfer.
I then utilized both wild type NG108-15 cells (Hamprecht et a l,  1985), which 
express endogenously a Gga-linked IP prostanoid receptor (Adie et a l ,  1992), and 
clones derived from these cells transfected to express differing levels of the human p2- 
adrenoceptor (Adie et al., 1993; 1994 a, b), to examine agonist regulation of the 
interaction of Gga and adenylyl cyclase.
Addition of the IP prostanoid receptor agonist iloprost to intact NG108-15 
cells resulted in a dose-dependent increase in formation of the complex of Gga and 
adenylyl cyclase (GSAC) as measured by the specific, high affinity binding of 
[^Hjforskolin. NG108-15 cells which were transfected to express either relatively 
high (clone pN22) or low (clone PN17) levels of the human p2-adrenoceptor both 
showed dose-dependent increases in specific [^HJforskolin binding in response to the 
P-adrenoceptor agonist isoprenaline and, maximally effective concentrations of 
isoprenaline resulted in the generation of close to the theoretically maximal number of 
GSAC complexes in both clones. The dose-effect curve in clone PN22, however, was 
some 15 fold to the left of that produced in clone PN17, similar to that noted for 
isoprenaline-mediated stimulation of adenylyl cyclase activity (Adie etal., 1994b). In 
contrast, dose-effect curves for iloprost-stimulation of [^Hjforskolin binding were not 
different in clones pN22 and PN17.
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Basai specific [^HJforskolin binding, in the absence of agonist, was 
significantly greater in cells of clone pN22 than clone PN17. This was not a reflection
of higher immunological levels of adenylyl cyclase in this clone, thus indicating that 
the elevated basal formation of GSAC is likely to be a reflection of empty receptor 
activation of G§a. This higher basal specific [^HJforskolin binding was partially 
reversed by the P-adrenoceptor antagonist propranolol.
To assess whether IP prostanoid receptor-mediated stimulation of high affinity 
[^Hjforskolin binding in NG108-15 cells would be compromised by activation of a 
receptor that mediates inhibition of adenylyl cyclase in these cells, I observed that the 
6  opioid peptide DADLE, which mediates inhibition of adenylyl cyclase via the 
activation of Gi2 a  (McKenzie et al., 1990a), was unable to reduce iloprost-stimulated 
[3H]forskolin binding in clone PN22 cells.
Sustained exposure of clone PN22 cells to isoprenaline or iloprost resulted in a 
substantial and selective down-regulation of Gga. Agonist-mediated selective down- 
regulation of the G-protein(s) activated upon receptor occupancy is a well established 
phenomenon (Milligan et al., 1993). Treatment of pN22 cells with the irreversible p- 
adrenoceptor antagonist bromoacetyl alprenolol menthane (BAAM) diminished both 
the potency and the maximal ability of isoprenaline but not of iloprost to cause Ggoc 
down-regulation. These results demonstrate that the extent of agonist-mediated Gga 
down-regulation is dependent upon the availability of receptor to agonist.
Receptor theory anticipates that the observed intrinsic activity and potency of 
agonist will also depend on the level of receptor expression and receptor reserve, and
potentially on the level at which the transmitted signal is measured (Kenakin et al.,
1989). Whether measuring agonist-stimulation of adenylyl cyclase activity in 
membranes of these cells or agonist-stimulation of the formation of the complex of
:
Gga and adenylyl cyclase which acts as the high affinity binding site for [^HJforskolin 
in whole cells, a series of P-adrenoceptor agonists, including dichloro-isoprenaline, 
ephedrine, dobutamine and salbutamol, displayed higher intrinsic activity and showed 
concentration-response curves which had substantially lower EC50 values in clone
215 ;.y"ê
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PN22 compared to clone pN17. Furthermore, following elimination of smaller 
fractions of the receptor population by treatment of the cells with the irreversible 
antagonist BA AM, the agonist properties of drugs with lower intrinsic activity are 
reduced more than other drugs with greater intrinsic activity. In clone pN22 cells and 
membranes, reduction in the observed intrinsic activity for ephedrine required 
elimination of a smaller fraction of the p2~adrenoceptor reserve than for salbutamol 
and reduction in the effect of the full agonists isoprenaline and epinephrine was only 
noted with high fractional elimination of the receptor pool. The effect of isoprenaline 
was substantially reduced, however, by BA AM treatment of clone pN17 cells, where 
p2-adrenoceptor number was approaching extremely low levels.
In NG108-15 cells transfected to express varying levels of the human p2- 
adrenoceptor, that maximal adenylyl cyclase activity can be achieved by occupation by 
isoprenaline of only some 200 fmol/mg membrane protein of this receptor. Expression 
of higher levels of the receptor do not result in greater adenylyl cyclase activity but 
only in a progressive shift in the agonist concentration-response curve to lower 
concentrations (Adie et a l,  1994b), indicative of the presence of spare receptors.
Increased expression of GgCt in this genetic backgound, as anticipated from the 
basal stoichiometries noted above, does not result in any significant alteration in the 
maximal effectiveness of the adenylyl cyclase cascade even though receptors can 
access and activate the introduced Gga as effectively as the endogenous G-protein 
pool (Mullaney e ta l ,  1994).
To further extend such analyses, I isolated stable clonal cell lines following 
transfection of adenylyl cyclase type 2 (Feinstein et a i,  1991; Lustig et a i,  1993) into 
this genetic background and examined how this alters the effectivness of signal 
transduction from both endogenously expressed and stably transfected Gga-coupled 
receptors in clones in which the total adenylyl cyclase content of the cell was increased 
by up to ten fold as assessed by guanine nucleotide-stimulated specific high affinity 
binding of [^HJforskolin to cellular membranes.
Basal adenylyl cyclase activity was markedly elevated compared to a clone 
expressing similar levels of the ^2-adrenoceptor in the absence of adenylyl cyclase 
type 2. Each of NaF, forskolin and the poorly hydrolysed analogue of GTP, 
Gpp(NH)p, produced substantially higher levels of adenylyl cyclase activity in 
membranes of the clones positive for expression of adenylyl cyclase type 2  than 
achieved with the parental cells. Both isoprenaline, acting at the introduced p2“ 
adrenoceptor, and iloprost, acting at the endogenously expressed IP prostanoid 
receptor, stimulated adenylyl cyclase activity to much higher levels in the clones 
expressing adenylyl cyclase type 2  compaied to the clone lacking this adenylyl cyclase; 
however, the concentration-effect curves for adenylyl cyclase stimulation to these two 
agonists were not different between parental and adenylyl cyclase type 2  expressing 
clones. A maximally effective concentration of the p-adrenoceptor partial agonist 
ephedrine displayed similar efficacy and potency to stimulate adenylyl cyclase in 
membranes of clones with and without adenylyl cyclase type 2. Both secretin and 
NECA (acting at an endogenous A% adenosine receptor) were also able to produce 
substantially greater maximal activations of adenylyl cyclase in the clones expressing 
excess adenylyl cyclase type 2  without alterations in agonist efficacy or potency. 
These results demonstrate that the maximal output of the stimulatory arm of the 
adenylyl cyclase cascade can be increased by increasing total levels of adenylyl cyclase 
in the genetic background of NG 108-15 cells. This is in contrast to increasing levels 
of receptor expression which results in increases in potency but not maximal 
effectiveness of full agonist ligands (Adie et al, 1994b).
Agonist-induced specific down-regulation of the pertussis-toxin-insensitive 
phospholipase C-linked G-proteins G qa  and G n a  were observed in human 
embryonic kidney (HEK-293) cells which express stably the long splice variant form 
of the rat thyrotropin releasing hormone (TRH) receptor.
The established mechanism of action of TRH is via activation of a 
phospholipase C to generate inositol 1,4,5 trisphosphate and hence release Ca^+ from 
intracellular stores to raise the cytoplasmic concentrations of this ion. It has been noted
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however, at least in pituitary GH3 cells which are one of the most popular model 
systems for the study of TRH receptor action, that TRH is also able to activate 
adenylyl cyclase (Paulssen et a i,  1992). It has been realised that GH3 cells express at 
least two separate isoforms of the TRH receptor which appear to arise via differential 
splicing of pre-mRNA transcribed from a single gene (de la Pena et a l ,  1992a). The 
modifications occur in the C-terminal tail of the receptor after the 7th transmembrane 
helix. Whilst the third intracellular loop of G-protein-coupled receptors is a key 
determinant for contacts with G-proteins, both the C-terminal region and the second 
intracellular loop have been implicated in contributing to the specificity of such 
interactions. It is thus possible that the multiple signalling effects of TRH noted in 
pituitary GH3 cells are actually produced by pharmacologically similar but genetically 
distinct receptors.
In addition, previous studies have not been able to assess whether both G qa 
and G l i a  are involved in this process and whether different splice variants of the 
receptor selectively interact with different G-proteins to regulate different signal 
transduction cascades as has recently been indicated for both the EF3 prostanoid 
receptor where, like the TRH receptor, the splice vairants occur in the C-terminal tail 
(Namba et a l ,  1993) and the PACAP receptor (Spengler et a l,  1993).
In chapter 4, I have demonstrated that activation of the long isoform of the 
TRH receptor caused a large stimulation of production of inositol phosphates in a 
manner which was insensitive to pretreatment of the cells with pertussis toxin. In 
contrast, TRH did not produce either activation of basal adenylyl cyclase or inhibition 
of forskolin-amplified adenylyl cyclase activity despite the fact that TRH has been 
reported also to stimulate adenylyl cyclase activity via activation of Gga and to 
stimulate L-type Ca^+ channels via activation of Gi2 a. The effect of TRH on inositol 
phosphate production in E2 HEK-293 cells was some 10 fold less potent than in GH3 
cells and was completely attenuated by pretreatment of the cells with TRH.
Sustained exposure of E2 HEK-293 cells to TRH resulted in a substantial 
reduction in cellular levels of Gqa-Iike immunoreactivity from some 12 to 5 pmol/mg
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of membrane protein without significant alterations in cellular levels of the a  subunits 
of G ga (22 pmol/mg membrane protein) and Gi2 a ,  the G-proteins involved 
respectively in stimulatory and inhibitory regulation of adenylyl cyclase, or G n a , 
Gi3 a  and Goa. Dose-response curves indicated that half-maximal effects on cellular 
G q-like immunoreactivity were produced by 50 nM TRH and time courses 
demonstrated that half-maximal loss in response to a maximally effective dose of TRH 
( 10 fxM) was produced by 3-4 h. Separation of clone E2 HEK-293 ceil membranes in 
SDS-PAGE conditions able to resolve individual members of the Gq family
variants of the rat TRH receptor in GH3 cells or the high steady-state levels (100
':y.
demonstrated the presence of two related G-proteins. In membranes of E2 HEK-293 
cells treated with TRH both of the expressed Gq-like G-proteins were observed to be 
down-regulated in parallel. The similarity of dose-response curves and time courses 
for loss of the two G-proteins indicates that the long isoform of the rat TRH receptor 
does not functionally select between these two transducer proteins. The differences in 
adenylyl cyclase and phospholipase C regulation in response to TRH in GH3 cells and
in E2 HEK-293 cells may reflect the co-expression of both long and short splice
,pmol/mg membrane protein) of Gga and ratio of expression of Gg/Gn-like G-proteins 
in GH3 cells (8 : 1) in comparison to E2 HEK-293 cells (2: 1).
The isolation of cDNA species corresponding to G qa and G n a  from a 
murine cDNA library has demonstrated these two G-proteins to be some 89% identical 
at the amino acid level (Strathmann et a l ,  1990). In the case of G n a ,  cDNA clones 
from murine, human and bovine have 97% identity in amino acid sequence between 
these forms. Paiticularly high sequence conservation is noted in the C-terminal portion 
of these G-proteins which, at least by analogy with other G-proteins, provides the 
sites for interaction of the G-protein with both receptor and effector polypeptides 
(Wilkie gr a/., 1991; Amatruda ef fl/., 1991; Kaziro ef a/., 1990).
Both because of this high degree of sequence identity and because 
heterologous expression of G-protein-linked receptors into cell lines derived from
different species regularly results in the expression of functionally coupled receptors,
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there has been little consideration as to whether individual receptors might display a 
degree of selectivity of interaction if concurrently offered the choice between species 
variants of the same G-protein. Furthermore, experimental designs to approach this 
question have been difficult to develop. In chapter 4.3, however, I have developed a 
6 M urea containing SDS-PAGE system which allowed the concurrent detection and 
unambiguous assignment of identity to species isoforms of the phospholipase C- 
iinked G-protein G not.
In an attempt to address whether a single receptor type can utilise species 
variants of the same G-protein equivalently, clone E2M11 cells which express the long 
isoform of the rat TRH receptor and stably co-express the endogenous human and 
exogenously introduced murine G n a  were generated. The cellular distribution in 
unstimulated clone E2M11 cells of human and murine G n a  was identical and the 
introduced murine G n a  displayed the same ability as the human G n a  to be 
solublized by treatment with sodium cholate. However, although treatment of E2M11 
cells with TRH results in a qualitatively similar pattern of cellular redistribution and 
down-regulation of the G n o t isoforms, quantitative analysis indicated that the 
exogenous murine isoform of G n o t was less effectively regulated by the long isoform 
of the rat TRH receptor than the endogenous human form of G not. A redistribution 
of both a  and p-subunits into low-density membrane fractions with transfer of a  
subunits only to the cytosol and a reduction in total cellular levels of these 
polypeptides was observed in response to TRH.
-m
Chapter 6. 
References,
a
II
' II
I
221
Abate, C., Luk, D. and Curran, T. (1991) Mol. Cell Biol. 11, 3624-3632.
Adie, E. J., Mullaney, I., McKenzie, F. R. and Milligan, G. (1992) Biochem. J.
285, 529-536.
Adie, E. J. and Milligan, G. (1993) Biochem. Soc. Trans. 21, 432-435.
Adie, E. J. and Milligan, G. (1994a) Biochem. J. 303, 803-808.
Adie, E. J. and Milligan, G. (1994b) Biochem. J. 300, 709-715.
Akamizu, T., Ikuyama, S., Saji, M., Kosugi, S., Kozak, C., McBridge, O. W. and 
Kohn, L. (1990) Proc. Natl. Acad. Sci. USA 87, 5677-5681.
Alousi, A. A., Jasper, J. R., Insel, P. A. and Motulsky, H. J. (1991) FASEB J. 5,
2300-2303.
Amatruda, T.T., III, Steele, D. A., Slepak, V. Z., and Simon, M. I. (1991) Proc.
Natl. Acad. Sci. (USA) 8 8 , 5587-5591.
Andersson, S., Davis, D. N., Dahlback, H., Jornvall, H. and Russell, D. W.
(1989) J. Biol. Chem. 264, 8222-8229.
Angel, P. and Karin, M. (1991) Biochim. Biophys. Acta. 1072, 129-150.
Appel, J. M., Robbins, J. D., De Souza, E. B. and Seamon, K. B. (1992) J.
Pharmacol. Exp. Ther. 263, 1415-1423.
Aragay, A. M., Katz, A. and Simon, M. I. (1992) J. Biol. Chem. 267, 24983- 
24988.
Arshavsky, V. Y. and Bownds, M. D. (1992) Nature 357, 416-417.
Ashkenazi, A., Winslow, J. W., Peratta, E. G., Peterson, G. L., Schimerlik, M. I.,
Capon, D. J. and Ramachandran, J. (1987) Science 238, 672-675.
Ashworth, R., Yu, R., Nelson, E. J., Dermer, S., Gershengorn, M. C. and Hinkle,
P. M. (1995) Proc. Natl. Acad. Sci. (USA) 92, 512-516.
Aub, D. L., Frey, E. A,, Sekura, R. D. and Cote, T. E. (1986) J. Biol. Chem. 261,
9333-9340.
Ausiello, D. A., Stow, J. L. Cantiello, H. F., De Almeida, J. B. and Benos, D. J.
(1992) J. Biol. Chem. 267, 4759-4765.
Barber, R. (1989) Second Messengers Phosphoproteins 12, 59-71.
222
I 
_
" S
ï
S
Benovic, J. L., Pike, L. J., Cerione, R. A., Staniszewski, D., Yoshimasa, T., 
Codina, J., Caron, M. G. and Lefkowitz, R. J. (1985) J. Biol, Chem. 260, 7094- 
7101.
Benovic, J. L., Kuhn, H., Weyand, L, Codina, J., Caron, M. G. and Lefkowitz, R. 
J. (1987) Proc. Natl. Acad. Sci. (USA) 84, 8879-8882.
Benovic, J. L., De Blasi, A., Stone, W. C., Caron, M. G. and Lefkowitz, R. J.
(1989) Science 246, 235-240.
Berstein, G., Blank, J. L., Smrcka, A. V,, Higashijima, T., Sternweis, P. C., Exton, 
J. H. and Ross, E. M. (1992a) J. Biol. Chem. 267, 8081-8088.
Berstein, G., Blank, J. L., Jhon, D. -Y., Exton, J. H., Rhee, S. G and Ross, E. M. 
(1992b) Cell 70,411-418.
Bigay, L, Deterre, P., Pfister, C. and Chabre, M. (1985) FEBS Lett. 191, 181-185. 
Bimbaumer, M. (1995) J. of Receptor & Signal Transduction Research 15, 131-160. 
Blank, J. L., Ross, A. H. and Exton, J. H. (1991) J. Biol. Chem. 266, 18206- 
18216.
Blenis, J. (1993) Proc. Natl. Acad. Sci. (USA) 90, 5889-5892.
Blitzer, R. D., Omri, G., De Vivo, M., Carty, D. J., Premont, R. T., Codina, J., 
Bimbaumer, L., Cotechia, S. Caron, M. G., Lefkowitz, R. J., Landau, E. M. and 
Iyengar, R. (1993) J. Biol. Chem. 268, 7532-7537.
Blumer, K. J. and Johnson, G. L, (1994) Trends Biochem. Sci. 19, 236-240. 
Bouvier, M., Hausdorff, W. P., De Blasi, A., O'Dowd, B. F., Kobilka, B. K., 
Caron, M. G. and Lefkowitz, R. J. (1988a) Nature 333, 370-373.
Bouvier, M., Hnatowich, M., Collins, S. K., Kobilka, B., Deblasi, A., Lefkowitz, 
R. J. and Caron, M. G. (1988b) Mol. Pharmacol. 33, 133-139.
Bouvier, M., Collins, S., O'Dowd, B. F., Campbell, P. T., De Blasi, A., Kobilka,
B. K., MacGregor, C., Irons, G. P., Caron, M. G. and Lefkowitz, R. J. (1989) J. 
Biol. Chem. 264, 16786-16792.
Brandt, D. R. and Ross, E. M. (1986) J. Biol. Chem. 261, 1656-1664.
i
223
Bray, P., Carter, A., Simons, C., Guo, V., Puckett, C„ Kamholz, J„ Spiegel, A.
'':k
and Nirenberg, M. (1986) Proc. Natl. Acad. Sci. (USA) 83, 8893-8897.
Bubis, J. and Khorana, H. C. (1990) J. Biol. Chem. 265, 12995-12999.
Bylund, D. B„ Ray, P. C. and Murphy, T. J. (1988) J. Pharmacol. Exp, Ther. 245, 
600-607.
!II
Cali, J. J., Balcueva, E. A., Rybalkin, I. and Robishaw, J. D. (1992) J. Biol. Chem.
267, 24023-24027.
Carlson, K. E. Brass, L. P., Manning, D. R. (1989) J. Biol. Chem. 264, 13298- 
13305.
Carr, F. E., Fisher, C. U., Fein, H. G. and Smallridge, R, C.(1993) Endocrinology 
133, 1700-1707.
Carroll, J. A. and Shaw, J. S. (1989) Br. J. Pharmacol. 98, 925p.
Carty, D. J., Padrell, E., Codina, J., Bimbaumer, L., Hildebrandt, J. D. and 
Iyengar, R. J. (1990) J. Biol. Chem. 265, 6268-6273.
Casey, P. J., Fong, H. K. W., Simon, M. I. and Gilman, A. G. (1990) J. Biol.
Chem. 265, 2383-2390.
Casey, P. J. (1994) Cuit. Opin. Cell Biol. 6 , 219-225.
Cassel, D. and Selinger, Z. (1976) Biochem. Biophphys. Acta. 452, 538-551.
Cerione, R. A., Regan, J. W., Nakata, H., Codina, J., Benovic, J. L., Gierschik,
P., Somers, R., Spiefel, A. M., Bimbaumer, L., Lefkowitz, R. J. and Caron, M. G.
(1986) J. Biol. Chem. 261,3901-3909.
Cerione, R. A. (1991) Biochim. Biophys. Acta 1071, 473-501.
Changeux, J. P., Giraudet, J. and Dennis, M. (1987) Trends Pharmacol. Sci. 8 , 459- 
465.
Chen, J., De Vi V O , M., Dingus, J., Harry, A., Li, J., Sui, J., Carty, D. J., Blank, J.
L., Exton, J. H., Stoffel, R. H., Inglese, J., Lefkowitz, R. J., Logothetis, D. E., 
Hildebrandt, J. D. and Iyengar, R. (1995) Science 268, 1166-1169.
Cheung, A. H., Huang, R-R. C., Graziano, M. P. and Strader, C. D. (1991) FEBS
.
Lett. 279, 277-280.
224
__
Codina, J., Hildebrandt, J., Iyengar, R., Bimbaumer, L., Sekura, R. D. and 
Manclark, C. R. (1983) Proc. Natl. Acad. Sci. (USA) 80, 4276-4280.
225
■r
Chidiac, P., Hebert, T. E., Valiquette, M., Dennis, M. and Bouvier, M. (1994) Mol. 
Pharmacol. 45, 490-499.
Chomczynski, P., and Sacchi, N.(1987) Anal. Biochem. 162, 156-159.
Clark, R. B., Friedman, J„ Prasad, N. and Ruoho, A. E. (1985) J. Cyclic Nucleotide 
Protein Phosphorylation Res. 10, 97-119.
Codina, J., Grenet, D., Chang, K. -J. and Bimbaumer, L. (1991) J. Receptor 
R e s .l l ,  587-601.
Coleman, D. E., Berghuis, A. M., Lee, E., Linder, M. E., Gilman, A. G. and 
Sprang, S. R. (1994) Science 265, 1405-1412.
Collins, S., Altschmied, J., Herbsman, O., Caron, M. G., Mellon, P. L. and 
Lefkowitz, R. J., (1990) J. Biol. Chem. 265, 19330-19335.
Conklin, B. R., Chabre, O., Wong, Y. H., Federman, A. D. and Bourne, H. R.
(1992) J. Biol. Chem. 267, 31-34.
Conklin, B. R., Farfel, Z., Lustig, K. D., Julius, D., and Bourne, H. R. (1993a) 
Nature 363, 274-276.
Conklin, B. R. and Bourne, H. R. (1993b) Cell 73, 631-641.
Cotecchia, S., Kobilka, B. K., Daniel, K. W., Nolan, R. D., Lapetina, E. T. Caron, 
M. G., Lefkowitz, R. J. and Regan, J. W. (1990a) J. Biol. Chem. 265, 63-69. 
Cotecchia, S., Exum, S., Caron, M. G. and Lefkowitz, R. J. (1990b) Proc. Natl. 
Acad. Sci. (USA) 87, 2896-2900.
Crespo, P., Xu, N., Simonds, W. F. and Gutkind, J. S. (1994) Nature 369, 418- 
420.
Crews, C. M. and Erikson, R. L. (1993) Cell 74, 215-217 
Curran, T. and Franza, JR B. R. (1988) Cell 55, 395-397.
Dalman, H. M. and Neubig, R. R. (1991) J. Biol. Chem. 266, 11025-11029.
Day, R. N., Walder, J. A. and Maurer, R. A. (1989) J. Biol. Chem. 264, 431-436.
DeBlasi, A., O'Reilly, K. and Motulsky, H. J. (1989) Trends Pharmacol. Sci. 10,
227-229.
Degtyarev, M. Y., Spiegel, A. M. and Jones, T. L. Z. (1993a) Biochemistry 32, 
8057-8061.
Degtyarev, M. Y., Spiegel, A. M. and Jones, T. L. Z. (1993b) J. Biol. Chem. 268, 
23769-23772..
'A
226
de la Pena, P., Delgado, L. M., del Camino, D. and Barros, F. (1992a) J. Biol. 
Chem. 267, 25703-25708.
de la Pena, P., Delgado, L. M„ del Camino, D. and Barros, F. (1992b) Biochem. J. 
284, 891-899.
DeLean, A., Stadel, J. M and Lefkowitz, R. J. (1980) J. Biol. Chem. 255, 7108-
7117.
Denker, B. M., Neer, E. J. and Schmidt, C. J. (1992a) J. B io l Chem. 267, 6272- 
6277.
Denker, B. M., Schmidt, C. J. and Neer, E. J. (1992b) J. Biol. Chem. 267, 9998- 
10002.
Dohlman, H. G., Bouvier, M., Benovic, J. C., Caron, M. G. and Lefkowitz, R. J.
(1987) J. Biol. Chem. 262, 14282-14288.
Dohlman, H. G., Caron, M. G., Strader, C. D., Amlaiky, N. and Lefkowitz, R. J.
(1988) Biochemistry 27, 1813-1817.
Donaldson, J. G. and Klausner, R (1994) Curr. Opin. Cell Biol. 6 , 527-532. 
Donnelly, L. E., Boyd, R. S. and MacDermot, J, (1992) Biochem. J. 288, 331-336. 
Drust, D. S. and Martin, T. F. J. (1984) J. Biol. Chem. 259, 14520-14530.
Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M, and 
Weinberg, R. A. (1993) Nature 363, 45-51.
Eide, B., Gierschik, P., Milligan, G., Mullaney, I., Unson, C., Goldsmith, P. and 
Spiegel, A. (1987) Biochem. Biophys. Res. Commun. 148, 1398-1405.
227
■■i-:
Feinstein, P. G., Schrader, K. A., Bakalyar, H. A., Tang, W. ~J., Ki'upinski, J., 
Gilman, A. G. and Reed, R. R. (1991) Proc. Natl. Acad. Sci. (USA) 8 8 , 10173- 
10177.
Fong, H. K. W., Amatruda III, T. T., Birren, B. W. and Simon, M. I. (1987) Proc. 
Natl. Acad. Sci. (USA) 84, 3792-3796.
Fong, H. K. W., Yoshimoto, K. K., Eversole-Cire, P. and Simon, M. I. (1988) 
Proc. Natl. Acad. Sci. (USA) 85, 3066-3070.
Freissmuth, M. and Gilman, A. G. (1989) J. Biol. Chem. 264, 21907-21914. 
Fujimoto, J., Narayanan, C. S., Benjamin, J. E., Heinfink, M. and Gershengorn, M.
C. (1992) Endocrinology 130, 1879-1884.
Fukada, Y., Takao, T., Ohguro, H., Yoshizawa, T., Akino, T. and Shimonishi, Y.
(1990) Nature 346, 658-660.
Fukuda, K., Higashida, H., Kubo, T., Maeda, A., Akiba, L, Bujo, H., Mishina, M. 
and Numa, S. (1988) Nature 335, 355-357.
Funatsu, K., Teshima, S. and Inanaga, K. (1985) J. Neurochem. 45, 390-397.
Fung, B. K. K., Yamane, H. K., Ota, I. M. and Clarke, S. (1990) FEBS Lett. 260, 
313-317.
Garritsen, A and Simonds, W. F. (1994) J. Biol. Chem. 269, 24418-24423.
Gandin, C., Ishikawa, Y., Wight, D. C., Mahdavi, V., Nadal-Ginard, B., Wagner, 
T. E., Vatner, D. E. and Homcy, C. J. (1995) J. Clin. Invest. 95, 1676-1683. 
Gautam, N., Northup, L, Tamir, H. and Simon, M. L (1990) Proc. Natl. Acad. Sci. 
(USA) 87, 7973-7977.
Gautvik, K. and Lystad, E. (1981) Eur. J. Biochem. 116, 235-242.
Gautvik, K., Gordeladze, J. O., Jansen, T., Haug, E., Hansson, V. and Lystad, E. 
(1983) J. Biol. Chem. 258, 10304-10311.
Gershengorn, M. C. (1986) Annu. Rev. Physiol. 48, 515-526.
Gershengorn, M. C., Heinflink, M., Nussenzveig, D. R., Hinkle, P. M. and Falck- 
Pedersen, E. (1994) J. Biol. Chem. 269, 6779-6783.
£
Gether, U., Johansen, T. E., Snider, M. R., Lowe, J. A., Nakanishi, S. and 
Schwartz, T. W. (1993) Nature 362, 345-348.
Gilman, A. G. (1987) Annu. Rev. Biochem. 56, 615-649.
Goldsmith, P., Backlund, P. S,, Rossiter, K., Carter, A., Milligan, G., Unson, C. 
G. and Spiegel, A, M. (1988) Biochemistry 27, 7085-7090.
Goldstein, J., Brown, M. S., Aderson, R. G. W., Russel, D. W. and Schneider, W. 
J. (1985) Annu. Rev. Cell Biol. 1, 1-39.
Gollasch, M., Haller, H., Schultz, G. and Hescheler, J. (1991) Proc. Natl. Acad. 
Sci. (USA) 8 8 , 10262-10266.
Gollasch, M., Kleuss, C., Hescheler, J., Wittig, B. and Schultz, G. (1993) Proc. 
Natl. Acad. Sci. (USA) 90, 6265-6269.
Graeser, D. and Neubig, R. R. (1993) Mol. Pharmacol. 43, 434-443.
Grassie, M. A., McCallum, J. P., Guzzi, F., Magee, A. I., Milligan, G. and Parenti, 
M. (1994) Biochem. J. 302, 913-920.
Green, A., Johnson, J. L. and Milligan, G. (1990) J. Biol. Chem. 265, 5206-5210. 
Green, A. G., Milligan, G. and Dobias, S. B. (1992) J. Biol. Chem.267, 3223- 
3229.
Gunning, P., Leavitt, J., Muscat, G., Ng, S. and Kedes, L. (1987) Proc. Natl. Acad. 
Sci. (USA) 84, 4831-4835.
Hadcock, J. R. and Malbon, C. C. (1988) Proc. Natl. Acad. Sci. (USA) 85, 5021- 
5025.
Hadcock, J. R., Wang, H. and Malbon, C. C. (1989) J. Biol. Chem. 264, 13956- 
13961.
Haga, K. and Haga, T. (1992) J. Biol. Chem. 267, 2222-2227.
Hall, J. M., Caulfield, M. P., Watson, S. P. and Guard, S.(1993) Trends Pharmacol. 
Sci. 14, 376-383.
Ham, R. G. (1963) Expt. Cell Res. 29, 515-526.
Hamprecht, B., Glaser, T., Reiser, G., Bayer, E. and Propst, F. (1985) Methods in 
Enzymol. 109, 316-341.
228
Insel, P. A. and Sanda, M (1979) J. Biol. Chem. 254, 6554-6559.
5183.
229
Harden, T. K., Cotton, C. U., Waldo, G. L., Lutton, J. K. and Perkins, J. P. (1980) 
Science 210, 441-443.
Hausdorff, W. P., Caron, M. G. and Lefkowitz, R. J. (1990) FASEB J. 4, 2881- 
2889.
Hertel, C., Muller, P., Portenier, M. and Staehelin, M. (1983) Biochem. J. 216, 
669-674.
Hescheler, L, Rosenthal, W., Trautwein, W. and Schultz, G. (1987) Nature 325, 
445-447.
Hildebrandt, J. D. (1993) In: GTPases in Biology (Dickey, B.F. and Bimbaumer, L. 
(eds)) Handb. Exp. Pharm. 108/II pp 417-428. Springer-Verlag, Berlin.
Higashida, H., Streatey, R. A., Klee, W. and Nireberg, M. (1986) Proc. Natl. Acad. 
Sci. (USA) 83, 942-946.
Hinkle, P. M. and Kinsella, P. A. (1984) J. Biol. Chem. 259, 3445-3449.
Hinkle, P. M. (1989) Annu. N. Y. Acad. Sci. 553, 176-187.
Hoon, M. A., Northup, J. K,, Margolskee, R. F. and Ryba, N. J. (1995) Biochem. 
J. 309, 629-636.
Houslay, M. D., Bojanic, D. and Wilson, A. (1986) Biochem, J. 234, 737-740. 
Hoyer, D. and Boddeke, H. W. G. M. (1993) Trends Pharmacol. Sci. 14, 270-275. 
Hsieh, K.P. and Martin, T. F. J. (1992) Mol. Endocrinol. 6 , 1673-1681.
Hudson, T. H. and Johnson, G. L. (1980) J. Biol. Chem. 255, 7480-7486.
Hunter, T. and Cooper, J. A. (1985) Annu. Rev. Biochem. 54. 897-930.
Imai, A. and Gershengorn, M. C. (1987) Methods in Enzymol. 141, 100-111. 
Inglese, J., Freedman, N. J., Koch, W. J. and Lefkowitz, R. J. (1993) J. Biol. 
Chem. 268, 23735-23738.
Inglese, J., Koch, W. J., Touhura, K. and Lefkowitz, R. J. (1995) Trends Biochem. 
Sci. 20, 151-156.
y 
-Iyengar, R. and Bimbaumer, L. (1982) Proc. Natl. Acad. Sci. (USA) 79, 5179-
t
Izzo, N. J., Seidman, C. E., Collins, S. and Coined, W. S. (1990) Proc. Natl. Acad. 
Sci. (USA) 87, 6268-6271.
Jacobowitz, O. and Iyengar, R. (1994) Proc. Natl. Acad. Sci. (USA) 91, 10630- 
10634.
Jiang, M., Pandey, S., Tran, V. T. and Wong, H. K. W. (1991) Proc. Natl. Acad. 
Sci. (USA) 8 8 , 3907-3911.
Johnson, G. L., Bourne, H. R., Gleason, M. K., Coffino, P., Insel, P. A. and 
Melmon, K. L. (1979) Mol. Pharmacol. 15, 16-27.
Johnson, W. A., Nathanson, N. M. and Horita, A. (1989) Annu. N. Y. Acad. Sci. 
553, 137-146.
Johnson, R. A. and Salomon, Y. (1991) Methods in Enzymol. 195, 3-21.
Jones, D. T. and Reed, R. R. (1987) J. Biol. Chem. 262, 14241-14249.
Jones, T. L. Z., Simonds, W. P., Merendino, J. J., Jr., Brann, M. R. and Spiegel, 
A. M. (1990) Proc. Natl. Acad. Sci. (USA) 87, 568-572.
Jouneaux, C., Audigier, Y., Goldsmith, P., Pecker, F. and Lotersztajn, S. (1993) J. 
Biol. Chem. 268, 2368-2372.
Journot, L., Pantaloni, C., Bockaert, J. and Audigier, Y. (1991) J. Biol. Chem. 266, 
9009-9015.
Kahn, R. A. and Gilman, A. G. (1984) J. Biol. Chem. 259, 6235-6240.
Karnik, S. S., Sakmar, T. P., Chen, H. B. and Khorana, H. G. (1988) Proc. Natl. 
Acad. Sci. (USA) 85, 8459-8463.
Karin, M. (1994) Curr. Opin. Cell Biol. 6 , 415-424.
Karpinski, B. A., Morle, G. D., Huggenvik, J., Uhler, M. D. and Leiden, J. M.
(1992) Proc. Natl. Acad. Sci. (USA) 89, 4820-4824.
Kassis, S., Olasma, M., Sullivan, M. and Fishman, P. H. (1986) J. Biol. Chem. 
261, 12233-12237.
Katz, A., Wu, D, and Simon, M. I. (1992) Nature 360, 684-686.
Katz, A. and Simon, M. I. (1995) Proc. Natl. Acad. Sci. (USA) 92, 1998-2002.
230
231
Kaziro, Y. (1990) In: G-proteins as regulators of cellular signalling processes, pp 47- 
6 6  (Houslay, M. D. and Milligan, G. (eds)) Wiley and sons, Chichester.
Kaziro, Y., Itoh, H., Kozasa, T., Nakafuku, M. and Satoh, T. (1991) Annu. Rev. 
Biochem. 60, 349-400.
Keen, M., Kelly, E., Nobbs, P. and MacDermot, J. (1989) Biochem. Pharmacol. 
38. 3827-3833.
Kelly, E., Keen, M., Nobbs, P. and MacDermot, J. (1990) Br. J. Pharmacol. 99, 
306-311.
Kenakin, T. P. (1989) Trends Pharmacol. Sci. 10, 18-22,
Kenimer, J. G. and Nirenberg, M. (1981) Mol, Pharmacol. 20, 585-591.
Kennedy, M. E. and Limbird, L. E. (1993) J. Biol. Chem. 268, 8003-8011.
Kim, S., Ang, S. L., Bloch, D. B., Bloch, K. D., Kawahara, Y., Tolman, C., Lee, 
R., Seidman, J. G. and Neer, E. J. (1988) Proc. N atl Acad. Sci. (USA) 85, 4153- 
4157.
Kjelsberg, M. A., Cotecchia, S., Ostrowski, J., Caron, M. G, and Lefkowitz, R. J.
(1992) J. Biol. Chem. 267, 1430-1433.
Klee, W. A., Milligan, G,, Simonds, W. P. and Tocque, B. (1985) Molec. Asp. 
C ell Regul 4, 117-129.
Kleuss, C., Hescheler, J., Ewel, C., Rosenthal, W., Schultz, G. and Wittig, B.
(1991) Nature 353, 43-48.
Kleuss, C., Scherubl, H., Hescheler, J., Schultz, G. and Wittig, B. (1992) Nature 
358, 424-426.
Kleuss, C., Scherubl, H., Hescheler, J., Schultz, G. and Wittig, B. (1993) Science
259, 832-834.
Kobayashi, I., Shibasaki, H., Takahashi, K., Tohyama, K., Kurachi, Y., Ito, H., 
Ui, M. and Katada, T. (1990) Eur. J. Biochem. 191, 499-506.
Kobilka, B. K., Kobilka, T. S., Daniel, K., Regan, J. W., Caron, M. G. and 
Lefkowitz, R. J. (1988) Science 240, 1310-1316.
Kobilka, B. K. (1992) Annu. Rev. Neurosci. 15, 87-114.
Koch, W. J., Rockman, H. A., Samama, P., Hamilton, R,, Bond, R. A., Milano, C.
A. and Lefkowitz, R. J. (1995) Science 268, 1350-1353.
Koski, G., Simonds, W. F. and Klee, W. A. (1981a) J. Biol. Chem. 256, 1536- 
1538.
'J
Koski, G. and Klee, M. (1981b) Proc. Natl. Acad. Sci. (USA) 78, 4185-4189.
Laemmli, U. K. (1970) Nature 227, 680-685.
Lambright, D. G., Noel, J. P., Hamm, H. E. and Sigler, P. B. (1994) Nature 369,
621-628.
Laurenza, A., Sutkowski, B. M. and Seamon, K. B. (1989) Trends Pharmacol. Sci.
10, 442-447.
Laurenza, A. and Seamon, K. B. (1991) Methods in Enzymol. 195, 52-65 
Laverriere, J. N., Morin, A., Tixier-Vidal, A., Truong, A. T., Gourdji, D. and 
Martial, J. A. (1983) EMBO J. 2, 1493-1499.
Lee, C. H., Park, D., Wu, D., Rhee, S. G. and Simon, M. I. (1992) J, Biol. Chem.
267, 16044-16047.
Lee, C. H., Katz, A. and Simon, M. I. (1995) Mol. Pharmacol. 47, 218-223.
Leiber, D., Jasper, J. R., Alousi, A. A., Martin, J., Bernstein, D. and Insel, P. A.
(1993) J. Biol. Chem. 268, 3833-3837.
Leigh, P.J. and MacDermot, J. (1985) Br. J. Pharmacol. 85, 237-247.
Lerea, C. L., Somers, D. E. and Hurley, J. B. (1986) Science 234, 77-80.
Lerea, C. L., Buntmilam, A. H. and Hurley, J. B. (1989) Neuron 3, 367-376.
Levine, M. A., Smallwood, P. M., Moen, P. T., Helman, L. J. and Ahn, T. G.
(1990) Proc. Natl. Acad. Sci. (USA) 87, 2329-2333.
Levis, M. J. and Bourne, H. R.(1992) J. Biol. Chem. 119, 1297-1307.
Levitski, A. (1990) In: G-proteins as mediators of cellular signalling processes
(Houslay, M.D. and Milligan, G. eds) pp 1-14. Wiley and Sons, Chichester.
Levitski, A., Marbach, I. and Bar-Sinai, A. (1993) Life Sciences 52, 2093-2100.
Lin, L. L., Wartmann, M., Lin, A. Y., Knopf, J. L., Seth, A. and Davis, R. J.
(1993) Cell 72, 269-278.
232
Linder, M. E., Ewald, D. A., Miller, R. J. and Gilman, A. G. (1990) J. Biol. Chem. 
265, 8243-8251.
Linder, M. E., Middleton, P., Helper, J. R., Taussig, R., Gilman, A. G. and 
Mumby, S. M. (1993) Proc. Natl. Acad. Sci. (USA) 90, 3675-3679.
Link, R., Daunt, D., Barsh, G., Chruscinski, A. and Kobilka, B. (1993) Mol. 
Pharmacol. 42, 16-27.
Lipinsky, D., Gershengorn, M. C. and Oron, Y. (1992) FEBS Lett. 307, 237-240.
Lohse, M. J., Benovic, J. L., Caron, M. G. and Lefkowitz, R. J. (1990) J. Biol. 
Chem. 265, 3202-3209.
Lohse, M. J., Andexinger, S., Pitcher, J., Trukawinski, S., Codina, J., Faure, J. P., 
Caron, M. G. and Lefkowitz, R. J. (1992) J. Biol. Chem. 267, 8558-8564.
Lohse, M. J. (1993) Biochimica Biophysica Acta 1179, 171-188.
Loundsbury, K. M., Casey, P. L, Brass, I. F. and Manning, D. R. (1991) J. Biol. 
Chem. 266, 22051-22056.
Loundsbury, K. M., Schlegel, B., Poncz, M,, Brass, L. F. and Manning, D. R.
(1993) J. Biol. Chem. 268, 3494-3498.
Lowry, O. H., Rosebrough, N. L, Farr, A. L. and Randall, R. J. (1951) J. Biol. 
Chem. 193, 265-275.
Lupas, A. N., Lupas, J. M. and Stock, J. B. (1992) FEBS Lett. 314, 105-108. 
Lustig, K. D., Conklin, B. R., Herzmark, P., Taussig, R. and Boume, H. R. (1993) 
J. Biol. Chem. 268, 13900-13905.
MacEwan, D. J., Kim, G. D. and Milligan, G. (1995) Mol. Pharmacol. 48, 316- 
325.
MacEwan, D. J., Kim, G. D. and Milligan, G. (1996) Biochem. J. (in press).
Mahan, L. C. and Insel, P. A. (1985) Mol. Pharmacol. 29, 7-15.
Marbach, L, Bar-Sinai, A., Minich, M. and Levitski, A. (1990) J. Biol. Chem. 265, 
9999-10004.
Matsui, H., Lefkowitz, R. J., Caron, M. G. and Regan, J. W. (1989) Biochemistry 
28, 4125-4130.
233
Matters, R., Graziano, M. P., Yatani, A., Graf, R., Godina, J., Gilman, A. G., 
Birnbaumer, L, and Brown, A. M. (1989) Science 243, 804-807.
McCallum, J. P., Wise, A., Grassie, M. A., Magee, A. I ,  Guzzi, P., Parent!, M. 
and Milligan, G. (1995) Biochem. J. 310, 1021-1027.
McClue, S. J., Selzer, P., Preissmuth, M. and Milligan, G. (1992) Neuron 3, 177-
182.
McPadzean, I., Mullaney, I., Brown, D. A. Milligan, G. (1989) Neuron 3, 177-182.
McKenzie, P. R. and Milligan, G. (1990a) Biochem. J. 267, 391-398.
■IMcKenzie, P. R. and Milligan, G. (1990b) J. Biol. Chem. 265, 17084-17093.
McKenzie, P. R., Adie, E. J. and Milligan, G. (1991) Biochem. Soc. Trans. 19, ^
81S.
McLaughlin, S. K., McKinnon, P. J. and Margolskee, R. P. (1992) Nature 357,
563-569.
Metcalf, G. and Jackson, I. M. D. (1989) Thyrotropin-releasing hormone: Biomedical t
Significance, New York Academy of Sciences, New York.
Milano, C. A., Allen, L. P., Rockman, H. A., Dolber, P. C., McMinn, T. R., Chien,
K. R., Johnson, T. D., Bond, R. A. and Lefkowitz, R. J. (1994) Science 264, 582- 
586.
Milligan, G. and Klee, W. A. (1985) J. Biol. Chem. 260, 2057-2063.
Milligan, G., Streaty, R. A., Gierschik, P., Spiegel, A. M. and Klee, W. A. (1987a)
J. Biol. Chem. 262, 8626-8630.
Milligan, G. (1987b) Biochem. J. 245, 501-505.
Milligan, G., Streaty, R. A., Gierschik, P., Spiegel, A. M. and Klee, W. A. (1987c)
J. Biol. Chem. 262, 8626-8630.
Milligan, G. (1988) Biochem.J. 255, 1-13.
Milligan, G. and Unson, C. G. (1989) Biochem. J. 260, 837-841.
Milligan, G., McKenzie, P. R., McClue, S. J., Mitchell, P. M. and Mullaney, I.
(1990) Int. J. Biochem. 22, 701-707.
■I
;s
234
Milligan, G., Carr, C., Gould, G. W., Mullaney, L and Lavan, B. E. (1991a) J. 
Biol. Chem. 266, 6447-6455.
235
Milligan, G. and Green, A. (1991b) Trends Pharmacol. Sci. 12, 207-209.
Milligan, G. (1992) Biochem. Soc.Trans. 20, 135-140.
Milligan, G. (1993a) J. Neurochem. 61,845-851.
Milligan, G. (1993b) Trends.Pharmacol.Sci. 14, 239-244.
Milligan, G.(1993c) Trends Pharmacol. Sci. 14, 413-418.
Milligan, G., Mullaney, I. and McCallum, J. F. (1993d) Biochim. Biophys. Ac ta 
1179, 208-212.
Milligan, G., Parenti, M. and Magee, A. I, (1995a) Trends. Biochem. Sci. 20, 181- 
186.
Milligan, G., Wise, A., MacEwan, D. J., Grassie, M. A., Kennedy, F. R., Lee, T. 
W., Adie, E. J., Kim, G. D., McCallum, J. P., Burt, A., Carr, L C., Svoboda, P.,
Shah, B. H. and Mullaney, I. (1995b) Biochem. Soc. Trans. 23, 166-170.
Mitchell, P. M., Mullaney, L, Godfrey, P. P., Arkinstall, S. J., Wakelam, M. J. O.
and Milligan, G. (1991) PEBS Lett. 287, 171-174.
Mitchell, P. M., Buckley, N. J. and Milligan, G. (1993) Biochem. J. 293, 495-499. 
Mochly-Rosen, D., Chang, P. H., Cheever, L., Kim, M., Diamond, I. and Gordon, 
A. S. (1988) Nature 333, 848-849.
Mochly-Rosen, D. and Gordon, A. S. (1990) Biochem. Biophys. Res. Comm. 173, 
388-395.
Moffett, S. W., Mouillac, B. Bonin, H. and Bouvier, M. (1993) EMBO J. 12, 349- 
356.
Moriarty, T. M., Padrell, E., Carty, D. J., Omri, G., Landau, E. M., Iyengar, R.
(1990) Nature 343, 79-82.
Morin, A., Rosenbaum, E. and Tixier-Vidal, A. (1984) Endocrinology 115, 2271- 
2277.
Morris, D., McHugh-Sutkowski, E., Moos, M. Jr., Simonds, W. P., Spiegel, A. M. 
and Seamon, K. B. (1990) Biochemistry 29, 9079-9084. 3
289, 125-131.
Mullaney, I and Milligan, G. (1994) FEB S Lett. 353, 231-234.
Muller, R., Bravo, R. and Burkhardt, J. (1984) Nature 312, 716-720.
Mumby, S. M., Heukeroth, R. O., Gordon, J. I. and Gilman, A. G. (1990) Proc. 
Natl. Acad. Sci. (USA) 87, 728-732.
Neer, E. J. (1994a) Protein Sci. 3, 3-14.
Neer, E. L, Schmidt, C. J., Nambudripad, R.,and Smith, T. F. (1994b) Nature 371, 
297-300.
236
Mouilliac, B., Caron, M. G., Bonin, H., Dennis, M. and Bouvier, M. (1992) J. Biol. 
Chem. 267, 21733-21737,
Mullaney, I. and Milligan, G. (1989) FEBS Lett. 244, 113-118.
Mullaney, I. and Milligan, G. (1990) J. Neurochem. 55, 1890-1898,
Mullaney, I., Mitchell, F. M., McCallum, J. P., Buckley, N. J. and Milligan, G. 
(1993a) PEBS Lett. 324, 241-245.
Mullaney, I,, Dodd, M. W., Buckley, N. J. and Milligan, G. (1993b) Biochem. J.
Mumby, S. M., Kleuss, C. and Gilman, A. G. (1994) Proc. Natl. Acad. Sci. (USA)
i
91. 2800-2804.
Murray-Whelan, R. and Schlegel, W. (1992) J. Biol. Chem. 267, 2960-2965. 
Nakamura, P., Ogata, K., Shizoaki, K.,  Kameyama, K., Ohara, K., Haga, T. and 
Nukada, T, (1991) J. Biol. Chem. 266, 12676-12681.
Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, P., Kakizuka, A., Ito, 
S., Ichikawa, A. and Narumiya, S. (1993) Nature 365, 166-170.
Navon, S. E. and Pung, B. K. -K. (1987) J. Biol. Chem. 262, 15746-15751. 
Negishi, M., Hashimoto, H. and Ichikawa, A. (1992) J. Biol. Chem. 267, 2364- 
2369.
Nemenoff, R., Winitz, S., Qian, N. X., Putten, V. V., Johnson, G. L. and Heasley, 
L. E. (1993) J. Biol. Chem. 268, 1960-1964.
Neer, E. J., Lok, J. M. and Wolf, L. G. (1984) J. Biol. Chem. 259, 14222-14229. 
Neer, E. J. and Clapham, D. W. (1988) Nature 333, 129-134.
■I'I
"'V '.!
I
5
237
'
I
I
Nemenoff, R. A., Wintz, S., Qian, N. X., Putten, V. V., Johnson, G. L. and 
Heasley, L. E. (1993) J. Biol. Chem. 268, 1960-1964.
Neubig, R. R. (1994) FASEB J. 8 , 939-946.
Noel, J. P., Hamm, H. E. and Sigler, P. B. (1993) Nature 366, 654-663. 
Nussenzveig, D. R., Heinflink, M. and Gershengorn, M. C. (1994) J. Biol. Chem. 
268, 2389-2392.
O'Dowd, B. P., Hnatowich, M., Cai'on, M. G., Lefkowitz, R. J. and Bouvier, M.
(1989) J. Biol, Chem. 264, 7564-7569.
Offermanns, S. and Schultz, G. and Rosenthal, W. (1989) Eur. J. Biochem. 180, 
283-287.
Offermans, S., Schfer R, R., Hoffmann, B., Bombien E., Spicher, K., Hinsch, K-
D., Schultz, G. and Rosenthal, W. (1990) PEBS Lett. 260, 14-18.
Offermanns, S., Laugwitz, K. L., Spicher, K. and Schultz, G. (1994a) Proc. Natl. 
Acad. Sci. (USA) 91, 504-508.
Offermanns, S. and Schultz, G. (1994b) Molecular and Cellular Endocrinology 100, 
71-74.
Ohmichi, M., Hirota, K., Koike, K., Kadawaki, K., Yamaguchi, M., Miyake, A. 
and Tanizawa, O. (1990) Neuroendocrinology 52, 75-81.
Ohmichi, M., Sawadw, T., Kanda, Y., Koike, K., Hirota, K., Miyake, A. and 
Saltiel, A. R. (1994) J. Biol. Chem. 269, 3783-3788.
Ohta, H., Okajima, P. and Ui, M. (1985) J. Biol. Chem. 260, 5771-5780.
Oliver, J. P., Raabe, T., Henkemeyer, M., Dickson, B., Mbamalu, G., Margolis, B., 
Schlessinger, J., Hafen, E. and Pawson, T. (1993) Cell 73, 179-191.
Ostowski, J., Kjelsberg, M. A., Caron, M. G. and Lefkowitz, R. J. (1992) Annu. 
Rev. Pharmacol. Toxicol. 32, 167-183.
Otto, S., Costa, T. and Herz, A. (1989) J. Neurochem. 52, 619-626.
Ovchinnokov, Y. A., Abdulaev, N. G. and Bogachuk, A. S. (1988) PEBS Lett. 
230, 1-5.
Pang, I.-H. and Sternweis, P.C. (1990) J. Biol. Chem. 265, 18707-18712.
»
238
ïh
Parenti, M., Vigano, M. A., Newman, C. M. H., Milligan, G. and Magee, A. I.
(1993) Biochem. J. 291, 349-353.
Parma, J., Duprez, L., Van Sande, J., Cochaux, P., Gervy, C., Mockel, J., Dumont, 
J. and Vassart, G. (1993) Nature 365, 649-651.
Paulssen, R. H., Paulssen, E. J., Gautvik, K. M. and Gordeladze, J. O. (1992) Eur. 
J. Biochem. 204, 413-418.
Peng, Y. W., Robishaw, J. D., Levine, M. A. and Yan, K. W.(1992) Proc. Natl. 
Acad. Sci. (USA) 89, 10882-10886.
Perlman, J. H., Nussenzveig, D. R., Osman, R. and Gershengorn, M. C. (1992) J. 
Biol. Chem. 267, 24413-24417.
Pert, C. B. and Snyder, S. H. (1973) Proc. Natl. Acad. Sci. (USA) 70, 2243-2247. 
Pfeuffer, E., Dreher, R. M., Metzger, H. and Pfeuffer, T (1985) Proc. Natl. Acad. 
Sci. (USA) 82, 3086-3090.
Pieroni, J. P., Jacobowitz, O., Chen, J. and Iyengar, R. (1993) Curr. Opin. 
Neurobiol. 3, 345-351.
Plevin, R., Palmer, S., Gardner, S. D. and Wakelam, M. J. O. (1990) Biochem. J. 
268, 605-610.
Premont, R. T., Chen, J., Jacobowitz, O. and Iyengar, R. (1993) In: GTPases in 
Biology (Dickey, B.F. and Birnbaumer, L. (eds)) Handb. Exp. Pharm. 108/11 pp 
189-212.Springer-Verlag, Berlin.
Premont, R.T., Inglese, J. and Lefkowitz, R.J. (1995) FASEB. J. 9, 175-182.
Pronin, A. N. and Gautam, N. (1992) Proc. Natl. Acad. Sci. (USA) 89, 6220-6224. 
Pumiglia, K. M., LeVine, H., Haske, T., Habib, T. R., Jove, R. and Decker, S. J. 
(1995) J. Biol. Chem. 270, 14251-14254.
Quick, M. W., Simon, M. I., Davidson, N., Lester, H. A. and Aragay, A. M. (1994) 
J. Biol. Chem. 269, 30164-30172.
Rahmatullah, M. and Robishaw, J. D. (1994) J. Biol. Chem. 269, 3574-3580.
Rands, E., Candelore, M. R., Cheung, A. H., Hill, W. S., Strader, C. D., Dixon, R.
A. F. (1990) J. Biol. Chem. 265, 759-764.
:
i i .
Ransnas, L. A and Insel, P. A (1988) J. Biol. Chem. 263, 9482-9485.
Ransnas, L. A Svoboda, P., Jasper, J. R. and Insel, P. A (1989) Proc. Natl. Acad. 
Sci. (USA) 8 6 , 7900-7903.
Ren, Q., Kurose, H., Lefkowitz, R. J. and Cotecchia, S. (1993) J. Biol. Chem. 
268, 16483-16487.
9587-9590.
Rodbell, M., Krans, H. M. J., Pohl, S. L. and Birnbaumer, L. (1971) J. Biol. 
Chem. 246, 1872-1876.
Rodbell, M. (1980) Nature 284, 17-22.
Rubenstein, R. C., Wong, S. K. P. and Ross, E. M. (1987) J. Biol. Chem. 262, 
16655-16662.
Salomon, Y., Londos, C. and Rodbell, M. (1974) Anal. Biochem. 58, 541-548. 
Salomon, Y. (1979) Adv. Cyclic Nucleotide Res. 10, 35-55.
N. Y.
Samama, P., Cotecchia, S., Costa, T. and Lefkowitz, R. J. (1993) J. Biol. Chem.
239
Î
Robishaw, J. D., Smigel, M. D. and Gilman, A. G. (1986) J. Biol. Chem. 261,
I
Rosenthal, H. E. (1967) Anal. Biochem. 20, 525-532.
Rosenthal, W .,  Antaramian, A., Gilbert, S. and Birnbaumer, M. (1993) J. Biol. 
Chem. 268, 13030-13033.
Ross, E., Maguire, M. E., Sturgill, T. W., Biltonen, R. L. and Gilman, A. G. (1977) 
J. Biol. Chem. 252, 5761-5775.
Rothenburg, P. L. and Kahn, C. R. (1988) J. Biol. Chem. 263, 15546-15552.
f
s
¥
Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A 
Laboratory Mannual (second edition) Cold Spring Harbor Lab., Cold Spring Harbor, II
268, 4625-4636.
Samama, P., Pei, G., Costa, T., Cotecchia, S. and Lefkowitz, R. J. (1994) Mol. 
Pharmacol. 45, 390-394.
Savarese, T. M. and Fraser, C. M. (1992) Biochem. J. 283, 1-19.
Scatchard, G. (1949) Annu. N. Y. Acad. Sci. 51, 660-672.
J
"3:
Schere, N., Toro, M. -J., Entman, M. L. and Birnbaumer, L. (1987) Arch. Biochem. 
Biophys. 259, 431-440.
Schubert, B., VanDongen, A. M. J., Kirsch, G. E. and Brown, A. M (1989) Science 
245, 516-519.
Schütz, W. and Preissmuth, M. (1993) Trends Pharmacol. Sci. 13, 376-380. 
Schwiebert, E. M., Light, D. B., Fejes-Toth, G., Naray-Fejes-toth, A. and Stanton,
B. A. (1990) J. Biol. Chem. 265, 7725-7728.
Sellar, R. E., Taylor, P. L., Lamb, R. F., Zabavnak, J., Anderson, L. and Eidne, K. 
A. (1993) J. Mol. Endocrinol. 10, 199-206.
Senogles, S. E., Benovic, J. L., Amlaiky, N., Unson, C., Milligan, G., Vinitsky, 
R., Spiegel, A. M. and Caron, M. G. (1987) J. Biol. Chem. 262, 4860-4867.
Shah, B. H., MacEwan, D. J. and Milligan, G. (1995) Proc. Natl. Acad. Sci. (USA) 
92, 1886-1890.
Shapira, H., Way, J., Lipinsky, D., Oron, Y, and Battey, J. F. (1994) FEBS Lett. 
348, 89-92.
Shenker, A., Goldsmith, P. A., Unson, C. G. and Spiegel, A. M. (1991) J. Biol. 
Chem. 266, 9309-9313.
Sibley, D. R. and Lefkowitz, R. J. (1985) Nature 317, 124-129.
Simon, M. I., Strathmann, M. P. and Gautam, N. (1991) Science 252, 802-808. 
Smigel, M. D. (1986) J. Biol. Chem. 261, 1976-1982.
Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P. H. 
and Journot, L. (1993) Nature 365, 170-175.
Spring, D. J. and Neer, E. J. (1994) J. Biol. Chem. 269, 22882-22886.
Steel, M. C., and Buckley, N. J.(1993) Mol. Pharmacol. 43, 694-701.
Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Sternweis, P. C. and 
Hawkins, P. T. (1994) Cell 77, 83-93.
Stephenson, R. P. (1956) Br. J. Pharmacol. 11, 379-393.
Sternweis, P. C. (1986) J. Biol. Chem. 261, 631-637.
Sternweis, P. C. and Simon, M. I. (1990) Trends Biochem. Sci. 17, 502-506.
240
241
Sternweis, P. C. and Smrcka, A. V. (1992) Trends. Biochem. Sci. 17, 502-506. 
Strader, C. D., Sibley, D. R. and Lefkowitz, R. J. (1984) Life Sci. 35, 1601-1610. 
Strader, C. D., Sigal, I. S., Blake, A. D., Cheung, A. H., Register, R. B., Rands,
E., Zemcik, B. A., Candelore, M. R. and Dixon, R. A. F. (1989) Cell 49, 855-863. 
Strathmann, M., Wilkie, T. M. and Simon, M. I, (1989) Proc. Natl. Acad. Sci. USA 
8 6 , 7407-7409.
Strathmann, M. and Simon, M. I. (1990) Proc. Natl. Acad. Sci. (USA) 87, 9113- 
9117.
Strathmann, M. P. and Simon, M. I. (1991) Proc. Natl. Acad. Sci. (USA) 8 8 , 5582- 
5586.
Straub, R. E., and Gershengorn, M. C. (1986) J. Biol. Chem. 261, 2712-2717. 
Straub, R. E., Freeh, G. C., Joho, R. H. and Gershengorn, M. C. (1990) Proc. 
Natl. Acad. Sci. (USA) 87, 9514-9518.
Stryer, L. (1986a) Annu. Rev. Neurosci. 9, 87-119.
Stryer, L. and Bourne, H. R. (1986b) Annu. Rev. Cell Biol. 2, 391-419.
Stryer, L. (1991) J. Biol. Chem. 266, 10711-10714.
Sugimoto, Y., Negishi, M., Hayashi, Y., Namba, T., Honda, A., Watabe, A., 
Hirata, M., Narumiya, S. and Ichikawa, A. (1993) J. Biol. Chem. 268, 2712-2718. 
Sullivan, K. A., Miller, R. T., Masters, S. B., Beiderman, B., Heideman, W. and 
Bourne, H. R. (1987) Nature 330, 758-760.
Suryanarayana, S., von Zastrow, M. and Kobilka, B. K. (1992) J. Biol. Chem. 267,
21991-21994.
Svoboda, P., Kvapil, P., Insel, P. A. and Ransnas, L. A. (1992) Eur. J. Biochem. 
208, 693-698.
Svoboda, P., Unnelius, L., Cannon, B. and Nedergaard, J. (1993) Biochem. J. 295, 
655-661.
Svoboda, P. and Milligan, G. (1994) Eur. J. Biochem. 224, 455-462.
Tang, W. -J. and Gilman, A. G. (1991) Science 254, 1500-1503.
Tang, W. -J. and Gilman, A. G. (1992) Cell 70, 869-872.
¥3
_
242
Tashjian, Jr., A. H.(1979) Methods in Enzymol. 58, 527-535.
Taussig, R. and Gilman, A. G. (1995) J. Biol. Chem. 270, 1-4.
Taylor, S. J. and Exton, J. H. (1991a) FEBS Lett. 286, 214-216.
Taylor, S. J., Chae, H. Z., Rhee, S. G. and Exton, J. H. (1991b) Nature 350, 516- 
518.
Towbin, H., Staehelin, T. and Gordon, J. (1979) Proc. Natl. Acad. Sci. (USA) 76, 
4350-4354.
Traber, J., Fisher, K., Buchen, C, and Hamprecht, B. (1975) Nature 255, 558-560. 
Trautwein, W. and Hescheler, J. (1990) Annu. Rev. Physiol. 52, 257-274.
Tsu, R. C., Allen, R. A. and Wong, Y. H. (1995) Mol. Pharmacol. 47, 835-841. 
Tsunoo, A., Yoshii, M. and Narahashi, T. (1986) Proc. Natl. Acad. Sci. (USA) 83, 
9832-9836.
Von Weizsacker, E., Strathmann, M. P. and Simon, M. I. (1992) Biochem. Biophys. 
Res. Commun. 183, 350-356.
Voyno-Yasenetskaya, T., Conklin, B. R., Gilbert, R. L., Hooley, R., Bourne, H. R. 
and Barber, D. L. (1994) J. Biol. Chem. 269, 4721-4724.
Waldo, G. L., Northup, J. K., Perkins, J. P. and Harden, T. K. (1983) J. Biol. 
Chem. 258, 13900-13908.
Wang, N., Yan, K. and Rasenik, M. M. (1990) J. Biol. Chem. 265, 1239-1242. 
Wang, S. Z., Hu, J., Long, R. M., Pou, W., Forray, C. and El-Fakahany, E. E.
(1990) FEBS Lett. 276, 185-188.
Wange, R. L., Smrcka, A. V., Sternweis, P. C. and Exton, J. H. (1991) J. Biol. 
Chem. 266, 11409-11412.
Wedegaertner, P. B., Chu, D. H., Wilson, P. T., Lewis, M. J. and Bourne, H. R.
(1993) J. Biol. Chem. 268, 25001-25008.
Wedegaertner, P. B. and Bourne, H. R. (1994) Cell 77, 1063-1070.
Weisman, A. S., Tixier-Vidal, A., Gourdji, D. (1987) In Vitro Cell Dev. Biol. 23, 
585-590.
___
GLASGOW i  n x o  UNIVERSITY *UBRARY
Wess, J., Bonner, T. L., Derje, F. and Brann, M. R. (1990) Mol. Pharmacol. 38, 
517-523.
Whaley, B. S., Yuan, N., Birnbaumer, L., Clark, R. B. and Barber, R. (1994) Mol. 
Pharmacol. 45, 481-489.
Wickman, K. D. and Clapham, D. E. (1995) Curr. Opin. Neurobiol. 5, 278-285. 
Wilkie, T. M., Scherle, P. A., Strathmann, M. P., Slepak, V. Z. and Simon, M. I,
(1991) Proc. Natl. Acad. Sci. (USA) 88, 10049-10053.
Wong, Y. H., Conklin, B. R. and Bourne, H. R. (1992) Science 255, 339-342. 
Wood, K. M., Sarnecki, C., Roberts, T. M. and Blenis, J. (1992) Cell 68, 1041- 
1050.
Wu, D., Lee, C. H., Rhee, S. G. and Simon, M. I. (1992a) J. Biol. Chem. 267, 
1811-1817.
Wu, D., Katz, A., Lee, C. H. and Simon, M. I. (1992b) J. Biol. Chem. 267, 25798- 
25802.
Xu., N., Bradley, L., Ambdukar, I. and Gutkind, J. S. (1993) Proc. Natl. Acad. Sci. 
(USA) 90, 6741-6745.
Yajima, Y., Akita, Y. and Saito, T. (1988) Mol. Pharmacol. 33, 592-597.
Yan, G. and Bancroft, C. (1991) Mol. Endocrinol. 5, 1488-1497.
Yatani, A., Codina, J., Imoto, Y., Reeves, J. P., Birnbaumer, L. and Brown, A. M. 
(1987a) Science 238, 1288-1291.
Yatani, A., Codina, J., Sekure, R. D., Birnbaumer, L. and Brown, A. M. (1987b) 
Mol. Endocrinol. 1, 283-289.
Yatani, A., Mattera, R., Codina, J., Graf, R., Okabe, K., Padrell, E., Iyengar, R., 
Brown, A. M. and Birnbaumer, L. (1988) Nature 336, 680-682.
Yatomi, Y., Arta, Y., Tada, S., Kume, S. and Ui, M. (1992) Eur. J. Biochem. 205, 
1003-1009.
Zastrow, M. V. and Kobilka, B. K. (1992) J. Biol. Chem. 267, 3530-3538. J
___
